Attached files

file filename
EX-24.7 - EX-24.7 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w7.htm
EX-24.5 - EX-24.5 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w5.htm
EX-21.1 - EX-21.1 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv21w1.htm
EX-24.8 - EX-24.8 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w8.htm
EX-24.6 - EX-24.6 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w6.htm
EX-24.9 - EX-24.9 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w9.htm
EX-24.3 - EX-24.3 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w3.htm
EX-24.4 - EX-24.4 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w4.htm
EX-24.2 - EX-24.2 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w2.htm
EX-10.9 - EX-10.9 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv10w9.htm
EX-32.2 - EX-32.2 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv32w2.htm
EX-31.2 - EX-31.2 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv31w2.htm
EX-31.1 - EX-31.1 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv31w1.htm
EX-32.1 - EX-32.1 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv32w1.htm
EX-24.1 - EX-24.1 - UNITED SURGICAL PARTNERS INTERNATIONAL INCd79018exv24w1.htm
Table of Contents

 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-K
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Fiscal Year Ended December 31, 2010
 
Commission file No. 333-144337
 
UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)
 
     
Delaware
  75-2749762
(State of Incorporation)   (I.R.S. Employer
Identification No.)
     
15305 Dallas Parkway, Suite 1600
Addison, Texas
  75001
(Zip Code)
(Address of principal executive offices)
   
 
(972) 713-3500
(Registrant’s telephone number, including area code)
 
Securities Registered Pursuant to Section 12(b) of the Act:
None
 
Securities Registered Pursuant to Section 12(g) of the Act:
None
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes o  No þ
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes þ  No o
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes o  No þ
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes o  No o
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  þ
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer o Accelerated filer o Non-accelerated filer þ Smaller reporting company o
(Do not check if a smaller reporting company)
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No þ
 
None of the registrant’s common stock is held by non-affiliates.
 
As of February 25, 2011, 100 shares of the Registrant’s common stock were outstanding.
 
Documents Incorporated by Reference
None.
 


 

 
UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
 
2010 ANNUAL REPORT ON FORM 10-K
 
TABLE OF CONTENTS
 
             
  Business     4  
  Risk Factors     27  
  Unresolved Staff Comments     39  
  Properties     39  
  Legal Proceedings     40  
 
PART II
  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities     40  
  Selected Financial Data     40  
  Management’s Discussion and Analysis of Financial Condition and Results of Operations     42  
  Quantitative and Qualitative Disclosures about Market Risk     73  
  Financial Statements and Supplementary Data     74  
  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure     74  
  Controls and Procedures     74  
  Other Information     76  
 
PART III
  Directors, Executive Officers and Corporate Governance     76  
  Executive Compensation     79  
  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters     89  
  Certain Relationships and Related Transactions, and Director Independence     91  
  Principal Accounting Fees and Services     93  
 
PART IV
  Exhibits, Financial Statement Schedules     94  
 EX-10.9
 EX-21.1
 EX-24.1
 EX-24.2
 EX-24.3
 EX-24.4
 EX-24.5
 EX-24.6
 EX-24.7
 EX-24.8
 EX-24.9
 EX-31.1
 EX-31.2
 EX-32.1
 EX-32.2


2


Table of Contents

FORWARD LOOKING STATEMENTS
 
Certain statements contained in this Annual Report on Form 10-K, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “continues,” “will,” “may,” “should,” “estimates,” “intends,” “plans” and similar expressions, and statements regarding the Company’s business strategy and plans, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and other factors, many of which the Company is unable to predict or control, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among others, the following: our significant indebtedness; general economic and business conditions, including without limitation the condition of the financial markets, both nationally and internationally; foreign currency fluctuations; demographic changes; changes in, or the failure to comply with, laws and governmental regulations; the ability to enter into or renew managed care provider arrangements on acceptable terms; changes in Medicare, Medicaid and other government funded payments or reimbursement in the United States (U.S.) and the United Kingdom (U.K.); the efforts of insurers, healthcare providers and others to contain healthcare costs; the impact of federal healthcare reform; liability and other claims asserted against us; the highly competitive nature of healthcare; changes in business strategy or development plans of healthcare systems with which we partner; the ability to attract and retain qualified physicians and personnel, including nurses and other health care professionals and other personnel; the availability of suitable acquisition and development opportunities and the length of time it takes to complete acquisitions and developments; our ability to integrate new and acquired businesses with our existing operations; the availability and terms of capital to fund the expansion of our business, including the acquisition and development of additional facilities and certain additional factors, risks and uncertainties discussed in this Annual Report on Form 10-K. We disclaim any obligation and make no promise to update any such factors or forward-looking statements or to publicly announce the results of any revisions to any such factors or forward-looking statements, whether as a result of changes in underlying factors, to reflect new information as a result of the occurrence of events or developments or otherwise. Given these uncertainties, investors and prospective investors are cautioned not to rely on such forward-looking statements.


3


Table of Contents

 
PART I
 
Item 1.   Business
 
General
 
United Surgical Partners International, Inc. (together with its subsidiaries, “we,” the “Company” or “USPI”) owns and operates short stay surgical facilities including surgery centers and hospitals in the United States and the United Kingdom. We focus on providing high quality surgical facilities that meet the needs of patients, physicians and payors better than hospital-based and other outpatient surgical facilities. We believe that our facilities (1) enhance the quality of care and the healthcare experience of patients, (2) offer significant administrative, clinical and economic benefits to physicians, (3) offer a strategic approach for our health system partners to expand capacity and access within the markets they serve, and (4) offer an efficient and low cost alternative for payors. We acquire and develop our facilities through the formation of strategic relationships with physicians and not-for-profit healthcare systems to better access and serve the communities in our markets. Our operating model is efficient and scalable, and we have adapted it to each of our markets. We believe that our acquisition and development strategy and operating model enable us to continue to grow by taking advantage of highly-fragmented markets and an increasing demand for short stay surgery.
 
Since physicians are critical to the direction of healthcare in the U.S. and U.K., we have developed our operating model to encourage physicians to affiliate with us and to use our facilities as an extension of their practices. We operate our facilities, structure our strategic relationships and adopt staffing, scheduling and clinical systems and protocols with the goal of increasing physician productivity. We believe that our focus on physician satisfaction, combined with providing high quality healthcare in a friendly and convenient environment for patients, will continue to increase the number of procedures performed at our facilities each year.
 
As of December 31, 2010, we operated 189 facilities, consisting of 185 in the United States and four in the United Kingdom. Of the 185 U.S. facilities, 132 are jointly owned with major not-for-profit healthcare systems. Overall, as of December 31, 2010, we held ownership interests in 188 of the facilities and operated one under a service and management contract. Due in large part to our partnerships with physicians and not-for-profit healthcare systems, we do not consolidate the financial results of 130 of the 188 facilities in which we have ownership, meaning that while we record a share of their net profit within our operating income, we do not include their revenues and expenses in the consolidated revenue and expense line items of our consolidated financial statements.
 
This trend in our business contributed to our consolidated revenues decreasing from $593.5 million in 2009 to $576.7 million in 2010, even as our operating income increased from $198.3 million to $210.5 million during the same period. To help understand this relationship in our consolidated financial statements, we review an operating measure called systemwide revenue growth, which includes both consolidated and unconsolidated facilities. While revenues of our unconsolidated facilities are not recorded as revenues by USPI, we believe the information is important in understanding USPI’s financial performance because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for USPI’s equity in earnings of unconsolidated affiliates. In addition, we disclose growth rates and operating margins for the facilities that were operational in both the current and prior year periods, a group we refer to as same store facilities.
 
Donald E. Steen, who is our chairman, formed USPI with the private equity firm Welsh, Carson, Anderson & Stowe in February 1998. USPI had publicly traded equity securities from June 2001 until April 2007. Pursuant to an Agreement and Plan of Merger (the merger) dated as of January 7, 2007, with an affiliate of Welsh, Carson, Anderson & Stowe X, L.P. (Welsh Carson), we became a wholly owned subsidiary of USPI Holdings, Inc. on April 19, 2007. USPI Holdings, Inc. is a wholly owned subsidiary of USPI Group Holdings, Inc., which is owned by an investor group that includes affiliates of Welsh Carson, members of our management and other investors. As a result of the merger, we no longer have publicly traded equity securities. In this Form 10-K, we have reported our operating results and financial position for the period subsequent to the merger date of April 19, 2007, as the “Successor Period” and all periods prior to April 19, 2007, as “Predecessor Periods.”


4


Table of Contents

Available Information
 
We file annual, quarterly and current reports with the Securities and Exchange Commission. You may read and copy any document that we file at the SEC’s public reference room located at 100 F Street, N.E., Washington, D.C. 20549. You may also call the Securities and Exchange Commission at 1-800-SEC-0330 for information on the operation of the public reference room. Our SEC filings are also available to you free of charge at the SEC’s web site at http://www.sec.gov. We also maintain a web site at http://www.uspi.com that includes links to our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports. These reports are available on our website without charge as soon as reasonably practicable after such reports are filed with or furnished to the SEC. Information on our web site is not deemed incorporated by reference into this Form 10-K.
 
Industry Background
 
We believe many physicians prefer surgery centers and surgical hospitals over general acute care hospitals. We believe that this is due to the non-emergency nature of the procedures performed at our surgery centers and surgical hospitals, which allows physicians to schedule their time more efficiently and therefore increase the number of surgeries they can perform in a given amount of time. In addition, outpatient facilities usually provide physicians with greater scheduling flexibility, more consistent nurse staffing and faster turnaround time between cases. While surgery centers and surgical hospitals generally perform scheduled surgeries, acute care hospitals and national health service facilities generally provide a broad range of services, including high priority and emergency procedures. Medical emergencies often demand the unplanned use of operating rooms and result in the postponement or delay of scheduled surgeries, disrupting physicians’ practices and inconveniencing patients. Surgery centers and surgical hospitals in the United States and the United Kingdom are designed to improve physician work environments and improve physician efficiency. In addition, many physicians choose to perform surgery in facilities like ours because their patients prefer the comfort of a less institutional atmosphere and the convenience of simplified admissions and discharge procedures.
 
United States
 
New surgical techniques and technology, as well as advances in anesthesia, have significantly expanded the types of surgical procedures that are being performed in surgery centers and have helped drive the growth in outpatient surgery. Lasers, arthroscopy, enhanced endoscopic techniques and fiber optics have reduced the trauma and recovery time associated with many surgical procedures. Improved anesthesia has shortened recovery time by minimizing post-operative side effects such as nausea and drowsiness, thereby avoiding the need for overnight hospitalization in many cases. In addition, some states in the United States permit surgery centers to keep a patient for up to 23 hours. This allows more complex surgeries, previously only performed in an inpatient setting, to be performed in a surgery center.
 
In addition to these technological and other clinical advancements, a changing payor environment has contributed to the rapid growth in outpatient surgery in recent years. Government programs, private insurance companies, managed care organizations and self-insured employers have implemented cost containment measures to limit increases in healthcare expenditures, including procedure reimbursement. These cost containment measures have contributed to the significant shift in the delivery of healthcare services away from traditional inpatient hospitals to more cost-effective alternate sites, including surgery centers. We believe that surgery performed at a surgery center is generally less expensive than hospital-based outpatient surgery because of lower facility development costs, more efficient staffing and space utilization and a specialized operating environment focused on quality of care and cost containment.
 
Today, large healthcare systems in the United States generally offer both inpatient and outpatient surgery on site. In addition, a number of not-for-profit healthcare systems have begun to expand their portfolios of facilities and services by entering into strategic relationships with specialty operators of surgery centers in order to expand capacity and access in the markets they serve. These strategic relationships enable not-for-profit healthcare systems to offer patients, physicians and payors the cost advantages, convenience and other benefits of outpatient surgery in a freestanding facility. Further, these relationships allow the not-for-profit healthcare systems to focus their attention and resources on their core business without the challenge of acquiring, developing and operating these facilities.


5


Table of Contents

United Kingdom
 
The United Kingdom provides government-funded healthcare to all of its residents through the National Health Service. However, due to funding and capacity limitations, the demand for healthcare services exceeds the public system’s capacity. In response to these shortfalls, private healthcare networks and private insurance companies have developed in the United Kingdom. Approximately 12% of the U.K. population has private insurance to cover elective surgical procedures, and another segment of the population pays for elective procedures from personal funds. For the year ended December 31, 2010, in the United Kingdom, we derived 67% of our revenues from private insurance, 25% from self-pay patients, who typically arrange for payment prior to surgery being performed, 4% from government payors, and 4% from other payors.
 
Our Business Strategy
 
Our goal is to steadily increase our revenues and cash flows. The key elements of our business strategy are to:
 
  •  attract and retain top quality surgeons and other physicians;
 
  •  expand our presence in existing markets;
 
  •  pursue strategic relationships with not-for-profit healthcare systems;
 
  •  expand selectively in new markets; and
 
  •  enhance operating efficiencies.
 
Attract and retain top quality surgeons and other physicians
 
Since physicians are critical to the direction of healthcare in the U.S. and U.K., we have developed our operating model to encourage physicians to affiliate with us and to use our facilities as an extension of their practices. We believe we attract physicians because we design our facilities, structure our strategic relationships and adopt staffing, scheduling and clinical systems and protocols to increase physician productivity and promote their professional and financial success. We believe this focus on physicians, combined with providing high quality healthcare in a friendly and convenient environment for patients, will continue to increase case volumes at our facilities. In addition, in the United States, we generally offer physicians the opportunity to purchase equity interests in the facilities they use as an extension of their practices. We believe this opportunity attracts quality physicians to our facilities and ownership increases the physicians’ involvement in facility operations, enhancing quality of patient care, increasing productivity and reducing costs.
 
Pursue strategic relationships with not-for-profit healthcare systems
 
Through strategic relationships with us, not-for-profit healthcare systems can benefit from our operating expertise and create a new cash flow opportunity with limited capital expenditures. We believe that these relationships also allow not-for-profit healthcare systems to attract and retain physicians and improve their hospital operations by focusing on their core business. We also believe that strategic relationships with these healthcare systems help us to more quickly develop relationships with physicians, communities, and payors. Generally, the healthcare systems with which we develop relationships have strong local market positions and excellent reputations that we use in branding our facilities. In addition, our relationships with not-for-profit healthcare systems enhance our acquisition and development efforts by (1) providing opportunities to acquire facilities the systems may own, (2) providing access to physicians already affiliated with the systems, (3) attracting additional physicians to affiliate with newly developed facilities, and (4) encouraging physicians who own facilities to consider a strategic relationship with us.
 
Expand our presence in existing markets
 
Our primary strategy is to grow selectively in markets in which we already operate facilities. We believe that selective acquisitions and development of new facilities in existing markets allow us to leverage our existing knowledge of these markets and to improve operating efficiencies. In particular, our experience has been that newly developed facilities in markets where we already have a presence and a not-for-profit hospital partner are the best use of our invested capital.


6


Table of Contents

Expand selectively in new markets
 
We may continue to enter targeted markets by acquiring and developing surgical facilities. In the United States, we expect to do this primarily in conjunction with a local not-for-profit healthcare system or hospital. We typically target the acquisition or development of multi-specialty centers that perform high volume, non-emergency, lower risk procedures requiring lower capital and operating costs than hospitals. In addition, we will also consider the acquisition of multi-facility companies.
 
In determining whether to enter a new market, we examine numerous criteria, including:
 
  •  the potential to achieve strong increases in revenues and cash flows;
 
  •  whether the physicians, healthcare systems and payors in the market are receptive to surgery centers and/or surgical hospitals;
 
  •  the demographics of the market;
 
  •  the number of surgical facilities in the market;
 
  •  the number and nature of outpatient surgical procedures performed in the market;
 
  •  the case mix of the facilities to be acquired or developed;
 
  •  whether the facility is or will be well-positioned to negotiate agreements with insurers and other payors; and
 
  •  licensing and other regulatory considerations.
 
Upon identifying a target facility, we conduct financial, legal and compliance, operational, technology and systems reviews of the facility and conduct interviews with the facility’s management, affiliated physicians and staff. Once we acquire or develop a facility, we focus on upgrading systems and protocols, including implementing our proprietary methodology of defined processes and information systems, to increase case volume and improve operating efficiencies.
 
Enhance operating efficiencies
 
Once we acquire a new facility in the U.S., we integrate it into our existing network by implementing a specific action plan to support the local management team and incorporate the new facility into our group purchasing contracts. We also implement our systems and protocols to improve operating efficiencies and contain costs. Our most important operational tool is our management system “Every Day Giving Excellence,” which we refer to as USPI’s EDGE. This proprietary measurement system allows us to track our clinical, service and financial performance, best practices and key indicators in each of our facilities. Our goal is to use USPI’s EDGE to ensure that we provide each of the patients using our facilities with high quality healthcare, offer physicians a superior work environment and eliminate inefficiencies. Using USPI’s EDGE, we track and monitor our performance in areas such as (1) providing surgeons the equipment, supplies and surgical support they need, (2) starting cases on time, (3) minimizing turnover time between cases, and (4) providing efficient case and personnel schedules. USPI’s EDGE compiles and organizes the specified information on a daily basis and is easily accessed over the Internet by our facilities on a secure basis. The information provided by USPI’s EDGE enables our employees, facility administrators and management to analyze trends over time and share processes and best practices among our facilities. In addition, the information is used as an evaluative tool by our administrators and as a budgeting and planning tool by our management. USPI’s EDGE is now deployed in substantially all of our U.S. facilities. In addition to continuing to invest in USPI’s EDGE, we are currently investing in other tools that will allow us to better manage our facilities.
 
Operations
 
Operations in the United States
 
Our operations in the United States consist primarily of our ownership and management of surgery centers. As of December 31, 2010, we had ownership interests in 171 surgery centers and 13 surgical hospitals and operate, through a service and management agreement, one additional surgery center. We also own interests in and expect to


7


Table of Contents

operate five more surgical facilities that are currently under construction and have one additional project under development, and numerous other potential projects in various stages of consideration, which may result in our adding additional facilities during 2011. All of the facilities under construction and in the earlier stages of development include a not-for-profit hospital partner. Approximately 8,000 physicians have privileges to use our facilities. Our surgery centers are licensed outpatient surgery centers, and our surgical hospitals are licensed as hospitals. Each of our facilities is generally equipped and staffed for multiple surgical specialties and located in freestanding buildings or medical office buildings. Our average surgery center has approximately 12,000 square feet of space with three operating rooms, as well as ancillary areas for preparation, recovery, reception and administration. Our surgery center facilities range from a 4,000 square foot, one operating room facility to a 33,000 square foot, nine operating room facility. Our surgery centers are normally open weekdays from 7:00 a.m. to approximately 5:00 p.m. or until the last patient is discharged. We estimate that a surgery center with four operating rooms can accommodate up to 6,000 procedures per year. Our surgical hospitals average 56,000 square feet of space with seven operating rooms, ranging in size from 30,000 to 167,000 square feet and having from four to eleven operating rooms.
 
Our surgery center support staff typically consists of registered nurses, operating room technicians, an administrator who supervises the day-to-day activities of the surgery center, and a small number of office staff. Each center also has appointed a medical director, who is responsible for and supervises the quality of medical care provided at the center. Use of our surgery centers is generally limited to licensed physicians, podiatrists and oral surgeons who are also on the medical staff of a local accredited hospital. Each center maintains a peer review committee consisting of physicians who use our facilities and who review the professional credentials of physicians applying for surgical privileges.
 
All of our U.S. surgical facilities are accredited by either the Joint Commission on Accreditation of Healthcare Organizations or by the Accreditation Association for Ambulatory Healthcare or are in the process of applying for such accreditation. We believe that accreditation is the quality benchmark for managed care organizations. Many managed care organizations will not contract with a facility until it is accredited. We believe that our historical performance in the accreditation process reflects our commitment to providing high quality care in our surgical facilities.
 
Generally, our surgical facilities are limited partnerships, limited liability partnerships or limited liability companies in which ownership interests are also held by local physicians who are on the medical staff of the facilities. Our ownership interests in the facilities range from 5% to 99%, with our average ownership being approximately 28%. Our partnership and limited liability company agreements typically provide for the monthly or quarterly pro rata distribution of cash equal to net profits from operations, less amounts held in reserve for expenses and working capital. Our facilities derive their operating cash flow by collecting a fee from patients, insurance companies, or other payors in exchange for providing the facility and related services a surgeon requires in order to perform a surgical case. Our billing systems estimate revenue and generate contractual adjustments based on a fee schedule for over 80% of the total cases performed at our facilities. For the remaining cases, the contractual allowance is estimated based on the historical collection percentages of each facility by payor group. The historical collection percentage is updated quarterly for each facility. We estimate each patient’s financial obligation prior to the date of service. We request payment of that obligation at the time of service. Any amounts not collected at the time of service are subject to our normal collection and reserve policy. We also have a management agreement with each of the facilities under which we provide day-to-day management services for a management fee that is typically a percentage of the net revenues of the facility.
 
Our business depends upon the efforts and success of the physicians who provide medical services at our facilities and the strength of our relationships with these physicians. Our business could be adversely affected by the loss of our relationship with, or a reduction in use of our facilities by, a key physician or group of physicians. The physicians that affiliate with us and use our facilities are not our employees. However, we generally offer the physicians the opportunity to purchase equity interests in the facilities they use.


8


Table of Contents

Strategic Relationships
 
A key element of our business strategy is to pursue strategic relationships with not-for-profit healthcare systems (hospital partners) in selected markets. Of our 185 U.S. facilities, 132 are jointly-owned with not-for-profit healthcare systems. Our strategy involves developing these relationships in three primary ways. One way is by adding new facilities in existing markets with our existing hospital partners. An example of this is our relationship with the Baylor Health Care System (Baylor) in Dallas, Texas. Our joint ventures with Baylor own a network of 27 surgical facilities that serve the approximately six million people in the Dallas / Fort Worth area. These joint ventures have added new facilities each year since their inception in 1999, including five during 2010. Another example of a growing single-market relationship is our network of facilities in Houston, Texas with Memorial Hermann Healthcare System, with whom we opened our first facility in 2003 and with whom we now operate 20 facilities, including three added during 2010.
 
A second way we develop these relationships is through expansion into new markets, both with existing hospital partners and with new partners. A good long-term example of this strategy is our relationship with Ascension Health, with whom we initially owned a single facility in Nashville, Tennessee and now have a total of 19 facilities in four states. Similarly, with Catholic Healthcare West (CHW) we began with one facility, which was in a suburb of Las Vegas, Nevada. This relationship has expanded to a total of 16 facilities, including seven in various California markets and seven in the Phoenix, Arizona market. During 2008, we entered into a new partnership with Legacy Health in Portland, Oregon where we now have ownership in and manage two surgical facilities. Also during 2008, we entered into a new partnership with Centura Health in Colorado where we now have ownership in and manage four surgical facilities, one of which was added in December 2010.
 
A third way we develop our strategic relationships with not-for-profit healthcare systems is through the contribution of our ownership interests in existing facilities to a joint venture relationship. For example, during 2007, we added a hospital partner, CHRISTUS Spohn, to two of our facilities in Corpus Christi, Texas. We engaged in similar transactions with existing partners, Memorial Hermann and CHW, during 2008 and 2010. We expect to add a not-for-profit hospital partner in the future to some of the remaining 53 facilities that do not yet have such a partner.
 
Operations in the United Kingdom
 
We operate three hospitals and an oncology center in greater London. We acquired Parkside Hospital and Holly House Hospital in 2000 and Highgate Hospital in 2003. In January 2011, we acquired an ownership interest in a diagnostic and surgery center in Edinburgh, Scotland. Parkside Hospital, located in Wimbledon, a suburb southwest of London, has 72 registered acute care beds, including four high dependency beds and four operating theatres, one of which is a dedicated endoscopy suite and an outpatient surgery unit. Parkside also has its own on-site pathology laboratory which provides services to the on-site cancer treatment center. The imaging department, which has been extensively upgraded in the past four years, has two MRI scanners, a CT scanner, and two X-ray screening rooms, plus mammography, dental and ultrasound services available. Over 500 surgeons, anesthesiologists, and physicians have admitting privileges to the hospital. Parkside’s key specialties include orthopedics, oncology, gynecology, neurosurgery, ear-nose-throat, endoscopy and general surgery. The expansion of Parkside’s outpatient clinic was completed in August 2010, and the refurbishment of a portion of the hospital is expected to be completed in the second quarter of 2011.
 
Cancer Centre London opened in August 2003. In 2010 we partnered with local physicians who purchased a 24% ownership in the centre, which has a state of the art equipment designed to provide a wide range of cancer treatments. The pre-treatment and planning suite houses a dedicated CT scanner, which, along with the linear accelerators and virtual simulation software, is linked to the department’s planning system. The centre provides inverse planned intensity-modulated radiation therapy (IMRT). The centre has its own pharmacy aseptic suite which provides chemotherapy to the day case unit at the hospital. The centre also has a nuclear medicine unit.
 
Holly House Hospital, located in a suburb northeast of London near Essex, has 55 registered acute care beds, including the ability to provide high dependency care. The hospital has three operating theatres and its own on-site pathology laboratory and pharmacy. A diagnostic suite houses MRI and CT scanners, X-ray screening rooms, mammography, ultrasound, and other imaging services. Approximately 300 surgeons, anesthesiologists, and


9


Table of Contents

physicians have admitting privileges at the hospital, and there are well-established orthopedic, cosmetic, in vitro fertilization, and general surgery practices. We have started a refurbishment and expansion program at Holly House which is due to be completed by late 2012. This expansion will provide three new operating theater suites, an endoscopy suite, ten additional patient rooms, an eight bed day unit, and six additional consulting rooms.
 
Highgate Hospital is a 32 bed acute care hospital located in the affluent Highgate area of London. The hospital has an established cosmetic surgery business and additional practices including endoscopy and general surgery. Approximately 200 surgeons, anesthesiologists, and physicians have admitting privileges at the hospital.
 
Case Mix
 
The following table sets forth the percentage of the internally reported case volume of our U.S. facilities and internally reported revenue from our U.K. facilities for the year ended December 31, 2010 from each of the following specialties:
 
                 
Specialty
  U.S.   U.K.
 
Orthopedic
    20 %     24 %
Pain management
    18       2  
Gynecology
    3       7 (1)
General surgery
    5       14  
Ear, nose and throat
    8       3  
Gastrointestinal
    21       2  
Cosmetic surgery
    3       15  
Ophthalmology
    12       1  
Other
    10       32  
                 
Total
    100 %     100 %
                 
 
 
(1) Also includes in vitro fertilization.
 
Payor Mix
 
The following table sets forth the percentage of the internally reported case volume of our U.S. surgical facilities and internally reported revenue from our U.K. facilities for the year ended December 31, 2010 from each of the following payors:
 
                 
Payor
  U.S.   U.K.
 
Private insurance
    60 %     67 %
Self-pay
    2       25  
Government
    31 (1)     4  
Other
    7       4  
                 
Total
    100 %     100 %
                 
 
 
(1) Based solely on case volume. Because government payors typically pay less than private insurance, the percentage of our U.S. revenue attributable to government payors is approximately 16% for Medicare and 2% for Medicaid.


10


Table of Contents

 
The following table sets forth information relating to the not-for-profit healthcare systems with which we were affiliated as of December 31, 2010:
 
             
        Number of
        Facilities
    Healthcare System’s
  Operated
Healthcare System
 
Geographical Focus
  with USPI
 
Single Market Systems:
           
Baylor Health Care System
  Dallas/Fort Worth, Texas     27  
Centura Health
  Colorado     4  
Cookeville Regional Medical Center
  Middle Tennessee     1  
Covenant Health
  Eastern Tennessee     2  
INTEGRIS Health
  Oklahoma     2  
Kennedy Health System
  New Jersey     1  
Legacy Health System
  Portland, Oregon     2  
McLaren Health Care Corporation
  Michigan     5  
Memorial Hermann Healthcare System
  Houston, Texas     20  
Meridian Health System
  New Jersey     5  
Mountain States Health Alliance
  Northeast Tennessee     1  
North Kansas City Hospital
  Kansas City, Missouri     3  
NorthShore University Health System
  Chicago, Illinois     4  
Scripps Health
  San Diego, California     1  
St. John Health System
  Oklahoma     1  
St. John’s Mercy Healthcare
  Missouri     1  
The Christ Hospital
  Cincinnati, Ohio     1  
Williamson Medical Center
  Franklin, Tennessee     1  
Multi-Market Systems:
           
Adventist Health System:
  12 states(a)     2  
Adventist Hinsdale Hospital
  Hinsdale, Illinois        
Huguley Memorial Medical Center
  Fort Worth, Texas        
Ascension Health:
  19 states and D.C.(b)     19  
Carondelet Health System (2 facilities)
  Blue Springs, Missouri        
St. Thomas Health Services System (13 facilities)
  Middle Tennessee        
St. Vincent Health (1 facility)
  Indiana        
Seton Healthcare Network (3 facilities)
  Austin, Texas        
Bon Secours Health System:
  Seven states(c)     5  
Bon Secours Health Center at Virginia Beach
  Virginia Beach, Virginia        
Mary Immaculate Hospital
  Newport News, Virginia        
Maryview Medical Center
  Suffolk, Virginia        
Memorial Regional Medical Center
  Richmond, Virginia        
St. Mary’s Hospital
  Richmond, Virginia        
Catholic Health Partners:
  Four states(d)     1  
Humility of Mary Health (1 facility)
           
Catholic Healthcare West:
  California, Arizona and Nevada     16  
Mercy Hospital of Folsom (1 facility)
  Sacramento, California        
Mercy Medical Center (3 facilities)
  Redding, California        
Mercy San Juan Medical Center (1 facility)
  Roseville, California        
Sierra Nevada Memorial Hospital (1 facility)
  Grass Valley, California        
St. Joseph’s Hospital and Medical Center (5 facilities) and Arizona Orthopedic Surgical Hospital (2 facilities)
  Phoenix, Arizona        


11


Table of Contents

             
        Number of
        Facilities
    Healthcare System’s
  Operated
Healthcare System
 
Geographical Focus
  with USPI
 
St. Joseph’s Medical Center (1 facility)
  Stockton, California        
St. Rose Dominican Hospital (2 facilities)
  Las Vegas, Nevada        
CHRISTUS Health:
  Eight states(e)     4  
CHRISTUS Health Central Louisiana (1 facility)
  Alexandria, Louisiana        
CHRISTUS Santa Rosa Health Corporation (1 facility)
  San Antonio, Texas        
CHRISTUS Spohn Health System (2 facilities)
  Corpus Christi, Texas        
Providence Health System:
  Five states(f)     2  
Providence Holy Cross Health Center
  Santa Clarita, California        
Providence Holy Cross Medical Center
  Mission Hills, California        
SSM Healthcare:
  Four states(g)        
SSM St. Clare Health System
  St. Louis, Missouri     1  
             
Totals
        132  
             
 
 
(a) Colorado, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri, North Carolina, Tennessee, Texas, West Virginia, and Wisconsin.
 
(b) Alabama, Arkansas, Arizona, Connecticut, District of Columbia, Georgia Florida, Idaho, Illinois, Indiana, Kansas, Louisiana, Maryland, Michigan, Missouri, New York, Tennessee, Texas, Washington, and Wisconsin.
 
(c) Florida, Kentucky, Maryland, New York, Pennsylvania, South Carolina, and Virginia
 
(d) Kentucky, Ohio, Pennsylvania and Tennessee
 
(e) Arkansas, Georgia, Louisiana, Oklahoma, Missouri, New Mexico, Texas, and Utah.
 
(f) Alaska, California, Montana, Oregon, and Washington.
 
(g) Illinois, Missouri, Oklahoma and Wisconsin.
 
Facilities
 
The following table sets forth information relating to the facilities that we operated as of December 31, 2010:
 
                             
    Date of
  Number
   
    Acquisition
  of
  Percentage
        or
  Operating
  Owned by
Facility
  Affiliation   Rooms   USPI
 
  United States
                       
  Atlanta
                       
    East West Surgery Center, Austell, Georgia     9/1/00 (2)     3       55 %
    Lawrenceville Surgery Center, Lawrenceville, Georgia     8/1/01       2       15  
    Northwest Georgia Surgery Center, Marietta, Georgia     11/1/00 (2)     3       15  
    Orthopaedic South Surgical Center, Morrow, Georgia     11/28/03       2       15  
    Resurgens Surgical Center, Atlanta, Georgia     10/1/98 (2)     4       48  
    Roswell Surgery Center, Roswell, Georgia     10/1/00 (2)     3       15  
  Austin
                       
*
  Cedar Park Surgery Center, Cedar Park, Texas     11/22/05       2       26  
*
  Medical Park Tower Surgery Center, Austin, Texas     8/27/10       5       33  
*
  Northwest Surgery Center, Austin, Texas(1)     5/30/07       6       29  
    Texan Surgery Center, Austin, Texas     6/1/03       3       55  
  Chicago
                       
*
  Hinsdale Surgical Center, Hinsdale, Illinois     5/1/06       4       21  
*
  Same Day Surgery 25 East, Chicago, Illinois     10/15/04       4       45  
*
  Same Day Surgery Elmwood Park, Elmwood Park, Illinois     10/15/04       3       33  
*
  Same Day Surgery North Shore, Evanston, Illinois     10/15/04       2       36  
*
  Same Day Surgery River North, Chicago, Illinois     10/15/04       4       34  

12


Table of Contents

                             
    Date of
  Number
   
    Acquisition
  of
  Percentage
        or
  Operating
  Owned by
Facility
  Affiliation   Rooms   USPI
 
  Corpus Christi
                       
*
  Corpus Christi Outpatient Surgery Center, Corpus Christi, Texas(1)     5/1/02       5       29  
*
  Shoreline Surgery Center, Corpus Christi, Texas     7/1/06       4       26  
  Dallas/Fort Worth
                       
*
  Baylor Medical Center at Frisco, Frisco, Texas(3)     9/30/02       11       25  
*
  Baylor Medical Center at Uptown, Dallas, Texas(3)     4/1/03       5       17  
*
  Baylor Orthopedic and Spine Hospital at Arlington, Arlington, Texas(3)     2/22/10       6       25  
*
  Baylor Surgicare at Bedford, Bedford, Texas(1)     12/18/98       5       32  
*
  Baylor Surgicare at Carrollton, Carrollton, Texas     7/1/10       2       26  
*
  Baylor Surgicare, Dallas, Texas(1)     6/1/99       6       34  
*
  Baylor Surgicare at Denton, Denton, Texas(1)     2/1/99       4       25  
*
  Baylor Surgicare at Garland, Garland, Texas     2/1/99       4       30  
*
  Baylor Surgicare at Granbury, Granbury, Texas     2/1/09       4       26  
*
  Baylor Surgicare at Grapevine, Grapevine, Texas     2/16/02       4       29  
*
  Baylor Surgicare at Lewisville, Lewisville, Texas(1)     9/16/02       6       37  
*
  Baylor Surgicare at Mansfield, Mansfield, Texas     5/1/10       5       26  
*
  Baylor Surgicare at North Garland, Garland, Texas     5/1/05       6       26  
*
  Baylor Surgicare at Plano, Plano, Texas     10/1/07       1       27  
*
  Baylor Surgicare at Trophy Club, Trophy Club, Texas(3)     5/3/04       6       34  
*
  Bellaire Surgery Center, Fort Worth, Texas     10/15/02       4       25  
*
  Doctor’s Surgery Center at Huguley, Burleson, Texas     2/14/06       3       26  
*
  Heath Surgicare, Rockwall, Texas(1)     11/1/04       3       25  
*
  Irving-Coppell Surgical Hospital, Irving, Texas(3)     10/20/03       5       9  
*
  Lone Star Endoscopy, Keller, Texas     11/1/10       1       26  
*
  Medical Centre Surgical Hospital, Fort Worth, Texas(3)     12/18/98       8       35  
*
  North Central Surgical Center, Dallas, Texas(3)     12/12/05       10       18  
*
  North Texas Surgery Center, Dallas, Texas(1)     12/18/98       4       36  
    Park Cities Surgery Center, Dallas, Texas(1)     6/9/03       4       55  
*
  Physicians Surgical Center of Fort Worth, Fort Worth, Texas     7/13/04       4       25  
*
  Rockwall Surgery Center, Rockwall, Texas     09/1/06       3       37  
    Southwestern Surgery Center, Ennis, Texas(4)     11/1/10 (6)     3        
*
  Surgery Center of Arlington, Arlington, Texas(1)     2/1/99       6       26  
*
  Tuscan Surgery Center at Las Colinas, Irving, Texas     12/1/10       1       26  
*
  Valley View Surgery Center, Dallas, Texas     12/18/98       4       31  
  Denver
                       
*
  Crown Point Surgical Center, Parker, Colorado     10/1/08       4       43  
*
  Harvard Park Surgery Center, Denver Colorado     1/1/09       3       30  
*
  Summit View Surgery Center, Littleton, Colorado     1/1/09       3       33  
  Houston
                       
*
  Doctors Outpatient Surgicenter, Pasadena, Texas(1)     9/1/99       5       43  
*
  Kingsland Surgery Center, Katy, Texas     12/31/08       4       28  
*
  KSF Orthopaedic Surgery Center, Houston, Texas(1)     5/1/07       3       45  
*
  Memorial Hermann Specialty Hospital Kingwood, Kingwood, Texas(3)     9/1/07       6       25  
*
  Memorial Hermann Surgery Center — Katy, Katy, Texas(1)     1/19/07       4       10  
*
  Memorial Hermann Surgery Center — Memorial Village, Houston, Texas     12/1/2010       4       11  
*
  Memorial Hermann Surgery Center — Northwest, Houston, Texas(1)     9/1/04       5       10  
*
  Memorial Hermann Surgery Center — Richmond, Richmond, Texas     12/31/09       2       26  
*
  Memorial Hermann Surgery Center — Southwest, Houston, Texas(1)     9/21/06       6       10  
*
  Memorial Hermann Surgery Center — Sugar Land, Sugar Land, Texas(1)     9/21/06       4       11  
*
  Memorial Hermann Surgery Center — Texas Medical Center, Houston, Texas(1)     1/17/07       5       17  
*
  Memorial Hermann Surgery Center — The Woodlands, The Woodlands, Texas     8/9/05       4       10  
*
  Memorial Hermann Surgery Center — West Houston , Houston, Texas     4/19/06 (5)     5       25  
*
  Memorial Hermann Surgery Center — Woodlands Parkway, Houston Texas     12/31/10       4       28  
*
  North Houston Endoscopy and Surgery, Houston, Texas     10/1/08       2       26  

13


Table of Contents

                             
    Date of
  Number
   
    Acquisition
  of
  Percentage
        or
  Operating
  Owned by
Facility
  Affiliation   Rooms   USPI
 
*
  North Houston GI, Houston, Texas     10/1/08       1       28  
*
  Sugar Land Surgical Hospital, Sugar Land, Texas(3)     12/28/02       4       13  
*
  TOPS Surgical Specialty Hospital, Houston, Texas(3)     7/1/99       7       45  
*
  United Surgery Center — Southeast, Houston, Texas(1)     9/1/99       3       30  
  Kansas City
                       
*
  Briarcliff Surgery Center, Kansas City, Missouri     6/1/05       2       29  
*
  Creekwood Surgery Center, Kansas City, Missouri(1)     7/29/98       4       38  
*
  Liberty Surgery Center, Liberty, Missouri     6/1/05       2       30  
*
  Saint Mary’s Surgical Center, Blue Springs, Missouri     5/1/05       4       27  
*
  Midwest Physicians Surgery Center, Lee’s Summit Missouri     11/1/10 (6)     3       26  
  Knoxville
                       
    Parkwest Surgery Center, Knoxville, Tennessee     7/26/01       5       22  
    Physician’s Surgery Center of Knoxville, Knoxville, Tennessee     1/1/08       6       26  
  Las Vegas
                       
*
  Durango Outpatient Surgery Center, Las Vegas, Nevada     12/9/08       4       33  
*
  Parkway Surgery Center, Henderson, Nevada     8/3/98       5       29  
  Los Angeles
                       
    Coast Surgery Center of South Bay, Torrance, California(1)     12/18/01       3       24  
    Pacific Endo-Surgical Center, Torrance, California     8/1/03       1       55  
*
  San Fernando Valley Surgery Center, Mission Hills, California     11/1/04       4       26  
    San Gabriel Valley Surgical Center, West Covina, California     11/16/01       3       48  
*
  Santa Clarita Ambulatory Surgery Center, Santa Clarita, California(1)     3/7/06       3       26  
    The Center for Ambulatory Surgical Treatment, Los Angeles, California(1)     11/14/02       4       38  
  Michigan
                       
*
  Clarkston Surgery Center, Clarkston, Michigan     6/1/09       4       36  
*
  Genesis Surgery Center, Lansing, Michigan     11/1/06       4       23  
*
  Lansing Surgery Center, Lansing, Michigan     11/1/06       4       23  
*
  McLaren ASC of Flint, Flint, Michigan     8/2/07       4       43  
*
  Utica Surgery and Endoscopy Center, Utica, Michigan     4/1/07       3       33  
  Nashville
                       
*
  Baptist Ambulatory Surgery Center, Nashville, Tennessee     3/1/98 (2)     6       29  
*
  Baptist Plaza Surgicare, Nashville, Tennessee     12/3/03       9       27  
*
  Center for Spinal Surgery, Nashville, Tennessee(3)     12/31/08       6       20  
*
  Eye Surgery Center of Nashville, Nashville, Tennessee     11/1/10 (6)     1       26  
*
  Franklin Endoscopy Center, Franklin, Tennessee     11/1/10 (6)     2       26  
*
  Lebanon Endoscopy Center, Lebanon, Tennessee     11/1/10 (6)     2       26  
*
  Middle Tennessee Ambulatory Surgery Center, Murfreesboro, Tennessee     7/29/98       4       35  
*
  Northridge Surgery Center, Nashville, Tennessee     4/19/06 (5)     5       31  
*
  Patient Partners Surgery Center, Gallatin, Tennessee     11/1/10 (6)     2       13  
*
  Physicians Pavilion Surgery Center, Smyrna, Tennessee     7/29/98       4       49  
*
  Saint Thomas Surgicare, Nashville, Tennessee     7/15/02       5       30  
*
  Tennessee Sports Medicine Surgery Center, Mt. Juliet, Tennessee     11/1/10 (6)     4       13  
*
  Williamson Surgery Center, Franklin, Tennessee     11/1/10 (6)     3       20  
  New Jersey
                       
*
  Central Jersey Surgery Center, Eatontown, New Jersey     11/1/04       3       35  
*
  Northern Monmouth Regional Surgery Center, Manalapan, New Jersey     7/10/06       4       39  
*
  Select Surgical Center at Kennedy, Sewell, New Jersey     10/29/09       3       29  
*
  Shore Outpatient Surgicenter, Lakewood, New Jersey     11/1/04       3       42  
*
  Shrewsbury Surgery Center, Shrewsbury, New Jersey     4/1/99       4       14  
    Suburban Endoscopy Services, Verona, New Jersey     4/19/06 (5)     2       51  
*
  Toms River Surgery Center, Toms River, New Jersey     3/15/02       4       20  
  Oklahoma City
                       
*
  Oklahoma Center for Orthopedic MultiSpecialty Surgery, Oklahoma City, Oklahoma(3)     8/2/04       4       24  

14


Table of Contents

                             
    Date of
  Number
   
    Acquisition
  of
  Percentage
        or
  Operating
  Owned by
Facility
  Affiliation   Rooms   USPI
 
*
  Southwest Orthopaedic Ambulatory Surgery Center, Oklahoma City, Oklahoma     8/2/04       2       24  
  Phoenix
                       
*
  Arizona Orthopedic Surgical Hospital, Chandler, Arizona(3)     5/19/04       6       36  
*
  Desert Ridge Outpatient Surgery Center, Phoenix, Arizona     3/30/07       4       33  
*
  Metro Surgery Center, Phoenix, Arizona     4/19/06 (5)     4       83  
    Physicians Surgery Center of Tempe, Tempe, Arizona     4/19/06 (5)     2       10  
*
  St. Joseph’s Outpatient Surgery Center, Phoenix, Arizona(1)     9/2/03       8       29  
*
  Surgery Center of Peoria, Peoria, Arizona     4/19/06 (5)     3       30  
*
  Surgery Center of Scottsdale, Scottsdale, Arizona     4/19/06 (5)     4       29  
    Surgery Center of Gilbert, Gilbert, Arizona     4/19/06 (5)     3       22  
*
  Warner Outpatient Surgery Center, Chandler, Arizona     7/1/99       4       36  
  Portland
                       
*
  East Portland Surgical Center, Portland, Oregon     12/31/09       4       29  
*
  Northwest Surgery Center, Portland, Oregon     12/1/08       3       26  
  Redding
                       
*
  Court Street Surgery Center, Redding, California     4/19/06 (5)     2       32  
*
  Mercy Surgery Center, Redding, California     3/1/08       4       32  
*
  Redding Surgery Center, Redding, California     4/19/06 (5)     2       32  
  Sacramento
                       
*
  Folsom Outpatient Surgery Center, Folsom, California     6/1/05       2       31  
*
  Grass Valley Surgery Center, Grass Valley, California     7/1/10       2       23  
*
  Roseville Surgery Center, Roseville, California     7/1/06       2       29  
  San Antonio
                       
*
  Alamo Heights Surgery Center, San Antonio, Texas(1)     12/1/04       3       59  
    San Antonio Endoscopy Center, San Antonio, Texas     5/1/05       1       54  
  St. Louis
                       
    Advanced Surgical Care, Creve Coeur, Missouri(1)     1/1/06       2       60  
    Chesterfield Surgery Center, Chesterfield, Missouri(1)     1/1/06       2       65  
    Frontenac Surgery and Spine Care Center, Frontenac, Missouri(1)     5/1/07       2       40  
    Gateway Endoscopy Center, St. Louis, Missouri     5/1/10       2       50  
    Manchester Surgery Center, St. Louis, Missouri     2/1/07       3       62  
    Mason Ridge Surgery Center, St. Louis, Missouri(1)     2/1/07       2       56  
    Mid Rivers Surgery Center, Saint Peters, Missouri     1/1/06       2       64  
    Old Tesson Surgery Center, St. Louis, Missouri     8/1/08       3       61  
    Olive Surgery Center, St. Louis, Missouri     1/1/06       2       62  
    Riverside Ambulatory Surgery Center, Florissant, Missouri     8/1/06       2       76  
    South County Outpatient Endoscopy Services, St. Louis, Missouri     10/1/08       2       25  
*
  SSM St. Clare Surgical Center, Fenton, Missouri     10/23/09       3       20  
*
  St. Louis Surgical Center, Creve Coeur, Missouri(1)     4/1/10       7       20  
    Sunset Hills Surgery Center, St. Louis, Missouri     1/1/06       2       66  
    The Ambulatory Surgical Center of St. Louis, Bridgeton, Missouri     8/1/06       2       66  
    Twin Cities Ambulatory Surgery Center, St. Louis, Missouri     9/1/08       2       61  
    Webster Surgery Center, Webster Groves, Missouri(1)     3/1/07       2       28  
  Virginia
                       
*
  Bon Secours Surgery Center at Harbour View, Suffolk, Virginia     11/12/07       6       21  
*
  Bon Secours Surgery Center at Virginia Beach, Virginia Beach, Virginia     5/30/07       2       22  
*
  Mary Immaculate Ambulatory Surgical Center, Newport News, Virginia     7/19/04       3       17  
*
  Memorial Ambulatory Surgery Center, Mechanicsville, Virginia     12/30/05       5       17  
*
  St. Mary’s Ambulatory Surgery Center, Richmond, Virginia     11/29/06       4       14  
    Surgi-Center of Central Virginia, Fredericksburg, Virginia     11/29/01       4       76  
  Additional Markets
                       
*
  Beaumont Surgical Affiliates, Beaumont, Texas(1)     4/19/06 (5)     6       25  
    Chico Surgery Center, Chico, California     4/19/06 (5)     3       80  
*
  CHRISTUS Cabrini Surgery Center, Alexandria, Louisiana     6/22/07       4       23  

15


Table of Contents

                             
    Date of
  Number
   
    Acquisition
  of
  Percentage
        or
  Operating
  Owned by
Facility
  Affiliation   Rooms   USPI
 
    Day-Op Center of Long Island, Mineola, New York(4)     12/4/98       4       99  
    Destin Surgery Center, Destin, Florida     9/25/02       2       61  
*
  Flatirons Surgery Center, Boulder, Colorado     12/1/10       3       32  
    Great Plains Surgery Center, Lawton, Oklahoma     4/19/06 (5)     2       49  
    Hope Square Surgical Center, Rancho Mirage, California     11/1/10 (6)     2       37  
    Idaho Surgery Center, Caldwell, Idaho     4/19/06 (5)     3       22  
*
  Memorial Surgery Center, Tulsa, Oklahoma     10/1/09       4       25  
*
  Mountain Empire Surgery Center, Johnson City, Tennessee     2/20/00 (2)     4       18  
    New Horizons Surgery Center, Marion, Ohio     4/19/06 (5)     2       11  
    New Mexico Orthopaedic Surgery Center, Albuquerque, New Mexico     2/29/00 (2)     6       51  
    Northeast Ohio Surgery Center, Cleveland, Ohio     4/19/06 (5)     3       49  
    Physicians Surgery Center of Chattanooga, Chattanooga, Tennessee     11/1/10 (6)     4       51  
    Reading Endoscopy Center, Wyomissing, Pennsylvania     11/1/10 (6)     2       51  
    Reading Surgery Center, Wyomissing, Pennsylvania     7/1/04       3       57  
    Redmond Surgery Center, Redmond, Oregon     4/19/06 (5)     2       69  
*
  Scripps Encinitas Surgery Center, Encinitas, California     2/6/08       3       20  
*
  St. Joseph’s Surgery Center, Stockton, California     2/1/09       6       5  
*
  Surgery Center of Canfield, Canfield, Ohio(1)     4/19/06 (5)     3       26  
    Surgery Center of Columbia, Columbia, Missouri(1)     8/1/06       2       59  
    Surgery Center of Fort Lauderdale, Fort Lauderdale, Florida     11/1/04       4       51  
    SurgiCenter of Baltimore, Owings Mills, Maryland     11/1/10 (6)     5       33  
*
  Terre Haute Surgical Center, Terre Haute, Indiana     12/19/07       2       23  
    Teton Outpatient Services, Jackson, Wyoming(1)     8/1/98 (2)     2       49  
*
  The Christ Hospital Spine Surgery Center(1)     12/31/09       3       26  
    Tri-City Orthopaedic Center, Richland, Washington(4)     4/19/06 (5)     2       17  
*
  Tullahoma Surgery Center, Tullahoma, Tennessee     12/31/10       2       26  
*
  Upper Cumberland Physician Surgery Center, Cookeville, Tennessee     11/1/10 (6)     2       10  
    University Surgical Center, Winter Park, Florida     10/15/98       3       38  
    Victoria Ambulatory Surgery Center, Victoria, Texas     4/19/06 (5)     2       59  
  United Kingdom
                       
    Parkside Hospital, Wimbledon     4/6/00       4       100  
    Cancer Centre London, Wimbledon     8/1/03             76  
    Holly House Hospital, Essex     4/6/00       3       100  
    Highgate Private Clinic, Highgate     4/29/03       3       100  
 
 
Facilities jointly owned with not-for-profit hospital systems.
 
(1) Certain of our surgery centers are licensed and equipped to accommodate 23-hour stays.
 
(2) Indicates date of acquisition by OrthoLink Physician Corporation. We acquired OrthoLink in February 2001.
 
(3) Surgical hospitals, all of which are licensed and equipped for overnight stays.
 
(4) Operated through a consulting and administrative agreement.
 
(5) Indicates the date of our acquisition of Surgis.
 
(6) Indicates the date of our acquisition of HealthMark.
 
We lease the majority of the facilities where our various surgery centers and surgical hospitals conduct their operations. Our leases have initial terms ranging from one to twenty years and most of the leases contain options to extend the lease period, in some cases for up to ten additional years.
 
Our corporate headquarters is located in a suburb of Dallas, Texas. We currently lease approximately 83,000 square feet of space at 15305 Dallas Parkway, Addison, Texas. The lease expires in October 2020.
 
Our administrative office in the United Kingdom is located in London. We currently lease 2,300 square feet. The lease expires in October 2013.

16


Table of Contents

We also lease approximately 40,000 square feet of total additional space in Brentwood, Tennessee; Chicago, Illinois; Houston, Texas; St. Louis, Missouri; Denver, Colorado; and Pasadena, California for regional offices. These leases expire between November 2012 and March 2021.
 
Acquisitions and Development
 
The following table sets forth information relating to facilities that are currently under construction at December 31, 2010:
 
                         
            Expected
  Number of
    Hospital
      Opening
  Operating
Facility Location
 
Partner
 
Type
  Date   Rooms
 
Dallas, Texas
  Baylor   Hospital     Q1’11       6  
Murfreesboro, Tennessee
  St. Thomas   Surgery center     Q1’11       2  
Phoenix, Arizona
  CHW   Hospital     Q2’11       8  
Austin, Texas
  Seton   Surgery center     Q2’11       4  
Jersey City, New Jersey
  Liberty Health   Surgery center     Q2’11       3  
 
The hospital under construction in Dallas, Texas at December 31, 2010 is a replacement facility for an existing facility. The new facility opened in January 2011. We also have additional projects under development, all of which involve a hospital partner. It is possible that some of these projects, as well as other projects which are in various stages of negotiation with both current and prospective joint venture partners, will result in our operating additional facilities sometime in 2011. While our history suggests that many of these projects will culminate with the opening of a profitable surgical facility, we can provide no assurance that any of these projects will reach that stage or will be successful thereafter.
 
Marketing
 
Our sales and marketing efforts are directed primarily at physicians, who are principally responsible for referring patients to our facilities. We market our facilities to physicians by emphasizing (1) the high level of patient and physician satisfaction with our facilities, which is based on surveys we take concerning our facilities, (2) the quality and responsiveness of our services, (3) the practice efficiencies provided by our facilities, and (4) the benefits of our affiliation with our hospital partners, if applicable. We also directly negotiate, together in some instances with our hospital partners, agreements with third-party payors, which generally focus on the pricing, number of facilities in the market and affiliation with physician groups in a particular market. Maintaining access to physicians and patients through third-party payor contracting is essential for the economic viability of most of our facilities.
 
Competition
 
In all of our markets, our facilities compete with other providers, including major acute care hospitals and other surgery centers. Hospitals have various competitive advantages over us, including their established managed care contracts, community position, physician loyalty and geographical convenience for physicians’ inpatient and outpatient practices. However, we believe that, in comparison to hospitals with which we compete, our surgery centers and surgical hospitals compete favorably on the basis of cost, quality, efficiency and responsiveness to physician needs in a more comfortable environment for the patient.
 
We compete with other providers in each of our markets for patients, physicians and for contracts with insurers or managed care payors. Competition for managed care contracts with other providers is focused on the pricing, number of facilities in the market and affiliation with key physician groups in a particular market. We believe that our relationships with our hospital partners enhance our ability to compete for managed care contracts. We also encounter competition with other companies for acquisition and development of facilities and in the United States for strategic relationships with not-for-profit healthcare systems and physicians.
 
There are several companies, both public and private, that acquire and develop freestanding multi-specialty surgery centers and surgical hospitals. Some of these competitors have greater resources than we do. The principal


17


Table of Contents

competitive factors that affect our ability and the ability of our competitors to acquire surgery centers and surgical hospitals are price, experience, reputation and access to capital. Further, in the United States many physician groups develop surgery centers without a corporate partner, and this presents a competitive threat to the Company.
 
In the United Kingdom, we face competition from both the National Health Service and other privately operated hospitals. Across the United Kingdom, a large number of private hospitals are owned by the four largest hospital operators. In addition, the two largest payors account for over half of the privately insured market. We believe our hospitals can effectively compete in this market due to location and specialty mix of our facilities. Our hospitals also have a higher portion of self pay business than the overall market. Although self pay business is not influenced by the private insurers, it is more dramatically affected by a downturn in the economy.
 
Employees
 
As of December 31, 2010, we employed approximately 7,100 people, 6,100 of whom are full-time employees and 1,000 of whom are part-time employees. Of these employees, we employ approximately 6,000 in the United States and 1,100 in the United Kingdom. The physicians that affiliate with us and use our facilities are not our employees. However, we generally offer the physicians the opportunity to purchase equity interests in the facilities they use.
 
Professional and General Liability Insurance
 
In the United States, we maintain professional and general liability insurance through a wholly-owned captive insurance company. We make premium payments to the captive insurance company and accrue for claims costs based on actuarially predicted ultimate losses and the captive insurance company then pays administrative fees and the insurance claims. We also maintain business interruption, property damage and umbrella insurance with third party providers. The governing documents of each of our surgical facilities require physicians who conduct surgical procedures at those facilities to maintain stated amounts of insurance. In the United Kingdom, we maintain general public insurance, malpractice insurance and property and business interruption insurance. Our insurance policies are generally subject to annual renewals. We believe that we will be able to renew current policies or otherwise obtain comparable insurance coverage at reasonable rates. However, we have no control over the insurance markets and can provide no assurance that we will economically be able to maintain insurance similar to our current policies.
 
Government Regulation
 
United States
 
General
 
The healthcare industry is subject to extensive regulation by federal, state and local governments. Government regulation affects our business by controlling growth, requiring licensing or certification of facilities, regulating how facilities are used and controlling payment for services provided. Further, the regulatory environment in which we operate may change significantly in the future. While we believe we have structured our agreements and operations in material compliance with applicable law, there can be no assurance that we will be able to successfully address changes in the regulatory environment.
 
Every state imposes licensing and other requirements on healthcare facilities. In addition, many states require regulatory approval, including certificates of need, before establishing or expanding various types of healthcare facilities, including ambulatory surgery centers and surgical hospitals, offering services or making capital expenditures in excess of statutory thresholds for healthcare equipment, facilities or programs. In addition, the federal Medicare program imposes additional conditions for coverage and payment rules for services furnished to Medicare beneficiaries. We may become subject to additional regulations as we expand our existing operations and enter new markets.
 
In addition to extensive existing government healthcare regulation, there have been numerous initiatives on the federal and state levels for comprehensive reforms affecting the payment for and availability of healthcare services. We believe that these healthcare reform initiatives will continue during the foreseeable future. If adopted, some aspects of proposed reforms, such as further reductions in Medicare or Medicaid payments, or additional


18


Table of Contents

prohibitions on physicians’ financial relationships with facilities to which they refer patients, could adversely affect us.
 
We believe that our business operations materially comply with applicable law. However, we have not received a legal opinion from counsel or from any federal or state judicial or regulatory authority to this effect, and many aspects of our business operations have not been the subject of state or federal regulatory scrutiny or interpretation. Some of the laws applicable to us are subject to limited or evolving interpretations; therefore, a review of our operations by a court or law enforcement or regulatory authority might result in a determination that could have a material adverse effect on us. Furthermore, the laws applicable to us may be amended or interpreted in a manner that could have a material adverse effect on us. Our ability to conduct our business and to operate profitably will depend in part upon obtaining and maintaining all necessary licenses, certificates of need and other approvals, and complying with applicable healthcare laws and regulations.
 
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (the “Acts”) were signed into law on March 23, 2010 and March 30, 2010, respectively, although a majority of the measures contained in the Acts do not take effect until 2014. The Acts are intended to provide coverage and access to substantially all Americans, to increase the quality of care provided and to reduce the rate of growth in healthcare expenditures. The changes include, among other things, reducing payments to Medicare Advantage plans (which require the federal government to contract with private health insurance payors to provide inpatient and outpatient benefits to beneficiaries who enroll in such plans), expanding Medicare’s use of value-based purchasing programs, tying facility payments to the satisfaction of certain quality criteria, bundling payments to hospitals and other providers, reducing Medicare and Medicaid payments, including disproportionate share payments, expanding Medicare and Medicaid eligibility, requiring many health plans (including Medicare) to cover, without cost-sharing, certain preventative services, and expanding access to health insurance. The Acts also place limitations on the Stark Law exception that allows physicians to have ownership interests in hospitals, referred to as the whole hospital exception. Among other things, the Acts prohibit hospitals from increasing the percentages of the total value of the ownership interests held in the hospital by physicians after March 23, 2010, as well as place restrictions on the ability of a hospital subject to the whole hospital exception to add operating rooms, procedure rooms and beds.
 
The Acts make several significant changes to health care fraud and abuse laws, provide additional enforcement tools to the government, increase cooperation between agencies by establishing mechanisms for the sharing of information and enhance criminal and administrative penalties for non-compliance. For example, the Acts: (i) provide $350 million in increased federal funding over the next 10 years to fight health care fraud, waste and abuse; (ii) expand the scope of the recovery audit contractor program to include Medicaid and Medicare Advantage plans; (iii) authorize the Department of Health and Human Services, in consultation with the Office of Inspector General, to suspend Medicare and Medicaid payments to a provider of services or a supplier “pending an investigation of a credible allegation of fraud;” (iv) provide Medicare contractors with additional flexibility to conduct random prepayment reviews; and (iv) strengthen the rules for returning overpayments made by governmental health programs, including expanding False Claims Act liability to extend to failures to timely repay identified overpayments.
 
As a result of the Acts, we also expect enhanced scrutiny of healthcare providers’ compliance with state and federal regulations, infection control standards and other quality control measures. Effective January 15, 2009, CMS promulgated three national coverage determinations that prevent Medicare from paying for certain serious, preventable medical errors performed in any healthcare facility, such as surgery performed on the wrong patient. Several commercial payors also do not reimburse providers for certain preventable adverse events. In addition, federal law authorizes CMS to require ambulatory surgery centers to submit data on certain quality measures. Ambulatory surgery centers that fail to submit the required data would face a two percentage point reduction in their annual reimbursement rate increase. CMS has not yet implemented the quality measure reporting requirement, but has announced that it expects to do so in future rulemaking. In addition, the Acts require the Department of Health and Human Services to present a plan to Congress in early 2011 for implementing a value-based purchasing system that would tie Medicare payments to ambulatory surgery centers to quality and efficiency measures. The Acts also require the Department of Health and Human Services to study whether to expand to ambulatory surgery centers its


19


Table of Contents

current policy of not paying additional amounts for care provided to treat conditions acquired during an inpatient hospital stay.
 
The Acts also require the Department of Health and Human Services to establish a Medicare Shared Savings Program to promote the coordination of care through Accountable Care Organizations (“ACOs”) by no later than January 1, 2012. The program will allow providers (including hospitals), physicians and other designated professionals and suppliers to form ACOs and work together to invest in infrastructure and redesign delivery processes with the goal of increasing the quality and efficient delivery of services. The program is intended to produce savings as a result of improved quality and operational efficiency. ACOs that achieve quality performance standards established by the Department of Health and Human Services will be eligible to share in a portion of the amounts saved by the Medicare program.
 
Licensure and certificate-of-need regulations
 
Capital expenditures for the construction of new facilities, the addition of capacity or the acquisition of existing facilities may be reviewable by state regulators under statutory schemes that are sometimes referred to as certificate of need laws. States with certificate of need laws place limits on the construction and acquisition of healthcare facilities and the expansion of existing facilities and services. In these states, approvals are required for capital expenditures exceeding certain specified amounts and that involve certain facilities or services, including ambulatory surgery centers and surgical hospitals.
 
State certificate of need laws generally provide that, prior to the addition of new beds, the construction of new facilities or the introduction of new services, a designated state health planning agency must determine that a need exists for those beds, facilities or services. The certificate of need process is intended to promote comprehensive healthcare planning, assist in providing high quality healthcare at the lowest possible cost and avoid unnecessary duplication by ensuring that only those healthcare facilities that are needed will be built.
 
Typically, the provider of services submits an application to the appropriate agency with information concerning the area and population to be served, the anticipated demand for the facility or service to be provided, the amount of capital expenditure, the estimated annual operating costs, the relationship of the proposed facility or service to the overall state health plan and the cost per patient day for the type of care contemplated. The issuance of a certificate of need is based upon a finding of need by the agency in accordance with criteria set forth in certificate of need laws and state and regional health facilities plans. If the proposed facility or service is found to be necessary and the applicant to be the appropriate provider, the agency will issue a certificate of need containing a maximum amount of expenditure and a specific time period for the holder of the certificate of need to implement the approved project.
 
Our healthcare facilities are also subject to state and local licensing regulations ranging from the adequacy of medical care to compliance with building codes and environmental protection laws. To assure continued compliance with these regulations, governmental and other authorities periodically inspect our facilities. The failure to comply with these regulations could result in the suspension or revocation of a healthcare facility’s license.
 
Our U.S. healthcare facilities receive accreditation from the Joint Commission on Accreditation of Healthcare Organizations or the Accreditation Association for Ambulatory Health Care, Inc., nationwide commissions which establish standards relating to the physical plant, administration, quality of patient care and operation of medical staffs of various types of healthcare facilities. Generally, our healthcare facilities must be in operation for at least six months before they are eligible for accreditation. As of December 31, 2010, all of our eligible healthcare facilities had been accredited by either the Joint Commission on Accreditation of Healthcare Organizations or the Accreditation Association for Ambulatory Health Care, Inc. or are in the process of applying for such accreditation. Many managed care companies and third-party payors require our facilities to be accredited in order to be considered a participating provider under their health plans.
 
Medicare and Medicaid Participation in Short Stay Surgical Facilities
 
Medicare is a federally funded and administered health insurance program, primarily for individuals entitled to social security benefits who are 65 or older or who are disabled. Medicaid is a health insurance program jointly


20


Table of Contents

funded by state and federal governments that provides medical assistance to qualifying low income persons. Each state Medicaid program has the option to determine coverage for ambulatory surgery center services and to determine payment rates for those services. All of the states in which we currently operate cover Medicaid short stay surgical facility services; however, these states may not continue to cover short stay surgical facility services and states into which we expand our operations may not cover or continue to cover short stay surgical facility services.
 
Medicare prospectively determines fixed payment amounts for procedures performed at short stay surgical facilities. These amounts are adjusted for regional wage variations. The various state Medicaid programs also pay us a fixed payment for our services, which amount varies from state to state. A portion of our revenues are attributable to payments received from the Medicare and Medicaid programs. For the years ended December 31, 2010, 2009 and 2008, 31%, 28%, and 26%, respectively, of our domestic case volumes were attributable to Medicare and Medicaid payments, although the percentage of our overall revenues these cases represent is significantly less because government payors typically pay less than private insurers. For example, approximately 16% and 2% of our 2010 domestic patient service revenues were contributed by Medicare and Medicaid, respectively, despite those cases representing a total of 31% of our domestic case volume during 2010.
 
In order to participate in the Medicare program, our facilities must satisfy regulations known as conditions of participation (COPs) for hospitals and conditions for coverage (CFCs) for ambulatory surgery centers. Each facility can meet this requirement through accreditation with the Joint Commission on Accreditation of Healthcare Organizations or other CMS-approved accreditation organizations, or through direct surveys at the direction of CMS. All of our short stay surgical facilities in the United States are certified or, with respect to newly acquired or developed facilities, are awaiting certification to participate in the Medicare program. We have established ongoing quality assurance activities to monitor and ensure our facilities’ compliance with these COPs or CFCs. Any failure by a facility to maintain compliance with these COPs or CFCs as determined by a survey could result in the loss of the facility’s provider agreement with CMS, which would prohibit reimbursement for services rendered to Medicare or Medicaid beneficiaries until such time as the facility is found to be back in compliance with the COPs or CFCs. This could have a material adverse affect on the individual facility’s billing and collections.
 
As with most government programs, the Medicare and Medicaid programs are subject to statutory and regulatory changes, possible retroactive and prospective rate adjustments, administrative rulings, freezes and funding reductions, all of which may adversely affect the level of payments to our short stay surgical facilities. Beginning in 2008, CMS began transitioning Medicare payments to ambulatory surgery centers to a system based upon the hospital outpatient prospective payment system. In 2011, that transition is now complete and payments to ambulatory surgery centers will be solely based on the outpatient prospective payment system (OPPS) relative weights. CMS has cautioned that the final OPPS relative weights may result in payment rates for the year being less than the payment rates for the preceding year. On November 2, 2010, CMS issued a final rule to update the Medicare program’s payment policies and rates for ambulatory surgery centers for 2011. The final rule applies a 0.2% increase to the ASC payment rate. The final rule will also add six procedures to the list of procedures for which Medicare will reimburse when performed in an ASC. The Acts require the Department of Health and Human Services to issue a plan in early 2011 for developing a value-based purchasing program for ambulatory surgery centers. Such a program may further impact Medicare reimbursement of ambulatory surgery centers or increase our operating costs in order to satisfy the value-based standards. For federal fiscal year 2011 and each subsequent federal fiscal year, the Acts provide for the annual market basket update to be reduced by a productivity adjustment. The amount of that reduction will be the projected nationwide productivity gains over the preceding 10 years. To determine the projection, the Department of Health and Human Services will use the Bureau of Labor Statistics 10-year moving average of changes in specified economy-wide productivity. The ultimate impact of the changes in Medicare reimbursement will depend on a number of factors, including the procedure mix at the centers and our ability to realize an increased procedure volume.
 
Federal Anti-Kickback Law
 
State and federal laws regulate relationships among providers of healthcare services, including employment or service contracts and investment relationships. These restrictions include a federal criminal law, referred to herein


21


Table of Contents

as the anti-kickback statute, that prohibits offering, paying, soliciting or receiving any form of remuneration in return for:
 
  •  referring patients for services or items payable under a federal healthcare program, including Medicare or Medicaid, or
 
  •  purchasing, leasing or ordering, or arranging for or recommending purchasing, leasing or ordering, any good, facility, service or item for which payment may be made in whole or in part by a federal healthcare program.
 
A violation of the anti-kickback statute constitutes a felony. Potential sanctions include imprisonment of up to five years, criminal fines of up to $25,000, civil money penalties of up to $50,000 per act plus three times the remuneration offered or three times the amount claimed and exclusion from all federally funded healthcare programs. The applicability of these provisions to some forms of business transactions in the healthcare industry has not yet been subject to judicial or regulatory interpretation. Moreover, several federal courts have held that the anti-kickback statute can be violated if only one purpose (not necessarily the primary purpose) of the transaction is to induce or reward a referral of business, notwithstanding other legitimate purposes.
 
Pursuant to the anti-kickback statute, and in an effort to reduce potential fraud and abuse relating to federal healthcare programs, the federal government has announced a policy of a high level of scrutiny of joint ventures and other transactions among healthcare providers. The Office of the Inspector General of the Department of Health and Human Services closely scrutinizes healthcare joint ventures involving physicians and other referral sources. The Office of the Inspector General published a fraud alert that outlined questionable features of “suspect” joint ventures in 1989 and a Special Advisory Bulletin related to contractual joint ventures in 2003, and the Office of the Inspector General has continued to rely on fraud alerts in later pronouncements.
 
The anti-kickback statute contains provisions that insulate certain transactions from liability. In addition, pursuant to the provisions of the anti-kickback statute, the Health and Human Services Office of the Inspector General has also published regulations that exempt additional practices from enforcement under the anti-kickback statute. These statutory exceptions and regulations, known as “safe harbors,” if fully complied with, assure participants in particular types of arrangements that the Office of the Inspector General will not treat their participation in that arrangement as a violation of the anti-kickback statute. The statutory exceptions and safe harbor regulations do not expand the scope of activities that the anti-kickback statute prohibits, nor do they provide that failure to satisfy the terms of a safe harbor constitutes a violation of the anti-kickback statute. The Office of the Inspector General has, however, indicated that failure to satisfy the terms of an exception or a safe harbor may subject an arrangement to increased scrutiny. Therefore, if a transaction or relationship does not fit within an exception or safe harbor, the facts and circumstances as well as intent of the parties related to a specific transaction or relationship must be examined to determine whether or not any illegal conduct has occurred.
 
Our partnerships and limited liability companies that are providers of services under the Medicare and Medicaid programs, and their respective partners and members, are subject to the anti-kickback statute. A number of the relationships that we have established with physicians and other healthcare providers do not fit within any of the statutory exceptions or safe harbor regulations issued by the Office of the Inspector General. All of the 184 surgical facilities in the United States in which we hold an ownership interest are owned by partnerships or limited liability companies, which include as partners or members physicians who perform surgical or other procedures at the facilities.
 
On November 19, 1999, the Office of the Inspector General promulgated regulations setting forth certain safe harbors under the anti-kickback statute, including a safe harbor applicable to surgery centers. The surgery center safe harbor generally protects ownership or investment interests in a center by physicians who are in a position to refer patients directly to the center and perform procedures at the center on referred patients, if certain conditions are met. More specifically, the surgery center safe harbor protects any payment that is a return on an ownership or investment interest to an investor if certain standards are met in one of four categories of ambulatory surgery centers (1) surgeon-owned surgery centers, (2) single-specialty surgery centers, (3) multi-specialty surgery centers, and (4) hospital/physician surgery centers.


22


Table of Contents

For multi-specialty ambulatory surgery centers, for example, the following standards, among several others, apply:
 
(1) all of the investors must either be physicians who are in a position to refer patients directly to the center and perform procedures on the referred patients, group practices composed exclusively of those physicians, or investors who are not employed by the entity or by any of its investors, are not in a position to provide items or services to the entity or any of its investors, and are not in a position to make or influence referrals directly or indirectly to the entity or any of its investors;
 
(2) at least one-third of each physician investor’s medical practice income from all sources for the previous fiscal year or twelve-month period must be derived from performing outpatient procedures that require an ambulatory surgery center or specialty hospital setting in accordance with Medicare reimbursement rules; and
 
(3) at least one third of the Medicare-eligible outpatient surgery procedures performed by each physician investor for the previous fiscal year or previous twelve-month period must be performed at the ambulatory surgery center in which the investment is made.
 
Similar standards apply to each of the remaining three categories of ambulatory surgery centers set forth in the regulations. In particular, each of the four categories includes a requirement that no ownership interests be held by a non-physician or non-hospital investor if that investor is (a) employed by the center or another investor, (b) in a position to provide items or services to the center or any of its other investors, or (c) in a position to make or influence referrals directly or indirectly to the center or any of its investors.
 
Because one of our subsidiaries is an investor in each partnership or limited liability company that owns one of our ambulatory surgery centers, and since this subsidiary provides management and other services to the surgery center, our arrangements with physician investors do not fit within the specific terms of the ambulatory surgery center safe harbor or any other safe harbor.
 
In addition, because we do not control the medical practices of our physician investors or control where they perform surgical procedures, it is possible that the quantitative tests described above will not be met, or that other conditions of the surgery center safe harbor will not be met. Accordingly, while the surgery center safe harbor is helpful in establishing that a physician’s investment in a surgery center should be considered an extension of the physician’s practice and not as a prohibited financial relationship, we can give no assurances that these ownership interests will not be challenged under the anti-kickback statute. In an effort to monitor our compliance with the safe harbor’s extension of practice requirement, we have implemented an internal certification process, which tracks each physician’s annual extension of practice certification. While this process provides support for physician compliance with the safe harbor’s quantitative tests, we can give no assurance of such compliance. However, we believe that our arrangements involving physician ownership interests in our ambulatory surgery centers do not fall within the activities prohibited by the anti-kickback statute.
 
With regard to our hospitals, the Office of Inspector General has not adopted any safe harbor regulations under the anti-kickback statute for physician investments in hospitals. Each of our hospitals is held in partnership with physicians who are in a position to refer patients to the hospital. There can be no assurances that these relationships will not be found to violate the anti-kickback statute or that there will not be regulatory or legislative changes that prohibit physician ownership of hospitals.
 
While several federal court decisions have aggressively applied the restrictions of the anti-kickback statute, they provide little guidance regarding the application of the anti-kickback statute to our partnerships and limited liability companies. We believe that our operations do not violate the anti-kickback statute. However, a federal agency charged with enforcement of the anti-kickback statute might assert a contrary position. Further, new federal laws, or new interpretations of existing laws, might adversely affect relationships we have established with physicians or other healthcare providers or result in the imposition of penalties on us or some of our facilities. Even the assertion of a violation could have a material adverse effect upon us.


23


Table of Contents

Federal Physician Self-Referral Law
 
Section 1877 of the Social Security Act, commonly known as the “Stark Law,” prohibits any physician from referring patients to any entity for the furnishing of certain “designated health services” otherwise payable by Medicare or Medicaid, if the physician or an immediate family member has a financial relationship such as an ownership interest or compensation arrangement with the entity that furnishes services to Medicare beneficiaries, unless an exception applies. Persons who violate the Stark Law are subject to potential civil money penalties of up to $15,000 for each bill or claim submitted in violation of the Stark Law and up to $100,000 for each “circumvention scheme” they are found to have entered into, and potential exclusion from the Medicare and Medicaid programs. In addition, the Stark Law requires the denial (or, refund, as the case may be) of any Medicare and Medicaid payments received for designated health services that result from a prohibited referral.
 
The list of designated health services under the Stark Law does not include ambulatory surgery services as such. However, some of the ten types of designated health services are among the types of services furnished by our ambulatory surgery centers. The Department of Health and Human Services, acting through the Centers for Medicare and Medicaid Services, has promulgated regulations implementing the Stark Law. These regulations exclude health services provided by an ambulatory surgery center from the definition of “designated health services” if the services are included in the surgery center’s composite Medicare payment rate. Therefore, the Stark Law’s self-referral prohibition generally does not apply to health services provided by an ambulatory surgery center. However, if the ambulatory surgery center is separately billing Medicare for designated health services that are not covered under the ambulatory surgery center’s composite Medicare payment rate, or if either the ambulatory surgery center or an affiliated physician is performing (and billing Medicare) for procedures that involve designated health services that Medicare has not designated as an ambulatory surgery center service, the Stark Law’s self-referral prohibition would apply and such services could implicate the Stark Law. We believe that our operations do not violate the Stark Law, as currently interpreted. However, it is possible that the Centers for Medicare and Medicaid Services will further address the exception relating to services provided by an ambulatory surgery center in the future. Therefore, we cannot assure you that future regulatory changes will not result in our ambulatory surgery centers becoming subject to the Stark Law’s self-referral prohibition.
 
Thirteen of our U.S. facilities are hospitals rather than ambulatory surgery centers. The Stark Law includes an exception for physician investments in hospitals if the physician’s investment is in the entire hospital and not just a department of the hospital. We believe that the physician investments in our hospitals fall within the exception and are therefore permitted under the Stark Law. However, over the past few years there have been various legislative attempts to change the way the hospital exception applies to physician investments in hospitals and it is possible that there could be another legislative attempt to alter this exception in the future. See “Risk Factors — Future Legislation could restrict our ability to operate our domestic surgical hospitals.”
 
False and Other Improper Claims
 
The federal government is authorized to impose criminal, civil and administrative penalties on any person or entity that files a false claim for payment from the Medicare or Medicaid programs. Claims filed with private insurers can also lead to criminal and civil penalties, including, but not limited to, penalties relating to violations of federal mail and wire fraud statutes. While the criminal statutes are generally reserved for instances of fraudulent intent, the government is applying its criminal, civil and administrative penalty statutes in an ever-expanding range of circumstances. For example, the government has taken the position that a pattern of claiming reimbursement for unnecessary services violates these statutes if the claimant merely should have known the services were unnecessary, even if the government cannot demonstrate actual knowledge. The government has also taken the position that claiming payment for low-quality services is a violation of these statutes if the claimant should have known that the care was substandard.
 
Over the past several years, the government has accused an increasing number of healthcare providers of violating the federal False Claims Act. The False Claims Act prohibits a person from knowingly presenting, or causing to be presented, a false or fraudulent claim to the U.S. government. The statute defines “knowingly” to include not only actual knowledge of a claim’s falsity, but also reckless disregard for or intentional ignorance of the truth or falsity of a claim. Because our facilities perform hundreds of similar procedures a year for which they are


24


Table of Contents

paid by Medicare, and there is a relatively long statute of limitations, a billing error or cost reporting error could result in significant penalties. Additionally, anti-Kickback or Stark Law claims can be “bootstrapped” to claims under the False Claims Act on the theory that, when a provider submits a claim to a federal health care program, the claim includes an implicit certification that the provider is in compliance with the Medicare Act, which would require compliance with other laws, including the anti-kickback statute and the Stark Law. As a result of this “bootstrap” theory, the U.S. government can collect additional civil penalties under the False Claims Act for claims that have been “tainted” by the anti-kickback or Stark Law violation. In addition, under the Acts, civil penalties may be imposed for the failure to report and return an overpayment within 60 days of identifying the overpayment or by the date a corresponding cost report is due, whichever is later.
 
Under the “qui tam,” or whistleblower, provisions of the False Claims Act, private parties may bring actions on behalf of the federal government. Such private parties, often referred to as relators, are entitled to share in any amounts recovered by the government through trial or settlement. Both direct enforcement activity by the government and whistleblower lawsuits have increased significantly in recent years and have increased the risk that a healthcare company, like us, will have to defend a false claims action, pay fines or be excluded from the Medicare and Medicaid programs as a result of an investigation resulting from a whistleblower case. Although we believe that our operations materially comply with both federal and state laws, they may nevertheless be the subject of a whistleblower lawsuit, or may otherwise be challenged or scrutinized by governmental authorities. A determination that we have violated these laws could have a material adverse effect on us.
 
State Anti-Kickback and Physician Self-Referral Laws
 
Many states, including those in which we do or expect to do business, have laws that prohibit payment of kickbacks or other remuneration in return for the referral of patients. Some of these laws apply only to services reimbursable under state Medicaid programs. However, a number of these laws apply to all healthcare services in the state, regardless of the source of payment for the service. Based on court and administrative interpretations of the federal anti-kickback statute, we believe that the federal anti-kickback statute prohibits payments only if they are intended to induce referrals. However, the laws in most states regarding kickbacks have been subjected to more limited judicial and regulatory interpretation than federal law. Therefore, we can give you no assurances that our activities will be found to be in compliance with these laws. Noncompliance with these laws could subject us to penalties and sanctions and have a material adverse effect on us.
 
A number of states, including those in which we do or expect to do business, have enacted physician self-referral laws that are similar in purpose to the Stark Law but which impose different restrictions. Some states, for example, only prohibit referrals when the physician’s financial relationship with a healthcare provider is based upon an investment interest. Other state laws apply only to a limited number of designated health services. Some states do not prohibit referrals, but require that a patient be informed of the financial relationship before the referral is made. We believe that our operations are in material compliance with the physician self-referral laws of the states in which our facilities are located.
 
Health Information Security and Privacy Practices
 
The regulations promulgated under the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) contain, among other measures, provisions that require many organizations, including us, to employ systems and procedures designed to protect the privacy and security of each patient’s individual healthcare information. Among the standards that the Department of Health and Human Services has adopted pursuant to HIPAA are standards for the following:
 
  •  electronic transactions and code sets;
 
  •  unique identifiers for providers, employers, health plans and individuals;
 
  •  security and electronic signatures;
 
  •  privacy; and
 
  •  enforcement.


25


Table of Contents

 
In August 2000, the Department of Health and Human Services finalized the transaction standards, with which we are in material compliance. The transaction standards require us to use standard code sets established by the rule when transmitting health information in connection with some transactions, including health claims and health payment and remittance advices.
 
The Department of Health and Human Services has also published a rule establishing standards for the privacy of individually identifiable health information, with which we are in material compliance. These privacy standards apply to all health plans, all healthcare clearinghouses and many healthcare providers, including healthcare providers that transmit health information in an electronic form in connection with certain standard transactions. We are a covered entity under the final rule. The privacy standards protect individually identifiable health information held or disclosed by a covered entity in any form, whether communicated electronically, on paper or orally. These standards not only require our compliance with rules governing the use and disclosure of protected health information, but they also require us to impose those rules, by contract, on any business associate to whom such information is disclosed. A violation of the privacy standards could result in civil money penalties of $100 per incident, up to a maximum of $25,000 per person per year per standard. The final rule also provides for criminal penalties of up to $50,000 and one year in prison for knowingly and improperly obtaining or disclosing protected health information, up to $100,000 and five years in prison for obtaining protected health information under false pretenses, and up to $250,000 and ten years in prison for obtaining or disclosing protected health information with the intent to sell, transfer or use such information for commercial advantage, personal gain or malicious harm.
 
Finally, the Department of Health and Human Services has also issued a rule establishing, in part, standards for the security of health information by health plans, healthcare clearinghouses and healthcare providers that maintain or transmit any health information in electronic form, regardless of format. We are an affected entity under the rule. These security standards require affected entities to establish and maintain reasonable and appropriate administrative, technical and physical safeguards to ensure integrity, confidentiality and the availability of the information. The security standards were designed to protect the health information against reasonably anticipated threats or hazards to the security or integrity of the information and to protect the information against unauthorized use or disclosure. Although the security standards do not reference or advocate a specific technology, and affected entities have the flexibility to choose their own technical solutions, the security standards required us to implement significant systems and protocols. We also comply with these regulations.
 
Signed into law on February 17, 2009, the American Recovery and Reinvestment Act of 2009 (“ARRA”) broadened the scope of the HIPAA privacy and security regulations. Among other things, the ARRA extends the application of certain provisions of the security and privacy regulations to business associates (entities that handle identifiable health information on behalf of covered entities) and subjects business associates to civil and criminal penalties for violation of the regulations. Violations of the HIPAA privacy and security regulations may result in civil and criminal penalties, and the ARRA has strengthened the enforcement provisions of HIPAA, which may result in increased enforcement activity. The ARRA increased the amount of civil penalties, with penalties now ranging up to $50,000 per violation for a maximum civil penalty of $1,500,000 in a calendar year for violations of the same requirement. In addition, the ARRA authorized state attorneys general to bring civil actions seeking either injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents.
 
In addition to HIPAA, many states have enacted their own security and privacy provisions concerning a patient’s health information. These state privacy provisions will control whenever they provide more stringent privacy protections than HIPAA. Therefore, a health care facility could be required to meet both federal and state privacy provisions if it is located in a state with strict privacy protections.
 
EMTALA
 
All of our hospitals in the United States are subject to the Emergency Medical Treatment and Active Labor Act (“EMTALA”). This federal law requires any hospital participating in the Medicare program to conduct an appropriate medical screening examination of every individual who presents to the hospital’s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. The obligation


26


Table of Contents

to screen and stabilize emergency medical conditions exists regardless of an individual’s ability to pay for treatment. There are severe penalties under EMTALA if a hospital fails to screen or appropriately stabilize or transfer an individual or if the hospital delays appropriate treatment in order to first inquire about the individual’s ability to pay. Penalties for violations of EMTALA include civil monetary penalties and exclusion from participation in the Medicare program. In addition, an injured individual, the individual’s family or a medical facility that suffers a financial loss as a direct result of a hospital’s violation of the law can bring a civil suit against the hospital. We believe our hospitals are in material compliance with EMTALA.
 
European Union and United Kingdom
 
The European Commission’s Directive on Data Privacy has been implemented in national EU data protection laws (such as the Data Protection Act of 1998). EU data protection legislation prohibits the transfer of personal data to non-EEA countries that do not meet the European “adequacy” standard for privacy protection. The European Union privacy legislation requires, among other things, the creation of government data protection agencies, registration of processing with those agencies, and in some instances prior approval before personal data processing may begin.
 
The U.S. Department of Commerce, in consultation with the European Commission, developed a “safe harbor” framework to protect data transferred in trans-Atlantic businesses like ours. The safe harbor provides a way for us to avoid experiencing interruptions in our business dealings in the European Union. It also provides a way to avoid prosecution by European authorities under European privacy laws. By certifying to the safe harbor, we will notify the European Union organizations that we provide “adequate” privacy protection, as defined by European privacy laws, in relation to international data transfers to the USA. To certify to the safe harbor, we must adhere to seven principles. These principles relate to notice, choice, onward transfer or transfers to third parties, access, security, data integrity and enforcement.
 
We intend to satisfy the requirements of the safe harbor. Even if we are able to formulate programs that attempt to meet these objectives, we may not be able to execute them successfully, which could have a material adverse effect on our revenues, profits or results of operations.
 
While there is no specific anti-kickback legislation in the United Kingdom that is unique to the medical profession, general criminal legislation prohibits bribery and corruption. Our hospitals in the United Kingdom do not pay commissions to or share profits with referring physicians who invoice patients or insurers directly for fees relating to the provision of their services, although we have explored the possibility of syndicating ownership in certain facilities in the U.K. with physicians. Hospitals in the United Kingdom are required to register with the Healthcare Commission pursuant to the Care Standards Act 2000, as amended by the Health and Social Care (Community Health and Standards) Act 2003, which provides for regular inspections of the facility by representatives of the Healthcare Commission. Beginning April 1, 2009, these registration and inspection functions will transfer to the Care Quality Commission established under the Health and Social Care Act 2008. Hospitals are also required to comply with the Private and Voluntary Health Care (England) Regulations 2001. The operation of a hospital without registration is a criminal offense. Under the Misuse of Drugs Act 1971, the supply, possession or production of controlled drugs without a license from the Secretary of State is a criminal offense. The Data Protection Act 1998 requires hospitals to register as “data controllers.” The processing of personal data, such as patient information and medical records, without prior registration or maintaining an inaccurate registration is a criminal offense. We believe that our operations in the United Kingdom are in material compliance with the laws referred to in this paragraph.
 
Item 1A.   Risk Factors
 
You should carefully read the risks and uncertainties described below and the other information included in this report. Any of the following risks could materially and adversely affect our business, financial condition or results of operations. Additional risks and uncertainties not currently known to us or those we currently view to be immaterial may also materially and adversely affect our business, financial condition or results of operations.


27


Table of Contents

We depend on payments from third party payors, including government healthcare programs. If these payments are reduced, our revenue will decrease.
 
We are dependent upon private and governmental third party sources of payment for the services provided to patients in our surgery centers and surgical hospitals. The amount of payment a surgical facility receives for its services may be adversely affected by market and cost factors as well as other factors over which we have no control, including Medicare and Medicaid regulations and the cost containment and utilization decisions of third party payors. In the United Kingdom, a significant portion of our revenues result from referrals of patients to our hospitals by the national health system. We have no control over the number of patients that are referred to the private sector annually. Fixed fee schedules, capitation payment arrangements, exclusion from participation in or inability to reach agreement with managed care programs or other factors affecting payments for healthcare services over which we have no control could also cause a reduction in our revenues.
 
If we are unable to acquire and develop additional surgical facilities on favorable terms, are not successful in integrating operations of acquired surgical facilities, or are unable to manage growth, we may be unable to execute our acquisition and development strategy, which could limit our future growth.
 
Our strategy is to increase our revenues and earnings by continuing to acquire and develop additional surgical facilities, primarily in collaboration with our hospital partners. Our efforts to execute our acquisition and development strategy may be affected by our ability to identify suitable candidates and negotiate and close acquisition and development transactions. We are currently evaluating potential acquisitions and development projects and expect to continue to evaluate acquisitions and development projects in the foreseeable future. The surgical facilities we develop typically incur losses in their early months of operation (more so in the case of surgical hospitals) and, until their case loads grow, they generally experience lower total revenues and operating margins than established surgical facilities, and we expect this trend to continue. Historically, most of our newly developed facilities have generated positive cash flow within the first 12 months of operations. We may not be successful in acquiring surgical facilities, developing surgical facilities or achieving satisfactory operating results at acquired or newly developed facilities. Further, the companies or assets we acquire in the future may not ultimately produce returns that justify our related investment. If we are not able to execute our acquisition and development strategy, our ability to increase revenues and earnings through future growth would be impaired.
 
If we are not successful in integrating newly acquired surgical facilities, we may not realize the potential benefits of such acquisitions. Likewise, if we are not able to integrate acquired facilities’ operations and personnel with ours in a timely and efficient manner, then the potential benefits of the transaction may not be realized. Further, any delays or unexpected costs incurred in connection with integration could have a material adverse effect on our operations and earnings. In particular, if we experience the loss of key personnel or if the effort devoted to the integration of acquired facilities diverts significant management or other resources from other operational activities, our operations could be impaired.
 
We have acquired interests in or developed all of our surgical facilities since our inception. We expect to continue to expand our operations in the future. Our rapid growth has placed, and will continue to place, increased demands on our management, operational and financial information systems and other resources. Further expansion of our operations will require substantial financial resources and management attention. To accommodate our past and anticipated future growth, and to compete effectively, we will need to continue to improve our management, operational and financial information systems and to expand, train, manage and motivate our workforce. Our personnel, systems, procedures or controls may not be adequate to support our operations in the future. Further, focusing our financial resources and management attention on the expansion of our operations may negatively impact our financial results. Any failure to improve our management, operational and financial information systems, or to expand, train, manage or motivate our workforce, could reduce or prevent our growth.


28


Table of Contents

Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, expose us to interest rate risk to the extent of our variable rate debt and prevent us from meeting our debt obligations.
 
We have a substantial amount of indebtedness. As of December 31, 2010, we had $1.1 billion of total indebtedness and a total indebtedness to total capitalization percentage ratio of approximately 54%.
 
Our and our subsidiaries’ high degree of leverage could have important consequences to you. For example, it:
 
  •  requires us and certain of our subsidiaries to dedicate a substantial portion of cash flow from operations to payments on indebtedness, reducing the availability of cash flow to fund working capital, capital expenditures, development activity, acquisitions and other general corporate purposes;
 
  •  increases vulnerability to adverse general economic or industry conditions;
 
  •  limits flexibility in planning for, or reacting to, changes in our business or the industry in which we operate;
 
  •  makes us and our subsidiaries more vulnerable to increases in interest rates, as borrowings under our senior secured credit facilities are at variable rates;
 
  •  limits our and our subsidiaries’ ability to obtain additional financing in the future for working capital or other purposes, such as raising the funds necessary to repurchase our senior subordinated notes upon the occurrence of specified changes of control, or
 
  •  places us at a competitive disadvantage compared to our competitors that have less indebtedness.
 
Our significant indebtedness could limit our flexibility.
 
We are significantly leveraged and will continue to have significant indebtedness in the future. Our acquisition and development program requires substantial capital resources, estimated to range from $60.0 million to $100.0 million per year over the next three years, although the range could be exceeded if we identify attractive multi-facility acquisition opportunities. The operations of our existing surgical facilities also require ongoing capital expenditures. We believe that our cash on hand, cash flows from operations and available borrowings under our revolving credit facility will be sufficient to fund our acquisition and development activities in 2010, but if we identify favorable acquisition and development opportunities that require additional resources, we may be required to incur additional indebtedness in order to pursue these opportunities. However, we may be unable to obtain sufficient financing on terms satisfactory to us, or at all, especially given the current uncertainty in the credit markets. In that event, our acquisition and development activities would have to be curtailed or eliminated and our financial results could be adversely affected.
 
Our debt agreements contain restrictions that limit our flexibility in operating our business.
 
The operating and financial restrictions and covenants in our debt instruments, including our senior secured credit facilities and the indenture governing our senior subordinated notes, may adversely affect our ability to finance our future operations or capital needs or engage in other business activities that may be in our interest. For example, our senior secured credit facility restricts, subject to certain exceptions, our and our subsidiaries’ ability to, among other things:
 
  •  incur, assume or permit to exist additional indebtedness or guarantees;
 
  •  incur liens and engage in sale leaseback transactions;
 
  •  make loans, investments and other advances;
 
  •  declare dividends, make payments or redeem or repurchase capital stock;
 
  •  engage in mergers, acquisitions and other business combinations;
 
  •  prepay, redeem or repurchase certain indebtedness including the notes;
 
  •  amend or otherwise alter terms of certain subordinated indebtedness including the notes;


29


Table of Contents

 
  •  enter into agreements limiting subsidiary distributions;
 
  •  sell assets;
 
  •  engage in certain transactions with affiliates;
 
  •  alter the business that we conduct; and
 
  •  issue and sell capital stock of subsidiaries.
 
In addition, the senior secured U.K. credit facility restricts, subject to certain exceptions, the ability of certain of our subsidiaries existing in the United Kingdom to, among other things:
 
  •  incur or permit to exist additional indebtedness;
 
  •  incur liens;
 
  •  make loans, investments or acquisitions;
 
  •  declare dividends or other distributions;
 
  •  enter into operating leases;
 
  •  engage in mergers, joint ventures or partnerships;
 
  •  sell assets;
 
  •  alter the business that the U.K. borrowers and their subsidiaries conduct; and
 
  •  incur financial lease expenditures.
 
The indenture governing our senior subordinated notes includes similar restrictions. Our senior secured credit facility also requires us to comply with a financial covenant with respect to the revolving credit facility that becomes more restrictive over time and the senior secured U.K. credit facility requires certain of our subsidiaries in the United Kingdom to comply with certain financial covenants, including a maximum leverage ratio test, a debt service coverage ratio test and an interest coverage ratio test. Our and our subsidiaries’ ability to comply with these covenants and ratios may be affected by events beyond our control. A breach of any covenant or required financial ratio could result in a default under the senior secured credit facilities. In the event of any default under the senior secured credit facilities, the applicable lenders could elect to terminate borrowing commitments and declare all borrowings and accrued interest and fees to be due and payable, to require us to apply all available cash to repay these borrowings or to prevent us from making or permitting subsidiaries to make distributions or dividends, the proceeds of which are used by us to make debt service payments on our senior subordinated notes, any of which would be an event of default under the notes.
 
If we incur material liabilities as a result of acquiring surgical facilities, our operating results could be adversely affected.
 
Although we conduct extensive due diligence prior to the acquisition of surgical facilities and seek indemnification from prospective sellers covering unknown or contingent liabilities, we may acquire surgical facilities that have material liabilities for failure to comply with healthcare laws and regulations or other past activities. Although we maintain professional and general liability insurance, we do not currently maintain insurance specifically covering any unknown or contingent liabilities that may have occurred prior to the acquisition of surgical facilities. If we incur these liabilities and are not indemnified or insured for them, our operating results and financial condition could be adversely affected.
 
We depend on our relationships with not-for-profit healthcare systems. If we are not able to maintain our relationships with these not-for-profit healthcare systems, or enter into new relationships, we may be unable to implement our business strategies successfully.
 
Our domestic business depends in part upon the efforts and success of our not-for-profit healthcare system partners and the strength of our relationships with those healthcare systems. Our business could be adversely


30


Table of Contents

affected by any damage to those healthcare systems’ reputations or to our relationships with them. We may not be able to maintain our existing agreements on terms and conditions favorable to us or enter into relationships with additional not-for-profit healthcare systems. Our relationships with not-for-profit healthcare systems and the joint venture agreements that represent these relationships are structured to comply with current revenue rulings published by the Internal Revenue Service as well as case law relevant to joint ventures between for-profit and not-for-profit healthcare entities. Material changes in these authorities could adversely affect our relationships with not-for-profit healthcare systems. If we are unable to maintain our existing arrangements on terms favorable to us or enter into relationships with additional not-for-profit healthcare systems, we may be unable to implement our business strategies successfully.
 
If we and our not-for-profit healthcare system partners are unable to successfully negotiate contracts and maintain satisfactory relationships with managed care organizations or other third party payors, our revenues may decrease.
 
Our competitive position has been, and will continue to be, affected by initiatives undertaken during the past several years by major domestic purchasers of healthcare services, including federal and state governments, insurance companies and employers, to revise payment methods and monitor healthcare expenditures in an effort to contain healthcare costs. As a result of these initiatives, managed care companies such as health maintenance and preferred provider organizations, which offer prepaid and discounted medical service packages, represent a growing segment of healthcare payors, the effect of which has been to reduce the growth of domestic healthcare facility margins and revenue. Similarly, in the United Kingdom, most patients at hospitals have private healthcare insurance, either paid for by the patient or received as part of their employment compensation. Our hospitals in the United Kingdom contract with healthcare insurers on an annual basis to provide services to insured patients.
 
As an increasing percentage of domestic patients become subject to healthcare coverage arrangements with managed care payors, we believe that our success will continue to depend upon our and our not-for-profit healthcare system partners’ ability to negotiate favorable contracts on behalf of our facilities with managed care organizations, employer groups and other private third party payors. We have structured our ventures with not-for-profit healthcare system partners in a manner we believe to be consistent with applicable regulatory requirements. If applicable regulatory requirements were interpreted to require changes to our existing arrangements, or if we are unable to enter into these arrangements on satisfactory terms in the future, we could be adversely affected. Many of these payors already have existing provider structures in place and may not be able or willing to change their provider networks. Similarly, if we fail to negotiate contracts with healthcare insurers in the United Kingdom on favorable terms, or if we fail to remain on insurers’ networks of approved hospitals, such failure could have a material adverse effect on us. We could also experience a material adverse effect to our operating results and financial condition as a result of the termination of existing third party payor contracts.
 
We depend on our relationships with the physicians who use our facilities. Our ability to provide medical services at our facilities would be impaired and our revenues reduced if we are not able to maintain these relationships.
 
Our business depends upon the efforts and success of the physicians who provide medical and surgical services at our facilities and the strength of our relationships with these physicians. Our revenues would be reduced if we lost our relationship with one or more key physicians or group of physicians or such physicians or groups reduce their use of our facilities. Any failure of these physicians to maintain the quality of medical care provided or to otherwise adhere to professional guidelines at our surgical facilities or any damage to the reputation of a key physician or group of physicians could also damage our reputation, subject us to liability and significantly reduce our revenues.
 
In addition, healthcare reform may contribute to increased physician employment with hospitals, which could weaken our relationships with these physicians. The Acts’ creation of ACOs may cause physicians to accept employment to become part of a network that includes an ACO. In addition, the Acts’ focus on investing in infrastructure to increase efficiencies may further contribute to shifting physicians’ practice patterns from private practice to employment with hospitals and ACOs. ACOs that achieve quality performance standards established by the Department of Health and Human Services will be eligible to share in a portion of the amounts saved by the Medicare program. Because an individual physician may view the costs associated with investing in technology and


31


Table of Contents

processes to increase efficiencies as too large to bear individually, the physician may turn to employment as a means to participate in the Medicare savings and the capital investments required by the Acts. Physicians who accept employment may be restricted from owning interests in or utilizing our facilities.
 
Our surgical facilities face competition for patients from other health care providers.
 
The health care business is highly competitive, and competition among hospitals and other health care providers for patients has intensified in recent years. Generally, other facilities in the local communities served by our facilities provide services similar to those offered by our surgery centers and surgical hospitals. In addition, the number of freestanding surgical hospitals and surgery centers in the geographic areas in which we operate has increased significantly. As a result, most of our surgery centers and surgical hospitals operate in a highly competitive environment. Some of the hospitals that compete with our facilities are owned by governmental agencies or not-for-profit corporations supported by endowments, charitable contributions and/or tax revenues and can finance capital expenditures and operations on a tax-exempt basis. Our surgery centers and surgical hospitals are facing increasing competition from unaffiliated physician-owned surgery centers and surgical hospitals for market share in high margin services and for quality physicians and personnel. If our competitors are better able to attract patients, recruit physicians, expand services or obtain favorable managed care contracts at their facilities than our surgery centers and surgical hospitals, we may experience an overall decline in patient volume.
 
Current economic conditions may adversely affect our financial condition and results of operations.
 
The current economic conditions will likely have an impact on our business. We regularly monitor quantitative as well as qualitative measures to identify changes in our business in order to react accordingly. The most likely impact on us from weakening economic conditions would be lower case volumes as elective procedures may be deferred or cancelled, which could have an adverse effect on our financial condition and results of operations.
 
Our United Kingdom operations are subject to unique risks, any of which, if they actually occur, could adversely affect our results.
 
We expect that revenue from our United Kingdom operations will continue to account for a significant percentage of our total revenue. Further, we may pursue additional acquisitions in the United Kingdom, which would require substantial financial resources and management attention. This focus of financial resources and management attention could have an adverse effect on our financial results. In addition, our United Kingdom operations are subject to risks such as:
 
  •  fluctuations in exchange rates;
 
  •  competition with government sponsored healthcare systems;
 
  •  unforeseen changes in foreign regulatory requirements or domestic regulatory requirements affecting our foreign operations;
 
  •  identifying, attracting, retaining and working successfully with qualified local management;
 
  •  difficulties in staffing and managing geographically and culturally diverse, multinational operations;
 
  •  the economic conditions in the United Kingdom, which could adversely affect the ability or willingness of employers and individuals in these countries to purchase private health insurance; and
 
  •  a higher concentration of self-pay business than our U.S. facilities.
 
These or other factors could have a material adverse effect on our ability to successfully operate in the United Kingdom and our financial condition and operations.
 
Our revenues may be reduced by changes in payment methods or rates under the Medicare or Medicaid programs.
 
The Department of Health and Human Services and the states in which we perform surgical procedures for Medicaid patients may revise the Medicare and Medicaid payment methods or rates in the future. Any such changes


32


Table of Contents

could have a negative impact on the reimbursements we receive for our surgical services from the Medicare program and the state Medicaid programs. In addition, the Acts’ requirement that the Department of Health and Human Services develop a value-based purchasing program for Ambulatory surgery centers may further impact Medicare reimbursement of ambulatory surgery centers or increase our operating costs in order to satisfy the value-based standards. The ultimate impact of the changes in Medicare reimbursement will depend on a number of factors, including the procedure mix at the centers and our ability to realize an increased procedure volume.
 
Efforts to regulate the construction, acquisition or expansion of healthcare facilities could prevent us from acquiring additional surgical facilities, renovating our existing facilities or expanding the breadth of services we offer.
 
Many states in the United States require prior approval for the construction, acquisition or expansion of healthcare facilities or expansion of the services they offer. When considering whether to approve such projects, these states take into account the need for additional or expanded healthcare facilities or services. In a number of states in which we operate, we are required to obtain certificates of need for capital expenditures exceeding a prescribed amount, changes in bed capacity or services offered and under various other circumstances. Other states in which we now or may in the future operate may adopt certificate of need legislation or regulatory provisions. Our costs of obtaining a certificate of need have ranged up to $500,000. Although we have not previously been denied a certificate of need, we may not be able to obtain the certificates of need or other required approvals for additional or expanded facilities or services in the future. In addition, at the time we acquire a facility, we may agree to replace or expand the acquired facility. If we are unable to obtain the required approvals, we may not be able to acquire additional surgery centers or surgical hospitals, expand the healthcare services provided at these facilities or replace or expand acquired facilities.
 
Failure to comply with federal and state statutes and regulations relating to patient privacy and electronic data security could negatively impact our financial results.
 
There are currently numerous federal and state statutes and regulations that address patient privacy concerns and federal standards that address the maintenance of the security of electronically maintained or transmitted electronic health information and the format of transmission of such information in common health care financing information exchanges. These provisions are intended to enhance patient privacy and the effectiveness and efficiency of healthcare claims and payment transactions. In particular, the Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act of 1996 required us to implement new systems and to adopt business procedures for transmitting health care information and for protecting the privacy and security of individually identifiable information.
 
We believe that we are in material compliance with existing state and federal regulations relating to patient privacy, security and with respect to the format for electronic health care transactions. However, if we fail to comply with the federal privacy, security and transactions and code sets regulations, we could incur significant civil and criminal penalties. Failure to comply with state laws related to privacy could, in some cases, also result in civil fines and criminal penalties.
 
If we fail to comply with applicable laws and regulations, we could suffer penalties or be required to make significant changes to our operations.
 
We are subject to many laws and regulations at the federal, state and local government levels in the jurisdictions in which we operate. These laws and regulations require that our healthcare facilities meet various licensing, certification and other requirements, including those relating to:
 
  •  physician ownership of our domestic facilities;
 
  •  the adequacy of medical care, equipment, personnel, operating policies and procedures;
 
  •  building codes;
 
  •  licensure, certification and accreditation;


33


Table of Contents

 
  •  billing for services;
 
  •  handling of medication;
 
  •  maintenance and protection of records; and
 
  •  environmental protection.
 
We believe that we are in material compliance with applicable laws and regulations. However, if we fail or have failed to comply with applicable laws and regulations, we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in Medicare, Medicaid and other government sponsored healthcare programs. A number of initiatives have been proposed during the past several years to reform various aspects of the healthcare system, both domestically and in the United Kingdom. In the future, different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses. Current or future legislative initiatives or government regulation may have a material adverse effect on our operations or reduce the demand for our services.
 
In pursuing our growth strategy, we may expand our presence into new geographic markets. In entering a new geographic market, we will be required to comply with laws and regulations of jurisdictions that may differ from those applicable to our current operations. If we are unable to comply with these legal requirements in a cost-effective manner, we may be unable to enter new geographic markets.
 
If a federal or state agency asserts a different position or enacts new laws or regulations regarding illegal remuneration under the Medicare or Medicaid programs, we may be subject to civil and criminal penalties, experience a significant reduction in our revenues or be excluded from participation in the Medicare and Medicaid programs.
 
The federal anti-kickback statute prohibits the offer, payment, solicitation or receipt of any form of remuneration in return for referrals for items or services payable by Medicare, Medicaid, or any other federally funded healthcare program. Additionally, the anti-kickback statute prohibits any form of remuneration in return for purchasing, leasing or ordering, or arranging for or recommending the purchasing, leasing or ordering of items or services payable by Medicare, Medicaid or any other federally funded healthcare program. The anti-kickback statute is very broad in scope and many of its provisions have not been uniformly or definitively interpreted by existing case law or regulations. Moreover, several federal courts have held that the anti-kickback statute can be violated if only one purpose (not necessarily the primary purpose) of a transaction is to induce or reward a referral of business, notwithstanding other legitimate purposes. Violations of the anti-kickback statute may result in substantial civil or criminal penalties, including up to five years imprisonment and criminal fines of up to $25,000 and civil penalties of up to $50,000 for each violation, plus three times the remuneration involved or the amount claimed and exclusion from participation in all federally funded healthcare programs. An exclusion, if applied to our surgery centers or surgical hospitals, could result in significant reductions in our revenues, which could have a material adverse effect on our business.
 
In July 1991, the Department of Health and Human Services issued final regulations defining various “safe harbors.” Two of the safe harbors issued in 1991 apply to business arrangements similar to those used in connection with our surgery centers and surgical hospitals: the “investment interest” safe harbor and the “personal services and management contracts” safe harbor. However, the structure of the partnerships and limited liability companies operating our surgery centers and surgical hospitals, as well as our various business arrangements involving physician group practices, do not satisfy all of the requirements of either safe harbor. Therefore, our business arrangements with our surgery centers, surgical hospitals and physician groups do not qualify for “safe harbor” protection from government review or prosecution under the anti-kickback statute. When a transaction or relationship does not fit within a safe harbor, it does not mean that an anti-kickback violation has occurred; rather, it means that the facts and circumstances as well as the intent of the parties related to a specific transaction or relationship must be examined to determine whether or not any illegal conduct has occurred.
 
On November 19, 1999, the Department of Health and Human Services promulgated final regulations creating additional safe harbor provisions, including a safe harbor that applies to physician ownership of or investment


34


Table of Contents

interests in surgery centers. The surgery center safe harbor protects four types of investment arrangements: (1) surgeon owned surgery centers; (2) single specialty surgery centers; (3) multi-specialty surgery centers; and (4) hospital/physician surgery centers. Each category has its own requirements with regard to what type of physician may be an investor in the surgery center. In addition to the physician investor, the categories permit an “unrelated” investor, who is a person or entity that is not in a position to provide items or services related to the surgery center or its investors. Our business arrangements with our surgical facilities typically consist of one of our subsidiaries being an investor in each partnership or limited liability company that owns the facility, in addition to providing management and other services to the facility. As a result, these business arrangements do not comply with all the requirements of the surgery center safe harbor, and, therefore, are not immune from government review or prosecution.
 
Although we believe that our business arrangements do not violate the anti-kickback statute, a government agency or a private party may assert a contrary position. Additionally, new domestic federal or state laws may be enacted that would cause our relationships with the physician investors to become illegal or result in the imposition of penalties against us or our facilities. If any of our business arrangements with physician investors were deemed to violate the anti-kickback statute or similar laws, or if new domestic federal or state laws were enacted rendering these arrangements illegal, our business could be adversely affected.
 
Also, most of the states in which we operate have adopted anti-kickback laws, many of which apply more broadly to all third-party payors, not just to federal or state healthcare programs. Many of the state laws do not have regulatory safe harbors comparable to the federal provisions and have only rarely been interpreted by the courts or other governmental agencies. We believe that our business arrangements do not violate these state laws. Nonetheless, if our arrangements were found to violate any of these anti-kickback laws, we could be subject to significant civil and criminal penalties that could adversely affect our business.
 
If physician self-referral laws are interpreted differently or if other legislative restrictions are issued, we could incur significant sanctions and loss of reimbursement revenues.
 
The U.S. federal physician self-referral law, commonly referred to as the Stark law, prohibits a physician from making a referral for a “designated health service” to an entity to furnish an item or service payable under Medicare if the physician or a member of the physician’s immediate family has a financial relationship with the entity such as an ownership interest or compensation arrangement, unless an exception applies. The list of designated health services under the Stark law does not include ambulatory surgery services as such. However, some of the designated health services are among the types of services furnished by our facilities.
 
The Department of Health and Human Services, acting through the Centers for Medicare and Medicaid Services, has promulgated regulations implementing the Stark law. These regulations exclude health services provided by an ambulatory surgery center from the definition of “designated health services” if the services are included in the facility’s composite Medicare payment rate. Therefore, the Stark law’s self-referral prohibition generally does not apply to health services provided by a surgery center. However, if the surgery center is separately billing Medicare for designated health services that are not covered under the surgery center’s composite Medicare payment rate, or if either the surgery center or an affiliated physician is performing (and billing Medicare) for procedures that involve designated health services that Medicare has not designated as an ambulatory surgery center service, the Stark law’s self-referral prohibition would apply and such services could implicate the Stark law. We believe that our operations do not violate the Stark Law, as currently interpreted.
 
In addition, we believe that physician ownership of surgery centers is not prohibited by similar self-referral statutes enacted at the state level. However, the Stark law and similar state statutes are subject to different interpretations with respect to many important provisions. Violations of these self-referral laws may result in substantial civil or criminal penalties, including large civil monetary penalties and exclusion from participation in the Medicare and Medicaid programs. Exclusion of our surgery centers or surgical hospitals from these programs through future judicial or agency interpretation of existing laws or additional legislative restrictions on physician ownership or investments in healthcare entities could result in significant loss of reimbursement revenues.


35


Table of Contents

Companies within the healthcare industry continue to be the subject of federal and state audits and investigations, which increases the risk that we may become subject to investigations in the future.
 
Both federal and state government agencies, as well as private payors, have heightened and coordinated audits and administrative, civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare organizations. These investigations relate to a wide variety of topics, including the following:
 
  •  cost reporting and billing practices;
 
  •  quality of care;
 
  •  financial reporting;
 
  •  financial relationships with referral sources; and
 
  •  medical necessity of services provided.
 
In addition, the Office of the Inspector General of the Department of Health and Human Services and the Department of Justice have, from time to time, undertaken national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. Moreover, another trend impacting healthcare providers is the increased use of the federal False Claims Act, particularly by individuals who bring actions under that law. Such “qui tam” or “whistleblower” actions allow private individuals to bring actions on behalf of the government alleging that a healthcare provider has defrauded the federal government. If the government intervenes and prevails in the action, the defendant may be required to pay three times the actual damages sustained by the government, plus mandatory civil monetary penalties of between $5,500 and $11,000 for each false claim submitted to the government. As part of the resolution of a qui tam case, the party filing the initial complaint may share in a portion of any settlement or judgment. If the government does not intervene in the action, the qui tam plaintiff may pursue the action independently. Additionally, some states have adopted similar whistleblower and false claims provisions. Although companies in the healthcare industry have been, and may continue to be, subject to qui tam actions, we are unable to predict the impact of such actions on our business, financial position or results of operations.
 
If laws governing the corporate practice of medicine change, we may be required to restructure some of our domestic relationships which may result in significant costs to us and divert other resources.
 
The laws of various domestic jurisdictions in which we operate or may operate in the future do not permit business corporations to practice medicine, exercise control over physicians who practice medicine or engage in various business practices, such as fee-splitting with physicians. The interpretation and enforcement of these laws vary significantly from state to state. We are not required to obtain a license to practice medicine in any jurisdiction in which we own or operate a surgery center or surgical hospital because our facilities are not engaged in the practice of medicine. The physicians who utilize our facilities are individually licensed to practice medicine. In most instances, the physicians and physician group practices performing medical services at our facilities do not have investment or business relationships with us other than through the physicians’ ownership interests in the partnerships or limited liability companies that own and operate our facilities and the service agreements we have with some of those physicians.
 
Through our OrthoLink subsidiary, we provide consulting and administrative services to a number of physicians and physician group practices affiliated with OrthoLink. Although we believe that our arrangements with these and other physicians and physician group practices comply with applicable laws, a government agency charged with enforcement of these laws, or a private party, might assert a contrary position. If our arrangements with these physicians and physician group practices were deemed to violate state corporate practice of medicine, fee-splitting or similar laws, or if new laws are enacted rendering our arrangements illegal, we may be required to restructure these arrangements, which may result in significant costs to us and divert other resources.


36


Table of Contents

If domestic regulations change, we may be obligated to purchase some or all of the ownership interests of the physicians affiliated with us.
 
Upon the occurrence of various fundamental regulatory changes, we could be obligated to purchase some or all of the ownership interests of the physicians affiliated with us in the partnerships or limited liability companies that own and operate our surgery centers and surgical hospitals. The regulatory changes that could create this obligation include changes that:
 
  •  make illegal the referral of Medicare or other patients to our surgical facilities by physicians affiliated with us;
 
  •  create the substantial likelihood that cash distributions from the limited partnerships or limited liability companies through which we operate our surgical facilities to physicians affiliated with us would be illegal; or
 
  •  make illegal the ownership by the physicians affiliated with us of interests in the partnerships or limited liability companies through which we own and operate our surgical facilities.
 
At this time, we are not aware of any regulatory amendments or proposed changes that would trigger this obligation. Typically, our partnership and limited liability company agreements allow us to use shares of our common stock as consideration for the purchase of a physician’s ownership interest. The use of shares of our common stock for that purpose would dilute the ownership interests of our common stockholders. In the event that we are required to purchase all of the physicians’ ownership interests and our common stock does not maintain a sufficient valuation, we could be required to use our cash resources for the acquisitions, the total cost of which we estimate to be up to approximately $469.0 million at December 31, 2010. The creation of these obligations and the possible termination of our affiliation with these physicians could have a material adverse effect on us.
 
Healthcare reform has restricted our ability to operate our domestic surgical hospitals.
 
The Acts provide, among other things:  (i) a prohibition on hospitals from having any physician ownership unless the hospital already had physician ownership as of March 23, 2010 and a Medicare provider agreement in effect on December 31, 2010; (ii) a limitation on the percentage of total physician ownership in the hospital to the percentage of physician ownership as of March 23, 2010; (iii) a requirement for written disclosures of physician ownership interests, along with an annual report to the government detailing such ownership; and (iv) severe restrictions on the ability of a hospital subject to the whole hospital exception to add operating rooms, procedure rooms and beds.
 
All of our existing hospitals and our hospital under construction in Dallas, Texas were grandfathered at the dates of enactment of the Acts, although they are largely prohibited from expanding their physical plants. Our hospital under development in Phoenix, Arizona will not be allowed to have any physician ownership unless the Acts, which are currently subject to certain judicial challenges, are overturned or otherwise amended. As a result, we may be required to purchase our share of the physician owners’ interest in the hospital for approximately $4.0 million in cash. If future legislation were to be enacted by Congress that prohibits physician referrals to hospitals in which the physicians own an interest, or that otherwise further limits physician ownership in existing facilities, our financial condition and results of operations could be materially adversely affected.
 
If we become subject to significant legal actions, we could be subject to substantial uninsured liabilities.
 
In recent years, physicians, surgery centers, hospitals and other healthcare providers have become subject to an increasing number of legal actions alleging malpractice or related legal theories. Many of these actions involve large monetary claims and significant defense costs. In particular, since all of our hospitals maintain emergency departments, there is an increased risk of claims at these facilities because of the nature of the cases seen in the emergency departments. We do not employ any of the physicians who conduct surgical procedures at our facilities and the governing documents of each of our facilities require physicians who conduct surgical procedures at our facilities to maintain stated amounts of insurance. Additionally, to protect us from the cost of these claims, we maintain (through a captive insurance company) professional malpractice liability insurance and general liability insurance coverage in amounts and with deductibles that we believe to be appropriate for our operations. Although


37


Table of Contents

we have excess coverage beyond our captive, we are effectively self-insured up to the excess. If we become subject to claims, however, our insurance coverage may not cover all claims against us or continue to be available at adequate levels of insurance. If one or more successful claims against us were not covered by or exceeded the coverage of our insurance, we could be adversely affected.
 
If we are unable to effectively compete for physicians, strategic relationships, acquisitions and managed care contracts, our business could be adversely affected.
 
The healthcare business is highly competitive. We compete with other healthcare providers, primarily other surgery centers and hospitals, in recruiting physicians and contracting with managed care payors in each of our markets. In the United Kingdom, we also compete with their national health system in recruiting healthcare professionals. There are major unaffiliated hospitals in each market in which we operate. These hospitals have established relationships with physicians and payors. In addition, other companies either are currently in the same or similar business of developing, acquiring and operating surgery centers and surgical hospitals or may decide to enter our business. Many of these companies have greater financial, research, marketing and staff resources than we do. We may also compete with some of these companies for entry into strategic relationships with not-for-profit healthcare systems and healthcare professionals. If we are unable to compete effectively with any of these entities, we may be unable to implement our business strategies successfully and our business could be adversely affected.
 
Because our senior management has been key to our growth and success, we may be adversely affected if we lose any member of our senior management.
 
We are highly dependent on our senior management, including Donald E. Steen, who is our chairman, and William H. Wilcox, who is our president and chief executive officer. Although we have employment agreements with Mr. Steen and Mr. Wilcox and other senior managers, we do not maintain “key man” life insurance policies on any of our officers. Because our senior management has contributed greatly to our growth since inception, the loss of key management personnel or our inability to attract, retain and motivate sufficient numbers of qualified management or other personnel could have a material adverse effect on us.
 
The growth of patient receivables and a deterioration in the collectability of these accounts could adversely affect our results of operations.
 
The primary collection risks of our accounts receivable relate to patient receivables for which the primary insurance carrier has paid the amounts covered by the applicable agreement but patient responsibility amounts (deductibles and copayments) remain outstanding. The allowance for doubtful accounts relates primarily to amounts due directly from patients.
 
We provide for bad debts principally based upon the aging of accounts receivable and use specific identification to write-off amounts against our allowance for doubtful accounts, without differentiation between payor sources. Our U.S. doubtful account allowance at December 31, 2010 and 2009, represented approximately 15% and 16% of our U.S. accounts receivable balance, respectively. Due to the difficulty in assessing future trends, we could be required to increase our provisions for doubtful accounts. A deterioration in the collectability of these accounts could adversely affect our collection of accounts receivable, cash flows and results of operations.
 
We may have a special legal responsibility to the holders of ownership interests in the entities through which we own surgical facilities, and that responsibility may prevent us from acting solely in our own best interests or the interests of our stockholders.
 
Our ownership interests in surgery centers and surgical hospitals generally are held through partnerships or limited liability companies. We typically maintain an interest in a partnership or limited liability company in which physicians or physician practice groups also hold interests. As general partner or manager of these entities, we may have a special responsibility, known as a fiduciary duty, to manage these entities in the best interests of the other owners. We also have a duty to operate our business for the benefit of our stockholders. As a result, we may encounter conflicts between our responsibility to the other owners and our responsibility to our stockholders. For example, we have entered into management agreements to provide management services to our domestic facilities


38


Table of Contents

in exchange for a fee. Disputes may arise as to the nature of the services to be provided or the amount of the fee to be paid. In these cases, we are obligated to exercise reasonable, good faith judgment to resolve the disputes and may not be free to act solely in our own best interests. Disputes may also arise between us and our affiliated physicians with respect to a particular business decision or regarding the interpretation of the provisions of the applicable partnership or limited liability company agreement. If we are unable to resolve a dispute on terms favorable or satisfactory to us, our business may be adversely affected.
 
We do not have exclusive control over the distribution of revenues from some of our domestic operating entities and may be unable to cause all or a portion of the revenues of these entities to be distributed.
 
All of the domestic surgical facilities in which we have ownership interests are partnerships or limited liability companies in which we own, directly or indirectly, ownership interests. Our partnership, and limited liability company agreements, which are typically with the physicians who perform procedures at our surgical facilities, usually provide for the monthly or quarterly pro-rata cash distribution of net profits from operations, less amounts to satisfy obligations such as the entities’ non-recourse debt and capitalized lease obligations, operating expenses and working capital. The creditors of each of these partnerships and limited liability companies are entitled to payment of the entities’ obligations to them, when due and payable, before ordinary cash distributions or distributions in the event of liquidation, reorganization or insolvency may be made. We generally control the entities that function as the general partner of the partnerships or the managing member of the limited liability companies through which we conduct operations. However, we do not have exclusive control in some instances over the amount of net revenues distributed from some of our operating entities. If we are unable to cause sufficient revenues to be distributed from one or more of these entities, our relationships with the physicians who have an interest in these entities may be damaged and we could be adversely affected. We may not be able to resolve favorably any dispute regarding revenue distribution or other matters with a healthcare system with which we share control of one of these entities. Further, the failure to resolve a dispute with these healthcare systems could cause the entity we jointly control to be dissolved.
 
Welsh Carson controls us and may have conflicts of interest with us or you in the future.
 
An investor group led by Welsh Carson owns substantially all of the outstanding equity securities of our Parent, USPI Group Holdings, Inc. Welsh Carson controls a majority of the voting power of such outstanding equity securities and therefore ultimately controls all of our affairs and policies, including the election of our board of directors, the approval of certain actions such as amending our charter, commencing bankruptcy proceedings and taking certain corporate actions (including, without limitation, incurring debt, issuing stock, selling assets and engaging in mergers and acquisitions), and appointing members of our management. The interests of Welsh Carson could conflict with your interests.
 
Additionally, Welsh Carson is in the business of making investments in companies and may from time to time acquire and hold interests in businesses that compete directly or indirectly with us. Welsh Carson may also pursue acquisition opportunities that may be complementary to our business and, as a result, those acquisition opportunities may not be available to us. So long as investment funds associated with or designated by Welsh Carson continue to indirectly own a significant amount of our capital stock, even if such amount is less than 50% of our outstanding common stock on a fully-diluted basis, Welsh Carson will continue to be able to strongly influence or effectively control our decisions.
 
Item 1B.   Unresolved Staff Comments
 
None.
 
Item 2.   Properties
 
The response to this item is included in Item 1.


39


Table of Contents

Item 3.   Legal Proceedings
 
From time to time, we may be named as a party to legal claims and proceedings in the ordinary course of business. We are not aware of any claims or proceedings against us or our subsidiaries that might have a material adverse impact on us.
 
PART II
 
Item 5.   Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
 
We are wholly-owned by USPI Holdings, Inc., which is wholly-owned by USPI Group Holdings, Inc., both of which are privately owned corporations. There is no public trading market for our equity securities or those of USPI Holdings, Inc. or USPI Group Holdings, Inc. As of February 25, 2011, there were 106 holders of USPI Group Holdings, Inc. common stock.
 
Item 6.   Selected Financial Data
 
The selected consolidated statement of operations data set forth below for the years ended December 31, 2010, 2009 and 2008, (Successor), the periods January 1 through April 18, 2007 (Predecessor) and April 19 through December 31, 2007 (Successor) and for the year ended December 31, 2006 (Predecessor), and the consolidated balance sheet data at December 31, 2010, 2009, 2008 and 2007 (Successor) and December 31, 2006 (Predecessor) are derived from our consolidated financial statements.
 
The historical results presented below are not necessarily indicative of results to be expected for any future period. The comparability of the financial and other data included in the table is affected by our merger transaction in 2007, loss on early retirement of debt in 2007 and 2006 and various acquisitions completed during the years presented. In addition, the results of operations of subsidiaries sold by us have been reclassified to “discontinued operations” for all data presented in the table below except for the “consolidated balance sheet data.” For a more detailed explanation of this financial data, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes included elsewhere in this report.
 


40


Table of Contents

                                                   
     
    Successor     Predecessor
                Period from
    Period from
   
                April 19
    January 1
   
    Year Ended
  Year Ended
  Year Ended
  through
    through
  Years Ended
    December 31
  December 31,
  December 31,
  December 31,
    April 18,
  December 31,
    2010   2009   2008   2007     2007   2006
Consolidated Statement of Operations Data:
                                                 
Total revenues
  $ 576,665     $ 593,475     $ 615,098     $ 435,699       $ 185,169     $ 553,290  
Equity in earnings of unconsolidated affiliates
    69,916       61,771       47,042       23,867         9,906       31,568  
Operating expenses excluding depreciation and amortization
    (406,266 )     (425,786 )     (431,731 )     (300,937 )       (156,227 )     (392,360 )
Depreciation and amortization
    (29,799 )     (31,165 )     (32,305 )     (23,765 )       (11,301 )     (32,319 )
                                                   
Operating income
    210,516       198,295       198,104       134,864         27,547       160,179  
Other income (expense):
                                                 
Interest income
    798       2,741       3,278       3,255         967       4,064  
Interest expense
    (70,038 )     (70,353 )     (84,916 )     (67,553 )       (9,394 )     (32,457 )
Loss on early retirement of debt
                              (2,435 )     (14,880 )
Other, net
    708       373       32       72         (67 )     51  
                                                   
Income from continuing operations before income taxes
    141,984       131,056       116,498       70,638         16,618       116,957  
Income tax benefit (expense)
    (32,328 )     879       (22,667 )     (14,588 )       (4,433 )     (22,661 )
                                                   
Income from continuing operations
    109,656       131,935       93,831       56,050         12,185       94,296  
Earnings (loss) from discontinued operations, net of tax
    (7,003 )     1,453       (1,179 )     (2,146 )       (786 )     (5,629 )
                                                   
Net income
    102,653       133,388       92,652       53,904         11,399       88,667  
Less: Net income attributable to noncontrolling interests
    (60,560 )     (63,722 )     (55,138 )     (45,175 )       (18,548 )     (54,421 )
                                                   
Net income attributable to USPI’s common stockholders
  $ 42,093     $ 69,666     $ 37,514     $ 8,729       $ (7,149 )   $ 34,246  
                                                   
Other Data:
                                                 
Number of facilities operated as of the end of period(a):
                                                 
Consolidated
    58       60       62       61         64       60  
Equity method
    130       109       102       94         85       81  
Management contract only
    1                                  
                                                   
Total
    189       169       164       155         149       141  
                                                   
Cash flows from operating activities
  $ 169,064     $ 180,610     $ 142,119     $ 109,933       $ 47,177     $ 155,466  

41


Table of Contents

                                           
     
                      Predecessor
    Successor
    As of
    As of December 31     December 31,
    2010   2009   2008   2007     2006
Consolidated Balance Sheet Data:
                                         
Working capital (deficit)
  $ (100,249 )   $ (113,016 )   $ (38,838 )   $ (12,569 )     $ (41,834 )
Cash and cash equivalents
    60,253       34,890       49,435       76,758         31,740  
Total assets
    2,372,739       2,325,392       2,268,163       2,277,393         1,231,856  
Total debt
    1,069,826       1,071,528       1,097,947       1,098,062         347,330  
Noncontrolling interests — redeemable
    81,668       63,865       51,961       52,769         49,261  
Total equity
    821,151       798,003       806,217       837,100         622,844  
 
 
(a) Not derived from audited financial statements.
 
Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operation
 
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with “Selected Financial Data” and our consolidated financial statements and related notes included elsewhere in this report.
 
 
Overview
 
We operate ambulatory surgery centers and surgical hospitals in the United States and the United Kingdom. As of December 31, 2010, we operated 189 facilities, consisting of 185 in the United States and four in the United Kingdom. All 185 of our U.S. facilities include local physician owners, and 132 of these facilities are also partially owned by various not-for-profit healthcare systems (hospital partners). In addition to facilitating the joint ownership of the majority of our existing facilities, our agreements with these healthcare systems provide a framework for the planning and construction of additional facilities in the future. All six facilities we are currently developing include a hospital partner.
 
Our U.S. facilities, consisting of ambulatory surgery centers and surgical hospitals, specialize in non-emergency surgical cases. Due in part to advancements in medical technology, the volume and complexity of surgical cases performed in an outpatient setting has steadily increased over the past two decades. Our facilities earn a fee from patients, insurance companies, or other payors in exchange for providing the facility and related services a surgeon requires in order to perform a surgical case. In addition, we earn a monthly fee from each facility we operate in exchange for managing its operations. All but four of our facilities are located in the U.S., where we have focused increasingly on adding facilities with hospital partners, which we believe improves the long-term profitability and potential of our facilities.
 
In the United Kingdom we operate three hospitals and an oncology clinic, which supplement the services provided by the government-sponsored healthcare system. Our patients choose to receive care at private hospitals primarily because of waiting lists to receive diagnostic procedures or elective surgery at government-sponsored facilities and pay us either from personal funds or through private insurance, which is offered by some employers as a benefit to their employees. Since acquiring our first two facilities in the United Kingdom in 2000, we have expanded selectively by adding a third facility and increasing the capacity and services offered at each facility, including the construction of an oncology clinic near the campus of one of our hospitals. In January 2011, we acquired an equity interest in a diagnostic and surgery center located in Edinburgh, Scotland.
 
Our growth and success depends on our ability to continue to grow volumes at our existing facilities, to successfully open new facilities we develop, to successfully integrate acquired facilities into our operations, and to maintain productive relationships with our physician and hospital partners. We believe we will have significant opportunities to operate more facilities in the future in existing and new markets and that many of these will include hospital partners.


42


Table of Contents

Due in large part to our partnerships with physician and hospital partners, we do not consolidate 130 of the 188 facilities in which we have ownership interests. To help analyze our results of operations, we disclose an operating measure we refer to as systemwide revenue growth, which includes both consolidated and unconsolidated facilities. While revenues of our unconsolidated facilities are not recorded as revenues by USPI, we believe the information is important in understanding USPI’s financial performance because these revenues are the basis for calculating the Company’s management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for USPI’s equity in earnings of unconsolidated affiliates. In addition, USPI discloses growth rates and operating margins (both consolidated and unconsolidated) for the facilities that were operational in both the current and prior year periods, a group the Company refers to as same store facilities.
 
Critical Accounting Policies and Estimates
 
Our discussion and analysis of our financial condition, results of operations and liquidity and capital resources are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of consolidated financial statements under GAAP requires our management to make certain estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. These estimates and assumptions also impact the reported amount of net earnings during any period. Estimates are based on information available as of the date financial statements are prepared. Accordingly, actual results could differ from those estimates. Critical accounting policies and estimates are defined as those that are both most important to the portrayal of our financial condition and operating results and that require management’s most subjective judgments. Our critical accounting policies and estimates include our policies and estimates regarding consolidation, revenue recognition and accounts receivable, income taxes, and goodwill and intangible assets.
 
Consolidation
 
We own less than 100% of each U.S. facility we operate. As discussed in “Results of Operations,” we operate all of our U.S. facilities through joint ventures with physicians. Increasingly, these joint ventures also include a hospital partner. We generally have a leadership role in these facilities through a significant voting and economic interest and a contract to manage each facility’s operations, but the degree of control we have varies from facility to facility. Accordingly, as of December 31, 2010, we consolidated the financial results of 58 of the facilities we operate, account for 130 under the equity method and operate one facility under a service and management contract.
 
Our consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and other investees over which we have control or of which the Company is the primary beneficiary. Investments in companies that we neither control nor are the primary beneficiary, but over whose operations we have the ability to exercise significant influence (including investments where we have less than 20% ownership), are accounted for under the equity method. We also consider the relevant sections of the Financial Accounting Standards Board’s Accounting Standards Codification, Topic 810, Consolidation to determine if we are the primary beneficiary of (and therefore should consolidate) any entity whose operations we do not control with voting rights. At December 31, 2010, we consolidated one entity as a result of being its primary beneficiary. See further discussion in Note 5 to the consolidated financial statements.
 
Accounting for an investment as consolidated versus equity method has no impact on our net income (loss) or stockholder’s equity in any accounting period, but it does impact individual balances within the statement of operations and balance sheet. Under either consolidation or equity method accounting, the investor’s results of operations includes its share of the investee entity’s net income or loss based generally on its ownership percentage.
 
Revenue Recognition and Accounts Receivable
 
We recognize revenue in accordance with Staff Accounting Bulletin No. 104, Revenue Recognition in Financial Statements, as updated, which has four criteria that must be met before revenue is recognized:
 
  •  Existence of persuasive evidence that an arrangement exists;


43


Table of Contents

 
  •  Delivery has occurred or services have been rendered;
 
  •  The seller’s price to the buyer is fixed or determinable; and
 
  •  Collectibility is reasonably assured.
 
Our revenue recognition policies are consistent with these criteria. Over 80% of our facilities’ surgical cases are performed under contracted or government mandated fee schedules or discount arrangements. The patient service revenues recorded for these cases are recorded at the contractually defined amount at the time of billing. We estimate the remaining revenue based on historical collections, and adjustments to these estimates in subsequent periods have not had a material impact in any period presented. If the discount percentage used in estimating revenues for the cases not billed pursuant to fee schedules were changed by 1%, our 2010 after-tax net income would change by approximately $0.2 million. The collection cycle for patient services revenue is relatively short, typically ranging from 30 to 60 days depending upon payor and geographic norms, which allows us to evaluate our estimates frequently. Our revenues earned under management and other service contracts are typically based upon objective formulas driven by an entity’s financial performance and are generally earned and paid monthly.
 
Our accounts receivable are comprised of receivables in both the United Kingdom and the United States. As of December 31, 2010, approximately 21% of our total accounts receivable were attributable to our U.K. business. Because our U.K. facilities only treat patients who have a demonstrated ability to pay, our U.K. patients arrange for payment prior to treatment and our bad debt expense in the U.K. is low. In 2010, U.K. bad debt expense was less than $0.1 million, as compared to our total U.K. revenues of $102.7 million. Our average days sales outstanding in the U.K. were 38 and 52 as of December 31, 2010 and 2009, respectively. The decrease in U.K. days sales outstanding was caused by the receipt of several payments made by large payors on December 31, 2010.
 
Our U.S. accounts receivable were approximately 79% of our total accounts receivable as of December 31, 2010. In 2010, uninsured or self-pay revenues only accounted for 2% of our U.S. revenue and approximately 6% of our accounts receivable balance was comprised of amounts owed from patients, including the patient portion of amounts covered by insurance. Insurance revenues (including government payors) accounted for 98% of our 2010 U.S. revenue and approximately 94% of our accounts receivable balance was comprised of amounts owed from contracted payors. Our U.S. facilities primarily perform surgery that is scheduled in advance by physicians who have already seen the patient. As part of our internal control processes, we verify benefits, obtain insurance authorization, calculate patient financial responsibility and notify the patient of their responsibility, usually prior to surgery. The nature of our business is such that we do not have any significant receivables that are pending approval from third party payors. We also focus our collection efforts on aged accounts receivable. However, due to complexities involved in insurance reimbursements and inherent limitations in verification procedures, our business will always have some level of bad debt expense. In both 2010 and 2009, our bad debt expense attributable to U.S. revenue was approximately 2%. In addition, as of December 31, 2010 and 2009, our average days sales outstanding in the U.S. were 33 and 34 days, respectively. The aging of our U.S. accounts receivable at December 31, 2010 was: 67% less than 60 days old, 13% between 60 and 120 days and 20% over 120 days old. Our U.S. bad debt allowance at December 31, 2010 and 2009 represented approximately 15% and 16% of our U.S. accounts receivable balance, respectively.
 
Due to the nature of our business, management relies upon the aging of accounts receivable as its primary tool to estimate bad debt expense. Therefore, we reserve for bad debt based principally upon the aging of accounts receivable, without differentiating by payor source. We write off accounts on an individual basis based on that aging. We believe our reserve policy allows us to accurately estimate our allowance for doubtful accounts and bad debt expense.
 
Income Taxes
 
Our income tax policy is to record the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and the bases of those assets and liabilities as reported in our consolidated balance sheets. This estimation process requires that we evaluate the need for a valuation allowance against deferred tax assets, based on factors such as historical financial information, expected timing of future events, the probability of expected future taxable income and available tax planning opportunities. While we recognized the benefit of the


44


Table of Contents

majority of our deferred tax assets in 2009, we still carry a valuation allowance against deferred tax assets that have restrictions as to use and are not considered more likely than not to be realized. If our estimates related to the above items change significantly, we may need to alter the amount of our valuation allowance in the future through a favorable or unfavorable adjustment to net income.
 
Goodwill and Intangible Assets
 
Given the significance of our intangible assets as a percentage of our total assets, we also consider our accounting policy regarding goodwill and intangible assets to be a critical accounting policy. Consistent with GAAP, we do not amortize goodwill or indefinite-lived intangibles but rather test them for impairment annually or more often when circumstances change in a manner that indicates they may be impaired. Impairment tests occur at the reporting unit level for goodwill; our reporting units are defined as our operating segments (United States and United Kingdom). Our intangible assets consist primarily of indefinite-lived rights to manage individual surgical facilities. The values of these rights are tested individually. Intangible assets with definite lives primarily consist of rights to provide management and other contracted services to surgical facilities, hospitals, and physicians. These assets are amortized over their estimated useful lives, and the portfolios are tested for impairment when circumstances change in a manner that indicates their carrying values may not be recoverable.
 
To determine the fair value of our reporting units, we generally use a present value technique (discounted cash flow) corroborated by market multiples when available and as appropriate. The factor most sensitive to change with respect to our discounted cash flow analyses is the estimated future cash flows of each reporting unit which is, in turn, sensitive to our estimates of future revenue growth and margins for these businesses. If actual revenue growth and/or margins are lower than our expectations, the impairment test results could differ. We base our fair value estimates on assumptions we believe to be reasonable and consistent with market participant assumptions, but that are unpredictable and inherently uncertain. The fair value of an indefinite-lived intangible asset is compared to its carrying amount. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values for indefinite-lived intangible assets are estimated based on market multiples and discounted cash flow models which have been derived based on our experience in acquiring surgical facilities, market participant assumptions and third party valuations we have obtained with respect to such transactions.
 
Based on the results of our 2010 goodwill impairment testing, both of our reporting units’ estimated fair values substantially exceed their carrying values. During 2010, we recorded a $5.9 million impairment charge related to six indefinite-lived intangible assets (management contracts) as further discussed in Note 8 to our consolidated financial statements.
 
Merger Transaction
 
USPI had publicly traded equity securities from June 2001 through April 2007. Pursuant to an Agreement and Plan of Merger (the merger) dated as of January 7, 2007, between an affiliate of Welsh, Carson, Anderson & Stowe X, L.P. (Welsh Carson), we became a wholly owned subsidiary of USPI Holdings, Inc. on April 19, 2007. USPI Holdings is a wholly owned subsidiary of USPI Group Holdings, Inc. (Parent), which is owned by an investor group that includes affiliates of Welsh Carson, members of our management and other investors.


45


Table of Contents

Acquisitions, Equity Investments and Development Projects
 
As part of our growth strategy, we acquire interests in existing surgical facilities from third parties and invest in new facilities that we develop in partnership with hospital partners and local physicians. Some of these transactions result in our controlling the acquired entity (business combinations). During the year ended December 31, 2010, we obtained control of the following entities:
 
             
Effective Date
 
Facility Location
  Amount  
 
Investments
           
December 2010
  Houston, Texas(1)   $ 9.0 million  
December 2010
  Reading, Pennsylvania(2)     1.1 million  
November 2010
  Various(3)     31.1 million  
October 2010
  Houston, Texas(1)     2.4 million  
May 2010
  St. Louis, Missouri(4)     4.6 million  
             
Total
      $ 48.2 million  
             
 
 
(1) Acquisition of a controlling interest in and right to manage a surgical facility in which we previously had no involvement. The remainder of this facility is owned by a hospital partner and local physicians.
 
(2) Acquisition of a controlling interest in a surgical facility in which we already held an ownership interest.
 
(3) We acquired 100% of the equity interests in HealthMark Partners, Inc. (HealthMark), a privately-held, Nashville-based owner and operator of surgery centers. HealthMark holds an equity interest in 14 surgery centers, all of which are accounted for under the equity method. Eleven of these facilities are located in markets in which we already operate. Local physicians have ownership in all 14 facilities and by December 31, 2010 and January 31, 2011, hospital partners had invested in nine and ten of these facilities, respectively.
 
(4) Acquisition of a controlling interest in and right to manage a surgical facility in which we previously had no involvement. This facility is jointly owned with local physicians.


46


Table of Contents

 
We also regularly engage in the purchase and sale of equity interests with respect to our investments in unconsolidated affiliates that do not result in a change of control. These transactions are primarily the acquisitions and sales of equity interests in unconsolidated surgical facilities and the investment of additional cash in surgical facilities under development. During the year ended December 31, 2010, these transactions resulted in a net cash outflow of approximately $21.3 million, which is summarized below:
 
             
Effective Date
 
Facility Location
  Amount  
 
Investments
           
December 2010
  Irving, Texas(1)   $ 1.9 million  
December 2010
  Boulder, Colorado(2)     4.7 million  
December 2010
  Houston, Texas(2)     0.9 million  
December 2010
  Chattanooga, Tennessee(3)     2.6 million  
December 2010
  Kansas City, Missouri(4)     1.2 million  
December 2010
  Nashville, Tennessee(5)     13.4 million  
November 2010
  Keller, Texas(1)     4.6 million  
July 2010
  Carrollton, Texas(1)     0.8 million  
July 2010
  Sacramento, California(2)     1.5 million  
May 2010
  Mansfield, Texas(1)     0.4 million  
April 2010
  Destin, Florida(3)     1.3 million  
April 2010
  St. Louis, Missouri(6)     0.4 million  
             
          33.7 million  
Sales(7)
           
December 2010
  Phoenix, Arizona(8)     4.1 million  
June 2010
  Cincinnati, Ohio(9)     7.9 million  
Various
  Various(10)     0.4 million  
             
          12.4 million  
             
Total
      $ 21.3 million  
             
 
 
(1) Acquisition of the right to manage a surgical facility in which we previously had no involvement. Concurrent with this transaction, an unconsolidated investee that we jointly own with a hospital partner used cash on hand to acquire an equity interest in this facility, resulting in our having an indirect ownership interest in the facility. The remainder of this facility is owned by local physicians.
 
(2) Acquisition of a noncontrolling interest in and right to manage a surgical facility in which we previously had no involvement. This facility is jointly owned with one of our hospital partners and local physicians.
 
(3) Acquisition of an additional noncontrolling interest in a surgical facility in which we already held an investment. This facility is jointly owned with local physicians.
 
(4) Acquisition of an additional noncontrolling interest in a surgical facility in which we already held an investment. This facility is jointly owned with one of our hospital partners and local physicians.
 
(5) Acquisition of an additional noncontrolling interest in three surgical facilities in which we already held an investment and one surgical facility in which we already provided management services. These facilities are jointly owned with one of our hospital partners and local physicians.
 
(6) Acquisition of a noncontrolling interest in a surgical facility in which we already provided management services. This facility is jointly owned with one of our hospital partners and local physicians.
 
(7) Sale transactions not involving our surrendering control of the facility are described in this section. Transactions involving the sale of our entire interest in a facility or our surrendering control of a facility are described in “Discontinued Operations and Other Dispositions.”


47


Table of Contents

 
(8) Sale of a portion of our equity ownership in two facilities to a hospital partner. The remainder of these facilities are owned by local physicians.
 
(9) Sale of a portion of our equity ownership in one facility to a hospital partner. The remainder of this facility is owned by local physicians.
 
(10) Represents the net receipt related to various other purchases and sales of equity interests and contributions of cash to equity method investees.
 
Similar to our investments in unconsolidated affiliates, we regularly engage in the purchase and sale of equity interests in our consolidated subsidiaries that do not result in a change of control. These types of transactions are accounted for as equity transactions, as they are undertaken among us, our consolidated subsidiaries, and noncontrolling interests. During the year ended December 31, 2010, we purchased and sold equity interests in various consolidated subsidiaries in the amounts of $2.9 million and $4.0 million, respectively. The difference between our carrying amount and the proceeds received or paid in each transaction is recorded as an adjustment to our additional paid-in capital. These transactions resulted in a $7.2 million decrease to our additional paid-in capital during the year ended December 31, 2010.
 
As further described in the section, “Discontinued Operations and Other Dispositions,” during 2010, we received proceeds of $32.5 million related to our sale of our wholly-owned subsidiary, American Endoscopy Services, Inc. (AES). We also received cash proceeds of $0.6 million related to the sale of a controlling interest in one facility to a hospital partner.
 
During 2009, we acquired interests in existing surgical facilities from third parties and invested in new facilities that we are developing in partnership with hospital partners and local physicians. Some of these transactions result in our controlling the acquired entity (business combinations). In December 2009, we invested $9.9 million in a subsidiary jointly operated with one of our hospital partners, which the subsidiary used to acquire a controlling interest in a facility in Houston, Texas.
 
We also regularly engage in the purchase and sale of equity interests with respect to our investments in unconsolidated affiliates that do not result in a change of control. These transactions are primarily the acquisitions and sales of equity interests in unconsolidated surgical facilities and the investment of additional cash in surgical facilities under development. During the year ended December 31, 2009, these transactions resulted in a net cash outflow of approximately $47.4 million, which is summarized below:
 
             
Effective Date
 
Facility Location
  Amount  
 
Investments
           
December 2009
  Cincinnati, Ohio(1)   $ 17.7 million  
December 2009
  Portland, Oregon(2)     11.1 million  
December 2009
  Nashville, Tennessee(3)     6.1 million  
September 2009
  Fort Worth, Texas(3)     1.2 million  
July 2009
  Fort Worth, Texas(3)     1.0 million  
May 2009
  St. Louis, Missouri(4)     0.9 million  
February 2009
  Fort Worth, Texas(2)     2.0 million  
February 2009
  Stockton, California(2)     2.5 million  
Various
  Various(5)     7.3 million  
             
Total
        49.8 million  
Sales (6)
           
December 2009
  Dallas, Texas(7)     2.4 million  
             
Total
      $ 47.4 million  
             
 
 
(1) Acquisition of a noncontrolling interest in and right to manage a surgical facility in which we previously had no involvement. This facility is jointly owned with local physicians.


48


Table of Contents

 
(2) Acquisition of a noncontrolling interest in and right to manage a surgical facility in which we previously had no involvement. This facility is jointly owned with one of our hospital partners and local physicians.
 
(3) Acquisition of additional ownership in one of our existing facilities.
 
(4) Acquisition of the right to manage a surgical facility in which we previously had no involvement. We have a purchase option to acquire a 20% equity interest in the facility within one year, and after approximately three years, an option to purchase an additional 20% equity interest. We acquired ownership in April 2010.
 
(5) Represents the net purchase of additional ownership and equity contributions in various unconsolidated affiliates, including $3.4 million of investment in four de novos.
 
(6) Sale transactions not involving our surrendering control of the facility are described in this section. Transactions involving the sale of our entire interest in a facility or our surrendering control of a facility are described in “Discontinued Operations and Other Dispositions.”
 
(7) Sale of a portion of our noncontrolling interest in two facilities to a hospital partner. This hospital partner is a related party (Note 12). We retained a noncontrolling interest in these facilities and continue to operate them.
 
Additionally, effective January 1, 2009, we acquired noncontrolling equity interests in and rights to manage two surgical facilities in which we previously had no involvement. These facilities are jointly owned with one of our hospital partners and local physicians. The total purchase price of $2.2 million was paid in December 2008.
 
Similar to our investments in unconsolidated affiliates, we regularly engage in the purchase and sale of equity interests in our consolidated subsidiaries that do not result in a change of control. These types of transactions are accounted for as equity transactions, as they are undertaken among us, our consolidated subsidiaries, and noncontrolling interests. During the year ended December 31, 2009, we purchased and sold equity interests in various consolidated subsidiaries in the amounts of $9.4 million and $7.4 million, respectively. The $9.4 million of purchases includes the partial exercise of our purchase option in one of our existing centers in St. Louis for $7.1 million. The difference between our carrying amount and the proceeds received or paid in each transaction is recorded as an adjustment to our additional paid-in capital. These transactions resulted in a $14.3 million decrease to our additional paid-in capital during the year ended December 31, 2009.
 
We engaged in the following business combinations and transactions, formerly known as step acquisitions, during the year ended December 31, 2008:
 
             
Effective Date
 
Facility Location
  Amount  
 
December 2008
  St. Louis, Missouri(1)   $ 0.4 million  
October 2008
  St. Louis, Missouri(2)     1.9 million  
September 2008
  St. Louis, Missouri(2)     15.8 million  
September 2008
  St. Louis, Missouri(3)     18.0 million  
August 2008
  St. Louis, Missouri(2)     3.0 million  
June 2008
  Dallas, Texas(4)     3.9 million  
April 2008
  St. Louis, Missouri(5)     14.1 million  
Various
  Various(6)     6.6 million  
             
Total
      $ 63.7 million  
             
 
 
(1) We acquired additional ownership in one of our existing facilities.
 
(2) We had no previous investment in this facility.
 
(3) We acquired additional ownership in two of our existing facilities.
 
(4) We purchased all of a healthcare system’s ownership interest in an entity it co-owned with us. This entity has ownership in and manages five facilities in the Dallas/Fort Worth area. This holding company was already a subsidiary of our company and is now wholly owned by us.
 
(5) We acquired additional ownership in three of our existing facilities.
 
(6) Represents the purchase of additional ownership in various consolidated entities.


49


Table of Contents

 
We also engaged in transactions that are not business combinations or step acquisitions. These transactions primarily consist of acquisitions and sales of noncontrolling equity interests in surgical facilities and the investment of additional cash in surgical facilities under development. During the year ended December 31, 2008, these transactions resulted in a net cash outflow of approximately $35.6 million, which is summarized below.
 
             
Effective Date
 
Facility Location
  Amount  
 
Investments
           
December 2008
  Nashville, Tennessee(1)   $ 18.3 million  
December 2008
  Houston, Texas(1)     5.4 million  
December 2008
  Portland, Oregon(1)     5.7 million  
December 2008
  Denver, Colorado(2)     2.2 million  
October 2008
  Houston, Texas(1)     5.2 million  
October 2008
  Denver, Colorado(1)     2.1 million  
January 2008
  Knoxville, Tennessee(1)     1.4 million  
January 2008
  Las Vegas, Nevada(1)     1.1 million  
             
          41.4 million  
             
Sales
           
April 2008
  Kansas City, Missouri(3)     3.6 million  
Various
  Various(4)     2.2 million  
             
          5.8 million  
             
Total
      $ 35.6 million  
             
 
 
(1) Acquisition of a noncontrolling equity interest in and right to manage a surgical facility in which we previously had no involvement. This facility is jointly owned with one of our hospital partners and local physicians.
 
(2) Acquisition of a noncontrolling equity interest in and right to manage two surgical facilities in which we previously had no involvement. These facilities are jointly owned with one of our hospital partners and local physicians. The purchase price was paid in December 2008 and our ownership became effective January 1, 2009.
 
(3) A not-for-profit hospital partner obtained ownership in a facility.
 
(4) Represents the net receipt related to various other purchases and sales of equity interests and contributions of cash to equity method investees.
 
As further described in the section, “Discontinued Operations and Other Dispositions,” during 2008, we received proceeds of $3.4 million related to our sale of all our ownership interests in five facilities. We also received cash proceeds of $5.2 million related to the sale of noncontrolling interests in five facilities to various not-for-profit hospital partners.
 
Discontinued Operations and Other Dispositions
 
Sales of consolidated subsidiaries in which we have no continuing involvement are classified as discontinued operations, as are consolidated subsidiaries that are held for sale. The gains or losses on these transactions are classified within discontinued operations in our consolidated statements of income. Also, we have reclassified our historical results of operations to remove the operations of these entities from our revenues and expenses, collapsing the net income or loss from these operations into a single line within discontinued operations.


50


Table of Contents

Discontinued operations are as follows :
 
                     
Date
 
Facility Location
  Proceeds     Gain (Loss)  
 
December 2010
  Nashville, Tennessee   $ 32.5 million     $ 2.8 million  
December 2010
  Orlando, Florida           (2.0 million )
December 2010
  Templeton, California(1)           (1.9 million )
December 2010
  Houston, Texas(1)           (0.2 million )
                     
Total
      $ 32.5 million     $ (1.3 million )
                     
June 2008
  Cleveland, Ohio   $ 1.6 million     $ (1.0 million )
 
 
(1) These investments were written down to estimated fair value less costs to sell at December 31, 2010, and were sold at amounts approximating these estimated values in February 2011.
 
Equity method investments that are sold do not represent discontinued operations under GAAP. We did not sell any equity method investments during 2010. During 2009 and 2008, we completed sales of investments in ten facilities operated through unconsolidated affiliates, including our equity ownership in these entities as well as the related rights to manage the facilities. Gains and losses on the disposals of these investments are classified within “Losses on deconsolidations, disposals and impairments” in the accompanying consolidated statements of income. These transactions are summarized below:
 
                     
Date
 
Facility Location
  Proceeds (Costs)     Loss  
 
December 2009
  Oxnard, California   $ 0.3 million     $ (0.3 million )
December 2009
  Baton Rouge, Louisiana(1)     (5.1 million )     (8.2 million )
September 2009
  San Antonio, Texas           (2.6 million )
July 2009
  Cleveland, Ohio(2)     1.0 million        
February 2009
  Las Cruces, New Mexico            
February 2009
  East Brunswick, New Jersey     0.7 million       (2.6 million )
                     
Total
      $ (3.1 million )   $ (13.7 million )
                     
July 2008
  Manitowoc, Wisconsin   $ 0.8 million     $  
July 2008
  Orlando, Florida     0.5 million       (0.4 million )
April 2008
  Los Angeles, California            
February 2008
  Sarasota, Florida     0.5 million        
                     
Total
      $ 1.8 million     $ (0.4 million )
                     
 
 
(1) We paid $5.1 million to settle contingent liabilities in conjunction with the sale of this center. Such amount was expensed and included in “Losses on deconsolidations, disposals and impairments” in the accompanying consolidated statements of income.
 
(2) We financed the entire purchase price with the buyer and have a security interest in the facility’s assets until the note is collected, which is due in 2011. As a result, we deferred the recognition of the gain, which is estimated at $0.6 million.
 
As further described in Note 5 to our consolidated financial statements, in 2010, we sold approximately 50% of our ownership interests in an entity that was developing and constructing a new hospital for one of our unconsolidated affiliates. We received $3.1 million in cash related to this sale.
 
In addition to the sales of ownership interests noted above, we sold controlling interests to various hospital partners during 2010, 2009, and 2008 which are described below, as part of our strategy for partnering with these systems. Our continuing involvement as an equity method investor and manager of the facilities precludes classification of these transactions as discontinued operations. Gains and losses are classified within “Losses on deconsolidations, disposals and impairments” in the accompanying consolidated statements of income.
 


51


Table of Contents

                             
Date
 
Facility Location
  Proceeds     Gain (Loss)        
 
December 2010
  Phoenix, Arizona(1)   $ 0.6 million     $ (1.5 million )        
December 2010
  Dallas, Texas(2)           1.6 million          
                             
Total
      $ 0.6 million     $ 0.1 million          
                             
December 2009
  Dallas, Texas(3)   $ 1.2 million     $ 0.3 million          
July 2009
  Oklahoma City, Oklahoma(4)     0.2 million       0.1 million          
March 2009
  Phoenix, Arizona(5)     0.1 million       (8.2 million )        
                             
Total
      $ 1.5 million     $ (7.8 million )        
                             
July 2008
  Beaumont, Texas   $ 1.2 million     $ (0.5 million )        
June 2008
  Dallas, Texas(3)     2.3 million       (0.9 million )        
June 2008
  Houston, Texas(6)     0.6 million                
March 2008
  Redding, California(7)     1.7 million                
                             
Total
      $ 5.8 million     $ (1.4 million )        
                             
 
 
(1) A hospital partner acquired a portion of our interest in this facility and shares control of it with us.
 
(2) We previously controlled this facility but now shares control with physician partners due to a change in the entity’s governing documents.
 
(3) The hospital partner acquired a controlling interest from us in this transaction. Additionally, this hospital partner is a related party (Note 12).
 
(4) We and the other owners of a facility consolidated by us agreed to merge the facility into another entity in which we hold an investment accounted for under the equity method.
 
(5) A controlling interest in an entity was sold to a hospital partner. The hospital partner already had a 49% ownership interest in this entity, which owns and manages two surgical facilities, and through the transaction acquired an additional 1.1% interest. The $8.2 million loss was primarily related to the revaluation of our remaining investment in the entity to fair value.
 
(6) Because we are considered the primary beneficiary of this entity, we consolidate the entity, and continue to consolidate the facility’s operating results. The sales price of $0.6 million was paid in the form of a note receivable from the buyer.
 
(7) We sold a controlling interest in two facilities and received a noncontrolling interest in a third facility in Redding.
 
Sources of Revenue
 
Revenues primarily include the following:
 
  •  net patient service revenues of the facilities that we consolidate for financial reporting purposes, which are those in which we have ownership interests of greater than 50% or otherwise maintain effective control or we are the primary beneficiary;
 
  •  management and contract service revenues, consisting of the fees that we earn from managing the facilities that we do not consolidate for financial reporting purposes and the fees we earn from providing certain consulting and other contracted services to physicians and hospitals. Our consolidated revenues and expenses do not include the management fees we earn from operating the facilities that we consolidate for financial reporting purposes as those fees are charged to subsidiaries and thus eliminated in consolidation.

52


Table of Contents

 
The following table summarizes our revenues by type and as a percentage of total revenue for the periods presented:
 
                         
    Years Ended December 31,
    2010   2009   2008
 
Net patient service revenues
    88 %     88 %     90 %
Management and contract service revenues
    11       10       9  
Other revenues
    1       2       1  
                         
Total revenues
    100 %     100 %     100 %
                         
 
As a percentage of total revenues, net patient service revenues remained consistent at 88% of our total revenues for the years ended December 31, 2010 and 2009. Our net patient services revenues decreased to 88% of total revenues in 2009 from 90% in 2008. This decrease was due in part to the U.S. dollar being stronger on average against the British pound in 2009 compared to 2008, and also is due to shifting of more of our facilities to joint ventures with hospital partners, which usually requires us to account for the facility under the equity method of accounting (as an unconsolidated affiliate). As we execute our strategy of partnering with not-for-profit healthcare systems, more of our business is being conducted through unconsolidated affiliates. With respect to unconsolidated facilities, we do not include the facilities’ net patient service revenues in our financial results; instead; our consolidated financial statements reflect revenues we earn for our management and contract services as noted below. Our share of the revenues, net of expenses of unconsolidated facilities, is reported in our consolidated financial statements as “equity in earnings of unconsolidated affiliates,” which is displayed between revenues and operating expenses. The percentage of our U.S. facilities we account for under the equity method was 70%, 64%, and 63% at December 31, 2010, 2009, and 2008, respectively.
 
Our management and contract service revenues are earned from the following types of activities (in thousands):
 
                         
    Years Ended December 31,  
    2010     2009     2008  
 
Management of surgical facilities
  $ 53,934     $ 46,438     $ 40,100  
Contract services provided to other healthcare providers
    10,904       11,888       12,927  
                         
Total management and contract service revenues
  $ 64,838     $ 58,326     $ 53,027  
                         
 
The following table summarizes our revenues by operating segment:
 
                         
    Years Ended December 31,
    2010   2009   2008
 
United States
    82 %     82 %     80 %
United Kingdom
    18       18       20  
                         
Total
    100 %     100 %     100 %
                         
 
The proportion of our total revenues derived from U.K. operations as stated in U.S. dollars remained constant at 18% for the years ended December 31, 2010 and 2009. From 2008 to 2009, the proportion of out total revenues derived from U.K. operations decreased from 20% to 18%, respectively. The decrease was primarily caused by the average value of the British pound as compared to the U.S. dollar weakening approximately 15% between December 31, 2008 and December 31, 2009.


53


Table of Contents

Results of Operations
 
The following table summarizes certain consolidated statements of income items expressed as a percentage of revenues for the periods indicated:
 
                         
    Years Ended December 31,
USPI
  2010   2009   2008
 
Total revenues
    100.0 %     100.0 %     100.0 %
Equity in earnings of unconsolidated affiliates
    12.1       10.4       7.6  
Operating expenses, excluding depreciation and amortization
    (70.5 )     (71.7 )     (70.2 )
Depreciation and amortization
    (5.1 )     (5.3 )     (5.2 )
                         
Operating income
    36.5       33.4       32.2  
Interest and other expense, net
    (11.9 )     (11.3 )     (13.3 )
                         
Income from continuing operations before income taxes
    24.6       22.1       18.9  
Income tax benefit (expense)
    (5.6 )     0.1       (3.7 )
                         
Income from continuing operations
    19.0       22.2       15.2  
Earnings (loss) from discontinued operations, net of tax
    (1.2 )     0.2       (0.1 )
                         
Net income
    17.8       22.4       15.1  
Less: Net income attributable to noncontrolling interests
    (10.5 )     (10.7 )     (9.0 )
                         
Net income attributable to USPI’s common stockholder
    7.3 %     11.7 %     6.1 %
                         
 
Our business model of partnering with not-for-profit hospitals and physicians results in our accounting for 130 of our surgical facilities under the equity method rather than consolidating their results. The following table reflects the summarized results of the unconsolidated facilities that we account for under the equity method of accounting (amounts are expressed as a percentage of unconsolidated affiliates revenues, and reflect 100% of the investees’ results on an aggregated basis):
 
                         
    Years Ended December 31,
USPI’s Unconsolidated Affiliates
  2010   2009   2008
 
Revenues
    100.0 %     100.0 %     100.0 %
Operating expenses, excluding depreciation and amortization
    (69.7 )     (69.6 )     (70.6 )
Depreciation and amortization
    (4.2 )     (4.3 )     (4.8 )
                         
Operating income
    26.1       26.1       24.6  
Interest expense, net
    (1.9 )     (2.1 )     (2.4 )
Other, net
          0.4        
                         
Income before income taxes
    24.2       24.4       22.2  
Income tax expense
    (0.6 )     (0.6 )     (0.6 )
                         
Net income
    23.6 %     23.8 %     21.6 %
                         
 
Executive Summary
 
Our strategy continues to focus on growing the profits of our existing facilities, developing new facilities with hospital partners, and adding other facilities selectively through acquisition. We added 27 facilities during 2010 and operated 189 facilities at year-end, up from 169 at the end of 2009. Consistent with our primary strategy, we continued to focus on partnering both existing facilities and newly acquired or constructed facilities with a not-for-profit health system (hospital partner). The number of facilities with hospital partners increased by 23 during 2010. We also sold two facilities and an endoscopy business and designated two additional facilities as held for sale at December 31, 2010. Our operating results were not as strong as in recent years, but improved during the course of the year.
 
Surgical case volumes and profits at our facilities decreased slightly in the early part of 2010 but improved during the year. Overall for 2010, this translated to a 5% year-over-year increase in the revenues of facilities we


54


Table of Contents

operated in both 2009 and 2010 (same store facilities), as compared to 8% for 2009 and 11% for 2008. However, in 2010 the volumes and revenues of our same store facilities improved during the year, with the fourth quarter growth rate of 8% representing a significant improvement over earlier quarters, particularly compared to the 2% rate we experienced during the first quarter of 2010. Factoring in acquisitions, our overall systemwide revenues increased 7% for the year (13% in the fourth quarter).
 
While our systemwide revenues grew, USPI’s 2010 reported revenues, which consist only of consolidated businesses, decreased compared to prior year by 3%. This decrease was driven by two factors related to the deployment of our primary business model, which is jointly owning our facilities with prominent local physicians and a hospital partner. We generally do not consolidate the businesses in these structures, but our profits from them, which are reflected in equity in earnings of unconsolidated affiliates, increased 13% in 2010. Excluding the impact of an impairment charge with respect to one investment, our equity in earnings of unconsolidated affiliates increased 19%. The revenues of these facilities, which are not included in USPI’s reported revenues, are growing more than our consolidated facilities; the revenues of the unconsolidated facilities we owned in both years increased $97.1 million during 2010 as compared to the prior year, and additionally increased through acquisitions and as a result of our partnering four of these facilities with a hospital partner in 2010, thereby deconsolidating them, which moves their revenues out of our consolidated revenues and into the revenues of our unconsolidated group of facilities. Our consolidated revenues decreased primarily due to these “deconsolidation” transactions, which moved $14.6 million from the consolidated to the unconsolidated group, and additionally due to declines in operational results ($9.4 million).
 
Operating income increased 6% year-over-year and was significantly impacted by several amounts not directly related to our facilities’ operating results. Excluding these amounts, shown below, operating income and margin were up 2% and 180 basis points, respectively (in millions):
 
                 
    2010     2009  
 
Losses on deconsolidations, disposals and impairments(1)
  $ 10.1     $ 29.2  
Expense related to previous acquisition and facility purchase option
    6.0        
Acquisition costs
    3.3        
VAT assessment(2)
    1.0       (1.0 )
                 
Total impact on operating income
  $ 20.4     $ 28.2  
                 
 
 
(1) Of the 2010 amount, $3.7 million is classified within equity in earnings of unconsolidated affiliates.
 
(2) U.K. taxing authority awarded us a value-added tax refund in 2009 but reversed its position in 2010. We are appealing the decision.
 
While this increase in operating margin reflects some leveraging of our consolidated operating expenses, we additionally focus on U.S. same store facility level operating income margins (which reflect all facilities’ results, consolidated and unconsolidated) as indicators of the trend of our business, because our earnings and cash flows are heavily driven by the results at those facilities, whether we consolidate them or not. For the full year, those margins actually decreased slightly, reflecting the slower revenue growth described above. Because of relationships like these (differences in the magnitude or direction of consolidated versus systemwide revenues and margins), which often are driven by “deconsolidations” such as those described above, we supplementally focus on systemwide revenues and facility level operating income margins as important indicators for our business, given that our earnings ultimately are driven heavily by facility level revenues and operating margins. Facility level operating income margins were down 60 basis points year-over-year, but as with revenues the results improved as the year progressed, culminating in facility operating income margins for the fourth quarter being 60 basis points higher than the fourth quarter of 2009.
 
As noted above, we continued to acquire and develop facilities in 2010, acquiring 25 existing facilities and opening two newly constructed facilities. Our U.S. development strategy continues to focus most heavily on markets in which we have a significant presence with prominent local physicians and often a hospital partner. We also invest capital selectively in our U.K. market and in new markets. Pursuing this strategy also leads us to deconsolidate or divest of centers from time to time, as we did in 2009 and 2010.


55


Table of Contents

Also impacting year-over-year comparisons in 2010 was the 2009 recognition of a $31.2 million tax benefit reflecting the Company’s expectation that the majority of its U.S. deferred tax assets would be utilized prior to their expiration.
 
Our Business and Key Measures
 
We operate surgical facilities in partnership with local physicians and, in the majority of cases, a not-for-profit health system partner. We hold an ownership interest in each facility, each being operated through a separate legal entity owned by us, the health systems and physicians. We operate each facility on a day-to-day basis through a management services contract. Our sources of earnings from each facility consist of:
 
  •  our share of each facility’s net income, which is computed by multiplying the facility’s net income times the percentage of each facility’s equity interests owned by us; and
 
  •  management services revenues, computed as a percentage of each facility’s net revenues (often net of bad debt expense).
 
Our role as an owner and day-to-day manager provides us with significant influence over the operations of each facility. In a growing majority of our facilities (currently 130 of our 189 facilities), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method, i.e., as an unconsolidated affiliate. Of the remaining facilities, we control 58 facilities and account for these investments as consolidated subsidiaries and operate one facility under a service and management contract.
 
Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than us is classified within “net income attributable to noncontrolling interests.”
 
For unconsolidated affiliates, our consolidated statements of income reflect our earnings in only two line items:
 
  •  equity in earnings of unconsolidated affiliates: our share of the net income of each facility, which is based on the facilities’ net income and the percentage of the facility’s outstanding equity interests owned by us; and
 
  •  management and administrative services revenues: income we earn in exchange for managing the day-to-day operations of each facility, usually quantified as a percentage of each facility’s net revenues less bad debt expense.
 
In summary, USPI’s operating income is driven by the performance of all facilities we operate and by our ownership interest in those facilities, but USPI’s individual revenue and expense line items only contain consolidated businesses, which represent less than half of our operations. This translates to trends in operating income that often do not correspond with changes in revenues and expenses. The divergence in these relationships is particularly significant when our strategy is heavily weighted to unconsolidated affiliates, as it has been in recent years during the ongoing deployment of our strategy to partner with not-for-profit health systems. Accordingly, we review several types of information in order to monitor and analyze USPI’s results of operations, including:
 
  •  The results of operations of USPI’s unconsolidated affiliates
 
  •  USPI’s average ownership share in the facilities we operate; and
 
  •  Facility operating indicators, such as systemwide revenue growth, same store revenue growth, and same store operating margins


56


Table of Contents

 
Our Consolidated and Unconsolidated Results
 
The following table shows USPI’s results of operations and the results of operations of USPI’s unconsolidated affiliates.
 
                                                 
    Year Ended December 31,              
    2010     2009     Variance to Prior Year  
    USPI As
          USPI As
          USPI As
       
    Reported
          Reported
          Reported
       
    Under
    Unconsolidated
    Under
    Unconsolidated
    Under
    Unconsolidated
 
    GAAP     Affiliates     GAAP     Affiliates     GAAP     Affiliates  
 
Revenues:
                                               
Net patient service revenues
  $ 504,765     $ 1,322,393     $ 523,899     $ 1,171,242     $ (19,134 )   $ 151,151  
Management and contract service revenues
    64,838             58,326             6,512        
Other income
    7,062       6,648       11,250       6,872       (4,188 )     (224 )
                                                 
Total revenues
    576,665       1,329,041       593,475       1,178,114       (16,810 )     150,927  
Equity in earnings of unconsolidated affiliates
    69,916             61,771             8,145        
Operating expenses:
                                               
Salaries, benefits, and other employee costs
    156,213       309,698       160,278       277,053       (4,065 )     32,645  
Medical services and supplies
    97,940       310,770       99,510       271,663       (1,570 )     39,107  
Other operating expenses
    99,075       273,649       89,347       243,241       9,728       30,408  
General and administrative expenses
    38,202             38,769             (567 )      
Provision for doubtful accounts
    8,458       31,396       8,720       28,528       (262 )     2,868  
Losses on deconsolidations, disposals and impairments
    6,378       1,025       29,162       (7 )     (22,784 )     1,032  
Depreciation and amortization
    29,799       55,216       31,165       50,251       (1,366 )     4,965  
                                                 
Total operating expenses
    436,065       981,754       456,951       870,729       (20,886 )     111,025  
                                                 
Operating income
    210,516       347,287       198,295       307,385       12,221       39,902  
Interest income
    798       378       2,741       456       (1,943 )     (78 )
Interest expense
    (70,038 )     (26,008 )     (70,353 )     (24,850 )     315       (1,158 )
Other, net
    708       (200 )     373       4,572       335       (4,772 )
                                                 
Total other expense, net
    (68,532 )     (25,830 )     (67,239 )     (19,822 )     (1,293 )     (6,008 )
                                                 
Income from continuing operations before income taxes
    141,984       321,457       131,056       287,563       10,928       33,894  
Income tax (expense) benefit
    (32,328 )     (7,562 )     879       (6,860 )     (33,207 )     (702 )
                                                 
Income from continuing operations
    109,656       313,895       131,935       280,703       (22,279 )     33,192  
Earnings (loss) from discontinued operations, net
    (7,003 )           1,453             (8,456 )      
                                                 
Net income
    102,653     $ 313,895       133,388     $ 280,703       (30,735 )   $ 33,192  
                                                 
Less: Net income attributable to noncontrolling interests
    (60,560 )             (63,722 )             3,162          
                                                 
Net income attributable to USPI
  $ 42,093             $ 69,666             $ (27,573 )        
                                                 
USPI’s equity in earnings of unconsolidated affiliates
          $ 69,916             $ 61,771             $ 8,145  
 


57


Table of Contents

                                                 
    Year Ended December 31,              
    2009     2008     Variance to Prior Year  
    USPI As
          USPI As
          USPI As
       
    Reported
          Reported
          Reported
       
    Under
    Unconsolidated
    Under
    Unconsolidated
    Under
    Unconsolidated
 
    GAAP     Affiliates     GAAP     Affiliates     GAAP     Affiliates  
 
Revenues:
                                               
Net patient service revenues
  $ 523,899     $ 1,171,242     $ 554,350     $ 996,315     $ (30,451 )   $ 174,927  
Management and contract service revenues
    58,326             53,027             5,299        
Other income
    11,250       6,872       7,721       6,066       3,529       806  
                                                 
Total revenues
    593,475       1,178,114       615,098       1,002,381       (21,623 )     175,733  
Equity in earnings of unconsolidated affiliates
    61,771             47,042       13       14,729       (13 )
Operating expenses:
                                               
Salaries, benefits, and other employee costs
    160,278       277,053       170,805       246,739       (10,527 )     30,314  
Medical services and supplies
    99,510       271,663       109,739       211,781       (10,229 )     59,882  
Other operating expenses
    89,347       243,241       101,846       218,337       (12,499 )     24,904  
General and administrative expenses
    38,769             40,155             (1,386 )      
Provision for doubtful accounts
    8,720       28,528       7,359       29,497       1,361       (969 )
Losses on deconsolidations, disposals and impairments
    29,162       (7 )     1,827       1,161       27,335       (1,168 )
Depreciation and amortization
    31,165       50,251       32,305       48,722       (1,140 )     1,529  
                                                 
Total operating expenses
    456,951       870,729       464,036       756,237       (7,085 )     114,492  
                                                 
Operating income
    198,295       307,385       198,104       246,157       191       61,228  
Interest income
    2,741       456       3,278       1,687       (537 )     (1,231 )
Interest expense
    (70,353 )     (24,850 )     (84,916 )     (25,788 )     14,563       938  
Other
    373       4,572       32       225       341       4,347  
                                                 
Total other expense, net
    (67,239 )     (19,822 )     (81,606 )     (23,876 )     14,367       4,054  
                                                 
Income from continuing operations before income taxes
    131,056       287,563       116,498       222,281       14,558       65,282  
Income tax benefit (expense)
    879       (6,860 )     (22,667 )     (5,566 )     23,546       (1,294 )
                                                 
Income from continuing operations
    131,935       280,703       93,831       216,715       38,104       63,988  
Earnings (loss) from discontinued operations
    1,453             (1,179 )           2,632        
                                                 
Net income
    133,388     $ 280,703       92,652     $ 216,715       40,736     $ 63,988  
                                                 
Less: Net income attributable to noncontrolling interests
    (63,722 )             (55,138 )             (8,584 )        
                                                 
Net income attributable to USPI
  $ 69,666             $ 37,514             $ 32,152          
                                                 
USPI’s equity in earnings of unconsolidated affiliates
          $ 61,771             $ 47,042     $       $ 14,729  
 
The following table provides other information regarding our unconsolidated affiliates (in thousands):
 
                         
    Years Ended December 31,
    2010   2009   2008
 
Long-term debt of USPI’s unconsolidated facilities
  $ 330,578     $ 271,781     $ 273,438  
USPI’s equity in earnings of unconsolidated affiliates
    69,916       61,771       47,042  
USPI’s imputed weighted average ownership percentage based on affiliates’ pretax income(1)
    21.7 %     21.5 %     21.2 %
USPI’s imputed weighted average ownership percentage based on affiliates’ debt(2)
    23.8 %     25.4 %     25.0 %
Unconsolidated facilities operated at period end
    130       109       101  

58


Table of Contents

 
(1) Our weighted average percentage ownership in our unconsolidated affiliates is calculated as USPI’s equity in earnings of unconsolidated affiliates divided by the total net income of unconsolidated affiliates for each respective period. This is a non-GAAP measure but management believes it provides further useful information about USPI’s involvement in unconsolidated affiliates.
 
(2) Our weighted average percentage ownership in our unconsolidated affiliates is calculated as the total debt of each unconsolidated affiliate, multiplied by the percentage ownership USPI held in the affiliate as of the end of each respective period, divided by the total debt of all of the unconsolidated affiliates as of the end of each respective period. This is a non-GAAP measure but management believes it provides further useful information about USPI’s involvement in unconsolidated affiliates.
 
One of our unconsolidated affiliates, Texas Health Ventures Group, L.L.C., is considered significant to our consolidated financial statements under regulations of the SEC. As a result, we have filed Texas Health Ventures Group, L.L.C.’s consolidated financial statements with this Form 10-K for the appropriate periods.
 
As shown above, USPI’s consolidated net patient service revenues for the year ended December 31, 2010 decreased $19.1 million compared to the prior year, and the net patient service revenues of USPI’s unconsolidated affiliates increased $151.2 million. These variances are analyzed more extensively in the “Revenues” section, but in general they reflect the fact that we are conducting more of our operations through unconsolidated affiliates. The increase in revenues of these unconsolidated affiliates, net of their expenses, led to the affiliates earning $33.2 million more compared to the prior year. The affiliates’ increase in net income, once allocated to USPI and the affiliates’ other investors, led to USPI’s equity in earnings of unconsolidated affiliates increasing by $8.1 million, which represents nearly 67% of the increase in USPI’s operating income from 2009 to 2010.
 
When comparing 2009 and 2008, the relationships were similar. USPI’s consolidated net patient services revenues decreased $30.5 million for the year ended December 31, 2009 compared to 2008, and the net patient service revenues of USPI’s unconsolidated affiliates increased $174.9 million, driving a $64.0 million increase in the net income of the unconsolidated affiliates and an overall increase of $14.7 million in USPI’s equity in earnings of unconsolidated affiliates.
 
Our Ownership Interests in the Facilities We Operate
 
Our earnings are predominantly driven by our investments in the facilities we operate, so we focus on those businesses’ performance together with the percentage ownership interest we hold in them to help us understand our results of operations. Our average ownership interest in the U.S. surgical facilities we operate is as follows:
 
                         
    Year Ended
  Year Ended
  Year Ended
    December 31,
  December 31,
  December 31,
    2010   2009   2008
 
Unconsolidated facilities(1)
    21.7 %     21.5 %     21.2 %
Consolidated facilities(2)
    46.7 %     48.1 %     48.8 %
Total(3)
    28.2 %     29.4 %     30.2 %
 
 
(1) Computed for unconsolidated facilities by dividing (a) our total equity in earnings of unconsolidated affiliates by (b) the aggregate net income of U.S. surgical facilities we account for under the equity method.
 
(2) Computed for consolidated facilities by dividing (a) the aggregate net income of U.S. surgical facilities we operate less our total minority interests in income of consolidated subsidiaries by (b) the aggregate net income of our consolidated U.S. surgical facilities.
 
(3) Computed in total by dividing our share of the facilities’ net income, defined as the sum of (a) in footnotes (1) and (2), by the aggregate net income of our U.S. surgical facilities, defined as the sum of (b) in footnotes (1) and (2).
 
Our average ownership interest for each group of facilities is determined by many factors, including the ownership levels we negotiate in our acquisition and development activities, the relative performance of facilities in which we own percentages higher or lower than average, and other factors. As described earlier, our increased focus on partnering our facilities with hospital partners in addition to physicians generally leads to our accounting for


59


Table of Contents

more facilities under the equity method (unconsolidated), and we have moved three facilities from consolidated to unconsolidated during 2010 and four facilities during each of 2009 and 2008. Accordingly, our consolidated financial statements show decreases in revenues and most expense line items compared to the respective prior year. However, since our average ownership in our facilities, as shown in the table above, did not significantly change from the respective prior year, our success in growing our facilities’ profits (whether consolidated or unconsolidated) translated to increases in USPI’s operating income in 2010, 2009 and 2008.
 
While our ownership interests remained higher for consolidated facilities than for unconsolidated facilities, our average ownership in our consolidated facilities decreased from 2009 to 2010 due to relative performance of certain consolidated facilities, namely that one market’s facilities, in which our ownership is higher than average, experienced steeper than average drops in profitability compared to our other consolidated facilities due to the execution of a long-term payor contract.
 
Revenues
 
USPI’s consolidated net revenues decreased approximately 3% during the year ended December 31, 2010, as compared to the year ended December 31, 2009. However, our operating income increased 6%. The table below quantifies several significant items impacting year over year growth.
 
                 
    Year Ended
 
    December 31, 2010  
    USPI as
       
    Reported Under
    Unconsolidated
 
    GAAP     Affiliates  
 
Total revenues, year ended December 31, 2009
  $ 593,475     $ 1,178,114  
Add: revenue from acquired facilities
    8,070       45,909  
Less: revenue of disposed facilities
          (12,169 )
Less: revenue of deconsolidated facilities
    (14,571 )     14,571  
Impact of exchange rate
    (1,199 )      
                 
Adjusted base year
    585,775       1,226,425  
(Decrease) increase from operations
    (9,366 )     97,093  
Non-facility based revenue
    256       5,523  
                 
Total revenues, year ended December 31, 2010
  $ 576,665     $ 1,329,041  
                 
 
The reason for the discrepancy between revenue growth and income growth is the increased proportion of our business being conducted through unconsolidated affiliates. Growing the volume and profits of unconsolidated facilities has relatively little impact on our consolidated revenues, but our share of their increasing net income (equity in earnings of unconsolidated affiliates, which grew by 13%, 31% and 39% in 2010, 2009 and 2008, respectively) is reflected in our operating income and net income. Accordingly, as described above, we focus on our systemwide results in order to understand where our growth in income is coming from. Our systemwide revenues, which include revenues of facilities we account for under the equity method as well as facilities we consolidate, grew by rates more commensurate with our overall income growth: 7%, 9% and 14% during the years ended December 31, 2010, 2009 and 2008, respectively. As depicted above, a major component of the decrease in consolidated revenues was the deconsolidation of facilities, which caused a corresponding increase in the revenues of unconsolidated affiliates. However, operations also were a significant factor, although differently for each of the two groups (consolidated and equity method). Despite only slight growth in case volumes, a shift to more complex surgical cases in several equity method facilities, and the resulting increased revenue per case, actually caused an approximate $97.1 million increase in the revenues of this group of facilities, whereas the consolidated facilities experienced decreases in average reimbursement as well as case volumes. These factors combined to reduce consolidated revenues by approximately $9.4 million.


60


Table of Contents

Facility Growth
 
As described above, our systemwide revenues (consisting of both consolidated subsidiaries and unconsolidated affiliates) grew 7% and 9% during 2010 and 2009. While systemwide revenue growth was partially driven by acquisitions and development of new facilities, the most significant component continued to be the results of facilities that have been open for more than one year (same store facilities). This group of facilities experienced revenue growth of 5% and 8% during 2010 and 2009, respectively. The growth in these facilities was driven more by increases in net revenue per case than by increases in volume. While some of this shift reflects increases in rates we negotiate with payors, we believe a more significant portion of the increase is driven by the type of cases we performed, which continue to shift to more complex cases on average, particularly at several of our larger facilities. Our U.S. case volumes started the year sluggishly, decreasing 2% in the first quarter on a year-over-year basis, but improved during the year, culminating in a 3% year-over-year growth rate in the fourth quarter. While the fourth quarter growth rate compares favorably with our 2% annual growth rates for the full years 2008 and 2009, U.S. cases for the full year 2010 were essentially flat as a result of the sluggish early months. We believe this overall lower case volume growth could have resulted from several factors, including changes to health insurance plans to require more patient responsibility for healthcare expenses and a generally soft economy.
 
Our United Kingdom facilities’ revenues, when measured in local currency (or constant exchange rate), declined 1% during 2010 as compared to 2009. This decline is largely due to a decrease in the National Health Service business and in self-pay business. While self-pay business represents only 2% of our U.S. business, it represents 25% of our U.K. business. Self-pay business is generally considered more susceptible to changes in general economic conditions, as the cost of care is borne entirely by the patient rather than shared with private insurers or borne by the National Health Service. The strengthening of the U.S. dollar versus the British pound caused a significant drop (approximately $19.0 million) in reported revenues during 2009 as compared to 2008, but in local currency, our U.K. facilities continued to generate revenue growth in 2009.
 
The following table summarizes our same store facility growth rates, as compared to the corresponding prior year period:
 
                         
    Years Ended December 31,
    2010   2009   2008
 
United States facilities:
                       
Net revenue
    5 %     8 %     11 %
Surgical cases
    %     2 %     2 %
Net revenue per case(1)
    5 %     5 %     9 %
United Kingdom facilities:
                       
Adjusted admissions
    (5 )%     (5 )%     9 %
Net revenue using actual exchange rates
    (2 )%     (14 )%     3 %
Net revenue using constant exchange rates(2)
    (1 )%     2 %     11 %
All same store facilities:
                       
Net revenue using actual exchange rates
    5 %     6 %     10 %
 
 
(1) Our overall domestic same store growth in net revenue per case for 2010 was favorably impacted by the 10% growth at our thirteen same store surgical hospitals, which on average perform more complex cases and thus earn a higher average net revenue per case than ambulatory surgery centers. The net revenue per case growth at our ambulatory surgery centers was 2% during 2010. The favorable impact, in the first quarter of 2008, of our collecting amounts related to past patient services in conjunction with our finalizing a new contract with a major payor has been excluded from 2008 growth rates as it relates to dates of service prior to January 1, 2008. The revenue reductions related to two similar, but adverse, adjustments in the second quarter of 2008 were excluded for similar reasons, as was the unfavorable impact of such an amount which arose during the second quarter of 2009.


61


Table of Contents

 
(2) Calculated using constant exchange rates for all periods. Although this computation represents a non-GAAP measure, we believe that using a constant currency translation rate more accurately reflects the trend of the business.
 
Joint Ventures with Not-for-Profit Hospitals
 
Our addition of new facilities continues to be more heavily weighted to U.S. surgical facilities with a hospital partner, both as we initiate joint venture agreements with new systems and as we add facilities to our existing arrangements. Facilities have been added to hospital joint ventures both through construction of new facilities (de novos) and through our contribution of our equity interests in existing facilities into a hospital joint venture structure, effectively creating three-way joint ventures by sharing our ownership in these facilities with a hospital partner while leaving the existing physician ownership intact.
 
Consistent with this strategy, our overall number of facilities increased by 20 from December 31, 2009 to December 31, 2010, driven by a net increase of 23 facilities partnered with not-for-profit hospitals and local physicians. All five facilities under construction at December 31, 2010, involve a hospital partner, and we continue to explore affiliating more facilities with hospital partners, especially for facilities in markets where we already operate other facilities with a hospital partner.
 
The following table summarizes the facilities we operated as of December 31, 2010, 2009, and 2008:
 
                         
    2010   2009   2008
 
United States facilities(1):
                       
With a hospital partner
    132       109       99  
Without a hospital partner
    53       56       62  
                         
Total U.S. facilities
    185       165       161  
United Kingdom facilities
    4       4       3  
                         
Total facilities operated
    189       169       164  
                         
Change from prior year-end:
                       
De novo (newly constructed)
    2       4       4  
Acquisition
    25       7       10  
Disposals(2)
    (7 )     (6 )     (5 )
                         
Total increase in number of facilities
    20       5       9  
                         
 
 
(1) At December 31, 2010, physicians own a portion of all of these facilities.
 
(2) During 2010, we merged two of our Dallas-area surgery centers into one location, and also merged two of our Ohio surgery centers into one location. We sold our ownership interests in a facility in Orlando, Florida and are classifying a facility in Templeton, California and Houston, Texas as held for sale at December 31, 2010 (sold in February 2011). During 2009, we sold our ownership interests in facilities in East Brunswick, New Jersey; Cleveland, Ohio; San Antonio, Texas; Baton Rouge, Louisiana; and Oxnard, California. We also merged one of our surgery centers into one of our surgical hospitals in Oklahoma. During 2008, we sold ownership interests in facilities in Sarasota, Florida; Los Angeles, California; Cleveland, Ohio; Manitowoc, Wisconsin; and Las Cruces, New Mexico.
 
Facility Operating Margins
 
Same store U.S. facility operating margins decreased 60 basis points for the year ended December 31, 2010 as compared to 2009. The decrease was broad-based, and was largely due to lower case volumes early in the year that were not offset by a proportionate decrease in operating expenses. Following the pattern of same facility revenues, and driven by similar factors, margins improved during the year, recovering from a 240 basis point drop in year-over-year margins for the first quarter of 2010 to finish the year down 60 basis points on a full year basis, due to an improvement each quarter ending with a fourth quarter that was up 60 basis points over prior year. Continuing a


62


Table of Contents

trend we experienced in 2008 and 2009, the year-over-year change in the operating margins of facilities partnered with a not-for-profit healthcare system was more favorable (or, in the case of 2010, less unfavorable) than the change experienced by the facilities that do not have a hospital partner.
 
In 2009, same store U.S. facility operating margins increased 250 basis points, largely driven by continued revenue growth together with cost saving measures introduced during 2009 at our facilities. While the improvement was broad-based, it was particularly notable in the group of facilities jointly owned with hospital partners, the margins of which improved 340 basis points. The margins of facilities we operate without a hospital partner did not fare as well, but were up 20 basis points as compared to the year ended December 31, 2008. We believe this disparity in recent years generally reflects the benefits of our increased focus on developing some of our larger markets, where we more often have a hospital partner. During 2008, same store U.S. facility operating margins increased slightly (10 basis points) largely due to improved leveraging of expenses at some of our larger facilities, which underwent expansions during 2007.
 
Our U.K. facilities, which comprise four of our 189 facilities at December 31, 2010, experienced a decrease in overall facility margins in 2010 as compared to 2009, also due to lower volumes that were not offset by a proportionate decrease in operating expenses. While margins were still down, expenses were controlled more successfully in 2010 than in 2009.
 
The following table summarizes our year-over-year increases (decreases) in same store operating margins (see footnote 1 below):
 
                         
    Year Ended December 31,
    2010   2009   2008
 
United States facilities:
                       
With a hospital partner
    (40 ) bps     340  bps     170  bps
Without a hospital partner
    (120 )     20       (260 )
Total U.S. facilities(2)
    (60 )     250       10  
United Kingdom facilities(3)
    (110 ) bps     (160 ) bps     80  bps
 
 
(1) Operating margin is calculated as operating income divided by total revenues. This table aggregates all of the same store facilities we operate using 100% of their results. This does not represent the overall margin for USPI’s operations in either the U.S. or U.K. because we have a variety of ownership levels in the facilities we operate, and facilities open for less than a year are excluded from same store calculations.
 
(2) The favorable impact, in the first quarter of 2008, of our collecting amounts related to past patient services in conjunction with our finalizing a new contract with a major payor has been excluded from these growth rates as it relates to dates of service prior to January 1, 2008. The revenue reductions related to two similar, but adverse, adjustments in the second quarter of 2008 were excluded for similar reasons, as was the unfavorable impact of such an amount which arose during the second quarter of 2009.
 
(3) Calculated using constant exchange rates for all periods. Although this computation represents a non-GAAP measure, we believe that using a constant translation rate more accurately reflects the trend of the business. In addition, The $1.0 million unfavorable impact of a payment of value-added tax in the first quarter of 2010 has been excluded from U.K. same store facility operating margins. The favorable impact of this value-added tax recorded in the second quarter of 2009 was also excluded.
 
Year Ended December 31, 2010 Compared to Year Ended December 31, 2009
 
As discussed more fully in “Revenues,” our consolidated revenues decreased by $16.8 million, or 2.8%, to $576.7 million for the year ended December 31, 2010 from $593.5 million for the year ended December 31, 2009 as our business continued to shift to unconsolidated affiliates, whose revenues increased 13% but are not included in our consolidated revenues. The number of facilities we account for under the equity method increased by 21 from December 31, 2009 to December 31, 2010; the number of facilities we consolidate decreased by two during this period.


63


Table of Contents

Equity in earnings of unconsolidated affiliates increased by $8.1 million, or 13.2% to $69.9 million for the year ended December 31, 2010 from $61.8 million for the year ended December 31, 2009. Excluding an impairment charge we recorded on an equity method investment during 2010 of $3.7 million, our equity in earnings increased 19%, driven by the growth in revenues of our unconsolidated affiliates.
 
Operating income increased 6% year-over-year and was significantly impacted by several items described in “Executive Summary,” the most significant of which were losses on deconsolidations, disposals, and impairments, which decreased $22.8 million to $6.4 million for the year ended December 31, 2010 from $29.2 million for the year ended December 31, 2009. During 2010, we recorded impairment charges of $5.9 million on six indefinite lived management contracts. These impairment charges were partially offset by a net gain on the sale or deconsolidation of various facilities of approximately $1.7 million. In 2009, we recorded approximately $21.4 million in losses on the sale or deconsolidation of various facilities, impairment charges totaling $5.7 million related to three management contracts and $2.1 million of termination fees related to two acquisitions we made in 2007. We elected not to purchase additional ownership in these facilities and expensed the termination fee. Operating expenses, like our revenues, were also reduced due to deconsolidations. This was the primary factor in the $1.4 million, or 4.3%, decrease in depreciation and amortization to $29.8 million for the year ended December 31, 2010 from $31.2 million for the year ended December 31, 2009.
 
Interest expense, net of interest income, increased $1.6 million to $69.2 million for the year ended December 31, 2010 from $67.6 million for the year ended December 31, 2009. While market interest rates and our debt balance were lower in 2010 than 2009, the $1.6 million increase can primarily be attributed to a $0.8 million interest income on a settlement we received in the second quarter of 2009 from the British tax authority related to the VAT noted above, whereas in the first quarter of 2010, we recorded a $0.8 million expense as the British tax authority reclaimed the amount.
 
Provision for income taxes was an income tax expense of $32.3 million for the year ended December 31, 2010 as compared to a $0.9 million benefit for the year ended December 31, 2009. The benefit in 2009 was primarily the result of our reversing the valuation allowance ($31.2 million) against a majority of our U.S. deferred tax assets. During the third quarter of 2009, we determined it was more likely than not that we would generate taxable income to recover these assets in future periods. Our effective tax rate for the year ended December 31, 2010 was approximately 40%. Our effective tax rate, excluding the benefit of reversing the deferred tax asset allowance, was approximately 45% for the year ended December 31, 2009.
 
Total (loss) gain from discontinued operations was a loss of $7.0 million for the year ended December 31, 2010 as compared to earnings of $1.5 million for the year ended December 31, 2009. The $7.0 million represents loss from discontinued operations of $0.2 million and a loss on disposal of discontinued operations of $6.8 million. We sold two entities in 2010 and designated two others as held for sale. Because these entities are classified as discontinued operations, our consolidated statements of income and the year over year comparisons reflect the historical results of their operations in discontinued operations for all periods presented.
 
Net income was $102.7 million for the year ended December 31, 2010 as compared to $133.4 million for the year ended December 31, 2009. While our surgical facilities earned more in 2010 than 2009, the factors described above, such as the 2009 tax benefit and 2010 loss on discontinued operations, resulted in our net income decreasing compared to 2009.
 
Net income attributable to noncontrolling interests decreased $3.2 million, or 5.0%, to $60.6 million for the year ended December 31, 2010 from $63.7 million for the year ended December 31, 2009, as a result of more of our profits coming from unconsolidated affiliates and less from consolidated subsidiaries, as discussed above.
 
Year Ended December 31, 2009 Compared to Year Ended December 31, 2008
 
Revenues decreased by $21.6 million, or 3.5%, to $593.5 million for the year ended December 31, 2009 from $615.1 million for the year ended December 31, 2008. This decrease was primarily the result of our selling a partial interest in four of our consolidated facilities, which resulted in our deconsolidating the facilities. This $42.4 million decrease, together with a decrease in U.K. revenues of $18.9 million as a result of the U.S. dollar strengthening against the British pound, more than offset the increases from growth in facilities we consolidated in both years or


64


Table of Contents

acquired during late 2008 or 2009. As described above, the fact that we account for the majority of our U.S. facilities under the equity method means that our growth in net income generally outpaces our growth in reported revenues.
 
Equity in earnings of unconsolidated affiliates increased by $14.7 million, or 31.3% to $61.8 million for the year ended December 31, 2009 from $47.0 million for the year ended December 31, 2008. This increase in equity in earnings was primarily driven by same store growth ($10.9 million), acquisitions of additional facilities we account for under the equity method ($3.6 million) and the deconsolidation of four facilities which we now account for under the equity method ($0.2 million). The number of facilities we account for under the equity method increased by eight from December 31, 2008 to December 31, 2009.
 
Operating expenses, excluding depreciation and amortization and losses on deconsolidations, disposals and impairments, decreased by $33.3 million, or 7.7%, to $396.6 million for the year ended December 31, 2009 from $429.9 million for the year ended December 31, 2008. This decrease was largely driven by the deconsolidation of four facilities (approximately $28.5 million) and the recovery of $1.0 million in value added tax previously expensed by our U.K. subsidiary. Operating expenses, excluding depreciation and amortization and losses on deconsolidations, disposals and impairments, decreased as a percentage of revenues to 66.8% for the year ended 2009, from 69.9% for the year ended 2008. This decrease as a percentage of revenues is primarily attributable to cost saving measures being employed across our facilities.
 
Losses on deconsolidations, disposals and impairments increased $27.3 million to $29.2 million for the year ended December 31, 2009 from $1.8 million for the year ended December 31, 2008. In 2009, we recorded approximately $21.4 million in losses on the sale or deconsolidation of various facilities, impairment charges totaling $5.7 million related to three management contracts and $2.1 million of termination fees related to two acquisitions we made in 2007. We elected not to purchase additional ownership in these facilities and expensed the termination fee. In 2008, the components were a $1.9 million loss on the sale of equity interests in four facilities offset by $1.0 million of other income related to a terminated administrative service contract and by a $0.8 million impairment of one of our management contracts.
 
Depreciation and amortization decreased $1.1 million, or 3.5%, to $31.2 million for the year ended December 31, 2009 from $32.3 million for the year ended December 31, 2008, primarily as a result of the deconsolidation of four facilities whose deprecation expense is no longer included in our consolidated statements of income. Depreciation and amortization, as a percentage of revenues, was 5.3% for the year ended December 31, 2009 and 5.2% for the year ended December 31, 2008.
 
Operating income increased $0.2 million to $198.3 million for the year ended December 31, 2009 from $198.1 million for the year ended December 31, 2008. Operating income, as a percentage of revenues, increased to 33.4% for the year ended December 31, 2009 from 32.2% for the prior year, primarily as a result of the growth in our equity in earnings of unconsolidated affiliates and cost saving measures, which was mostly offset by losses on deconsolidations, disposal and impairments of $29.2 million noted above.
 
Interest expense, net of interest income, decreased $14.0 million to $67.6 million for the year ended December 31, 2009 from $81.6 million for the year ended December 31, 2008, primarily due to lower interest rates and additionally due to lower overall debt balances as compared to the prior period.
 
Income from continuing operations before income taxes increased $14.6 million, or 12.5%, to $131.1 million for the year ended December 31, 2009 from $116.5 million for the year ended December 31, 2008, increased primarily as a result of the growth in our equity in earnings of unconsolidated affiliates and cost saving measures, which was mostly offset by losses on deconsolidations, disposal and impairments of $29.2 million noted above, and benefited from lower net interest expense of $14.0 million.
 
Provision for income taxes was a $0.9 million benefit for the year ended December 31, 2009, compared to $22.7 million of tax expense for the year ended December 31, 2008. The benefit in 2009 was primarily the result of our reversing the valuation allowance ($31.2 million) against a majority of our U.S. deferred tax assets. During the third quarter of 2009, we determined it was more likely than not that we would generate taxable income to recover these assets in future periods. Our effective tax rate in 2008 was 36.9%. Our effective tax rate, excluding the benefit of reversing the deferred tax asset allowance, was 47.6% at December 31, 2009.


65


Table of Contents

Total (loss) gain from discontinued operations was earnings of $1.5 million for the year ended December 31, 2009 as compared to a loss of $1.2 million for the year ended December 31, 2008. The $1.5 million represents the net earnings of four facilities we are accounting for as discontinued operations at December 31, 2010. In 2008, we classified the operations of surgery center as discontinued operations. We recorded a loss of approximately $0.6 million, net of tax, related to the sale of this facility and a net loss of $0.6 million on its operations.
 
Net income was $133.4 million for the year ended December 31, 2009 as compared to $92.7 million for the year ended December 31, 2008. Represents the net effect of many factors described above, including an increase in equity in earnings of unconsolidated affiliates ($14.7 million), a decrease in interest expense ($14.0 million), and the recognition of the benefit of U.S. deferred tax assets ($31.2 million), which together more than offset $29.2 million in losses on disposals, deconsolidations, and impairments. In addition, despite our U.K. operations growing their profits in local currency, the strengthening U.S. dollar decreased our reported net income by $2.2 million.
 
Net income attributable to noncontrolling interests increased $8.6 million, or 15.6%, to $63.7 million for the year ended December 31, 2009 from $55.1 million for the year ended December 31, 2008. The increase was due to increased profitability of certain of our existing consolidated facilities and our acquisition activities, which primarily involve our acquiring less than 100% ownership.
 
Liquidity and Capital Resources
 
                         
    Years Ended December 31,
    2010   2009   2008
 
Net cash provided by operating activities
  $ 169,064     $ 180,610     $ 142,119  
Net cash used in investing activities
    (72,040 )     (85,829 )     (100,863 )
Net cash used in financing activities
    (73,999 )     (111,247 )     (70,168 )
 
Overview
 
At December 31, 2010, we had cash and cash equivalents totaling $60.3 million, as compared to $34.9 million at December 31, 2009. A more detailed discussion of changes in our liquidity follows.
 
Operating Activities
 
Our cash flows from operating activities were $169.1 million, $180.6 million, and $142.1 million in the years ended December 31, 2010, 2009, and 2008, respectively. Operating cash flows in 2010 were lower than 2009 by $11.5 million, or 6.4%, primarily due to the Company utilizing U.S. net operating loss carryforwards to settle the bulk of its U.S. federal tax liability in 2009. Operating cash flows in 2009 were higher than 2008 primarily due to lower interest costs during 2009, facility-wide cost reductions and the timing of distributions of earnings to our unconsolidated affiliates. Operating cash flows in 2008 were also impacted by these factors, but the impact on 2008 was unfavorable.
 
A significant element of our cash flows from operating activities is the collection of patient receivables and the timing of payments to our vendors and service providers. Collections efforts for patient receivables are conducted primarily by our personnel at each facility or in centralized service centers for some metropolitan areas with multiple facilities. These collection efforts are facilitated by our patient accounting system, which prompts individual account follow-up through a series of phone calls and/or collection letters written 30 days after a procedure is billed and at 30 day intervals thereafter. Bad debt reserves are established in increasing percentages by aging category based on historical collection experience. Generally, the entire amount of all accounts remaining uncollected 180 days after the date of service are written off as bad debt and sent to an outside collection agency. Net amounts received from collection agencies are recorded as recoveries of bad debts. Our operating cash flows, including changes in accounts payable and other current liabilities, are impacted by the timing of payments to our vendors. We typically pay our vendors and service providers in accordance with invoice terms and conditions, and take advantage of invoice discounts when available. In 2010, 2009 and 2008, we did not make any significant changes to our payment timing to our vendors.


66


Table of Contents

Our net working capital deficit was $100.2 million at December 31, 2010 as compared to a net working capital deficit of $113.0 million in the prior year. The overall negative working capital position at December 31, 2010 and 2009 is primarily the result of $116.1 million and $129.3 million due to affiliates associated with our cash management system being employed for our unconsolidated facilities. As discussed further below, we have sufficient availability under our revolving credit agreement, together with our expected future operating cash flows, to service our obligations.
 
Investing Activities
 
During the years ended December 31, 2010, 2009 and 2008, respectively, our net cash used for investing activities was $72.0 million, $85.8 million and $100.9 million, respectively. The majority of the cash used in our investing activities relates to our purchases of businesses, incremental investment in unconsolidated affiliates and purchases of property and equipment and was funded by cash flows from operating activities. The cash used in investing activities was funded primarily from cash on hand as well as draws upon the revolving feature of our senior secured credit facility.
 
Acquisitions and Sales
 
During the year ended December 31, 2010, we invested $33.3 million, net of cash received, for the purchase and sales of businesses and investments in unconsolidated affiliates. These 2010 transactions are described earlier in this Item 7 under the captions “Acquisitions, Equity Investments and Development Projects” and “Discontinued Operations and Other Dispositions.” These transactions are summarized below:
 
             
Effective Date
 
Facility Location
  Amount  
 
Investments
           
December 2010
  Houston, Texas   $ 9.0 million  
December 2010
  Reading, Pennsylvania     1.1 million  
December 2010
  Irving, Texas     1.9 million  
December 2010
  Boulder, Colorado     4.7 million  
December 2010
  Houston, Texas     0.9 million  
December 2010
  Chattanooga, Tennessee     2.6 million  
December 2010
  Kansas City, Missouri     1.2 million  
December 2010
  Nashville, Tennessee     13.4 million  
November 2010
  Various (HealthMark)     31.1 million  
November 2010
  Keller, Texas     4.6 million  
October 2010
  Houston, Texas     2.4 million  
July 2010
  Carrollton, Texas     0.8 million  
July 2010
  Sacramento, California     1.5 million  
May 2010
  St. Louis, Missouri     4.6 million  
May 2010
  Mansfield, Texas     0.4 million  
April 2010
  Destin, Florida     1.3 million  
April 2010
  St. Louis, Missouri     0.4 million  
Various
  Various     1.8 million  
             
          83.7 million  
Sales
           
December 2010
  Nashville, Tennessee     32.5 million  
December 2010
  Phoenix, Arizona     4.7 million  
June 2010
  Cincinnati, Ohio     7.9 million  
Various
  Various     5.3 million  
             
          50.4 million  
             
Total
      $ 33.3 million  
             


67


Table of Contents

During the years 2009 and 2008, we invested $59.5 million and $64.3 million, respectively (all net of cash acquired) to make similar acquisitions. These transactions are summarized in this Item 7 under the caption “Acquisitions, Equity Investments and Development Projects.”
 
As part of our business strategy, we have made, and expect to continue to make, selective acquisitions in existing markets to leverage our existing knowledge of these markets and to improve operating efficiencies. Additionally, we may also make acquisitions in new markets. In making such acquisitions, we may use available cash on hand or draw upon our revolving credit facility as discussed below.
 
Property and Equipment/Facilities under Development
 
During the year ended December 31, 2010, approximately $21.3 million of the property and equipment purchases related to expansion and development projects, and the remaining $18.7 million primarily represents purchase of equipment at existing facilities. We added $29.7 million of property and equipment in the year 2009, of which $14.7 million related to expansion and development projects and the remaining $15.0 million related to purchases at existing facilities. Additionally, in 2008, we added $17.4 million of property and equipment for expansion and development projects and purchased $13.3 million of property and equipment for existing facilities. Approximately $8.1 million of the property and equipment purchases was paid to acquire property adjacent to one of our London facilities.
 
At December 31, 2010, we and our affiliates had five surgical facilities under construction and one additional facility in the development stage in the United States; one of these facilities opened in January 2011. Costs to develop a short-stay surgical facility, which include construction, equipment and initial operating losses, vary depending on the range of specialties that will be undertaken at the facility. Our affiliates have budgeted a total of $80.0 million for development costs for the projects under construction. Development costs are typically funded with approximately 50% debt at the entity level with the remainder provided as equity from the owners of the entity. Additionally, as each of these facilities becomes operational, each will have obligations associated with debt and capital lease arrangements.
 
Generally, we estimate that we will add 12 to 15 facilities per year through a combination of acquisition and de novo projects. This program will continue to require substantial capital resources, which for this number of facilities we would estimate to range from $60.0 million to $100.0 million per year over the next three years. If we identify strategic acquisition opportunities that are larger than usual for us, then these costs could increase greatly.
 
Other than the specific transactions described above, our acquisition and development activities primarily include the development of new facilities, buyups of additional ownership in facilities we already operate, and acquisitions of additional facilities. In addition, the operations of our existing surgical facilities will require ongoing capital expenditures. The amount and timing of these purchases and related cash outflows in future periods is difficult to predict and is dependent on a number of factors including hiring of employees, the rate of change in technology/equipment used in our business and our business outlook.
 
Financing Activities
 
Cash flows used in financing activities were $74.0 million, $111.2 million and $70.2 million in the years ended December 31, 2010, 2009 and 2008, respectively. Historically, our cash flows from financing activities have been received through proceeds from long-term debt, offset by payments on long-term debt, as well as proceeds received from the issuance of our common stock. We also manage the cash of our unconsolidated affiliates. Cash distributions to noncontrolling interests are also a large component of our financing activities and were $59.0 million, $63.6 million and $56.5 million in the years ended December 31, 2010, 2009 and 2008, respectively.
 
We intend to fund our ongoing capital and working capital requirements through a combination of cash flows from operations and borrowings under our $85.0 million revolving credit facility. We believe that funds generated by operations and funds available under the revolving credit facility will be sufficient to meet working capital requirements over at least the next 12 months. However, in the future, we may have to incur additional debt or issue additional debt or equity securities from time to time. We may be unable to obtain sufficient financing on satisfactory terms or at all.


68


Table of Contents

We and our subsidiaries, affiliates (subject to certain limitations imposed by existing indebtedness), or significant stockholders, in their sole discretion, may from time to time, purchase, redeem, exchange or retire any of our outstanding debt in privately negotiated or open market purchases, or otherwise. Such transactions will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.
 
Dividend Payment
 
On December 1, 2009, our board of directors declared and we paid a special cash dividend in the amount of $88.6 million on our common stock. The proceeds of the dividend were used by USPI Holdings, Inc., our sole stockholder, to pay a special cash dividend on its common stock. In turn, the proceeds were used by USPI Group Holdings, Inc., the sole stockholder of USPI Holdings, Inc., to pay amounts currently accrued on its preferred stock.
 
Debt
 
Senior secured credit facility
 
The senior secured credit facility (credit facility) provides for borrowings of up to $615.0 million (with a $150.0 million accordion feature described below), consisting of (1) an $85.0 million revolving credit facility with a maturity of six years, including a $20.0 million letter of credit sub-facility, and a $20.0 million swing-line loan sub-facility; and (2) a $530.0 million term loan facility (including a $100.0 million delayed draw facility) with a maturity of seven years. We have utilized the availability under the $530.0 million term loan facility and are making scheduled quarterly principal payments. The term loans require principal payments each year in an amount of $4.3 million per annum in equal quarterly installments and $0.2 million per quarter with respect to the delayed draw facility with the remaining balance maturing in 2014. No principal payments are required on the revolving credit facility until its maturity in 2013.
 
We may request additional tranches of term loans or additional commitments to the revolving credit facility in an aggregate amount not exceeding $150.0 million, subject to certain conditions. Interest rates on the credit facility are based on LIBOR plus a margin of 2.00% to 2.25%. Additionally, we currently pay 0.50% per annum on the daily-unused commitment of the revolving credit facility. We also currently pay a quarterly participation fee of 2.13% per annum related to outstanding letters of credit. At December 31, 2010, we had $553.4 million of debt outstanding under the credit facility at a weighted average interest rate of approximately 3.5%. At December 31, 2010, we had $58.4 million available for borrowing under the revolving credit facility, representing the facility’s $85.0 million capacity, net of the $25.0 million outstanding balance at December 31, 2010 and $1.6 million of outstanding letters of credit. The $25.0 million outstanding on the revolving line of credit was repaid in January 2011.
 
The credit facility is guaranteed by USPI Holdings, Inc. and its current and future direct and indirect wholly-owned domestic subsidiaries, subject to certain exceptions, and borrowings under the credit facility are secured by a first priority security interest in all real and personal property of these subsidiaries, as well as a first priority pledge of our capital stock, the capital stock of each of our wholly owned domestic subsidiaries and 65% of the capital stock of certain of our wholly-owned foreign subsidiaries. Additionally, the credit facility contains various restrictive covenants, including financial covenants that limit our ability and the ability of our subsidiaries to borrow money or guarantee other indebtedness, grant liens, make investments, sell assets, pay dividends, enter into sale-leaseback transactions or issue and sell capital stock. We believe we were in compliance with these covenants as of December 31, 2010.
 
Senior subordinated notes
 
Also in connection with the merger, we issued $240.0 million of 87/8% senior subordinated notes and $200.0 million of 91/4%/10% senior subordinated toggle notes (together, the Notes), all due in 2017. Interest on the Notes is payable on May 1 and November 1 of each year, which commenced on November 1, 2007. All interest payments on the senior subordinated notes are payable in cash. The initial interest payment on the toggle notes was payable in cash. For any interest period after November 1, 2007 through November 1, 2012, we may pay interest on the toggle notes (i) in cash, (ii) by increasing the principal amount of the outstanding toggle notes or by issuing payment-in-kind notes (PIK Interest) or (iii) by paying interest on half the principal amount of the toggle notes in


69


Table of Contents

cash and half in PIK Interest. PIK Interest is paid at 10% and cash interest is paid at 91/4% per annum. To date, we have paid all interest payments in cash. During 2009, we repurchased approximately $2.5 million in principal amount of the senior subordinated toggle notes in the open market. At December 31, 2010, we had $437.5 million of Notes outstanding. The Notes are unsecured senior subordinated obligations of our Company; however, the Notes are guaranteed by all of our current and future direct and indirect wholly-owned domestic subsidiaries. Additionally, the Notes contain various restrictive covenants, including financial covenants that limit our ability and the ability of our subsidiaries to borrow money or guarantee other indebtedness, grant liens, make investments, sell assets, pay dividends, enter into sale-leaseback transactions or issue and sell capital stock. We believe we were in compliance with these covenants as of December 31, 2010.
 
United Kingdom borrowings
 
In April 2007, we entered into an amended and restated credit agreement, which covered our existing overdraft facility and term loan facility (Term Loan A). This agreement provides a total overdraft facility of £2.0 million, and an additional Term Loan B facility of £10 million, which was drawn in April 2007. In March 2008, we further amended our U.K. Agreement to provide for a £2.0 million Term Loan C facility. We borrowed the entire £2.0 million in March 2008 to acquire property adjacent to one of our hospitals in London. In June 2009, we renewed our overdraft facility. Under the renewal, we must pay a commitment fee of 0.5% per annum on the unused portion of the overdraft facility each quarter. Excluding availability on the overdraft facility, no additional borrowings can be made under the Term Loan A, B or C facilities. At December 31, 2010, we had approximately £32.5 million (approximately $50.0 million) outstanding under the U.K. credit facility at a weighted average interest rate of approximately 4.6%.
 
Interest on the borrowings is based on a three-month or six-month LIBOR, or other rate as the bank may agree, plus a margin of 1.25% to 2.00%. Quarterly principal payments are required on the Term Loan A, which began in June 2007, and approximate $4.6 million in the first and second year, $6.2 million in the third and fourth year; $7.7 million in the fifth year, with the remainder due in the sixth year after the April 2007 closing. The Term Loan B does not require any principal payments prior to maturity and matures in 2013. The Term Loan C requires quarterly principal payments of approximately £0.1 million ($0.2 million), which began in June 2008 and continue through its maturity date of February 2013 when the final payment of £0.5 million ($0.8 million) is due. The borrowings are guaranteed by certain of our subsidiaries in the United Kingdom with a security interest in various assets, and a pledge of the capital stock of the U.K. borrowers and the capital stock of certain guarantor subsidiaries. The Agreement contains various restrictive covenants, including financial covenants that limit our ability and the ability of certain U.K. subsidiaries to borrow money or guarantee other indebtedness, grant liens on our assets, make investments, use assets as security in other transactions, pay dividends, enter into leases or sell assets or capital stock. We believe we were in compliance with these covenants as of December 31, 2010.
 
We also have the ability to borrow under a capital asset finance facility in the U.K. of up to £2.5 million ($3.8 million). We borrowed against the facility in June 2010 and November 2010 and have £1.5 million ($2.3 million) outstanding at December 31, 2010. The terms of the borrowings require monthly principal and interest payments over 48 months. We have pledged capital assets as collateral against these borrowings. No amounts were outstanding at December 31, 2009.
 
Purchases and Sales of Noncontrolling Interests
 
During 2010, 2009 and 2008, we purchased and sold a net of $1.1 million, $2.1 million and $26.4 million of noncontrolling interests. Transactions with noncontrolling interests in which we do not lose control of an entity are classified as financing activities. These transactions represent equity transactions because they are between us (or our subsidiaries) and noncontrolling interests.


70


Table of Contents

Contractual Cash Obligations
 
Our contractual cash obligations as of December 31, 2010 are summarized as follows:
 
                                         
    Payments Due by Period  
          Within
    Years
    Years
    Beyond
 
Contractual Cash Obligations
  Total     1 Year     2 and 3     4 and 5     5 Years  
                (In thousands)              
 
Long term debt obligations:
                                       
Senior secured credit facility(1)
  $ 533,445     $ 5,265     $ 35,530     $ 492,650     $  
Senior subordinated notes, due 2017(1)
    240,000                         240,000  
Senior subordinated toggle notes, due 2017(1)
    197,515                         197,515  
U.K. credit facility(1)
    49,981       7,797       42,184              
Other debt at operating subsidiaries(1)
    22,347       5,275       8,004       3,550       5,518  
Interest on long-term debt obligations(2)
    326,410       62,450       121,640       85,496       56,824  
Capitalized lease obligations(3)
    43,089       6,549       10,850       6,001       19,689  
Operating lease obligations
    72,255       13,651       22,170       13,986       22,448  
                                         
Total contractual cash obligations
  $ 1,485,042     $ 100,987     $ 240,378     $ 601,683     $ 541,994  
                                         
 
 
(1) Scheduled principal payments.
 
(2) Represents interest due on long-term debt obligations. For variable rate debt, the interest is calculated using the December 31, 2010 rates applicable to each debt instrument and also gives effect to the interest rate swaps designated in a cash flow hedging relationship against portions of the U.K. credit facility and the senior secured credit facility in the U.S.
 
(3) Includes principal and interest.
 
Debt at Operating Subsidiaries
 
Our operating subsidiaries, many of which have noncontrolling interest holders who share in the cash flow of these entities, have debt consisting primarily of capitalized lease obligations. This debt is generally non-recourse to USPI and is generally secured by the assets of those operating entities. The total amount of these obligations, which was $46.6 million at December 31, 2010, is included in our consolidated balance sheet because the borrower or obligated entity meets the requirements for consolidated financial reporting. Our average percentage ownership, weighted based on the individual subsidiary’s amount of debt and capitalized lease obligations, of these consolidated subsidiaries was approximately 45% at December 31, 2010. As further discussed below, our unconsolidated affiliates that we account for under the equity method have debt and capitalized lease obligations that are generally non-recourse to USPI and are not included in our consolidated financial statements.
 
We believe that existing funds, cash flows from operations, borrowings under our credit facilities, and borrowings under capital lease arrangements at newly developed or acquired facilities will provide sufficient liquidity for the next twelve months. We may require additional debt or equity financing for our future acquisitions and development projects. There are no assurances that needed capital will be available on acceptable terms, if at all. If we are unable to obtain funds when needed or on acceptable terms, we will be required to curtail our acquisition and development program.
 
In connection with our acquisition of equity interests in a surgery center in 2007, we had the option to purchase additional ownership in the facility during a specified time period in the purchase agreement. If we did not exercise the purchase option, we were required to pay an option termination fee, which was equal to the lesser of an EBITDA calculation, as specified in the purchase agreement, or $2.5 million. We elected to purchase only a portion of the ownership as stated in the agreement and therefore paid a $1.5 million termination fee in 2009. The parties agreed to another purchase option that can be exercised at any time during the 60 day period following September 30, 2011 or the remaining $1.0 million option termination fee would be required to be paid. The $1.5 million termination fee


71


Table of Contents

was recorded in “Losses on deconsolidations, disposals and impairments” in the accompanying consolidated statements of income for 2009.
 
In addition, our U.K. subsidiary has begun expanding our Parkside hospital, already our largest facility. Located outside London in the Wimbledon area, this facility’s expansion is expected to cost approximately £11.5 million (approximately $17.7 million). The expansion of the outpatient clinic was completed in August 2010 and the refurbishment of a portion of the hospital is expected to be completed by the second quarter of 2011. A £17.0 million ($26.2 million) refurbishment and extension program has also begun at our Holly House hospital and is due to be completed by late 2012. This expansion will provide three new operating theater suites, an endoscopy suite, ten additional patient rooms, an eight bed day unit, and six additional consulting rooms.
 
Off-Balance Sheet Arrangements
 
As a result of our strategy of partnering with physicians and not-for-profit health systems, we do not own controlling interests in the majority of our facilities. We account for 130 of our 189 surgical facilities under the equity method. Similar to our consolidated facilities, our unconsolidated facilities have debts, including capitalized lease obligations, that are generally non-recourse to USPI. With respect to our unconsolidated facilities, these debts are not included in our consolidated financial statements. At December 31, 2010, the total debt on the balance sheets of our unconsolidated affiliates was approximately $330.6 million. Our average percentage ownership, weighted based on the individual affiliate’s amount of debt, of these unconsolidated affiliates was approximately 24% at December 31, 2010. USPI or one of its wholly-owned subsidiaries had collectively guaranteed $22.5 million of the $330.6 million in total debt of our unconsolidated affiliates as of December 31, 2010. In addition, our unconsolidated affiliates have obligations under operating leases, of which USPI or a wholly-owned subsidiary had guaranteed $13.4 million as of December 31, 2010, of which $8.7 million represents guarantees of two facilities we have sold. We have full recourse to the buyers with respect to such amounts. Some of the facilities we are currently developing will be accounted for under the equity method. As these facilities become operational, they will have debt and lease obligations.
 
As described above, our unconsolidated affiliates own operational surgical facilities or surgical facilities that are under development. These entities are structured as limited partnerships, limited liability partnerships, or limited liability companies. None of these affiliates provide financing, liquidity, or market or credit risk support for us. They also do not engage in hedging, research and development services with us. Moreover, we do not believe that they expose us to any of their liabilities that are not otherwise reflected in our consolidated financial statements and related disclosures. Except as noted above with respect to guarantees, we are not obligated to fund losses or otherwise provide additional funding to these affiliates other than as we determine to be economically required in order to successfully implement our development plans.
 
Related Party Transactions
 
We have entered into agreements with certain majority and minority owned surgery centers to provide management services. As compensation for these services, the surgery centers are charged management fees which are either fixed in amount or represent a fixed percentage of each center’s net revenue less bad debt. The percentages range from 3% to 8%. Amounts recognized under these agreements, after elimination of amounts from consolidated surgery centers, totaled approximately $52.1 million, $45.2 million, and $39.1 million in 2010, 2009, and 2008, respectively, and are included in management and contract service revenues in our consolidated statements of income.
 
We regularly engage in purchases and sales of ownership interests in our facilities. We operate 27 surgical facilities in partnership with the Baylor Health Care System (Baylor) and local physicians in the Dallas/Fort Worth area. Baylor’s Chief Executive Officer is a member of our board of directors. The following table summarizes transactions with Baylor during 2009 and 2008. We had no such transactions in 2010. We believe that the sale prices


72


Table of Contents

were approximately the same as if they had been negotiated on an arms’ length basis, and the prices equaled the value assigned by an external appraiser who valued the businesses immediately prior to the sale.
 
                     
Date
 
Facility Location
  Proceeds     Gain (Loss)  
 
December 2009
  Dallas, Texas(1)   $ 1.2 million     $ 0.3 million  
December 2009
  Fort Worth, Texas(2)     2.4 million       0.1 million  
                     
Total
      $ 3.6 million     $ 0.4 million  
                     
June 2008
  Dallas, Texas(3)   $ 2.3 million     $ (0.9 million )
 
 
(1) Baylor acquired a controlling interest in a facility from us, which transferred control of the facility from us to Baylor.
 
(2) Baylor acquired a controlling interest in two facilities. We continue to account for these facilities under the equity method of accounting.
 
(3) Baylor acquired an additional ownership interest in a facility it already co-owned with us and local physicians, which transferred control of the facility from us to Baylor.
 
In June 2009, we agreed to lend up to $10.0 million to Trinity MC, LLC (Trinity), an acute care hospital in the Dallas/Fort Worth area. A majority interest (71%) in Trinity is owned by BRMCG Holdings, LLC, a wholly owned subsidiary of Baylor Regional Medical Center at Grapevine, a controlled affiliate of Baylor. Trinity operates Baylor Medical Center at Carrollton (BMCC). We have no ownership in Trinity. The revolving note earned interest at a rate of 6.0% per annum and was paid in full in December 2009. We believe the terms of the revolving note were approximately the same as if they had been negotiated on an arms’ length basis.
 
In June 2008, we purchased all of Baylor’s ownership interests in an entity Baylor co-owned with us. This entity had ownership and managed five facilities in the Dallas/Fort Worth area. The purchase price was approximately $3.9 million in cash. This entity is now wholly owned by us. We believe that the sales price was approximately the same as if it had been negotiated on an arms’ length basis, and the price equaled the value assigned by an external appraiser who valued the business immediately prior to the sale. After this transaction, we account for all of the facilities we operate with Baylor under the equity method.
 
Our Parent issued warrants with an estimated fair value of $0.3 million to Baylor in January 2008. Similar grants have been made to other healthcare systems with which we operate facilities.
 
Included in general and administrative expenses are management fees payable to an affiliate of Welsh Carson, which holds a controlling interest in our company, in the amount of $2.0 million for the years ended December 31, 2010, 2009 and 2008. Such amounts accrue at an annual rate of $2.0 million. We pay $1.0 million in cash per year with the unpaid balance due and payable upon a change in control. At December 31, 2010, we had approximately $4.5 million accrued related to such management fee, of which $0.8 million is included in other current liabilities and $3.7 million is included in other long term liabilities in the accompanying consolidated balance sheet. At December 31, 2009, we had approximately $3.5 million accrued related to such management fee, of which $0.8 million is included in other current liabilities and $2.7 million is included in other long term liabilities in the accompanying consolidated balance sheet.
 
Item 7A.   Quantitative and Qualitative Disclosures about Market Risk
 
Market risk represents the risk of loss that may impact our financial position, results of operations or cash flows due to adverse changes in interest rates and other relevant market risks. Our primary market risk is a change in interest rates associated with variable-rate borrowings. Historically, we have not held or issued derivative financial instruments other than the use of variable-to-fixed interest rate swaps for portions of our borrowings under credit facilities with commercial lenders as required by credit agreements. We do not use derivative instruments for speculative purposes. The interest rate swaps serve to stabilize our cash flow and expense but ultimately may cost more or less in interest than if we had carried all of our debt at a variable rate over the swap term.
 
As further discussed in Note 10 to the accompanying consolidated financial statements, in order to manage interest rate risk related to a portion of our variable-rate U.K. debt, on February 29, 2008, we entered into an interest


73


Table of Contents

rate swap agreement for a notional amount of £20.0 million ($30.8 million). The interest rate swap requires us to pay 4.99% and to receive interest at a variable rate of three-month GBP-LIBOR (0.8% at December 31, 2010), which is reset quarterly. The interest rate swap expires in March 2011. No collateral is required under the interest rate swap agreement. As of December 31, 2010, the rate under our swap agreement was unfavorable compared to the market.
 
Additionally, effective July 24, 2008, in order to manage interest rate risk related to a portion of our variable-rate U.S. Term Loan B, we entered into an interest rate swap agreement for a notional amount of $200.0 million. The interest rate swap requires us to pay 3.6525% and to receive interest at a variable rate of three-month USD-LIBOR (0.3% at December 31, 2010), which is paid and reset on a quarterly basis. The interest rate swap expires in July 2011. No collateral is required under the interest rate swap agreement. As of December 31, 2010, the rate under our swap agreement was unfavorable compared to the market.
 
At December 31, 2010, the fair values of the U.K. and U.S. interest rate swaps were current liabilities of approximately $0.3 million and $3.6 million, respectively. The estimated fair value of the interest rate swaps was determined using present value models of the contractual payments. Inputs to the models were based on prevailing LIBOR market data and incorporate credit data that measure nonperformance risk. The estimated fair value represents the theoretical exit cost we would have to pay to transfer the obligations to a market participant with similar credit risk. These estimated fair values may not be representative of actual values that will be realized in the future.
 
Our financing arrangements with many commercial lenders are based on the spread over Prime or LIBOR. At December 31, 2010, $690.6 million of our outstanding debt was in fixed rate instruments and the remaining $352.6 million was in variable rate instruments. Accordingly, a hypothetical 100 basis point increase in market interest rates would result in additional annual expense of approximately $3.5 million.
 
Our United Kingdom revenues are a significant portion of our total revenues. We are exposed to risks associated with operating internationally, including foreign currency exchange risk and taxes and regulatory changes. Our United Kingdom facilities operate in a natural hedge to a large extent because both expenses and revenues are denominated in the local currency. Additionally, our borrowings in the United Kingdom are currently denominated in the local currency. Historically, the cash generated from our operations in the United Kingdom has been utilized within that country to finance development and acquisition activity as well as for repayment of debt denominated in the local currency. Accordingly, we have not generally utilized financial instruments to hedge our foreign currency exchange risk.
 
Item 8.   Financial Statements and Supplementary Data
 
For the financial statements and supplementary data required by this Item 8, see the Index to Consolidated Financial Statements included elsewhere in this Form 10-K.
 
Item 9.   Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
 
None.
 
Item 9A.   Controls and Procedures
 
Evaluation of Disclosure Controls and Procedures
 
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our filings under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Commission. Such information is accumulated and communicated to our management, including the principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. As of the end of the period covered by this Annual Report on Form 10-K, we have carried out an evaluation, under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the principal executive officer and principal financial officer concluded that, as of December 31, 2010, our disclosure controls and procedures are effective in timely alerting them to material information required to be included in our reports filed


74


Table of Contents

with the Commission. There have been no significant changes in our internal controls which could significantly affect the internal controls subsequent to the date of their evaluation in connection with the preparation of this Annual Report on Form 10-K.
 
Management’s Report on Internal Control Over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.
 
Our internal control over financial reporting includes those policies and procedures that:
 
  •  Pertain to the maintenance of records that in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets.
 
  •  Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and board of directors; and
 
  •  Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
 
Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2010. In making this assessment, management used criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework. Management’s assessment included an evaluation of the design and testing of the operational effectiveness of the Company’s internal control over financial reporting. USPI acquired several subsidiaries and equity method investments during 2010. Accordingly, management’s evaluation excluded the operations of the following subsidiaries and equity method investments acquired during 2010, with total assets of approximately $69.4 million and approximately $3.9 million of revenues included in the Company’s consolidated financial statements as of December 31, 2010:
 
  •  HealthMark Partners, Inc.
 
  •  USP Denver, Inc. (Investment in Flatirons Surgery Center, LLC)
 
  •  USP Houston, Inc. (Investments in Memorial Hermann Endoscopy & Surgery Center North Houston, LLC; Memorial Hermann Surgery Center Woodlands Parkway, LLC and Memorial Hermann Surgery Center Memorial City, LLC)
 
  •  USP Gateway, Inc.
 
  •  USP North Texas, Inc. (Investments in Metrocrest Surgery Center, LP; Baylor Surgicare of Duncanville, LLC; Tuscan Surgery Center at Las Colinas, LLC; and Lone Star Endoscopy, LLC)
 
  •  USP Sacramento, Inc. (Investment in Grass Valley Outpatient Surgery Center, LP)
 
Based on this assessment, management did not identify any material weakness in the Company’s internal control, and management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2010.
 
KPMG LLP, the registered public accounting firm that audited the Company’s consolidated financial statements included in this report, has issued an attestation report on management’s assessment of internal control over financial reporting, a copy of which is included with the Company’s consolidated financial statements in Item 15(a)(1).


75


Table of Contents

Limitations on the Effectiveness of Controls
 
Our management, including the principal executive officer and the principal financial officer, recognizes that any set of controls and procedures, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. For these reasons, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
Changes in Internal Control Over Financial Reporting
 
There were no changes in our internal control over financial reporting identified in connection with the evaluation described above that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
Item 9B.   Other Information
 
None.
 
PART III
 
ITEM 10.   Directors, Executive Officers and Corporate Governance
 
Directors and Executive Officers
 
Executive officers of USPI are elected annually by the board of directors and serve until their successors are duly elected and qualified. Directors are elected by USPI’s stockholders and serve until their successors are duly elected and qualified. There are no arrangements or understandings between any officer or director and any other person pursuant to which any officer or director was, or is to be, selected as an officer, director, or nominee for officer or director. There are no family relationships among any of our executive officers or directors. The names, ages as of February 25, 2011, and positions of the executive officers and directors of USPI are listed below along with their relevant business experience.
 
             
Name
 
Age
 
Position(s)
 
Donald E. Steen
    64     Chairman of the Board
William H. Wilcox
    59     President, Chief Executive Officer and Director
Brett P. Brodnax
    46     Executive Vice President and Chief Development Officer
Mark A. Kopser
    46     Executive Vice President and Chief Financial Officer
Niels P. Vernegaard
    54     Executive Vice President and Chief Operating Officer
Philip A. Spencer
    41     Senior Vice President, Business Development
Joel T. Allison
    63     Director
Michael E. Donovan
    34     Director
John C. Garrett, M.D. 
    68     Director
D. Scott Mackesy
    42     Director
James Ken Newman
    67     Director
Boone Powell, Jr. 
    74     Director
Paul B. Queally
    46     Director
Raymond A. Ranelli
    63     Director


76


Table of Contents

Donald E. Steen founded USPI in February 1998 and served as its chief executive officer until April 2004. Mr. Steen continues to serve as chairman of the board of directors and the executive committee. Mr. Steen was chairman of AmeriPath, Inc. and chief executive officer of AmeriPath, Inc. from July 2004 until May 2007. Mr. Steen served as president of the International Group of HCA, Inc. from 1995 until 1997 and as president of the Western Group of HCA from 1994 until 1995. Mr. Steen founded Medical Care International, Inc., a pioneer in the surgery center business, in 1982. Mr. Steen also serves as a director of Kinetic Concepts, Inc. Mr. Steen’s experience in the healthcare industry as well as his leadership of USPI and his role as a director since its founding provides the board with a deeper insight into the Company’s business, challenges and opportunities.
 
William H. Wilcox joined USPI as its president and a director in September 1998. Mr. Wilcox has served as USPI’s president and chief executive officer since April 2004 and is a member of the executive committee. Mr. Wilcox served as president and chief executive officer of United Dental Care, Inc. from 1996 until joining USPI. Mr. Wilcox served as president of the Surgery Group of HCA and president and chief executive officer of the Ambulatory Surgery Division of HCA from 1994 until 1996. Prior to that time, Mr. Wilcox served as the chief operating officer and a director of Medical Care International, Inc. Mr. Wilcox, through his intimate knowledge of the operational, financial and strategic development of USPI and his experience in the healthcare industry, provides the board with a valuable perspective into the opportunities and challenges facing the Company.
 
Brett P. Brodnax serves as the executive vice president and chief development officer of USPI. Prior to joining USPI in December 1999, Mr. Brodnax was an assistant vice president of the Baylor Health Care System (Baylor) from 1990 until 1999. Mr. Brodnax also served as a director of AmeriPath, Inc. from January 2005 until May 2007.
 
Mark A. Kopser serves as the executive vice president and chief financial officer of USPI. Prior to joining USPI in May 2000, Mr. Kopser served as chief financial officer for the International Division of HCA from 1997 until 2000 and as chief financial officer for the London Division of HCA from 1992 until 1996.
 
Niels P. Vernegaard joined USPI as the executive vice president and chief operating officer in June 2006. Prior to joining USPI, Mr. Vernegaard served in various positions with HCA (or predecessors) for 25 years, including as president and chief executive officer of HCA’s Research Medical Center in Kansas City, Missouri, and chief executive officer of the Wellington Hospital in London, England.
 
Philip A. Spencer joined USPI in July 2009. From November 2006 until joining USPI, Mr. Spencer served as President, Anatomic Pathology Services for AmeriPath, Inc. From November 2003 to November 2006, he served as Executive Vice President of Healthcare Sales and Marketing for LabOne, Inc. From December 2000 to November 2003, Mr. Spencer served as Vice President, Business Development for Laboratory Corporation of America.
 
Joel T. Allison has served on our board since March 2002. Mr. Allison has served as president and chief executive officer of Baylor since 2000 and served as its senior executive vice president from 1993 until 2000. Mr. Allison brings an important perspective to the board through his role in leading a major healthcare system and his familiarity with issues impacting physicians and the delivery of healthcare in the U.S.
 
Michael E. Donovan joined our board in April 2007 and serves as a member of the executive and audit and compliance committees. Mr. Donovan is currently a general partner at Welsh, Carson, Anderson & Stowe. Prior to joining Welsh Carson in 2001, Mr. Donovan worked at Windward Capital Partners and in the investment banking division at Merrill Lynch. He is a member of the board of directors of several private companies. Mr. Donovan’s experience in healthcare transactions and finance provides the board greater insight into the healthcare industry and financial strategy.
 
John C. Garrett, M.D. has served on our board since February 2001 and is a member of the audit and compliance committee. Dr. Garrett had been a director of OrthoLink Physicians Corporation, which was acquired by USPI in February 2001, since July 1997. Dr. Garrett founded Resurgens, P.C. in 1986, where he maintained a specialized orthopedics practice in arthroscopic and reconstructive knee surgery until his retirement in 2007. Dr. Garrett is a Fellow of the American Academy of Orthopedic Surgeons. The board benefits from Dr. Garrett’s knowledge of clinical and regulatory issues impacting our facilities and physician partners and his familiarity with USPI with which he has served as a director since 2001.


77


Table of Contents

D. Scott Mackesy joined our board, executive committee and compensation committee in April 2007. Mr. Mackesy is a general partner of Welsh, Carson, Anderson & Stowe, where he focuses primarily on investments in the healthcare industry and is a managing member of the general partner of Welsh, Carson, Anderson & Stowe X, L.P. Prior to joining Welsh Carson, Mr. Mackesy was a research analyst at Morgan Stanley Dean Witter, where he was responsible for coverage of the healthcare services industry. He is a member of the board of directors of several private companies. Mr. Mackesy, through his lengthy and broad focus on the healthcare industry, offers the board greater insight into industry dynamics as well as investment and acquisition strategies.
 
James Ken Newman has served on our board since May 2005 and is a member of the audit and compliance committee. Mr. Newman served as president and chief executive officer of Horizon Health Corporation from May 2003 until its sale in June 2007 and as chairman of the board from February 1992 until June 2007. From July 1989 until September 1997, he served as president of Horizon Health and from July 1989 until October 1998, he also served as chief executive officer of Horizon Health. Mr. Newman’s leadership and experience in the healthcare industry helps the board better assess the challenges and opportunities facing USPI.
 
Boone Powell, Jr. has served on our board since June 1999. Mr. Powell served as the chairman of Baylor until June 2001 and served as its president and chief executive officer from 1980 until 2000. Mr. Powell also serves as a director of US Oncology, Inc. Mr. Powell, through over a decade of experience with USPI, provides the board with a comprehensive knowledge of the Company and its structure and management team. In addition, his experience in overseeing the management of a major healthcare system gives him valuable insight into the competitive environment of the healthcare industry.
 
Paul B. Queally has served as a director of USPI since its inception in February 1998 and serves as the chairman of the compensation committee and a member of the executive committee. Mr. Queally is Co-President of Welsh, Carson, Anderson & Stowe, where he focuses primarily on investments in the healthcare industry and is a managing member of the general partner of Welsh, Carson, Anderson & Stowe IX, L.P. Prior to joining Welsh Carson in 1996, Mr. Queally was a general partner at the Sprout Group, the private equity group of the former Donaldson, Lufkin & Jenrette. He is a member of the boards of directors of AGA Medical Corporation, Aptuit, Inc. and several private companies. Mr. Queally’s service on the boards of multiple private and public companies and his extensive experience in corporate transactions, including M&A, leveraged buyouts and private equity financing, provide the board with an important perspective in making strategic decisions.
 
Raymond A. Ranelli joined our board in May 2007 and serves as the chairman of the audit and compliance committee. Mr. Ranelli retired from PricewaterhouseCoopers in 2003 where he was a partner for over 20 years. Mr. Ranelli held several positions at PricewaterhouseCoopers including Vice Chairman and Global Leader of the Financial Advisory Services practice. Mr. Ranelli is also a director of United Vision Logistics, Ozburn-Hessey Logistics and Syniverse Technologies, Inc. Mr. Ranelli possesses in-depth, practical knowledge of financial and accounting principles, having served in the financial services sector for over 20 years and serving on other boards and committees. This background, along with his past experience as a certified public accountant, is important to his role as chairman of the audit and compliance committee.
 
Audit Committee Financial Expert
 
Our board has determined that Raymond A. Ranelli, a director and chairman of the audit and compliance committee, is a financial expert and is independent as that term is used in the rules of the National Association of Securities Dealers’ listing standards (“NASDAQ Rules”).
 
Nominations for the Board of Directors
 
Our board of directors does not have a separately designated, standing nominating committee, a nominating committee charter, or a formal procedure for security holders to recommend nominees to the board of directors. USPI is not listed on a national securities exchange or in an automated inter-dealer quotation system of a national securities association, and we are not subject to either the listing standards of the New York Stock Exchange or the NASDAQ Rules.


78


Table of Contents

Section 16(a) Beneficial Ownership Reporting Compliance
 
USPI does not have any class of equity securities registered under Section 12 of the Exchange Act. Consequently, Section 16(a) of the Exchange Act is not applicable.
 
Code of Ethics
 
We have adopted a Code of Conduct and a Financial Code of Ethics both applicable to our principal executive officer, principal financial officer, principal accounting officer or controller, or other persons performing similar functions. Copies of the Code of Conduct and the Financial Code of Ethics may be obtained, free of charge, by writing to the secretary of the Company at: United Surgical Partners International, Inc., 15305 Dallas Parkway, Suite 1600, Addison, Texas 75001.
 
Item 11.   Executive Compensation
 
Overview
 
The compensation committee of our board of directors makes decisions regarding salaries, annual bonuses and equity incentive compensation for our named executive officers. Our named executive officers include our chief executive officer, our chief financial officer and our three most highly compensated executive officers other than our chief executive officer and chief financial officer. The compensation committee is also responsible for reviewing and approving corporate goals and objectives relevant to the compensation of our named executive officers, as well as evaluating their performance in light of those goals and objectives. Based on this evaluation, the compensation committee determines and approves the named executive officers’ compensation. The compensation committee solicits input from our chief executive officer regarding the performance of the company’s other named executive officers. Finally, the compensation committee also administers our equity incentive plan.
 
The chief executive officer reviews our compensation plan. Based on his analysis, the chief executive officer recommends a level of compensation to the compensation committee, other than for himself, which he views as appropriate to attract, retain and motivate executive talent. The compensation committee determines and approves the chief executive officer’s and other named executive officers’ compensation.
 
Our Compensation Philosophy and Objectives
 
We have sought to create an executive compensation program that balances short-term versus long-term payments and awards, cash payments versus equity awards and fixed versus contingent payments and awards in ways that we believe are most appropriate to motivate our executive officers. Our executive compensation program is designed to:
 
  •  attract and retain superior executive talent in the healthcare industry;
 
  •  motivate and reward executives to achieve optimum short-term and long-term corporate operating results;
 
  •  align the interests of our executive officers and stockholders by motivating executive officers to increase stockholder value; and
 
  •  provide a compensation package that recognizes individual contributions as well as overall business results.
 
In determining each component of, and the overall, compensation of our named executive officers, the compensation committee does not exclusively use quantitative methods or formulas, but instead considers various factors, including the position of the named executive officer, the compensation of officers of comparable companies within the healthcare industry, the performance of the named executive officer with respect to specific objectives, increases in responsibilities, recommendations of the chief executive officer and other objective and subjective criteria as the compensation committee deems appropriate. The specific objectives for each named executive officer vary each year in accordance with the scope of the officer’s position, the potential inherent in that position for impacting the Company’s operating and financial results and the actual operating and financial contributions produced by the officer in previous years.


79


Table of Contents

Compensation Components
 
Our compensation consists primarily of three elements: base salary, annual bonus and long-term equity incentives. We describe each element of compensation in more detail below.
 
Base Salary
 
Base salaries for our named executive officers are established based on the scope of their responsibilities and their prior relevant experience, taking into account competitive market compensation paid by other companies in our industry for similar positions and the overall market demand for such executives at the time of hire. A named executive officer’s base salary is also determined by reviewing the executive’s other compensation to ensure that the executive’s total compensation is in line with our overall compensation philosophy. Base salaries are reviewed annually and may be increased for merit reasons, based on the executive’s success in meeting or exceeding individual performance objectives. Additionally, we may adjust base salaries as warranted throughout the year for promotions or other changes in the scope or breadth of an executive’s role or responsibilities. For 2010, the compensation committee determined that the existing base salaries for the Company’s named executive officers when combined with the bonus opportunities available under the Company’s incentive programs were generally competitive for the healthcare industry and accordingly did not increase base salaries for any of the named executive officers. See “Employment Arrangements and Agreements.”
 
Annual Bonus
 
Our compensation program includes eligibility for an annual incentive cash bonus. The compensation committee assesses the level of the named executive officer’s achievement of meeting individual goals, as well as that officer’s contribution towards our long-term, Company-wide goals. The amount of the cash bonus depends primarily on the Company meeting budgeted EBITDA goals, with a target bonus for each named executive officer generally set as a percentage of base salary. Target bonuses for the named executive officers were set at 50% of base salary for 2010, except for Mr. Wilcox whose target bonus was set at 75% of base salary for 2010. Based on the Company’s EBITDA performance compared to budget in 2010, all named executive officers received a bonus of 25% of their base salaries.
 
EBITDA is not a measure defined under GAAP. The Company believes EBITDA is an important measure for purposes of assessing performance. EBITDA, which is computed by adding operating income plus depreciation and amortization and losses on deconsolidations, disposals and impairments, is commonly used as an analytical indicator within the healthcare industry and also serves as a measure of leverage capacity and debt service ability. EBITDA should not be considered as measures of financial performance under GAAP and EBITDA targets and the Company’s achievement of such targets should not be understood as management’s prediction of future performance or guidance to investors.
 
Long-Term Equity Incentives
 
We believe that equity-based awards allow us to reward named executive officers for their sustained contributions to the Company. We also believe that equity awards reward continued employment by a named executive officer, with an associated benefit to us of employee continuity and retention. We believe that equity awards provide management with a strong link to long-term corporate performance and the creation of stockholder value. The compensation committee has the authority to grant shares of restricted stock and options to purchase shares of certain classes of common and preferred equity securities of our Parent. The compensation committee does not award equity awards according to a prescribed formula or target. Instead, the compensation committee takes into account the individual’s position, scope of responsibility, ability to affect profits and the individual’s historic and recent performance and the value of the awards in relation to other elements of the individual executive’s total compensation. No equity awards were awarded in 2010. For a further description of the Company’s equity-based plan, see “Restricted Stock and Option Plan” below.


80


Table of Contents

Termination Based Compensation
 
For payments due to our named executive officers upon termination, and the acceleration of vesting of equity-based awards in the event of a change of control under our new equity plan, see “Restricted Stock and Option Plan” and “Employment Arrangements and Agreements” below.
 
Other Benefits and Perquisites
 
We provide health and welfare benefits to our named executive officers that are available to all of the Company’s employees. Included in these benefits is a 401(k) plan that we maintain because we wish to encourage our employees to save a percentage of their cash compensation, through voluntary deferrals, for their eventual retirement. We match fifty percent of the first six percent of cash compensation contributed by individual employees subject to IRS limitations.
 
We also make available to our named executive officers certain perquisites and other benefits that we believe are reasonable and consistent with the perquisites that would be available to them at companies with whom we compete for experienced senior management. The primary perquisite we currently provide to named executive officers as well as certain other select members of the management team is access to a Deferred Compensation Plan (“DCP”) through which the individuals can voluntarily defer up to 75% of their base salary and 100% of their bonus. We match fifty percent of the first ten percent of compensation voluntarily deferred under this plan. Additionally, in 2010 we contributed $200,000 and $75,000 respectively to Messrs. Wilcox’s and Vernegaard’s DCP accounts.
 
Compensation Committee Report
 
The compensation committee of USPI has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, the compensation committee has recommended to the board of directors that the Compensation Discussion and Analysis be included in this Annual Report on Form 10-K.
 
The Compensation Committee
 
Paul B. Queally, Chairman
D. Scott Mackesy


81


Table of Contents

 
Summary Compensation Table for 2010
 
The following table sets forth the total remuneration paid by us for each of the last three fiscal years to the named executive officers.
 
                                                                         
                            Change in
       
                            Nonqualified
       
                        Non-Equity
  Deferred
       
                Stock
  Option
  Incentive Plan
  Compensation
  All Other
   
Name and Principal Position
  Year   Salary   Bonus   Awards(1)   Awards(1)   Compensation   Earnings   Compensation   Total
 
William H. Wilcox
    2010     $ 600,000     $ 150,000 (2)   $     $           $ 147,624     $ 273,866 (3)   $ 1,171,490  
President, Chief
    2009       600,000       750,000 (2)                       243,982       264,350 (3)     1,858,332  
Executive Officer and
    2008       600,000       540,000 (4)                       (129,167 )     251,275 (3)     1,262,108  
Director
                                                                       
Brett P. Brodnax
    2010       384,000       96,000 (5)                       78,887       40,860 (3)     599,747  
Executive Vice President
    2009       384,000       288,000 (5)                       129,867       38,050 (3)     839,917  
and Chief Development
    2008       379,167       230,000 (5)                       (100,590 )     32,702 (3)     541,279  
Officer
                                                                       
Mark A. Kopser
    2010       358,000       89,500 (2)                       39,159       38,591 (3)     525,250  
Executive Vice President
    2009       358,000       268,500 (2)                       81,803       35,546 (3)     743,849  
and Chief Financial
    2008       353,000       205,917 (2)                       (92,177 )     29,238 (3)     495,978  
Officer
                                                                       
Philip A. Spencer
    2010       325,000       81,250 (2)                       3,505       23,600 (3)     433,355  
Senior Vice President,
    2009       139,167       104,375       380,000                         2,505 (3)     626,047  
Business Development
    2008                                                    
Niels P. Vernegaard
    2010       428,000       107,000 (2)                       74,782       119,700 (3)     729,482  
Executive Vice President
    2009       428,000       321,000 (2)                       91,422       116,039 (3)     956,461  
and Chief Operating
    2008       421,333       245,778 (2)                       22,187       110,592 (3)     799,890  
Officer
                                                                       
 
 
(1) We account for the cost of stock-based compensation awarded under the 2007 Equity Incentive Plan adopted by our Parent under which the cost of equity awards to employees is measured by the aggregate grant date fair value of the awards on their grant date calculated in accordance with the FASB’s Accounting Standards Codification Topic 718. No forfeitures occurred during 2008, 2009 or 2010. The stock awards issued to Mr. Spencer in August 2009 were valued at $0.76 per share equal to the fair value per share of common stock as determined by the compensation committee. Assumptions used in calculation of these amounts are included in Note 14 to our consolidated audited financial statements for the fiscal year ended December 31, 2010, included in this Annual Report on Form 10-K.
 
(2) Ninety percent of the amount shown was paid in cash and ten percent was deferred at our named executive officers’ election pursuant to USPI’s Deferred Compensation Plan (the “DCP”).


82


Table of Contents

 
(3) Includes discretionary contributions to the named executive officers’ DCP and matching contributions to the named executive officers’ DCP and 401(k) accounts as follows:
 
                         
    Discretionary
  Matching
  Matching
    Contribution
  Contribution
  Contribution
    to DCP   401(k)   DCP
 
Mr. Wilcox
                       
2010
  $ 200,000     $ 7,350     $ 66,516  
2009
    200,000       7,350       57,000  
2008
    200,000       6,900       44,375  
Mr. Brodnax
                       
2010
          7,350       33,510  
2009
          7,350       30,700  
2008
          6,900       25,433  
Mr. Kopser
                       
2010
          7,350       31,241  
2009
          7,350       28,196  
2008
          6,900       24,024  
Mr. Spencer
                       
2010
          7,350       16,250  
2009
          2,505        
2008
                 
Mr. Vernegaard
                       
2010
    75,000       7,350       37,350  
2009
    75,000       7,350       33,689  
2008
    75,000       6,900       28,692  
 
(4) Seventy-five percent of the amount shown was paid in cash and twenty-five percent was deferred at Mr. Wilcox’s election pursuant to the DCP.
 
(5) Fifty percent of the amount shown was paid in cash and fifty percent was deferred at Mr. Brodnax’s election pursuant to the DCP.
 
Grant of Plan-Based Awards
 
No plan-based awards were granted to the named executive officers during 2010.
 
Outstanding Equity Awards at Fiscal Year-End
 
The following table shows all outstanding equity awards held by our named executive officers as of December 31, 2010.
 
                 
    Stock Awards(1)
    Number of Shares
  Fair Value of
    or Units of Stock
  Shares or Units of
    that have not
  Stock that have
Name
  Vested   not Vested(2)
 
William H. Wilcox
    2,968,750 (3)   $ 5,492,188  
      495,536 (4)     916,742  
Brett P. Brodnax
    1,187,500 (3)     2,196,875  
      275,853 (4)     510,328  
Mark A. Kopser
    1,062,500 (3)     1,965,625  
      220,683 (4)     408,264  
Philip A. Spencer
    375,000 (5)     693,750  
             
Niels P. Vernegaard
    1,062,500 (3)     1,965,625  
      245,203 (4)     453,626  


83


Table of Contents

 
(1) Upon consummation of the merger, our named executive officers received new stock awards under the 2007 Equity Incentive Plan.
 
(2) Because there is no active trading market for our common stock, we rely on members of the compensation committee and Welsh Carson to determine in good faith the fair value of our common stock. As of December 31, 2010, this value was determined to be $1.85 per share of common stock. Neither USPI, USPI Holdings, Inc. nor USPI Group Holdings, Inc. has any class of equity securities registered under Section 12 of the Exchange Act.
 
(3) The restrictions with respect to 20% of such shares will lapse on April 19, 2011. The restrictions with respect to the remaining shares will lapse on April 19, 2015; provided however, that such restrictions may lapse sooner if certain internal rate of return targets are met.
 
(4) The restrictions with respect to such shares will lapse upon a change of control or other exit event provided that Welsh Carson shall have disposed of all of its shares of our Parent acquired in connection with the merger and received its cost basis in such shares plus a return of at least 100%.
 
(5) The restrictions with respect to 33% of such shares will lapse on April 19, 2011. The restrictions with respect to the remaining shares will lapse on April 19, 2015; provided however, that such restrictions may lapse sooner if certain internal rate of return targets are met.
 
Option Exercises and Stock Values
 
The following table shows all stock options exercised during 2010 and the value realized upon exercise, and all stock awards vested during 2010 and the value realized upon vesting.
 
                                 
    Option Awards   Stock Awards
    Number of
      Number of
   
    Shares
  Value
  Shares
  Value
    Acquired on
  Realized on
  Acquired on
  Realized
Name
  Exercise   Exercise   Vesting   on Vesting(1)
 
William H. Wilcox
    N/A     $       593,750     $ 961,875  
Brett P. Brodnax
    N/A             237,500       384,750  
Mark A. Kopser
    N/A             212,500       344,250  
Philip A. Spencer
    N/A             125,000       202,500  
Niels P. Vernegaard
    N/A             212,500       344,250  
 
 
(1) Because there is no active trading market for our common stock, we rely on members of the compensation committee and Welsh Carson to determine in good faith the fair value of our common stock. As of April 19, 2010, this value was determined to be $1.62 per share of common stock. Neither USPI, USPI Holdings, Inc. nor USPI Group Holdings, Inc. has any class of equity securities registered under Section 12 of the Exchange Act.
 
Restricted Stock and Option Plan
 
Our Parent adopted the 2007 Equity Incentive Plan which became effective contemporaneously with the consummation of the merger, which we sometimes refer to as the equity plan. The purposes of the equity plan are to attract and retain the best available personnel, provide additional incentives to our employees, directors and consultants and to promote the success of our business. A maximum of 20,726,523 shares of common stock may be delivered in satisfaction of awards made under the equity plan.
 
The compensation committee administers the equity plan (the “Administrator”). Participation in the plan is limited to those key employees and directors, as well as consultants and advisors, who in the Administrator’s opinion are in a position to make a significant contribution to the success of USPI and its affiliated corporations and who are selected by the Administrator to receive an award. The plan provides for awards of stock appreciation rights (“SARs”), stock options, restricted stock, unrestricted stock, stock units, including restricted stock units, and performance awards pursuant to the Administrator’s discretion and the provisions set forth in the plan. Eligibility for incentive stock options (“ISOs”) is limited to employees of USPI or of a “parent corporation” or “subsidiary corporation” of USPI as those terms are defined in Section 424 of the United States Internal Revenue Code of 1986,


84


Table of Contents

as amended. Each option granted pursuant to the plan will be treated as providing by its terms that it is to be a non-incentive stock option unless, as of the date of grant, it is expressly designated as an ISO.
 
The exercise price of each stock option and the share value above which appreciation is to be measured in the case of a SAR will be 100% of the fair value of the stock subject to the stock option or SAR, determined as of the date of grant, or such higher amount as the Administrator may determine in connection with the grant.
 
Neither ISOs nor, except as the Administrator otherwise expressly provides, other awards may be transferred other than by will or by the laws of descent and distribution. During a recipient’s lifetime an ISO and, except as the Administrator may provide, other non-transferable awards requiring exercise may be exercised only by the recipient. Awards permitted by the Administrator to be transferred may be transferred only to a permitted transferee.
 
No awards may be made after April 18, 2017, but previously granted awards may continue beyond that date in accordance with their terms. The Administrator may at any time amend the equity plan or any outstanding award for any purpose which may at the time be permitted by law, and may at any time terminate the equity plan as to any future grants of awards; provided, that except as otherwise expressly provided in the plan, the Administrator may not, without the participant’s consent, alter the terms of an award so as to affect adversely the participant’s right under the award, unless the Administrator expressly reserved the right to do so at the time of the award.
 
Upon termination of a named executive officer’s employment for any reason (including, without limitation, as a result of death, disability, incapacity, retirement, resignation, or dismissal with or without cause), then any vested shares as of the date of such termination shall remain vested shares, and no additional shares will become vested after the date of such termination, except if otherwise determined by the Administrator or within 180 days after the executive’s termination, USPI consummates a change of control, in which case, the provisions pertaining to a change of control will apply.
 
The shares acquired under the equity plan shall vest in full upon a change of control if, as a result of such change of control, Welsh Carson shall have disposed of all of the investor shares and received its cost basis in its investor shares plus an investor return of at least 100%. In the event the shares do not vest on such change of control, such shares shall be forfeited upon the closing of such change of control.
 
Nonqualified Deferred Compensation
 
The following table shows certain information regarding the named executive officers’ DCP accounts as of December 31, 2010.
 
                                         
    2010 Activity   Aggregate
                Aggregate
  Balance at
    Executive
  USPI
  Aggregate
  Withdrawals/
  December 31,
Name
  Contribution   Contribution   Earnings   Distributions   2010
 
William H. Wilcox
  $ 133,031     $ 266,516     $ 147,624     $ 600,033     $ 2,554,397  
Brett P. Brodnax
    181,500       33,510       78,887       230,246       725,530  
Mark A. Kopser
    62,482       31,241       39,159       130,840       375,969  
Philip A. Spencer
    32,500       16,250       3,505             52,255  
Niels P. Vernegaard
    74,699       112,350       74,782             1,015,544  
 
Deferred Compensation Plan
 
USPI has a deferred compensation plan that certain of its directors, executive officers and other employees participate in which allows such participants to defer a portion of their compensation to be paid upon certain specified events (including death, termination of employment, disability or some future date). Under the terms of the DCP, all amounts payable under the DCP would become immediately vested in connection with a change of control of USPI, and as a result, each participant would be entitled to be paid their full account balance upon consummation of such a transaction. Notwithstanding the foregoing, USPI amended the DCP to exclude the merger from the definition of a change of control for purposes of the DCP. As a result, the merger had no effect on the vesting of the account balance of any participant in the deferred compensation plan.


85


Table of Contents

Our board of directors designates those persons who are eligible to participate in the DCP. Currently, each of Messrs. Steen, Wilcox, Brodnax, Vernegaard, Kopser and Spencer are eligible to participate in the DCP. The DCP enables participants to defer all or a portion of their bonus in a calendar year and up to 75% of their base salary, typically by making a deferral election in the calendar year prior to the year in which the bonus relates or the annual salary is otherwise payable.
 
Although participants are 100% vested in their deferrals of salary and bonus, USPI contributions to the DCP are subject to vesting schedules established by the compensation committee in its sole discretion (which may vary among different contributions). Notwithstanding such vesting schedules, participants will become 100% vested in their accounts under the DCP in the event of (i) retirement on or after the earlier to occur of (a) age 60 following the completion of five years of service with USPI or (b) age 65, (ii) a change in control or (iii) death.
 
Benefits are payable upon termination of employment. Participants may also elect, at the time they make an annual deferral, to receive a lump sum in-service distribution payable in a calendar year that is three or more years after the calendar year to which the deferral is related. A participant who elects an in-service distribution may defer the distribution for an additional five years from the original payment date so long as such election is made at least 12 months prior to the original payment date. Participants may also make an in-service withdrawal from the DCP on account of an unforeseeable emergency (as defined in the DCP). Amounts under the DCP are distributed in a lump sum cash payment, except as provided below, unless the distribution is on account of retirement at normal retirement age under the DCP. A participant can elect, at the time of a deferral under the DCP, to receive his retirement benefit in either a lump sum or pursuant to annual installments over five, 10 or 15 years. Participants may change the form of payment of their retirement benefit from a lump sum to an annual installment payment, provided such election is submitted one year prior to the participant’s retirement.
 
A participant’s account will be credited with earnings and losses based on returns on deemed investment options selected by the participant from a group of deemed investments established by the deferred compensation plan committee.
 
USPI may make a discretionary contribution on behalf of any or all participants depending upon the financial strength of USPI. The amount of the contribution, if any, is determined in the sole discretion of the compensation committee. Currently, USPI matches fifty percent of any deferral by a named executive officer, subject to a total cap on the matching contribution of five percent of the officer’s compensation.
 
The DCP is administered by USPI’s compensation committee. The DCP is an “unfunded” arrangement for purposes of ERISA. Accordingly, the DCP consists of a mere promise by USPI to make payments in accordance with the terms of the DCP and participants and beneficiaries have the status of general unsecured creditors of USPI. A participant’s account and benefits payable under the DCP are not assignable. USPI may amend or terminate the DCP provided that no amendment adversely affects the rights of any participant with respect to amounts that have been credited to his account under the DCP prior to the date of such amendment. Upon termination of the DCP, a participant’s account will be paid out as though the participant experienced a termination of employment on the date of the DCP’s termination or, for participants who have attained normal retirement age, in the form of payment elected by the participant.
 
Employment Arrangements and Agreements
 
Set forth below is a description of our employment agreements and other compensation arrangements with our named executive officers.
 
We have employment agreements with William H. Wilcox as President and Chief Executive Officer, Mark A. Kopser as Executive Vice President and Chief Financial Officer, Brett P. Brodnax as Executive Vice President and Chief Development Officer, Niels Vernegaard as Executive Vice President and Chief Operating Officer and Philip A. Spencer as Senior Vice President, Business Development.
 
The initial term of our employment agreement with William H. Wilcox was for two years from April 18, 2007. Thereafter, Mr. Wilcox’s employment agreement automatically renews for additional two-year terms unless at least 30 days prior to the end of a two-year term, USPI or Mr. Wilcox gives notice that it or he does not wish to extend the


86


Table of Contents

agreement. Mr. Wilcox is paid a base salary of $600,000 per year, subject to increase from time to time with the possibility of a bonus, determined by the compensation committee in its sole discretion.
 
The initial term of our employment agreements with Mark A. Kopser and Brett P. Brodnax was for one year from April 18, 2007 to April 18, 2008. Thereafter, each agreement automatically renews for additional one-year terms unless at 30 days prior to the end of a one-year term, USPI or the executive gives notice that it or he does not wish to extend the agreement. Mr. Kopser is paid a base salary of $358,000 per year and Mr. Brodnax, $384,000 per year, and each is subject to increase from time to time with the possibility of a bonus, determined by the compensation committee in its sole discretion.
 
The initial term of our employment agreement with Niels P. Vernegaard was for two years from April 18, 2007. Thereafter, Mr. Vernegaard’s employment agreement automatically renews for additional one-year terms unless at 30 days prior to the end of a one-year term, USPI or Mr. Vernegaard gives notice that it or he does not wish to extend the agreement. Mr. Vernegaard is paid a base salary of $428,000 per year, subject to increase from time to time with the possibility of a bonus determined by the compensation committee in its sole discretion.
 
The initial term of our employment agreement with Philip A. Spencer is for three years from July 29, 2009. Thereafter, Mr. Spencer’s employment agreement automatically renews for additional one-year terms unless at 30 days prior to the end of a one-year term, USPI or Mr. Spencer gives notice that it or he does not wish to extend the agreement. Mr. Spencer is paid a base salary of $325,000 per year, subject to increase from time to time with the possibility of a bonus determined by the compensation committee in its sole discretion.
 
Each of the employment agreements with our named executive officers also provides that if the executive is terminated for cause, or if he terminates his employment agreement without certain enumerated good reasons, we shall pay to him any accrued or unpaid base salary through the date of his termination. In addition, if we terminate the employment without cause or upon failure to renew his employment agreement, or if he terminates his employment for certain enumerated good reasons, we will (i) continue to pay him his base salary at the rate in effect on the date of his termination for twelve months (or, for Mr. Spencer, until July 29, 2012 if the date of termination occurs more than twelve months prior to July 29, 2012); (ii) continue his health insurance benefits for 12 months following his date of termination (24 months for Mr. Wilcox and, for Mr. Spencer, until July 29, 2012 if the date of termination occurs more than twelve months prior to July 29, 2012) or the economic equivalent thereof if such continuation is not permissible under the terms of our health insurance plan; and (iii) pay him a good faith estimate of the bonus he would have received had he remained employed through the end of the fiscal year in which his termination occurred (or, for Mr. Spencer, a good faith estimate of the bonus compensation he would have received until July 29, 2012, which shall be no less than fifty percent of his base salary on the date of termination, if his date of termination occurs more than twelve months prior to July 29, 2012). Our obligations set forth in items (i) to (iii) above are conditioned on the executive signing a release of claims and the continued performance of his continuing obligations under his employment agreement.
 
In connection with the consummation of the merger and the adoption of our Parent’s equity plan, certain of our executive officers, including our named executive officers, were awarded restricted shares of our Parent’s common stock under the equity plan pursuant to an agreement between each such named executive officer and our Parent. Pursuant to these restricted stock award agreements with our named executive officers, upon termination of such named executive officer’s employment for any reason (including, without limitation, as a result of death, disability, incapacity, retirement, resignation, or dismissal with or without cause), any vested shares as of the date of such termination shall remain vested shares and no additional shares will become vested after the date of such termination unless USPI consummates a change of control within 180 days after such named executive officer’s termination, in which case, such unvested shares shall become fully vested if such awards would have become fully vested had such named executive officer not been terminated on the date of such change of control as described below. Additionally, pursuant to such restricted stock award agreements with our named executive officers, all unvested restricted shares vest in full upon a change of control if, as a result of such change of control, Welsh Carson shall have disposed of all of its shares of our Parent acquired in connection with the merger and received its cost basis in such shares plus a return of at least 100%. In the event such restricted shares do not vest on such change of control, then such restricted shares shall be forfeited upon the closing of such change of control.


87


Table of Contents

Potential Payments Upon Termination or Change of Control
 
The following table sets forth for each named executive officer potential post-employment payments and payments on a change in control and assumes that the triggering event took place on December 31, 2010.
 
                                 
    Cash
          Accelerated
    Severance
  Accrued
      Vesting upon
Name
  Payment   Bonus(1)(2)   Benefits(3)   Change of Control(4)
 
William H. Wilcox
  $ 1,200,000 (5)   $ 150,000     $ 13,464 (5)   $ 6,408,930  
Brett P. Brodnax
    384,000 (6)     96,000       6,432 (6)     2,707,203  
Mark A. Kopser
    358,000 (6)     89,500       8,388 (6)     2,373,889  
Philip A. Spencer
    514,583 (7)     257,292       18,620 (7)     693,750  
Niels P. Vernegaard
    428,000 (6)     107,000       8,388 (6)     2,419,251  
 
 
(1) Amounts are based on the bonus amount paid with respect to 2010.
 
(2) Amounts will be paid at such time as annual bonuses are payable to other executive and officers of USPI in accordance with USPI’s normal payroll practices.
 
(3) Amounts consist of the cost to continue to pay such named executive officer’s health insurance benefits for the designated term or the economic equivalent thereof if such continuation is not permissible under the terms of the USPI’s health insurance plan.
 
(4) Pursuant to the restricted stock award agreements with our named executive officers, all unvested restricted shares of our Parent’s common stock will vest in full upon a change of control if, as a result of such change of control, Welsh Carson shall have disposed of all of its shares of our Parent acquired in connection with the merger and received its cost basis in such shares plus a return of at least 100%. A change of control is not defined to include an initial public offering of our stock. In the event such restricted shares do not vest on such change of control, then such restricted shares shall be forfeited upon the closing of such change of control transaction. The results in this column are the result of multiplying the total possible number of restricted shares of our Parent’s common stock that vest upon a change of control by $1.85 per share. Because there is no active trading market for our common stock, we rely on members of the compensation committee and Welsh Carson to determine in good faith the fair value of our common stock. As of December 31, 2010, this value was determined to be $1.85 per share of common stock. Neither USPI, USPI Holdings, Inc. nor USPI Group Holdings, Inc. has any class of equity securities registered under Section 12 of the Exchange Act.
 
(5) Amounts to be paid over twenty-four months.
 
(6) Amounts to be paid over twelve months.
 
(7) Amounts to be paid over nineteen months.
 
Director Compensation
 
The chairman and members of our board of directors who are also officers or employees of USPI, affiliates of Welsh Carson and Mr. Allison do not receive compensation for their services as directors. At Mr. Allison’s direction, his compensation for his service as a director are paid to his employer Baylor. The other directors (“non- employee directors”) receive cash compensation in the amount of $25,000 per year and are eligible to participate in our group insurance benefits. If a non-employee director elects to participate, the director will pay the full cost of such benefits. Non-employee directors also receive the following for all meetings attended: $2,500 per board meeting, $1,250 per telephonic meeting, $1,500 per audit committee meeting and $1,000 per other committee meeting. In addition, the audit committee chairman is paid a retainer of $20,000 per year.


88


Table of Contents

The following table sets forth the compensation paid to our non-employee directors in 2010.
 
2010 Non-Employee Director Compensation Table
 
                                 
    Fees Earned or
  Stock
  All Other
   
Name
  Paid in Cash   Awards   Compensation   Total
 
Joel T. Allison
  $     $     $     $  
John C. Garrett, M.D. 
    39,750                   39,750  
James Ken Newman
    39,750                   39,750  
Boone Powell, Jr. 
    33,750                   33,750  
Raymond A. Ranelli
    59,750                   59,750  
 
Compensation Risk Assessment
 
At the request of the Compensation Committee, management conducted an assessment of the Company’s compensation plans to determine whether such plans encourage excessive or inappropriate risk taking by our employees. This assessment included a review of the risk characteristics of our business and the design of our compensation plans. Although a significant portion of our executive compensation program is performance-based, the Compensation Committee has focused on aligning the Company’s compensation plans with the long-term interests of the Company and its stockholders and avoiding rewards or incentive structures that could encourage unnecessary risks to the Company.
 
Management reported its findings from this assessment to the Compensation Committee. The Compensation Committee agreed that the Company’s compensation plans do not encourage excessive or inappropriate risk taking and are not reasonably likely to have a material, adverse effect on the Company.
 
Compensation Committee Interlocks and Insider Participation
 
The compensation committee of the board of directors consists of Messrs. Queally (Chairman) and Mackesy. None of such persons are officers or employees or former officers or employees of the Company. None of the executive officers of the Company served as a member of the compensation committee of any other company during 2010, except that Mr. Wilcox served on the compensation committee of Concentra, Inc. No officer or employee of Concentra, Inc. serves on our board of directors.
 
Item 12.   Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
 
USPI does not issue any of its equity securities in conjunction with an equity compensation plan. See Item 11, “Executive Compensation- Restricted Stock and Option Plan,” for a discussion of Parent’s equity compensation plan.


89


Table of Contents

All of the issued and outstanding stock of USPI is owned by Holdings, which in turn is wholly-owned by Parent. The following table sets forth information as of February 25, 2011, with respect to the beneficial ownership of the capital stock of our Parent by (i) our chief executive officer and each of the other named executive officers, (ii) each of our directors, (iii) all of our directors and executive officers as a group and (iv) each holder of five percent (5%) or more of any class of our Parent’s outstanding capital stock.
 
                                 
            Participating
  Percent of
    Common
  Percent of
  Preferred
  Outstanding
    Shares
  Outstanding
  Shares
  Participating
    Beneficially
  Common
  Beneficially
  Preferred
Name of Beneficial Owner(1)
  Owned   Shares   Owned   Shares
 
Welsh, Carson, Anderson & Stowe(2)
    136,448,356       86.4 %     17,326,775       96.3 %
California State Teacher’s Retirement System(3)
    22,183,099       14.0 %     2,816,901       15.7 %
CPP Investment Board (USRE II) Inc.(4)
    26,619,718       16.8 %     3,380,282       18.8 %
Silvertech Investment PTE Ltd(5)
    8,873,239       5.6 %     1,126,761       6.3 %
Donald E. Steen(6)
    1,421,127       *       78,873       *  
William H. Wilcox(7)
    6,488,790       4.1 %     157,746       *  
Brett P. Brodnax(8)
    2,388,811       1.5 %     27,042       *  
Mark A. Kopser(9)
    2,364,345       1.5 %     56,338       *  
Niels P. Vernegaard(10)
    2,007,194       1.3 %     7,872       *  
Philip A. Spencer(11)
    500,000       *             *  
Joel T. Allison
                       
Michael E. Donovan(12)(13)
    40,000       *              
John C. Garrett, M.D.(13)
    173,095       *       16,901       *  
D. Scott Mackesy(12)(13)
    40,000       *              
James K. Newman(13)
    217,463       *       22,535       *  
Boone Powell, Jr.(13)
    111,001       *       9,016       *  
Paul B. Queally (12)(14)
    215,457       *       22,281       *  
Raymond A. Ranelli(13)
    95,448       *       7,435       *  
All directors and executive officers as a group(15)
    16,380,659       10.3 %     411,673       2.3 %
 
 
Less than one percent
 
(1) Unless otherwise indicated, the principal executive offices of each of the beneficial owners identified are located at 15305 Dallas Parkway, Suite 1600, Addison, Texas 77001.
 
(2) Represents (A) 54,671,610 common shares and 6,942,423 participating preferred shares held by Welsh Carson over which Welsh Carson has sole voting and investment power, (B) 25,200 common shares and 3,200 participating preferred shares held by WCAS Management Corporation, an affiliate of Welsh Carson, over which WCAS Management Corporation has sole voting and investment power, (C) an aggregate 1,462,785 common shares and 185,752 participating preferred over which individuals who are general partners of WCAS X Associates LLC, the sole general partner of Welsh Carson, and/or otherwise employed by an affiliate of Welsh, Carson, Anderson & Stowe have voting and investment power, and (D) an aggregate 80,288,761 common shares and 10,195,400 participating preferred shares held by other co-investors, over which Welsh Carson has sole voting power. WCAS X Associates LLC, the sole general partner of Welsh Carson and the individuals who serve as general partners of WCAS X Associates LLC, including D. Scott Mackesy, Paul B. Queally and Michael E. Donovan, may be deemed to beneficially own the shares beneficially owned by Welsh Carson. Such persons disclaim beneficial ownership of such shares. The principal executive offices of Welsh, Carson, Anderson & Stowe are located at 320 Park Avenue, Suite 2500, New York, New York 10022.
 
(3) Such beneficial owner has granted to Welsh Carson sole voting power over its shares. The principal executive offices of such beneficial owner is 7667 Folsom Blvd., Suite 250, Sacramento, California 95826.


90


Table of Contents

 
(4) Such beneficial owner has granted to Welsh Carson sole voting power over its shares. The principal executive offices of such beneficial owner is One Queen Street East, Suite 2600, Toronto, Ontario, M5C 2W5, Canada.
 
(5) Such beneficial owner has granted to Welsh Carson sole voting power over its shares. The principal executive offices of such beneficial owner is 255 Shoreline Drive, Suite 600, Redwood City, California 94065.
 
(6) Includes 100,000 common shares owned by the Michelle Ann Steen Trust and 100,000 common shares owned by the Marcus Anthony Steen Trust for which, in each case, Mr. Steen acts as a trustee and has voting and investment power over such shares. Such shares are subject to restrictions on transfer set forth in a restricted stock award agreement entered into at the time of the consummation of the merger. Also included are another 600,000 common shares which are subject to restrictions on transfer set forth in a restricted stock award agreement entered into at the time of the consummation of the merger.
 
(7) Includes 5,246,536 common shares which are subject to restrictions on transfer set forth in a restricted stock award agreement entered into at the time of the consummation of the merger.
 
(8) Includes 2,175,853 common shares which are subject to restrictions on transfer set forth in a restricted stock award agreement entered into at the time of the consummation of the merger.
 
(9) Includes 1,920,683 common shares which are subject to restrictions on transfer set forth in a restricted stock award agreement entered into at the time of the consummation of the merger.
 
(10) Includes 1,945,203 common shares which are subject to restrictions on transfer set forth in a restricted stock award agreement entered into at the time of the consummation of the merger.
 
(11) Includes 500,000 common shares which are subject to restrictions on transfer set forth in a restricted stock award agreement entered into at the time of initial employment with USPI.
 
(12) Does not include (A) 54,671,610 common shares or 6,942,423 participating preferred shares owned by Welsh Carson, or (B) 25,200 common shares or 3,200 participating preferred shares owned by WCAS Management Corporation. Messrs Queally, Mackesy and Donovan, as general partners of WCAS X Associates LLC, the sole general partner of Welsh Carson, and officers of WCAS Management Corporation, may be deemed to beneficially own the shares beneficially owned by Welsh Carson and WCAS Management Corporation. Each of Messrs Queally, Mackesy and Donovan disclaims beneficial ownership of such shares. The principal executive offices of Messrs Queally, Mackesy and Donovan are located at 320 Park Avenue, Suite 2500, New York, New York 10022.
 
(13) Includes 40,000 common shares which are subject to restrictions on transfer set forth in a restricted stock award agreement.
 
(14) Includes (A) an aggregate 3,090 common shares and 393 preferred shares owned by certain trusts established for the benefit of Mr. Queally’s children for which, in each case, Mr. Queally acts as a trustee and has voting and investment power over such shares and (B) 40,000 common shares which are subject to restrictions on transfer set forth in a restricted stock awards agreement.
 
(15) Does not include (A) 54,671,610 common shares or 6,942,423 participating preferred shares owned by Welsh Carson, or (B) 25,200 common shares or 3,200 participating preferred shares owned by WCAS Management Corporation. Includes an aggregate 12,361,836 common shares which are subject to restrictions on transfer set forth in restricted stock award agreements entered into at the time of the consummation of the merger.
 
Item 13.   Certain Relationships and Related Transactions, and Director Independence
 
This Item 13 describes certain relationships and transactions involving us and certain of our directors, executive officers, and other related parties. We believe that all the transactions described in this Item 13 are upon fair and reasonable terms no less favorable than could be obtained in comparable arm’s length transactions with unaffiliated third parties under the same or similar circumstances.
 
Arrangements with Our Investors
 
Welsh Carson, its co-investors and the rollover stockholders entered into agreements described below with our Parent. Welsh Carson’s co-investors includes individuals and entities invited by Welsh Carson to participate in our Parent’s financings such as affiliated investment funds, individuals employed by affiliates of Welsh Carson and limited partners of Welsh Carson.


91


Table of Contents

Stockholders Agreement
 
The stockholders agreement contains certain restrictions on the transfer of equity securities of our Parent and provides certain stockholders with certain preemptive and information rights.
 
Management Agreement
 
In connection with the merger, USPI entered into a management agreement with WCAS Management Corporation, an affiliate of Welsh Carson, pursuant to which WCAS Management Corporation will provide management and financial advisory services to us. WCAS Management Corporation receives an annual management fee of $2.0 million, of which $1.0 million will be payable in cash on an annual basis and the remainder will accrue annually over time, and annual reimbursement for out-of-pocket expenses incurred in connection with the provision of such services.
 
Other Arrangements with Directors and Executive Officers
 
Restricted Stock and Option Plan
 
In connection with the merger, our Parent adopted a new restricted stock and option plan. Members of our management, including some of those who are participating in the merger as rollover stockholders, received awards under this plan. See “Compensation Discussion and Analysis — Restricted Stock and Option Plan.”
 
Employment Agreements
 
Each of the named executive officers of USPI have employment agreements with us. See “Compensation Discussion and Analysis — Employment Arrangements and Agreements.”
 
Other Arrangements
 
We have entered into agreements with certain majority and minority owned surgery centers to provide management services. As compensation for these services, the surgery centers are charged management fees which are either fixed in amount or represent a fixed percentage of each center’s net revenue less bad debt. The percentages range from 3% to 8%. Amounts recognized under these agreements, after elimination of amounts from consolidated surgery centers, totaled approximately $52.1 million, $45.2 million, and $39.1 million in 2010, 2009 and 2008, respectively, and are included in management and contract service revenue in our consolidated statements of income.
 
We regularly engage in purchases and sales of ownership interests in our facilities. We operate 27 surgical facilities in partnership with the Baylor Health Care System (Baylor) and local physicians in the Dallas/Fort Worth area. Baylor’s Chief Executive Officer is a member of our board of directors. The following table summarizes transactions with Baylor during 2009 and 2008. We had no such transactions in 2010. We believe that the sale prices were approximately the same as if they had been negotiated on an arms’ length basis, and the prices equaled the value assigned by an external appraiser who valued the businesses immediately prior to the sale.
 
                         
Date
 
Facility Location
    Proceeds     Gain  
 
December 2009
    Dallas, Texas(1 )   $ 1.2 million     $ 0.3 million  
December 2009
    Fort Worth, Texas(2 )     2.4 million       0.1 million  
                         
Total
          $ 3.6 million     $ 0.4 million  
                         
 
 
(1) Baylor acquired a controlling interest in a facility from us, which transferred control of the facility to Baylor.
 
(2) Baylor acquired a controlling interest in two facilities. We continue to account for these facilities under the equity method of accounting.
 
Additionally, we derived 2% of our revenues and approximately 45% of our equity in earnings of unconsolidated affiliates in 2010 from our joint venture with Baylor.


92


Table of Contents

Marc Steen, the son of Donald E. Steen, is employed by USPI as the market president for Atlanta. During 2010, Marc Steen earned approximately $230,300 in salary and bonus.
 
USPI does not have a written policy on related party transactions, however, the audit and compliance committee will review and approve all related party transactions required to be reported pursuant to item 404(a) of Regulation S-X.
 
Neither the Company, UPSI Holdings, Inc. nor Parent are listed on a national securities exchange or in an automated inter-dealer quotation system of a national securities association, and we are not subject to either the listing standards of the New York Stock Exchange or the NASDAQ Rules. For the purposes of the following determinations of director independence, we have chosen to use the NASDAQ Rules. Using such Rules, we have determined that each of the directors on our board of directors are independent for general board service, except Messrs. Steen, Wilcox, Mackesy, Queally, Donovan and Allison.
 
Our board of directors has a separately designated, standing audit and compliance committee comprised of the following members of the board: Messrs. Ranelli (Chairman), Donovan, Garrett and Newman. Under the NASDAQ Rules, Messrs. Ranelli, Garrett and Newman would be considered independent for the purposes of audit and compliance committee service.
 
Our board of directors also has a separately designated, standing compensation committee comprised of the following members of the board: Messrs. Queally (Chairman) and Mackesy. Under the NASDAQ Rules, Messrs. Queally and Mackesy would not be considered independent for the purposes of compensation committee service.
 
ITEM 14.   Principal Accounting Fees and Services
 
The following table shows the aggregate fees billed by KPMG LLP, our independent registered public accounting firm, during the years ended December 31, 2010 and 2009:
 
                 
Description of Fees
  2010     2009  
 
Audit Fees(1)
  $ 1,489,640     $ 1,331,900  
Audit Related Fees(2)
          41,995  
Tax Fees(3)
           
All Other Fees(4)
    332,250       198,000  
                 
    $ 1,821,890     $ 1,571,895  
                 
 
 
(1) Audit Fees.   Includes fees billed for professional services rendered for the audit of our annual financial statements included in our Form 10-K, reviews of our quarterly financial statements included in Forms 10-Q, audits of subsidiaries, reviews of our other filings with the SEC, and other research work necessary to comply with generally accepted accounting standards for the years ended December 31, 2010 and 2009.
 
(2) Audit Related Fees.  Includes fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees.” These services include other accounting and reporting consultations.
 
(3) Tax Fees.  Includes fees billed for tax compliance, tax advice, and tax planning.
 
(4) All Other Fees.  Includes fees billed for assistance with preparation of Medicare cost reports and due diligence procedures on potential acquisitions.
 
The charter of our audit and compliance committee provides that the committee must approve in advance all audit and non-audit services provided by KPMG LLP. The audit and compliance committee approved all of these services.


93


Table of Contents

 
PART IV
 
Item 15.   Exhibits, Financial Statement Schedules
 
(a) (1) Financial Statements
 
The following consolidated financial statements are filed as part of this Form 10-K:
 
         
    F-1  
    F-3  
    F-4  
    F-5  
    F-6  
    F-7  
    F-8  
    S-1  
(3) The following consolidated financial statements of Texas Health Ventures Group, L.L.C. and Subsidiaries are presented pursuant to Rule 3-09 of Regulation S-X:
       
    3  
    4  
    5  
    6  
    7  
    8  
    23  
    24  
    25  
    26  
    27  
    28  
    29  
    IV-1  


94


Table of Contents

 
Report of Independent Registered Public Accounting Firm
 
The Board of Directors and Stockholder
United Surgical Partners International, Inc.:
 
We have audited the accompanying consolidated balance sheets of United Surgical Partners International, Inc. (the Company) and subsidiaries as of December 31, 2010 and 2009, and the related consolidated statements of income, comprehensive income (loss), changes in equity and cash flows for each of the years in the three year period ended December 31, 2010. In connection with our audits of the consolidated financial statements, we also have audited the financial statement schedule. These consolidated financial statements and the financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements and financial statement schedule based on our audits.
 
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
 
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of United Surgical Partners International, Inc. and subsidiaries as of December 31, 2010 and 2009, and the results of their operations and their cash flows for each of the years in the three year period ended December 31, 2010, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, present fairly, in all material respects, the information set forth therein.
 
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), United Surgical Partners International, Inc.’s internal control over financial reporting as of December 31, 2010, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 25, 2011 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
 
/s/  KPMG LLP
 
Dallas, Texas
February 25, 2011


F-1


Table of Contents

 
Report of Independent Registered Public Accounting Firm
 
The Board of Directors and Stockholder
United Surgical Partners International, Inc.:
 
We have audited United Surgical Partners International, Inc.’s (the Company) internal control over financial reporting as of December 31, 2010, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). United Surgical Partners International, Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
 
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
 
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
 
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
 
In our opinion, United Surgical Partners International, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2010, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.
 
United Surgical Partners International, Inc. acquired several subsidiaries and equity method investments during 2010, and management excluded from its assessment of the effectiveness of United Surgical Partners International, Inc.’s internal control over financial reporting as of December 31, 2010, the Company’s internal control over financial reporting associated with total assets of $69.4 million and $3.9 million of revenues included in the consolidated financial statements of United Surgical Partners International, Inc. and subsidiaries as of and for the year ended December 31, 2010. Our audit of internal control over financial reporting of United Surgical Partners International, Inc. also excluded an evaluation of the internal control over financial reporting of those subsidiaries and equity method investments which are listed below:
 
  •  HealthMark Partners, Inc.
 
  •  USP Denver, Inc. (Investment in Flatirons Surgery Center, LLC)
 
  •  USP Houston, Inc. (Investments in Memorial Hermann Endoscopy & Surgery Center North Houston, LLC; Memorial Hermann Surgery Center Woodlands Parkway, LLC and Memorial Hermann Surgery Center Memorial City, LLC)
 
  •  USP Gateway, Inc.
 
  •  USP North Texas, Inc. (Investments in Metrocrest Surgery Center, LP; Baylor Surgicare of Duncanville, LLC; Tuscan Surgery Center at Las Colinas, LLC; and Lone Star Endoscopy, LLC)
 
  •  USP Sacramento, Inc. (Investment in Grass Valley Outpatient Surgery Center, LP)
 
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of United Surgical Partners International, Inc. and subsidiaries as of December 31, 2010 and 2009, and the related consolidated statements of income, comprehensive income (loss), changes in equity and cash flows for each of the years in the three year period ended December 31, 2010 and our report dated February 25, 2011 expressed an unqualified opinion on those consolidated financial statements.
 
/s/  KPMG LLP
 
Dallas, Texas
February 25, 2011


F-2


Table of Contents

 
UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Balance Sheets
December 31, 2010 and 2009
 
                 
    2010     2009  
    (In thousands,
 
    except share amounts)  
 
ASSETS
Cash and cash equivalents (Note 1)
  $ 60,253     $ 34,890  
Accounts receivable, net of allowance for doubtful accounts of $7,481 and $8,160, respectively
    50,082       54,237  
Other receivables (Note 6)
    15,242       15,246  
Inventories of supplies
    9,191       8,789  
Deferred tax asset, net (Note 13)
    14,961       16,400  
Prepaids and other current assets
    14,682       14,382  
                 
Total current assets
    164,411       143,944  
Property and equipment, net (Note 7)
    202,260       198,506  
Investments in unconsolidated affiliates (Note 3)
    393,561       355,499  
Goodwill (Note 8)
    1,268,663       1,279,291  
Intangible assets, net (Note 8)
    319,213       322,896  
Other assets
    24,631       25,256  
                 
Total assets
  $ 2,372,739     $ 2,325,392  
                 
 
LIABILITIES AND EQUITY
Accounts payable
  $ 23,488     $ 23,475  
Accrued salaries and benefits
    26,153       33,015  
Due to affiliates
    116,104       129,296  
Accrued interest
    8,714       8,784  
Current portion of long-term debt (Note 9)
    22,386       23,337  
Other current liabilities
    67,815       39,053  
                 
Total current liabilities
    264,660       256,960  
Long-term debt, less current portion (Note 9)
    1,047,440       1,048,191  
Other long-term liabilities
    26,615       32,466  
Deferred tax liability, net (Note 13)
    131,205       125,907  
                 
Total liabilities
    1,469,920       1,463,524  
Noncontrolling interests — redeemable (Note 4)
    81,668       63,865  
Commitments and contingencies (Notes 4 and 16)
               
Equity (Note 14):
               
United Surgical Partners International, Inc. (USPI) stockholder’s equity:
               
Common stock, $0.01 par value; 100 shares authorized, issued and outstanding
           
Additional paid-in capital
    784,573       789,505  
Accumulated other comprehensive loss, net of tax
    (66,351 )     (58,845 )
Retained earnings
    68,535       27,292  
                 
Total USPI stockholder’s equity
    786,757       757,952  
Noncontrolling interests — nonredeemable (Note 4)
    34,394       40,051  
                 
Total equity
    821,151       798,003  
                 
Total liabilities and equity
  $ 2,372,739     $ 2,325,392  
                 
 
See accompanying notes to consolidated financial statements


F-3


Table of Contents

 
UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Statements of Income
 
                         
    Year Ended
    Year Ended
    Year Ended
 
    December 31,
    December 31,
    December 31,
 
    2010     2009     2008  
          (In thousands)        
 
Revenues:
                       
Net patient service revenues
  $ 504,765     $ 523,899     $ 554,350  
Management and contract service revenues
    64,838       58,326       53,027  
Other revenues
    7,062       11,250       7,721  
                         
Total revenues
    576,665       593,475       615,098  
Equity in earnings of unconsolidated affiliates
    69,916       61,771       47,042  
Operating expenses:
                       
Salaries, benefits, and other employee costs
    156,213       160,278       170,805  
Medical services and supplies
    97,940       99,510       109,739  
Other operating expenses
    99,075       89,347       101,846  
General and administrative expenses
    38,202       38,769       40,155  
Provision for doubtful accounts
    8,458       8,720       7,359  
Losses on deconsolidations, disposals and impairments (Notes 2 and 8)
    6,378       29,162       1,827  
Depreciation and amortization
    29,799       31,165       32,305  
                         
Total operating expenses
    436,065       456,951       464,036  
                         
Operating income
    210,516       198,295       198,104  
Interest income
    798       2,741       3,278  
Interest expense
    (70,038 )     (70,353 )     (84,916 )
Other, net
    708       373       32  
                         
Total other expense, net
    (68,532 )     (67,239 )     (81,606 )
                         
Income from continuing operations before income taxes
    141,984       131,056       116,498  
Income tax benefit (expense) (Note 13)
    (32,328 )     879       (22,667 )
                         
Income from continuing operations
    109,656       131,935       93,831  
Discontinued operations, net of tax (Note 2):
                       
Income (loss) from discontinued operations
    (221 )     1,453       (554 )
Loss on disposal of discontinued operations
    (6,782 )           (625 )
                         
Total earnings (loss) from discontinued operations
    (7,003 )     1,453       (1,179 )
                         
Net income
    102,653       133,388       92,652  
Less: Net income attributable to noncontrolling interests
    (60,560 )     (63,722 )     (55,138 )
                         
Net income attributable to USPI’s common stockholder
  $ 42,093     $ 69,666     $ 37,514  
                         
Amounts attributable to USPI’s common stockholder:
                       
Income from continuing operations, net of tax
  $ 49,123     $ 68,023     $ 38,488  
Earnings (loss) from discontinued operations, net of tax
    (7,030 )     1,643       (974 )
                         
Net income attributable to USPI’s common stockholder
  $ 42,093     $ 69,666     $ 37,514  
                         
 
See accompanying notes to consolidated financial statements


F-4


Table of Contents

 
UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income (Loss)
 
                         
    Year Ended
    Year Ended
    Year Ended
 
    December 31,
    December 31,
    December 31,
 
    2010     2009     2008  
          (In thousands)        
 
Net income
  $ 102,653     $ 133,388     $ 92,652  
Other comprehensive income (loss):
                       
Foreign currency translation adjustments
    (11,638 )     21,967       (71,790 )
Unrealized gain (loss) on interest rate swaps, net of tax
    3,408       3,894       (10,051 )
Pension adjustments, net of tax
    724       (698 )     (682 )
                         
Total other comprehensive income (loss)
    (7,506 )     25,163       (82,523 )
                         
Comprehensive income
    95,147       158,551       10,129  
Less: Comprehensive income attributable to noncontrolling interests
    (60,560 )     (63,722 )     (55,138 )
                         
Comprehensive income (loss) attributable to USPI’s common stockholder
  $ 34,587     $ 94,829     $ (45,009 )
                         
 
See accompanying notes to consolidated financial statements


F-5


Table of Contents

 
UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Statements of Changes in Equity
 
                                                                 
          USPI Common Stockholder        
                                  Accumulated
             
                            Additional
    Other
          Noncontrolling
 
          Comprehensive
    Outstanding
          Paid-in
    Comprehensive
    Retained
    Interests —
 
    Total     Income (Loss)     Shares     Par Value     Capital     Income (Loss)     Earnings     Nonredeemable  
                (In thousands, except share amounts)              
 
Balance, December 31, 2007
  $ 837,100               100     $     $ 799,562     $ (1,485 )   $ 8,729     $ 30,294  
Distributions to noncontrolling interests
    (5,112 )                                           (5,112 )
Purchases and sales of noncontrolling interests, net and other
    14,359                                             14,359  
Contribution related to equity award grants by USPI Group Holdings, Inc. 
    2,340                           2,340                    
Comprehensive income (loss):
                                                               
Net income
    40,053     $ 37,514                               37,514       2,539  
Other comprehensive loss:
                                                               
Foreign currency translation adjustments
    (71,790 )     (71,790 )                       (71,790 )            
Unrealized loss on interest rate swaps, net of tax
    (10,051 )     (10,051 )                       (10,051 )            
Pension liability adjustment, net of tax
    (682 )     (682 )                       (682 )            
                                                                 
Other comprehensive loss
    (82,523 )     (82,523 )                                    
                                                                 
Comprehensive loss
    (42,470 )   $ (45,009 )                                   2,539  
                                                                 
Balance, December 31, 2008
    806,217               100             801,902       (84,008 )     46,243       42,080  
Distributions to noncontrolling interests
    (5,749 )                                           (5,749 )
Purchases of noncontrolling interests
    (3,814 )                         (8,411 )                 4,597  
Sales of noncontrolling interests
    (6,062 )                         (5,922 )                 (140 )
Deconsolidation of subsidiaries
    (6,682 )                                           (6,682 )
Payment of common stock dividend
    (88,617 )                                     (88,617 )      
Contribution related to equity award grants by USPI Group Holdings, Inc. and other
    1,936                           1,936                    
Comprehensive income (loss):
                                                               
Net income
    75,611     $ 69,666                               69,666       5,945  
Other comprehensive income:
                                                               
Foreign currency translation adjustments
    21,967       21,967                         21,967              
Unrealized gain on interest rate swaps, net of tax
    3,894       3,894                         3,894              
Pension liability adjustment, net of tax
    (698 )     (698 )                       (698 )            
                                                                 
Other comprehensive income
    25,163       25,163                                      
                                                                 
Comprehensive income
    100,774     $ 94,829                                     5,945  
                                                                 
Balance, December 31, 2009
    798,003               100             789,505       (58,845 )     27,292       40,051  
Distributions to noncontrolling interests
    (5,710 )                                           (5,710 )
Purchases of noncontrolling interests
    (123 )                         (452 )                 329  
Sales of noncontrolling interests
    (6,096 )                         (6,774 )                 678  
Deconsolidation of subsidiaries
    (6,621 )                                           (6,621 )
Contribution related to equity award grants by USPI Group Holdings, Inc. and other
    2,294                           2,294                    
Dividend to USPI Holdings, Inc/USPI Group Holdings, Inc. 
    (850 )                                     (850 )      
Comprehensive income (loss):
                                                               
Net income
    47,760     $ 42,093                               42,093       5,667  
Other comprehensive income:
                                                               
Foreign currency translation adjustments
    (11,638 )     (11,638 )                       (11,638 )            
Unrealized gain on interest rate swaps, net of tax
    3,408       3,408                         3,408              
Pension liability adjustment, net of tax
    724       724                         724              
                                                                 
Other comprehensive loss
    (7,506 )     (7,506 )                                    
                                                                 
Comprehensive income
    40,254     $ 34,587                                     5,667  
                                                                 
Balance, December 31, 2010
  $ 821,151               100     $     $ 784,573     $ (66,351 )   $ 68,535     $ 34,394  
                                                                 
 
See accompanying notes to consolidated financial statements


F-6


Table of Contents

 
UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Statements of Cash Flows
 
                         
    Year Ended
    Year Ended
    Year Ended
 
    December 31,
    December 31,
    December 31,
 
    2010     2009     2008  
    (In thousands)  
 
Cash flows from operating activities:
                       
Net income
  $ 102,653     $ 133,388     $ 92,652  
Adjustments to reconcile net income to net cash provided by operating activities:
                       
Loss (income) from discontinued operations
    7,003       (1,453 )     1,179  
Provision for doubtful accounts
    8,458       8,720       7,359  
Depreciation and amortization
    29,799       31,165       32,305  
Amortization of debt issue costs and discount
    3,348       3,337       2,860  
Deferred income taxes
    8,290       (10,401 )     14,214  
Loss on deconsolidations, disposals and impairments
    6,378       29,162       1,827  
Equity in earnings of unconsolidated affiliates, net of distributions received
    1,265       (6,951 )     (8,591 )
Equity-based compensation
    1,694       1,695       1,785  
Increases (decreases) in cash from changes in operating assets and liabilities, net of effects from purchases of new businesses:
                       
Accounts receivable
    (5,416 )     (7,780 )     (9,332 )
Other receivables
    (3,304 )     (1,491 )     (8,347 )
Inventories of supplies, prepaids and other assets
    4,386       (3,607 )     7,921  
Accounts payable and other current liabilities
    1,545       2,561       7,157  
Other long-term liabilities
    2,965       2,265       (870 )
                         
Net cash provided by operating activities
    169,064       180,610       142,119  
                         
Cash flows from investing activities:
                       
Purchases of new businesses and equity interests, net of cash received
    (83,676 )     (59,549 )     (76,450 )
Proceeds from sales of businesses and equity interests, net
    50,377       22       12,151  
Purchases of property and equipment
    (40,035 )     (29,704 )     (30,689 )
Returns of capital from unconsolidated affiliates
    1,193       2,894       3,039  
Decrease (increase) in deposits and notes receivable
    101       508       (8,914 )
                         
Net cash used in investing activities
    (72,040 )     (85,829 )     (100,863 )
                         
Cash flows from financing activities:
                       
Proceeds from long-term debt, net of debt issuance costs
    38,974       5,600       45,090  
Payments on long-term debt
    (40,126 )     (25,670 )     (26,914 )
Net equity contribution from USPI Group Holdings, Inc. 
    72       (39 )     40  
(Purchases) sales of noncontrolling interests, net
    1,086       (2,067 )     (26,430 )
Payment of common stock dividend
    (850 )     (88,617 )      
(Decrease) increase in cash held on behalf of unconsolidated affiliates
    (14,166 )     63,101       (5,440 )
Distributions to noncontrolling interests
    (58,989 )     (63,555 )     (56,514 )
                         
Net cash used in financing activities
    (73,999 )     (111,247 )     (70,168 )
                         
Cash flows of discontinued operations:
                       
Operating cash flows
    4,339       4,602       3,627  
Investing cash flows
    (1,471 )     (2,099 )     (550 )
Financing cash flows
    (699 )     (778 )     (1,439 )
                         
Net cash provided by discontinued operations
    2,169       1,725       1,638  
                         
Effect of exchange rate changes on cash
    169       196       (49 )
                         
Net (decrease) increase in cash and cash equivalents
    25,363       (14,545 )     (27,323 )
Cash and cash equivalents at beginning of period
    34,890       49,435       76,758  
                         
Cash and cash equivalents at end of period
  $ 60,253     $ 34,890     $ 49,435  
                         
Supplemental information:
                       
Interest paid, net of amounts capitalized
  $ 69,331     $ 70,920     $ 86,025  
Income taxes (refund received) paid, net
    16,955       8,060       (1,906 )
Non-cash transactions:
                       
Assets acquired under capital lease obligations
  $ 13,481     $ 2,985     $ 1,966  
Receipt of note receivable for sale of noncontrolling interest
                601  
 
See accompanying notes to consolidated financial statements


F-7


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements
December 31, 2010, 2009 and 2008
 
(1)   Summary of Significant Accounting Policies and Practices
 
(a)   Description of Business
 
United Surgical Partners International, Inc., a Delaware Corporation, and subsidiaries (USPI or the Company) was formed in February 1998 for the primary purpose of ownership and operation of ambulatory surgery centers, surgical hospitals and related businesses in the United States and Europe. At December 31, 2010 the Company, headquartered in Dallas, Texas, operated 189 short-stay surgical facilities. Of these 189 facilities, the Company consolidates the results of 58, accounts for 130 under the equity method and operates the remaining facility under a services and management contract. The Company operates in two countries, with 185 of its 189 facilities located in the United States of America; the remaining four facilities are located in the United Kingdom. The majority of the Company’s U.S. facilities are jointly owned with local physicians and a not-for-profit healthcare system that has other healthcare businesses in the region. At December 31, 2010, the Company had agreements with not-for-profit healthcare systems providing for joint ownership of 132 of the Company’s 185 U.S. facilities and also providing a framework for the planning and construction of additional facilities in the future. All of the Company’s U.S. facilities include physician owners.
 
Global Healthcare Partners Limited (Global), a USPI subsidiary incorporated in England, manages and wholly owns three surgical hospitals and an oncology clinic in the greater London area.
 
The Company is subject to changes in government legislation that could impact Medicare, Medicaid and foreign government reimbursement levels and is also subject to increased levels of managed care penetration and changes in payor patterns that may impact the level and timing of payments for services rendered.
 
The Company maintains its books and records on the accrual basis of accounting, and the consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.
 
The Company had publicly traded equity securities from June 2001 through April 2007. Pursuant to an Agreement and Plan of Merger (the merger) dated as of January 7, 2007, between an affiliate of Welsh, Carson, Anderson & Stowe X, L.P. (Welsh Carson), the Company became a wholly owned subsidiary of USPI Holdings, Inc. on April 19, 2007. USPI Holdings is a wholly owned subsidiary of USPI Group Holdings, Inc. (Parent), which is owned by an investor group that includes affiliates of Welsh Carson, members of the Company’s management and other investors.
 
Certain amounts in the consolidated financial statements for prior periods have been reclassified to conform to the 2010 presentation. Net operating results have not been affected by these reclassifications.
 
(b)   Translation of Foreign Currencies
 
The financial statements of foreign subsidiaries are measured in local currency and then translated into U.S. dollars. All assets and liabilities have been translated using the current rate of exchange at the balance sheet date. Results of operations have been translated using the average rates prevailing throughout the year. Translation gains or losses resulting from changes in exchange rates are accumulated in a separate component of stockholder’s equity.
 
(c)   Principles of Consolidation
 
The consolidated financial statements include the financial statements of USPI and its wholly-owned and majority-owned subsidiaries. In addition, the Company consolidates the accounts of certain investees of which it does not own a majority ownership interest because the Company maintains effective control over the investees’


F-8


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
assets and operations. All significant intercompany balances and transactions have been eliminated in consolidation.
 
The Company also determines if it is the primary beneficiary of (and therefore should consolidate) any entity whose operations it does not control with voting rights. At December 31, 2010 and 2009, the Company consolidated one and two such entities, respectively (Note 5).
 
(d)   Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 
(e)   Cash and Cash Equivalents
 
For purposes of the consolidated statements of cash flows, the Company considers all highly liquid debt instruments with original or remaining maturities of three months or less to be cash equivalents. Cash and cash equivalents at times may exceed the FDIC limits. The Company believes no significant concentration of credit risk exists with respect to these cash investments.
 
The Company’s wholly-owned insurance subsidiary maintains certain balances in cash and cash equivalents that are used in connection with its retained professional and general liability risks and are not designated for general corporate purposes. At December 31, 2010 and 2009, these cash and cash equivalents balances were $6.0 million and $2.9 million, respectively.
 
(f)   Inventories of Supplies
 
Inventories of supplies are stated at cost, which approximates market, and are expensed as used.
 
(g)   Property and Equipment
 
Property and equipment are stated at cost or, when acquired as part of a business combination, fair value at date of acquisition. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets. Upon retirement or disposal of assets, the asset and accumulated depreciation accounts are adjusted accordingly, and any gain or loss is reflected in earnings or loss of the respective period. Maintenance costs and repairs are expensed as incurred; significant renewals and betterments are capitalized. Assets held under capital leases are classified as property and equipment and amortized using the straight-line method over the shorter of the useful lives or lease terms, and the related obligations are recorded as debt. Amortization of assets under capital leases and of leasehold improvements is included in depreciation expense. The Company records operating lease expense on a straight-line basis unless another systematic and rational allocation is more representative of the time pattern in which the leased property is physically employed. The Company amortizes leasehold improvements, including amounts funded by landlord incentives or allowances, for which the related deferred rent is amortized as a reduction of lease expense, over the shorter of their economic lives or the lease term.
 
(h)   Goodwill and Intangible Assets
 
Intangible assets consist of costs in excess of net assets acquired (goodwill), costs of acquired management and other contract service rights, and other intangibles, which consist primarily of debt issue costs. Most of the Company’s intangible assets have indefinite lives. Accordingly, these assets, along with goodwill, are not amortized but are instead tested for impairment annually, or more frequently if changing circumstances warrant. Goodwill is


F-9


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
tested for impairment at the reporting unit level, which corresponds to the Company’s operating segments, or countries. The Company amortizes intangible assets with definite useful lives over their respective useful lives to their estimated residual values and reviews them for impairment in the same manner as long-lived assets, discussed below.
 
(i)   Impairment of Long-lived Assets
 
Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset, or related groups of assets, may not be fully recoverable from estimated future cash flows. In the event of impairment, measurement of the amount of impairment may be based on appraisal, market values of similar assets or estimates of future discounted cash flows using market participant assumptions with respect to the use and ultimate disposition of the asset.
 
(j)   Fair Value Measurements
 
The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2) or unobservable inputs for assets or liabilities (Level 3), depending on the nature of the item being valued. The Company discloses on a yearly basis the valuation techniques and discloses any change in method of such within the body of each applicable footnote. The estimated fair values may not be representative of actual values that will be realized or settled in the future.
 
The carrying amounts of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable approximate fair value because of the short maturity of these instruments.
 
(k)   Derivative Instruments and Hedging Activities
 
The Company accounts for its derivative instruments at fair value and records the value on its consolidated balance sheet as an asset or liability. The Company does not engage in derivative instruments for speculative purposes. Because the Company’s current derivatives (interest rate swaps) qualify for hedge accounting, gains or losses resulting from changes in the values of the Company’s derivatives are reported in accumulated other comprehensive income (loss), a separate component of equity (Note 10).
 
(l)   Revenue Recognition
 
Revenues consist primarily of net patient service revenues, which are based on the facilities’ established billing rates less allowances and discounts, principally for patients covered under contractual programs with private insurance companies. The Company derives approximately 70% of its net patient service revenues from private insurance payors, approximately 15% from governmental payors and approximately 15% from self-pay and other payors. Amounts are recognized as services are provided.
 
With respect to management and contract service revenues, amounts are also recognized as services are provided. The Company is party to agreements with certain surgical facilities, hospitals and physician practices to provide management services. As compensation for these services each month, the Company charges the managed entities management fees which are either fixed in amount or represent a fixed percentage of each entity’s earnings, typically defined as net revenue less a provision for doubtful accounts or operating income. In many cases the Company also holds equity ownership in these entities (Note 12). Amounts charged to consolidated facilities eliminate in consolidation.


F-10


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(m)   Concentration of Credit Risk
 
Concentration of credit risk with respect to accounts receivable is limited due to the large number of customers comprising the Company’s customer base and their breakdown among geographical locations in which the Company operates. The Company provides for bad debts principally based upon the aging of accounts receivable and uses specific identification to write off amounts against its allowance for doubtful accounts. The Company believes the allowance for doubtful accounts adequately provides for estimated losses as of December 31, 2010 and 2009. The Company has a risk of incurring losses if such allowances are not adequate.
 
(n)   Investments and Equity in Earnings of Unconsolidated Affiliates
 
Investments in unconsolidated companies in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. The Company’s ownership in these entities range from 5% to 69%. Certain investments in unconsolidated companies in which the Company owns a majority interest are not consolidated due to the substantive participating rights of the minority owners.
 
These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The carrying amounts of these investments are greater than the Company’s equity in the underlying net assets of many of these companies due in part to goodwill, which is not subject to amortization. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
 
Equity in earnings of unconsolidated affiliates consists of the Company’s share of the profits or losses generated from its noncontrolling equity investments in 130 surgical facilities. Because these operations are central to the Company’s business strategy, equity in earnings of unconsolidated affiliates is classified as a component of operating income in the accompanying consolidated statements of income. The Company has contracts to manage these facilities, which results in the Company having an active role in the operations of these facilities and devoting a significant portion of its corporate resources to the fulfillment of these management responsibilities.
 
(o)   Income Taxes
 
The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets may not be realized.
 
(p)   Equity-Based Compensation
 
The Company accounts for equity-based compensation, such as stock options and other stock-based awards to employees and directors, at fair value. The fair value is measured at the date of grant and recognized as expense over the employee’s requisite service period. The Company also accounts for equity instruments issued to non-employees at fair value.


F-11


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(q)   Commitments and Contingencies
 
Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
 
(2)   Discontinued Operations and Other Dispositions
 
Sales of consolidated subsidiaries in which the Company has no continuing involvement are classified as discontinued operations, as are consolidated subsidiaries that are held for sale. The gains or losses on these transactions are classified within discontinued operations in our consolidated statements of income. Also, the Company has reclassified its historical results of operations to remove the operations of these entities from its revenues and expenses, collapsing the net income or loss from these operations into a single line within discontinued operations.
 
Discontinued operations are as follows :
 
                     
Date
 
Facility Location
  Proceeds     Gain (Loss)  
 
December 2010
  Nashville, Tennessee(1)   $ 32.5 million     $ 2.8 million  
December 2010
  Orlando, Florida           (2.0 million )
December 2010
  Templeton, California(2)           (1.9 million )
December 2010
  Houston, Texas(2)           (0.2 million )
                     
Total
      $ 32.5 million     $ (1.3 million )
                     
June 2008
  Cleveland, Ohio   $ 1.6 million     $ (1.0 million )
 
 
(1) The Company sold an endoscopy service business that was based in Nashville, Tennessee.
 
(2) These investments were written down to estimated fair value less costs to sell at December 31, 2010, and were sold at amounts approximating these estimated values in February 2011. The assets and liabilities of these entities were not material.
 
The table below summarizes certain amounts related to the Company’s discontinued operations for the periods presented (in thousands):
 
                         
    Year Ended
    Year Ended
    Year Ended
 
    December 31,
    December 31,
    December 31,
 
    2010     2009     2008  
 
Revenues
  $ 29,180     $ 28,889     $ 30,234  
Income (loss) from discontinued operations before income taxes
  $ (340 )   $ 2,235     $ (853 )
Income tax (expense) benefit
    119       (782 )     299  
                         
Income (loss) from discontinued operations
  $ (221 )   $ 1,453     $ (554 )
                         
Loss on disposal of discontinued operations before income taxes
  $ (1,332 )   $     $ (963 )
Income tax (expense) benefit
    (5,450 )           338  
                         
Total loss from disposal of discontinued operations
  $ (6,782 )   $     $ (625 )
                         


F-12


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
Equity method investments that are sold do not represent discontinued operations under GAAP. During 2009 and 2008, the Company completed sales of investments in ten facilities operated through unconsolidated affiliates, including its equity ownership in these entities as well as the related rights to manage the facilities. The Company did not sell any equity method investments during 2010. Gains and losses on the disposals of these investments are classified within “Losses on deconsolidations, disposals and impairments” in the accompanying consolidated statements of income. These transactions are summarized below:
 
                     
Date
 
Facility Location
  Proceeds (Costs)     Loss  
 
December 2009
  Oxnard, California   $ 0.3 million     $ (0.3 million )
December 2009
  Baton Rouge, Louisiana(1)     (5.1 million )     (8.2 million )
September 2009
  San Antonio, Texas           (2.6 million )
July 2009
  Cleveland, Ohio(2)     1.0 million        
February 2009
  Las Cruces, New Mexico            
February 2009
  East Brunswick, New Jersey     0.7 million       (2.6 million )
                     
Total
      $ (3.1 million )   $ (13.7 million )
                     
July 2008
  Manitowoc, Wisconsin   $ 0.8 million     $  
July 2008
  Orlando, Florida     0.5 million       (0.4 million )
April 2008
  Los Angeles, California            
February 2008
  Sarasota, Florida     0.5 million        
                     
Total
      $ 1.8 million     $ (0.4 million )
                     
 
 
(1) The Company paid $5.1 million to settle contingent liabilities in conjunction with the sale of this center. Such amount was expensed and included in “Losses on deconsolidations, disposals and impairments” in the accompanying consolidated statements of income.
 
(2) The Company financed the entire purchase price with the buyer and has a security interest in the facility’s assets until the note is collected, which is due in 2011. As a result, the Company deferred the recognition of the gain, which is estimated at $0.6 million.
 
The Company from time to time surrenders control of an entity but retains a noncontrolling interest (classified within “investments in unconsolidated affiliates”). These types of transactions result in a gain or loss, computed as the difference between (a) the sales proceeds and fair value of the retained investment and (b) the Company’s carrying value of the investment prior to the transaction. Gains or losses for such transactions are classified within “Losses on deconsolidations, disposals and impairments” in the accompanying consolidated statements of income. The Company’s continuing involvement as an equity method investor and manager of the facilities precludes classification of these transactions as discontinued operations. Fair values for the retained noncontrolling interests are estimated based on market multiples and discounted cash flow models which have been derived from the Company’s experience in acquiring surgical facilities and third party valuations it has obtained with respect to such transactions.


F-13


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
During the years ended December 31, 2010, 2009, and 2008, the Company surrendered control of, but retained an equity method investment in, ten entities as summarized below:
 
                     
Effective Date
 
Facility Location
  Proceeds     Gain (Loss)  
 
December 2010
  Phoenix, Arizona(1)   $ 0.6 million     $ (1.5 million)  
December 2010
  Dallas, Texas(2)           1.6 million  
                     
Total
      $ 0.6 million     $ 0.1 million  
                     
December 2009
  Dallas, Texas(3)   $ 1.2 million     $ 0.3 million  
July 2009
  Oklahoma City, Oklahoma(4)     0.2 million       0.1 million  
March 2009
  Phoenix, Arizona(5)     0.1 million       (8.2) million  
                     
Total
      $ 1.5 million     $ (7.8 million)  
                     
July 2008
  Beaumont, Texas   $ 1.2 million     $ (0.5 million)  
June 2008
  Dallas, Texas(6)     2.3 million       (0.9 million)  
June 2008
  Houston, Texas(7)     0.6 million        
March 2008
  Redding, California(8)     1.7 million        
                     
Total
      $ 5.8 million     $ (1.4 million)  
                     
 
 
(1) A hospital partner acquired a portion of the Company’s interest in this facility and shares control of the facility with the Company.
 
(2) The Company previously controlled this facility but now shares control with physicians due to a change in the entity’s governing documents.
 
(3) A controlling interest in a facility was sold to a hospital partner as part of the Company’s strategy for partnering with this hospital system. The Company recorded a net gain of $0.3 million on the sale and deconsolidation of the facility. The gain is comprised of a $1.4 million gain related to the remeasurement of the Company’s retained interest to fair value, offset by a loss of $1.1 million, the amount by which the carrying value of the investment exceeded the proceeds received. This hospital system is a related party (Note 12).
 
(4) The Company and other owners of a facility consolidated by the Company agreed to merge the facility into another entity in which the Company holds an investment accounted for under the equity method. The Company recorded a gain of $0.1 million on the sale and deconsolidation of the facility.
 
(5) A controlling interest in an entity was sold to a hospital partner as part of the Company’s strategy for partnering with this hospital system. The hospital partner already had a 49% ownership interest in this entity, which owns and manages two surgical facilities, and through the transaction acquired an additional 1.1% interest. The $8.2 million loss was primarily related to the revaluation of the Company’s remaining investment in the entity to fair value.
 
(6) The hospital partner already had an ownership interest in the facility and acquired a controlling interest from the Company in this transaction. Additionally, this hospital partner is a related party (Note 12).
 
(7) Because the Company is considered the primary beneficiary of this entity, the Company consolidates the entity to which it transferred its interest in the facility, and accordingly continues to consolidate the facility’s operating results. The sales price of $0.6 million was paid in the form of a note receivable from the buyer.
 
(8) The Company sold a controlling interest in two facilities and received a noncontrolling interest in a third facility in Redding.


F-14


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(3)   Business Combinations and Investments in Unconsolidated Affiliates
 
The Company acquires interests in existing surgery centers from third parties and invests in new facilities that it develops in partnership with hospital partners and local physicians. Some of these transactions result in the Company controlling the acquired entity and meet the GAAP definition of a business combination. The financial results of the acquired entities are included in the Company’s consolidated financial statements beginning on the acquisition’s effective closing date. The adjustments to arrive at pro forma operating results for these acquisitions are not material.
 
During the year ended December 31, 2010, the Company obtained control of the following entities:
 
             
Effective Date
 
Facility Location
  Amount  
 
Investments
           
May 2010
  St. Louis, Missouri(1)   $ 4.6 million  
October 2010
  Houston, Texas(2)     2.4 million  
November 2010
  Various(3)     31.1 million  
December 2010
  Houston, Texas(2)     9.0 million  
December 2010
  Reading, Pennsylvania(4)     1.1 million  
             
Total
      $ 48.2 million  
             
 
 
(1) Acquisition of a noncontrolling interest in and right to manage a surgical facility in which the Company previously had no involvement. This facility is jointly owned with local physicians.
 
(2) Acquisition of a controlling interest in and right to manage a surgical facility in which the Company previously had no involvement. The remainder of this facility is owned by a hospital partner and local physicians.
 
(3) As further discussed below, the Company acquired 100% of the equity interests in HealthMark Partners, Inc. (HealthMark). HealthMark has an equity investment in 14 surgery centers. Local physicians have ownership in all 14 facilities and by December 31, 2010 and January 31, 2011, hospital partners had invested in nine and ten of these facilities, respectively.
 
(4) Acquisition of a controlling interest in a surgical facility in which the Company already held an ownership interest. The Company’s original ownership was acquired in the HealthMark acquisition.
 
Effective November 1, 2010, the Company completed the acquisition of 100% of the equity interests in HealthMark, a privately-held, Nashville-based owner and operator of surgery centers. HealthMark has an equity investment in 14 surgery centers, 11 of which are located in markets in which the Company already operates. The Company paid cash totaling approximately $31.1 million, subject to certain purchase price adjustments set forth in the purchase agreement. The purchase price was allocated to the HealthMark’s tangible and identifiable intangible assets and liabilities based upon estimates of fair value, with the remainder allocated to goodwill. The Company funded the purchase through cash on hand and a $25.0 million borrowing under the Company’s revolving credit agreement. The Company incurred approximately $1.7 million in acquisition and severance costs, of which $0.4 million is included in “other operating expenses” and the remaining $1.3 million is included in “salaries, benefits, and other employee costs” in accompanying consolidated statements of income.


F-15


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
The following is a summary of the assets acquired and liabilities assumed in the acquisition of HealthMark:
 
                 
Purchase price allocated
          $ 31,072  
                 
Estimated fair value of net tangible assets acquired:
               
Cash
          $ 4,280  
Other current assets
            26  
Investments in affiliates
            12,140  
Property and equipment
            344  
Current liabilities
            (1,431 )
Long term liabilities
            (153 )
                 
Net tangible assets acquired
            15,206  
Intangible assets acquired
            6,559  
Goodwill
            9,307  
                 
Total purchase price
          $ 31,072  
                 
 
The goodwill recorded in conjunction with the HealthMark acquisition was allocated to the Company’s United States reporting unit and the Company expects that approximately $0.7 million of the goodwill will be deductible for income tax purposes. Indefinite-lived intangibles of $6.0 million relate to long-term management contracts and are not subject to amortization. Other service contract intangibles of approximately $0.6 million are being amortized over their estimate lives of approximately one to five years.
 
The Company controls 58 of its entities and therefore consolidates their results. However, the Company accounts for an increasing majority (130 of its 185 U.S. facilities at December 31, 2010) as investments in unconsolidated affiliates, i.e., under the equity method, as the Company’s level of influence is significant but does not reach the threshold of controlling the entity. The majority of these investments are partnerships or limited liability companies, which require the associated tax benefit or expense to be recorded by the partners or members. Summarized financial information for the Company’s equity method investees on a combined basis is as follows


F-16


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(amounts are in thousands, except number of facilities, and reflect 100% of the investees’ results on an aggregated basis and are unaudited):
 
                         
    2010     2009     2008  
 
Unconsolidated facilities operated at year-end
    130       109       101  
Income statement information:
                       
Revenues
  $ 1,329,041     $ 1,178,114     $ 1,002,394  
Operating expenses:
                       
Salaries, benefits, and other employee costs
    309,698       277,053       246,739  
Medical services and supplies
    310,770       271,663       211,781  
Other operating expenses
    305,045       271,769       247,834  
Loss (gain) on asset disposals, net
    1,025       (7 )     1,161  
Depreciation and amortization
    55,216       50,251       48,722  
                         
Total operating expenses
    981,754       870,729       756,237  
                         
Operating income
    347,287       307,385       246,157  
Interest expense, net
    (25,630 )     (24,394 )     (24,101 )
Other, net
    (200 )     4,572       225  
                         
Income before income taxes
  $ 321,457     $ 287,563     $ 222,281  
                         
Balance sheet information:
                       
Current assets
  $ 303,627     $ 264,944     $ 236,108  
Noncurrent assets
    495,765       412,977       403,956  
Current liabilities
    177,909       152,081       138,199  
Noncurrent liabilities
    343,007       283,951       288,429  
 
The Company’s equity method investment in Texas Health Ventures Group, L.L.C., is considered significant to the Company’s 2010 consolidated financial statements under regulations of the SEC. As a result, the Company has filed Texas Health Ventures Group, L.L.C.’s consolidated financial statements with this Form 10-K for the required periods.
 
During 2010, the Company recorded an impairment on one of its equity method investments due to the decline in the fair value of the investment being other than temporary. The impairment was approximately $3.7 million and is recorded within “Equity in earnings of unconsolidated affiliates” in the accompanying consolidated statement of income.
 
The Company also regularly engages in the purchase and sale of equity interests with respect to its investments in unconsolidated affiliates that do not result in a change of control. These transactions are primarily the acquisitions and sales of equity interests in unconsolidated surgical facilities and the investment of additional


F-17


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
cash in surgical facilities under development. During the year ended December 31, 2010, these transactions resulted in a cash outflow of approximately $21.3 million, which is summarized as follows:
 
             
Effective Date
 
Facility Location
  Amount  
 
Investments
           
December 2010
  Nashville, Tennessee(1)   $ 13.4 million  
December 2010
  Boulder, Colorado(2)     4.7 million  
December 2010
  Chattanooga, Tennessee(3)     2.6 million  
December 2010
  Irving, Texas(4)     1.9 million  
December 2010
  Kansas City, Missouri(5)     1.2 million  
December 2010
  Houston, Texas(2)     0.9 million  
November 2010
  Keller, Texas(4)     4.6 million  
July 2010
  Sacramento, California(2)     1.5 million  
July 2010
  Carrollton, Texas(4)     0.8 million  
May 2010
  Mansfield, Texas(4)     0.4 million  
April 2010
  Destin, Florida(3)     1.3 million  
April 2010
  St. Louis, Missouri(6)     0.4 million  
             
          33.7 million  
Sales
           
December 2010
  Phoenix, Arizona(7)     4.1 million  
June 2010
  Cincinnati, Ohio(8)     7.9 million  
Various
  Various(9)     0.4 million  
             
          12.4 million  
             
Total
      $ 21.3 million  
             
 
 
(1) Acquisition of an additional noncontrolling interest in three surgical facilities in which the Company already held an investment and one surgical facility in which the Company already provided management services. These facilities are jointly owned with one of the Company’s hospital partners and local physicians.
 
(2) Acquisition of a noncontrolling interest in and right to manage a surgical facility in which the Company previously had no involvement. This facility is jointly owned with one of the Company’s hospital partners and local physicians.
 
(3) Acquisition of an additional noncontrolling interest in a surgical facility in which the Company already held an investment. This facility is jointly owned with local physicians.
 
(4) Acquisition of the right to manage a surgical facility in which the Company previously had no involvement. Concurrent with this transaction, an unconsolidated investee that the Company jointly owns with a hospital partner used cash on hand to acquire an equity interest in this facility, resulting in the Company having an indirect ownership interest in the facility. The remainder of this facility is owned by local physicians.
 
(5) Acquisition of an additional noncontrolling interest in a surgical facility in which the Company already held an investment. This facility is jointly owned with one of the Company’s hospital partners and local physicians.
 
(6) Acquisition of a noncontrolling interest in a surgical facility in which the Company already provided management services. This facility is jointly owned with one of the Company’s hospital partners and local physicians.


F-18


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
 
(7) Sale of a portion of the Company’s equity ownership in two facilities to a hospital partner. The remainder of these facilities are owned by local physicians. The Company recorded a loss of $1.2 million related to this sale, which is classified in “Losses on deconsolidations, disposals and impairments” on the accompanying consolidated statements of income.
 
(8) Sale of a portion of the Company’s equity ownership in one facility to a hospital partner. The remainder of this facility is owned by local physicians. The Company recorded a loss of $0.2 million related to this sale, which is classified in “Losses on deconsolidations, disposals and impairments” on the accompanying consolidated statements of income.
 
(9) Represents the net receipt related to various other purchases and sales of equity interests and contributions of cash to equity method investees.
 
(4)   Noncontrolling Interests
 
The Company controls and therefore consolidates the results of 58 of its 189 facilities. Similar to its investments in unconsolidated affiliates, the Company regularly engages in the purchase and sale of equity interests with respect to its consolidated subsidiaries that do not result in a change of control. These transactions are accounted for as equity transactions, as they are undertaken among the Company, its consolidated subsidiaries, and noncontrolling interests, and their cash flow effect is classified within financing activities.
 
During the year ended December 31, 2010, the Company purchased and sold equity interests in various consolidated subsidiaries in the amounts of $2.9 million and $4.0 million, respectively. The basis difference between the Company’s carrying amount and the proceeds received or paid in each transaction is recorded as an adjustment to additional paid-in capital. The impact of these transactions is summarized as follows (in thousands):
 
                 
    Year Ended
    Year Ended
 
    December 31,
    December 31,
 
    2010     2009  
 
Net income attributable to USPI’s common stockholder
  $ 42,093     $ 69,666  
Transfers to the noncontrolling interests:
               
Decrease in USPI’s additional paid-in capital for sales of subsidiaries’ equity interests
    (6,774 )     (5,922 )
Decrease in USPI’s additional paid-in capital for purchases of subsidiaries’ equity interests
    (452 )     (8,411 )
                 
Net transfers to noncontrolling interests
    (7,226 )     (14,333 )
                 
Change in equity from net income attributable to USPI and transfers to noncontrolling interests
  $ 34,867     $ 55,333  
                 


F-19


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
Upon the occurrence of various fundamental regulatory changes, the Company could be obligated, under the terms of its investees’ partnership and operating agreements, to purchase some or all of the noncontrolling interests related to the Company’s consolidated U.S. subsidiaries. These repurchase requirements are limited to the portions of its facilities that are owned by physicians who perform surgery at the Company’s facilities and would be triggered by regulatory changes making the existing ownership illegal. While the Company is not aware of events that would make the occurrence of such a change probable, regulatory changes are outside the control of the Company. Accordingly, the noncontrolling interests subject to these repurchase provisions, and the income attributable to those interests, are not included as part of the Company’s equity and are carried as noncontrolling interests-redeemable on the Company’s consolidated balance sheets. The activity for the years ended December 31, 2010, 2009 and 2008 is summarized below (in thousands):
 
         
    Noncontrolling
 
    Interests —
 
    Redeemable  
 
Balance, December 31, 2007
  $ 52,769  
Net income attributable to noncontrolling interests
    52,599  
Distributions to noncontrolling interests
    (51,401 )
Purchases of noncontrolling interests
    (7,446 )
Sales of noncontrolling interests
    8,928  
Deconsolidation of noncontrolling interests and other
    (3,488 )
         
Balance, December 31, 2008
    51,961  
Net income attributable to noncontrolling interests
    57,777  
Distributions to noncontrolling interests
    (57,807 )
Purchases of noncontrolling interests
    (2,519 )
Sales of noncontrolling interests
    12,403  
Deconsolidation of noncontrolling interests and other
    2,050  
         
Balance, December 31, 2009
    63,865  
Net income attributable to noncontrolling interests
    54,893  
Distributions to noncontrolling interests
    (53,485 )
Purchases of noncontrolling interests
    (2,180 )
Sales of noncontrolling interests
    9,984  
Deconsolidation of noncontrolling interests and other
    8,591  
         
Balance, December 31, 2010
  $ 81,668  
         
 
(5)   Other Investments
 
The consolidated financial statements include the financial statements of USPI and subsidiaries the Company effectively controls, usually indicated by majority ownership. The Company also determines if it is the primary beneficiary of (and therefore should consolidate) any entity whose operations it does not control with voting rights. At December 31, 2010, the Company consolidated one such entity. At December 31, 2009, the Company consolidated two entities in accordance with this accounting guidance.
 
One of these entities operates and manages six surgical facilities in the Houston, Texas area. Despite not holding a controlling voting interest, the Company is the primary beneficiary because the Company has lent the entity funds to purchase surgical facilities, but the Company does not have full recourse to the entity’s other owner with respect to repayment of the loans. As the entity earns management fees and receives cash distributions of


F-20


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
earnings from the surgical facilities, a portion of those proceeds are used to repay the loans prior to being eligible for distribution to the entity’s other owner. At December 31, 2010 and 2009, $8.1 million and $11.3 million, respectively, of such advances are outstanding and are included in other long-term assets. The Company has no exposure for the entity’s losses beyond this investment. Accordingly, the Company did not provide any financial or other support to the entity that it was not previously contractually required to provide during the years ended December 31, 2010 or 2009. At December 31, 2010 and 2009, the total assets of this entity were $82.3 million and $55.4 million, and the total liabilities owed to third parties were $22.6 million and $22.8 million, respectively. Such amounts are included in the accompanying consolidated balance sheets.
 
In November 2010, due to changes in the economic structuring of the second entity, the entity is no longer considered a variable interest entity, and the Company does not hold voting control of the entity. As a result, it was deconsolidated in November 2010. The Company recorded no gain or loss on the deconsolidation. The entity was developing and constructing a new hospital for one of the Company’s unconsolidated affiliates, which opened in January 2011. The total project cost was approximately $25.0 million, which was funded by cash contributions from its partners and debt financing. The Company made its required equity contribution of $6.3 million in December 2009. The Company sold approximately 50% of its interest for $3.1 million in November 2010. The entity arranged bank financing totaling $17.4 million, of which 70% is guaranteed by the Company, which is now indemnified for approximately 50% of its guarantee by the entity’s new investors. None of the bank financing was borrowed at December 31, 2009 and approximately $11.8 million is outstanding at December 31, 2010. The Company had no exposure for the entity’s losses beyond its investment and bank guarantee. The Company did not provide any financial or other support to the entity that it was not previously contractually required to provide during the years ended December 31, 2010 or 2009. At December 31, 2009, total assets and liabilities of this entity were $9.0 million and $0.1 million, respectively. Such amounts are included in the accompanying 2009 consolidated balance sheet.
 
The Company also has investments in two unconsolidated variable interest entities in which it was not considered the primary beneficiary. These entities own real estate and fixed assets that are leased to various surgical facilities. The total assets of these entities were $7.2 million and $8.8 million, and the total liabilities of these entities were $8.3 million and $8.7 million at December 31, 2010 and 2009, respectively. The Company’s investment in these entities and maximum exposure to loss as a result of its involvement with these entities is not material. The Company did not provide any financial or other support to these entities that it was not previously contractually required to provide during the years ended December 31, 2010 or 2009.
 
(6)   Other Receivables
 
Other receivables consist primarily of amounts receivable for services performed and funds advanced under management and administrative service agreements. As discussed in Note 12, many of the entities to which the Company provides management and administrative services are related parties, due to the Company being an investor in those facilities. At December 31, 2010 and 2009, the amounts receivable from related parties, which are included in other receivables on the Company’s consolidated balance sheet, totaled $6.2 million and $4.4 million, respectively.


F-21


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(7)   Property and Equipment
 
At December 31, 2010 and 2009, property and equipment consisted of the following (in thousands):
 
                         
    Estimated
             
    Useful Lives     2010     2009  
 
Land
        $ 29,379     $ 34,259  
Buildings and leasehold improvements
    7-50 years       135,631       118,669  
Equipment
    3-12 years       113,135       106,091  
Furniture and fixtures
    4-20 years       10,137       9,526  
Construction in progress
          7,248       7,676  
                         
              295,530       276,221  
Accumulated depreciation
            (93,270 )     (77,715 )
                         
Net property and equipment
          $ 202,260     $ 198,506  
                         
 
At December 31, 2010 and 2009, assets recorded under capital lease arrangements, included in property and equipment, consisted of the following (in thousands):
 
                 
    2010     2009  
 
Land and buildings
  $ 16,955     $ 21,037  
Equipment and furniture
    15,666       10,769  
                 
      32,621       31,806  
Accumulated amortization
    (10,450 )     (8,258 )
                 
Net property and equipment under capital leases
  $ 22,171     $ 23,548  
                 
 
(8)   Goodwill and Intangible Assets
 
Under GAAP, goodwill and intangible assets with indefinite useful lives are not amortized but instead are tested for impairment at least annually, with tests of goodwill occurring at the reporting unit level (defined as an operating segment or one level below an operating segment). Intangible assets with definite useful lives are amortized over their respective useful lives to their estimated residual values. The Company determined that its reporting units are at the operating segment (country) level. The Company completed the required annual impairment tests during 2010, 2009 and 2008. No impairment losses were identified in any reporting unit as a result of these goodwill impairment tests.
 
As a result of impairment testing performed on the Company’s indefinite-lived management contracts, the Company recorded impairment losses on six contracts in 2010 and three contracts in 2009. These losses totaled approximately $5.9 million and $5.7 million, respectively, and were primarily triggered by a reduction in the Company’s expected earnings under the contracts. The Company recorded a similar impairment charge of $0.8 million in 2008 related to one of its indefinite-lived management contracts. Fair values for indefinite-lived intangible assets are estimated based on market multiples and discounted cash flow models which have been derived from the Company’s experience in acquiring surgical facilities, market participant assumptions and third party valuations it has obtained with respect to such transactions. The inputs used in these models are Level 3 inputs, which under GAAP, are significant unobservable inputs. Inputs into these models include expected revenue growth, expected gross margins and discount factors. Such expense is recorded in “Losses on deconsolidations, disposals and impairments” in the accompanying consolidated statements of income.


F-22


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
The following is a summary of changes in the carrying amount of goodwill by operating segment and reporting unit for the years ended December 31, 2010 and 2009 (in thousands):
 
                         
    United
    United
       
    States     Kingdom     Total  
 
Balance at December 31, 2008
  $ 1,075,609     $ 194,678     $ 1,270,287  
Additions
    4,047             4,047  
Disposals
    (15,517 )           (15,517 )
Other
          20,474       20,474  
                         
Balance at December 31, 2009
    1,064,139       215,152       1,279,291  
Additions
    27,474             27,474  
Disposals
    (27,820 )           (27,820 )
Other
          (10,282 )     (10,282 )
                         
Balance at December 31, 2010
  $ 1,063,793     $ 204,870     $ 1,268,663  
                         
 
Goodwill additions resulted primarily from business combinations and additionally from purchases of additional interests in subsidiaries. Disposals of goodwill relate to businesses that the Company has sold or the deconsolidation of entities the Company no longer controls. In the United Kingdom, the other changes were primarily due to foreign currency translation adjustments.
 
Intangible assets with definite useful lives are amortized over their respective estimated useful lives, ranging from approximately one to nine years, to their estimated residual values. The majority of the Company’s management contracts have indefinite useful lives. Most of these contracts have evergreen renewal provisions that do not contemplate a specific termination date. Some of the contracts have provisions which make it possible for the facility’s other owners to terminate them at certain dates and under certain circumstances. Based on the Company’s history with these contracts, the Company’s management considers the lives of these contracts to be indefinite and therefore does not amortize them unless facts and circumstances indicate otherwise.
 
The following is a summary of intangible assets at December 31, 2010 and 2009 (in thousands):
 
                         
    December 31, 2010  
    Gross
             
    Carrying
    Accumulated
       
    Amount     Amortization     Total  
 
Definite Useful Lives
                       
Management and other service contracts
  $ 17,242     $ (7,856 )   $ 9,386  
Other
    30,405       (11,580 )     18,825  
                         
Total
  $ 47,647     $ (19,436 )   $ 28,211  
                         
Indefinite Useful Lives
                       
Management contracts
                    291,002  
                         
Total intangible assets
                  $ 319,213  
                         
 


F-23


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
                         
    December 31, 2009  
    Gross
             
    Carrying
    Accumulated
       
    Amount     Amortization     Total  
 
Definite Useful Lives
                       
Management and other service contracts
  $ 26,605     $ (8,500 )   $ 18,105  
Other
    30,401       (8,262 )     22,139  
                         
Total
  $ 57,006     $ (16,762 )   $ 40,244  
                         
Indefinite Useful Lives
                       
Management contracts
                    282,652  
                         
Total intangible assets
                  $ 322,896  
                         
 
Amortization expense from continuing operations related to intangible assets with definite useful lives was $2.0 million and $2.5 million for the year ended December 31, 2010 and 2009, respectively. The amortization of debt issuance costs, which is included within interest expense, was $3.3 million in each of the years ended December 31, 2010 and 2009.
 
The following table provides estimated amortization expense, including amounts that will be classified within interest expense, related to intangible assets with definite useful lives for each of the years in the five-year period ending December 31, 2015 (in thousands):
 
         
2011
  $ 5,563  
2012
    5,703  
2013
    5,556  
2014
    4,270  
2015
    3,887  
 
(9)   Long-term Debt
 
At December 31, 2010 and 2009 long-term debt consisted of the following (in thousands):
 
                 
    2010     2009  
 
Senior secured credit facility
  $ 533,445     $ 518,710  
U.K. senior credit agreement
    49,981       59,966  
Senior subordinated notes
    437,515       437,515  
Notes payable to financial institutions
    22,347       25,045  
Capital lease obligations (Note 11)
    26,538       30,292  
                 
Total long-term debt
    1,069,826       1,071,528  
Current portion
    (22,386 )     (23,337 )
                 
Long-term debt, less current portion
  $ 1,047,440     $ 1,048,191  
                 
 
(a)   Senior secured credit facility
 
The senior secured credit facility (credit facility) provides for borrowings of up to $615.0 million (with a $150.0 million accordion feature described below), consisting of (1) an $85.0 million revolving credit facility with a maturity of six years, including a $20.0 million letter of credit sub-facility, and a $20.0 million swing-line loan

F-24


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
sub-facility; and (2) a $530.0 million term loan facility (including a $100.0 million delayed draw facility) with a maturity of seven years. The Company has utilized the availability under the
 
$530.0 million term loan facility and is making scheduled quarterly principal payments. The term loans require principal payments each year in an amount of $4.3 million per annum in equal quarterly installments and $0.2 million per quarter with respect to the delayed draw facility with the remaining balance maturing in 2014. No principal payments are required on the revolving credit facility until its maturity in 2013.
 
The Company may request additional tranches of term loans or additional commitments to the revolving credit facility in an aggregate amount not exceeding $150.0 million, subject to certain conditions. Interest rates on the credit facility are based on LIBOR plus a margin of 2.00% to 2.25%. Additionally, the Company currently pays 0.50% per annum on the daily-unused commitment of the revolving credit facility. The Company also currently pays a quarterly participation fee of 2.13% per annum related to outstanding letters of credit. At December 31, 2010, the Company had $533.4 million of debt outstanding under the credit facility at a weighted average interest rate of approximately 3.5%. At December 31, 2010, the Company had $58.4 million available for borrowing under the revolving credit facility, representing the facility’s $85.0 million capacity, net of the $25.0 million outstanding balance at December 31, 2010 and $1.6 million of outstanding letters of credit. The $25.0 million outstanding on the revolving line of credit was repaid in January 2011.
 
The credit facility is guaranteed by USPI Holdings, Inc. and its current and future direct and indirect wholly-owned domestic subsidiaries, subject to certain exceptions, and borrowings under the credit facility are secured by a first priority security interest in all real and personal property of these subsidiaries, as well as a first priority pledge of the Company’s capital stock, the capital stock of each of its wholly owned domestic subsidiaries and 65% of the capital stock of certain of its wholly-owned foreign subsidiaries. Additionally, the credit facility contains various restrictive covenants, including financial covenants that limit the Company’s ability and the ability of its subsidiaries to borrow money or guarantee other indebtedness, grant liens, make investments, sell assets, pay dividends, enter into sale-leaseback transactions or issue and sell capital stock.
 
Fees paid for unused portions of the senior secured credit facility were approximately $0.4 million, $0.5 million and $0.8 million for the years ended December 31, 2010, 2009 and 2008, respectively, and are included within interest expense in the Company’s consolidated statements of income.
 
(b)   Senior subordinated notes
 
Also in connection with the merger, the Company issued $240.0 million of 87/8% senior subordinated notes and $200.0 million of 91/4%/10% senior subordinated toggle notes (together, the Notes), all due in 2017. Interest on the Notes is payable on May 1 and November 1 of each year, which commenced on November 1, 2007. All interest payments on the senior subordinated notes are payable in cash. The initial interest payment on the toggle notes was payable in cash. For any interest period after November 1, 2007 through November 1, 2012, the Company may pay interest on the toggle notes (i) in cash, (ii) by increasing the principal amount of the outstanding toggle notes or by issuing payment-in-kind notes (PIK Interest) or (iii) by paying interest on half the principal amount of the toggle notes in cash and half in PIK Interest. PIK Interest is paid at 10% and cash interest is paid at 91/4% per annum. To date, the Company has paid all interest payments in cash. During 2009, the Company repurchased approximately $2.5 million in principal amount of the senior subordinated toggle notes in the open market. At December 31, 2010, the Company had $437.5 million of Notes outstanding. The Notes are unsecured senior subordinated obligations of the Company; however, the Notes are guaranteed by all of its current and future direct and indirect wholly-owned domestic subsidiaries. Additionally, the Notes contain various restrictive covenants, including financial covenants that limit its ability and the ability of its subsidiaries to borrow money or guarantee other indebtedness, grant liens, make investments, sell assets, pay dividends, enter into sale-leaseback transactions or issue and sell capital stock.


F-25


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(c)   United Kingdom borrowings
 
In April 2007, the Company entered into an amended and restated credit agreement, which covered its existing overdraft facility and term loan facility (Term Loan A). This agreement provides a total overdraft facility of £2.0 million, and an additional Term Loan B facility of £10 million, which was drawn in April 2007. In March 2008, the Company further amended its U.K. Agreement to provide for a £2.0 million Term Loan C facility. The Company borrowed the entire £2.0 million in March 2008 to acquire property adjacent to one of its hospitals in London. In June 2009, the Company renewed its overdraft facility. Under the renewal, the Company must pay a commitment fee of 0.5% per annum on the unused portion of the overdraft facility each quarter. Excluding availability on the overdraft facility, no additional borrowings can be made under the Term Loan A, B or C facilities. At December 31, 2010, the Company had approximately £32.5 million (approximately $50.0 million) outstanding under the U.K. credit facility at a weighted average interest rate of approximately 4.6%.
 
Interest on the borrowings is based on a three-month or six-month LIBOR, or other rate as the bank may agree, plus a margin of 1.25% to 2.00%. Quarterly principal payments are required on the Term Loan A, which began in June 2007, and approximate $4.6 million in the first and second year, $6.2 million in the third and fourth year; $7.7 million in the fifth year, with the remainder due in the sixth year after the April 2007 closing. The Term Loan B does not require any principal payments prior to maturity and matures in 2013. The Term Loan C requires quarterly principal payments of approximately £0.1 million ($0.2 million), which began in June 2008 and continue through its maturity date of February 2013 when the final payment of £0.5 million ($0.8 million) is due. The borrowings are guaranteed by certain of the Company’s subsidiaries in the United Kingdom with a security interest in various assets, and a pledge of the capital stock of the U.K. borrowers and the capital stock of certain guarantor subsidiaries. The Agreement contains various restrictive covenants, including financial covenants that limit the Company’s ability and the ability of certain U.K. subsidiaries to borrow money or guarantee other indebtedness, grant liens on its assets, make investments, use assets as security in other transactions, pay dividends, enter into leases or sell assets or capital stock.
 
The Company also has the ability to borrow under a capital asset finance facility in the U.K. of up to £2.5 million ($3.8 million). The Company borrowed against the facility in June 2010 and November 2010 and have £1.5 million ($2.3 million) outstanding at December 31, 2010. The terms of the borrowings require monthly principal and interest payments over 48 months. The Company has pledged capital assets as collateral against these borrowings. No amounts were outstanding at December 31, 2009.
 
(d)   Other Long-term Debt
 
The Company and its subsidiaries have notes payable to financial institutions and other parties of $22.3 million, which mature at various dates through 2020 and accrue interest at fixed and variable rates ranging from 4.4% to 8.8%. Capital lease obligations in the carrying amount of $26.5 million are secured by underlying real estate and equipment and have implicit interest rates ranging from 3.7% to 18.6%.
 
The aggregate maturities of long-term debt for each of the five years subsequent to December 31, 2010 are as follows (in thousands): 2011, $22,386; 2012, $21,964; 2013, $70,618; 2014, $496,375; 2015, $2,537 and thereafter, $455,946.
 
The fair value of the Company’s long-term debt is determined by either (i) estimation of the discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders, or (ii) quoted market prices at the reporting date for traded debt securities. At December 31, 2010, the aggregate carrying amount and estimated fair value of long-term debt was $1.1 billion. At December 31, 2009, the aggregate carrying amount and estimated fair value of long-term debt was $1.1 billion and $1.0 billion, respectively.


F-26


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(10)   Interest Rate Swaps
 
The Company does not enter into derivative contracts for speculative purposes but has at times entered into interest rate swaps to fix the rate of interest owed on a portion of its variable rate debt. By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. If the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. The Company minimizes the credit risk in derivative instruments by entering into transactions with counterparties who maintain a strong credit rating. Market risk is the risk of an adverse effect on the value of a derivative instrument that results from a change in interest rates. This risk essentially represents the risk that variable interest rates decline to a level below the fixed rate the Company has locked in. The market risk associated with interest rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.
 
At the inception of the interest rate swap, the Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged item, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method of measuring ineffectiveness. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in cash flows of hedged items.
 
In order to manage the Company’s interest rate risk related to a portion of its variable-rate U.K. debt, on February 29, 2008, the Company entered into an interest rate swap agreement for a notional amount of £20.0 million ($30.8 million). The interest rate swap requires the Company to pay 4.99% and to receive interest at a variable rate of three- month GBP-LIBOR (0.8% at December 31, 2010), which is reset quarterly. The interest rate swap matures in March 2011. No collateral is required under the interest rate swap agreement.
 
In order to manage the Company’s interest rate risk related to a portion of its variable-rate senior secured credit facility, effective July 24, 2008, the Company entered into a three-year interest rate swap agreement for a notional amount of $200.0 million. The interest rate swap requires the Company to pay 3.6525% and to receive interest at a variable rate of three-month USD-LIBOR (0.3% at December 31, 2010), which is reset quarterly. No collateral is required under the interest rate swap agreement.
 
The proceeds from the swaps are used to settle the Company’s interest obligations on the hedged portion of the variable rate debt, which has the overall outcome of the Company paying and expensing a fixed rate of interest on the hedged debt.
 
The Company recognizes all derivative instruments as either assets or liabilities at fair value in the consolidated balance sheet. The Company designated the interest rate swaps as cash flow hedges of certain of its variable-rate borrowings. For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (loss) and reclassified to earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivatives representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings and would be classified as interest expense in the Company’s consolidated statements of income. The Company recorded no expense related to ineffectiveness for the years ended December 31, 2010, 2009 or 2008. For the years ended December 31, 2010, 2009 and 2008, the Company reclassified $7.9 million, $6.4 million and $0.5 million, respectively, out of other comprehensive income to interest expense related to the swaps. Through the expiration date of the swaps, if current interest rates remain at December 31, 2010 levels, the Company will record $4.1 million more interest expense than if it had not entered into the interest rate swaps.


F-27


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
At December 31, 2010, the fair values of the U.K. and U.S. interest rate swaps were current liabilities of $0.3 million and $3.6 million, respectively and were included in other current liabilities in the accompanying 2010 consolidated balance sheet, with the offset to other comprehensive income (loss). At December 31, 2009, the fair values of the U.K. and U.S. interest rate swaps were liabilities of approximately $1.5 million and $7.7 million, respectively and were included in other long-term liabilities in the accompanying 2009 consolidated balance sheet, with the offset to other comprehensive income (loss). During the years ended December 31, 2010, 2009 and 2008, the amounts, net of taxes, recorded in other comprehensive income (loss) related to the interest rate swaps were $3.4 million, $3.9 million and ($10.1 million), respectively. The estimated fair value of the interest rate swaps was determined using present value models of the contractual payments. Inputs to the models were based on prevailing LIBOR market data and incorporate credit data that measure nonperformance risk. The estimated fair value represents the theoretical exit cost the Company would have to pay to transfer the obligations to a market participant with similar credit risk. The interest rate swap agreements are classified within Level 3 of the valuation hierarchy.
 
(11)   Leases
 
The Company leases various office equipment and office space under a number of operating lease agreements, which expire at various times through the year 2024. Such leases do not involve contingent rentals, nor do they contain significant renewal or escalation clauses. Office leases generally require the Company to pay all executory costs (such as property taxes, maintenance and insurance).
 
Minimum future payments under noncancelable leases, with remaining terms in excess of one year as of December 31, 2010 are as follows (in thousands):
 
                 
    Capital
    Operating
 
    Leases     Leases  
 
Year ending December 31,
               
2011
  $ 6,549     $ 13,651  
2012
    6,472       12,147  
2013
    4,378       10,023  
2014
    3,216       7,786  
2015
    2,785       6,200  
Thereafter
    19,689       22,448  
                 
Total minimum lease payments
    43,089     $ 72,255  
                 
Amount representing interest
    (16,551 )        
                 
Present value of minimum lease payments
  $ 26,538          
                 
 
Total rent expense from continuing operations under operating leases was $15.8 million, $16.4 million and $17.3 million for the years ended December 31, 2010, 2009 and 2008, respectively.
 
(12)   Related Party Transactions
 
The Company has entered into agreements with certain majority and minority owned surgery centers to provide management services. As compensation for these services, the surgery centers are charged management fees which are either fixed in amount or represent a fixed percentage of each center’s net revenue less bad debt. The percentages range from 3% to 8%. Amounts recognized under these agreements, after elimination of amounts from consolidated surgery centers, totaled approximately $52.1 million, $45.2 million and $39.1 million for the years ended December 31, 2010, 2009 and 2008, respectively. Such amounts are included in management and contract service revenues in the accompanying consolidated statements of income.


F-28


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
As discussed in Notes 3 and 4, the Company regularly engages in purchases and sales of ownership interests in its facilities. The Company operates 27 surgical facilities in partnership with the Baylor Health Care System (Baylor) and local physicians in the Dallas/Fort Worth area. Baylor’s Chief Executive Officer is a member of the Company’s board of directors. The following table summarizes transactions with Baylor during 2009 and 2008. The Company did not sell any ownership interests in facilities to Baylor during 2010. The Company believes that the sale prices were approximately the same as if they had been negotiated on an arms’ length basis, and the prices equaled the value assigned by an external appraiser who valued the businesses immediately prior to the sale.
 
                     
Date
 
Facility Location
  Proceeds     Gain (Loss)  
 
December 2009
  Dallas, Texas(1)   $ 1.2 million     $ 0.3 million  
December 2009
  Fort Worth, Texas(2)     2.4 million       0.1 million  
                     
Total
      $ 3.6 million     $ 0.4 million  
                     
June 2008
  Dallas, Texas(3)   $ 2.3 million     $ (0.9 million )
 
 
(1) Baylor acquired a controlling interest in a facility from the Company, which transferred control of the facility to Baylor.
 
(2) Baylor acquired a controlling interest in two facilities. The Company continues to account for these facilities under the equity method of accounting.
 
(3) Baylor acquired an additional ownership interest in a facility it already co-owned with the Company and local physicians, which transferred control of the facility from the Company to Baylor.
 
In June 2009, the Company agreed to lend up to $10.0 million to Trinity MC, LLC (Trinity), an acute care hospital in the Dallas/Fort Worth area. A majority interest (71%) in Trinity is owned by BRMCG Holdings, LLC, a wholly owned subsidiary of Baylor Regional Medical Center at Grapevine, a controlled affiliate of Baylor. Trinity operates Baylor Medical Center at Carrollton (BMCC). The Company has no ownership in Trinity. The revolving note earned interest at a rate of 6.0% per annum and was paid in full in December 2009. The Company believes the terms of the revolving note were approximately the same as if they had been negotiated on an arms’ length basis.
 
In June 2008, the Company purchased all of Baylor’s ownership interests in an entity Baylor co-owned with the Company. This entity had ownership and managed five facilities in the Dallas/Fort Worth area. The purchase price was approximately $3.9 million in cash. This entity is now wholly owned by the Company. The Company believes that the sales price was approximately the same as if it had been negotiated on an arms’ length basis, and the price equaled the value assigned by an external appraiser who valued the business immediately prior to the sale. After this transaction, the Company accounts for all of the facilities it operates with Baylor under the equity method.
 
As discussed in Note 14, the Company’s parent issued warrants with an estimated fair value of $0.3 million to Baylor in 2008. Similar grants have been made to other healthcare systems with which the Company operates facilities.
 
Included in general and administrative expenses are management fees payable to an affiliate of Welsh Carson, which holds a controlling interest in the Company, in the amount of $2.0 million for the years ended December 31, 2010, 2009 and 2008. Such amounts accrue at an annual rate of $2.0 million. The Company pays $1.0 million in cash per year with the unpaid balance due and payable upon a change in control. At December 31, 2010, the Company had approximately $4.5 million accrued related to such management fee, of which $0.8 million is included in other current liabilities and $3.7 million is included in other long term liabilities in the accompanying consolidated balance sheet. At December 31, 2009, the Company had approximately $3.5 million accrued related to such management fee, of which $0.8 million is included in other current liabilities and $2.7 million is included in other long term liabilities in the accompanying consolidated balance sheet.


F-29


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(13)   Income Taxes
 
The components of income from continuing operations before income taxes were as follows (in thousands):
 
                         
    2010     2009     2008  
 
Domestic
  $ 129,174     $ 112,508     $ 96,259  
Foreign
    12,810       18,548       20,239  
                         
    $ 141,984     $ 131,056     $ 116,498  
                         
 
Income tax expense (benefit) attributable to income from continuing operations consists of (in thousands):
 
                         
    Current     Deferred     Total  
 
Year ended December 31, 2010:
                       
U.S. federal
  $ 17,024     $ 7,726     $ 24,750  
State and local
    3,880       627       4,507  
Foreign
    3,134       (63 )     3,071  
                         
Net income tax expense
  $ 24,038     $ 8,290     $ 32,328  
                         
 
                         
    Current     Deferred     Total  
 
Year ended December 31, 2009:
                       
U.S. federal
  $ 1,260     $ (9,859 )   $ (8,599 )
State and local
    3,144             3,144  
Foreign
    5,118       (542 )     4,576  
                         
Net income tax expense (benefit)
  $ 9,522     $ (10,401 )   $ (879 )
                         
 
                         
    Current     Deferred     Total  
 
Year ended December 31, 2008:
                       
U.S. federal
  $ 43     $ 14,156     $ 14,199  
State and local
    3,020             3,020  
Foreign
    5,390       58       5,448  
                         
Net income tax expense
  $ 8,453     $ 14,214     $ 22,667  
                         


F-30


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
Income tax expense differed from the amount computed by applying the U.S. federal income tax rate of 35% to pretax income from continuing operations is as follows (in thousands):
 
                         
    Year Ended
    Year Ended
    Year Ended
 
    December 31,
    December 31,
    December 31,
 
    2010     2009     2008  
 
Computed “expected” tax expense
  $ 49,694     $ 45,870     $ 40,778  
Increase (reduction) in income taxes resulting from:
                       
Book income of consolidated entities attributable to noncontrolling interests
    (21,195 )     (22,303 )     (19,298 )
Differences between U.S. financial reporting and foreign statutory reporting
    (218 )     (152 )     23  
State tax expense, net of federal benefit
    2,979       1,824       1,963  
Removal of foreign tax rate differential
    (982 )     (1,211 )     (1,227 )
Nondeductible goodwill
    1,366       6,338        
Valuation allowance
          (31,193 )     (223 )
Other
    684       (52 )     651  
                         
Total
  $ 32,328     $ (879 )   $ 22,667  
                         
 
The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities at December 31, 2010 and 2009 are presented below (in thousands).
 
                 
    December 31,  
    2010     2009  
 
Deferred tax assets:
               
Net operating loss and other tax carryforwards
  $ 8,276     $ 4,413  
Accrued expenses
    11,687       10,730  
Bad debts/reserves
    3,334       3,741  
Interest rate swaps
    1,359       3,091  
Capitalized costs and other
    1,605       2,983  
                 
Total deferred tax assets
    26,261       24,958  
Valuation allowance
    (685 )     (3,283 )
                 
Total deferred tax assets, net
  $ 25,576     $ 21,675  
                 
Deferred tax liabilities:
               
Basis difference of acquisitions
  $ 139,362     $ 128,474  
Accelerated depreciation
    1,126       1,826  
Capitalized interest and other
    1,332       882  
                 
Total deferred tax liabilities
  $ 141,820     $ 131,182  
                 
 
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment.


F-31


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
In conjunction with Welsh Carson’s acquisition of the Company in April 2007, which increased the Company’s debt, caused the Company to generate U.S. taxable losses, and reduced the likelihood of the Company generating U.S. taxable income, the Company established a valuation allowance against its U.S. deferred tax assets. Subsequent to the acquisition, the Company continued to establish a full valuation allowance against newly generated U.S. deferred tax assets and has continuously assessed the likelihood of the assets being realized at a future date. During the third quarter of 2009, the Company determined, based on factors such as those described above, including recent favorable operating trends, expected future taxable income, and other factors, that it is more likely than not that the majority of these assets, which include net operating loss carryforwards and other items, will be realized in the future. Accordingly, the Company’s results of operations for 2009 include an income tax benefit of $31.2 million related to the reversal of a majority of the Company’s valuation allowance against its deferred tax assets. The Company still carries a valuation allowance totaling $0.7 million against certain of its deferred tax assets, which relates to deferred tax assets that have restrictions as to use and are not considered more likely than not to be realized. It the Company’s estimates related to the above items change significantly, the Company may need to alter the amount of its valuation allowance in the future through a favorable or unfavorable adjustment to net income.
 
At December 31, 2010, the Company had federal net operating loss carryforwards for U.S. federal income tax purposes of approximately $22.0 million. The Company’s ability to offset future taxable income with these carryforwards would begin to be forfeited in 2022, if unused. The Company does not believe that it is more likely than not that it will be able to generate state taxable income in future periods to utilize its net operating loss carryforwards and other deferred tax assets.
 
The Company’s U.K. operations have no net operating loss carryforwards or other deferred tax assets. These operations continued to be profitable in 2010, and the Company therefore has accrued the related income tax expense.
 
The Company has analyzed its income tax filing positions in all of the federal and state jurisdictions where it is required to file income tax returns for all open tax years in these jurisdictions for uncertainty in tax positions. The Company believes, based on the facts and technical merits associated with each of its income tax filing positions and deductions, that each of its income tax filing positions would be sustained on audit. Further, the Company has concluded that to the extent any adjustments to its income tax filing positions were not to be sustained upon an IRS or other audit, such adjustments would not have a material effect on the Company’s consolidated financial statements. As a result, no reserves for uncertain income tax positions have been recorded. The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. The Company has not recorded any material amounts for interest or penalties related to audit or other activity.
 
(14)   Equity and Equity-Based Compensation
 
On December 1, 2009, the Company’s board of directors declared and the Company paid a special cash dividend in the amount of $88.6 million on the Company’s common stock. The proceeds of the dividend were used by USPI Holdings, Inc., the sole stockholder of the Company, to pay a special cash dividend on its common stock. In turn, the proceeds were used by USPI Group Holdings, Inc., the sole stockholder of USPI Holdings, Inc., to pay amounts currently accrued on its preferred stock.
 
The Company accounts for equity-based compensation, such as stock options and other stock-based awards to employees and directors, at fair value. The fair value of the compensation is measured at the date of grant and recognized as expense over the recipient’s requisite service period.
 
The Company’s parent, USPI Group Holdings, Inc. (Parent), granted stock options and nonvested share awards to certain employees and members of the board of directors. These awards were granted pursuant to the 2007 Equity Incentive Plan (the Plan) which was adopted by Parent’s board of directors. The board of directors or a designated


F-32


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
administrator has the sole authority to determine which individuals receive grants, the type of grant to be received, the vesting period and all other option terms. Stock options granted generally have a term not to exceed eight years. A maximum of 20,726,523 shares of stock may be delivered under the Plan. As 5,534,125 shares had been delivered under the Plan at December 31, 2010, 15,192,398 remained available for delivery, with 15,823,832 having been granted at December 31, 2010.
 
Total equity-based compensation included in the consolidated statements of income, classified by line item, is as follows (in thousands):
 
                         
    Year Ended
    Year Ended
    Year Ended
 
    December 31,
    December 31,
    December 31,
 
    2010     2009     2008  
 
Salaries, benefits and other employee costs
  $ 566     $ 548     $ 471  
General and administrative expenses
    1,128       1,016       978  
Other operating expenses
          131       336  
Discontinued operations
    474       256       512  
                         
Expense before income tax benefit
    2,168       1,951       2,297  
Income tax benefit
    (494 )     (389 )     (463 )
                         
Total equity-based compensation expense, net of tax
  $ 1,674     $ 1,562     $ 1,834  
                         
 
Total equity-based compensation, included in the consolidated statements of income, classified by type of award, is as follows (in thousands):
 
                         
    Year Ended
    Year Ended
    Year Ended
 
    December 31,
    December 31,
    December 31,
 
    2010     2009     2008  
 
Share awards
  $ 1,331     $ 1,215     $ 1,150  
Stock options
    837       605       811  
Warrants
          131       336  
                         
Expense before income tax benefit
    2,168       1,951       2,297  
Income tax benefit
    (494 )     (389 )     (463 )
                         
Total equity-based compensation expense, net of tax
  $ 1,674     $ 1,562     $ 1,834  
                         
 
Total unrecognized compensation related to nonvested awards of stock options and nonvested shares was $12.1 million at December 31, 2010 of which $3.3 million is expected to be recognized over a weighted average period of approximately two years. The remaining $8.8 million relates to restricted share awards exchanged in conjunction with the merger and will be expensed only upon the occurrence of a change in control or other qualified exit event.
 
During the years ended December 31, 2010 and 2008, the Company received immaterial cash proceeds from the exercise of stock options. No stock options were exercised during the year ended December 31, 2009.
 
Stock Options
 
Parent generally grants stock options vesting 25% per year over four years and having an eight-year contractual life. The fair value of stock options is estimated using the Black-Scholes formula. The expected lives of options are determined using the “simplified method” which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. The risk-free interest rates are equal to rates of U.S. Treasury notes with maturities approximating the expected life of the option. Volatility was


F-33


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
calculated as a weighted average based on the historical volatility of the Company’s predecessor before the merger as well as industry peers. The assumptions are as follows:
 
                         
    Year Ended
  Year Ended
  Year Ended
    December 31,
  December 31,
  December 31,
    2010   2009   2008
 
Assumptions:
                       
Expected life in years
    4.82       4.82       4.82  
Risk-free interest rates
    1.35-2.59 %     2.09 %     2.37-2.75 %
Dividend yield
    0.0 %     0.0 %     0.0 %
Volatility
    45.16 %     45.16 %     45.16 %
Weighted average grant-date fair value
  $ 0.65     $ 0.37     $ 0.55  
 
Stock option activity during the year ended December 31, 2010 was as follows:
 
                                 
            Weighted
   
        Weighted
  Average
   
        Average
  Remaining
  Aggregate
Successor
  Number of
  Exercise
  Contractual
  Intrinsic
Stock Options
  Shares (000)   Price   Life (Years)   Value ($000)
 
Outstanding at January 1, 2010
    4,562     $ 0.59       5.7     $ 3,051  
Additional grants
    479       1.62              
Exercised
    (137 )     0.38              
Forfeited or expired
    (229 )     1.17              
                                 
Outstanding at December 31, 2010
    4,675     $ 0.68       4.9     $ 5,480  
                                 
Exercisable at December 31, 2010
    2,789     $ 0.49       4.5     $ 3,784  
                                 
 
Share Awards
 
On April 19, 2007, Parent granted nonvested share awards to certain company employees. The first tranche (50%) of the share awards vest 25% over four years, while the second tranche (50%) vests 100% in April 2015, but can vest earlier upon the occurrence of a qualified exit event and Company performance. An additional grant was made to Parent’s board of directors in August 2007. The nonvested shares granted to the board of directors vests 25% each year over four years. The value of such share awards is equal to the share price on the date of grant.
 
Additionally, in conjunction with the merger, Parent cancelled 379,000 restricted share awards of the Company’s predecessor. These share awards were replaced with 2,212,957 nonvested shares of Parent. This cancellation and exchange was accounted for as a modification. The replacement awards vest only upon the occurrence of a change in control or other exit event as defined in the award agreement and Company performance. As a result of the modification, approximately $8.8 million of unamortized compensation cost related to the Predecessor awards will only be expensed upon the occurrence of a change in control or qualified exit event, and the completion of the derived service period. At December 31, 2010, 2,212,957 of these share awards were outstanding and unvested.


F-34


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
The grants of nonvested share awards, excluding the awards exchanged concurrent with the merger, during the year ended December 31, 2010 are summarized as follows:
 
                 
        Weighted
        Average
Successor
  Number of
  Grant-Date
Nonvested Shares
  Shares (000)   Fair Value
 
Nonvested at January 1, 2010
    10,598     $ 0.47  
Additional grants
    200       1.62  
Vested
    (1,861 )     0.49  
Forfeited
           
                 
Nonvested at December 31, 2010
    8,937     $ 0.49  
                 
 
The weighted average grant-date fair value per share award was $1.62 and $0.76 for the year ended December 31, 2010 and 2009, respectively. The total fair value of shares which vested during the years ended December 31, 2010 and 2009 was approximately $3.0 million and $1.7 million, respectively.
 
Warrants
 
During 2009, Parent granted warrants to a not-for-profit healthcare system (hospital partner) that holds ownership in some of the Company’s facilities. The warrants are to purchase Parent’s common stock and were fully vested and non-forfeitable at the date of grant but contain exercise restrictions. Because the warrants are fully vested, the expense associated with them was recorded upon grant within other operating expenses at a fair value determined using the Black-Scholes formula. The assumptions included an expected life equal to the contractual life; a risk free interest rate of 2.7%; a dividend yield of 0.0%; and an estimated volatility of approximately 58%. In this grant, the hospital partner received 333,330 warrants with an exercise price of $3.00 per share, of which 55,555 were exercisable immediately; the exercise restrictions on additional tranches of 55,555 warrants lapse each December 1 which began in 2009 and ends in 2013. At December 31, 2010, 166,665 warrants are exercisable. The warrants have a contractual life of approximately 81/2 years and a fair value of approximately $0.1 million.
 
During 2008, one of the Company’s hospital partners, Baylor, was granted 666,666 warrants to purchase Parent’s common stock for $3.00 per share. The warrants are fully vested and nonforfeitable but contain exercise restrictions. The exercise restrictions on 111,111 warrants lapse each December 31 which began in 2008 and ends in 2013. The warrants have a contractual life of ten years. The total fair value of the warrants was approximately $0.3 million and was determined using the Black Scholes formula. The assumptions included an expected life equal to the contractual life of the warrants; a risk free interest rate of 3.5%, a dividend yield of 0.0%; and an estimated volatility of approximately 59%. Because the warrants are fully vested, the expense associated with these warrants was recorded upon grant within other operating expenses. Baylor’s Chief Executive Officer is a member of the Company’s Board of Directors (Note 12). At December 31, 2010, 333,333 warrants are exercisable.
 
During 2007, Parent granted a total of 2,333,328 warrants to purchase its common stock to four of the Company’s hospital partners. The exercise price of the warrants was $3.00 per share. All of the warrants are fully vested and non-forfeitable but contain exercise restrictions. Of the 2,333,328 warrants outstanding at December 31, 2010, 1,499,997 warrants are exercisable and a portion of the remaining 833,331 warrants will become exercisable in 2011 and become fully exercisable by 2013. The warrants have a contractual life of eight to ten years. The total fair value of the warrants was approximately $1.1 million and was determined using the Black Scholes formula. The assumptions included an expected life equal to the contractual life of each warrant; a risk free interest rate of 3.6% to 4.6%; a dividend yield of 0.0%; and an estimated volatility of approximately 59%. Because the warrants are fully vested, the expense associated with these warrants was recorded upon grant within other operating expenses.


F-35


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(15)   Segment Disclosures
 
The Company’s business is the operation of surgical facilities and related businesses in the United States and the United Kingdom. The Company’s chief operating decision maker, as that term is defined in GAAP, regularly reviews financial information about its surgical facilities for assessing performance and allocating resources both domestically and abroad. Accordingly, the Company’s reportable segments consist of (1) U.S. based facilities and (2) United Kingdom based facilities. All amounts related to discontinued operations have also been removed from all periods presented (Note 2).
 
                         
    United
    United
       
    States     Kingdom     Total  
 
Year Ended December 31, 2010
                       
Net patient service revenues
  $ 402,049     $ 102,716     $ 504,765  
Other revenues
    71,900             71,900  
                         
Total revenues
  $ 473,949     $ 102,716     $ 576,665  
                         
Depreciation and amortization
  $ 22,493     $ 7,306     $ 29,799  
Operating income
    194,610       15,906       210,516  
Net interest expense
    (66,144 )     (3,096 )     (69,240 )
Income tax expense
    (29,257 )     (3,071 )     (32,328 )
Total assets
    2,051,144       321,595       2,372,739  
Capital expenditures
    31,149       22,367       53,516  
 
                         
    United
    United
       
    States     Kingdom     Total  
 
Year Ended December 31, 2009
                       
Net patient service revenues
  $ 418,802     $ 105,097     $ 523,899  
Other revenues
    69,576             69,576  
                         
Total revenues
  $ 488,378     $ 105,097     $ 593,475  
                         
Depreciation and amortization
  $ 24,432     $ 6,733     $ 31,165  
Operating income
    178,176       20,119       198,295  
Net interest expense
    (66,041 )     (1,571 )     (67,612 )
Income tax benefit (expense)
    5,455       (4,576 )     879  
Total assets
    2,000,087       325,305       2,325,392  
Capital expenditures
    20,296       12,393       32,689  
 


F-36


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
                         
    United
    United
       
    States     Kingdom     Total  
 
Year Ended December 31, 2008
                       
Net patient service revenues
  $ 432,319     $ 122,031     $ 554,350  
Other revenues
    60,748             60,748  
                         
Total revenues
  $ 493,067     $ 122,031     $ 615,098  
                         
Depreciation and amortization
  $ 25,480     $ 6,825     $ 32,305  
Operating income
    172,642       25,462       198,104  
Net interest expense
    (76,465 )     (5,173 )     (81,638 )
Income tax expense
    (17,215 )     (5,452 )     (22,667 )
Total assets
    1,983,676       284,487       2,268,163  
Capital expenditures
    15,772       16,883       32,655  
 
(16)   Commitments and Contingencies
 
(a)   Financial Guarantees
 
As of December 31, 2010, the Company had issued guarantees of the indebtedness and other obligations of its investees to third parties, which could potentially require the Company to make maximum aggregate payments totaling approximately $61.0 million. Of the total, $25.2 million relates to the obligations of consolidated subsidiaries, whose obligations are included in the Company’s consolidated balance sheet and related disclosures, and $23.0 million of the remaining $35.8 million relates to the obligations of unconsolidated affiliated companies, whose obligations are not included in the Company’s consolidated balance sheet and related disclosures. The remaining $12.8 million represents a guarantee of obligations of three facilities. The Company has full recourse to third parties with respect to this amount.
 
The Company has recorded long-term liabilities totaling approximately $0.2 million related to the guarantees the Company has issued to unconsolidated affiliates on or after January 1, 2003, and has not recorded any liabilities related to guarantees issued prior to that date. Generally, these arrangements (a) consist of guarantees of real estate and equipment financing, (b) are secured by the related property and equipment, (c) require payments by the Company, when the collateral is insufficient, in the event of a default by the investee primarily obligated under the financing, (d) expire as the underlying debt matures at various dates through 2022, and (e) provide no recourse for the Company to recover any amounts from third parties. The Company also has $1.6 million of letters of credit outstanding, as discussed in Note 9.
 
(b)   Litigation
 
From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company’s management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company.
 
(c)   Self Insurance and Professional Liability Claims
 
The Company is self-insured for certain losses related to health and workers’ compensation claims, although we obtain third-party insurance coverage to limit our exposure to these claims. The Company estimates its self-insured liabilities using a number of factors including historical claims experience, an estimate of incurred but not reported claims, demographic factors, severity factors and actuarial valuations. The Company believes that the accruals established at December 31, 2010, which were estimated based on actual employee health claim patterns,

F-37


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
adequately provide for its exposure under this arrangement. The Company’s potential for losses related to professional and general liability is managed through a wholly-owned insurance captive.
 
(d)   Employee Benefit Plans
 
The Company’s eligible U.S. employees may choose to participate in the United Surgical Partners International, Inc. 401(k) Plan under which the Company may elect to make contributions that match from zero to 100% of participants’ contributions. Charges to expense under this plan were $2.0 million in each of the years ended December 31, 2010, 2009 and 2008.
 
One of the Company’s U.K. subsidiaries, which the Company acquired in 2000, has obligations remaining under a defined benefit pension plan that originated in 1991 and was closed to new participants at the end of 1998. The plan’s overall strategy is to outperform the CAPS Pooled Fund Median over rolling three year periods. To implement this strategy the plan invests in a wide diversification of asset types and fund strategies. The target allocations for plan assets are approximately 82% equity securities, 12% bonds and 6% to all other types of investments. At December 31, 2010, the plan had 59 participants, plan assets of $10.4 million, an accumulated pension benefit obligation of $13.1 million, and a projected benefit obligation of $13.1 million. At December 31, 2009, the plan had 64 participants, plan assets of $9.6 million, an accumulated pension benefit obligation of $13.5 million, and a projected benefit obligation of $13.5 million. Pension expense for the years ended December 31, 2010, 2009 and 2008 was $0.5 million, $0.5 million and $0.3 million, respectively.
 
At December 31, 2010, the estimated fair value of U.K.’s pension plan assets by asset type was: $8.6 million — equities; $1.0 million — bonds; $0.5 million — cash; and $0.3 million of other investments, which are primarily mutual funds invested in real estate properties. At December 31, 2009, the estimated fair value of U.K.’s pension plan assets by asset type was: $7.9 million — equities; $0.9 million — bonds; $0.5 million — cash; and $0.3 million of other investments, which are primarily mutual funds invested in real estate properties. The estimated fair value of equities, bonds and cash are calculated using Level 1 inputs. The estimated fair value of property mutual funds are based on Level 3 inputs. There was no significant activity within the Level 3 investments during 2010 or 2009.
 
The Company’s Deferred Compensation Plan covers select members of management as determined by its Compensation Committee. Under the plan, eligible employees may contribute a portion of their salary and annual bonus on a pretax basis. The plan is a non-qualified plan; therefore, the associated liabilities are included in the Company’s consolidated balance sheets as of December 31, 2010 and 2009. In addition, the Company maintains an irrevocable grantor’s trust to hold assets that fund benefit obligations under the plan, including corporate-owned life insurance policies. The cash surrender value of such policies is included in the consolidated balance sheets in other noncurrent assets and totaled $11.0 million and $10.2 million at December 31, 2010 and 2009, respectively. The Company’s obligations related to the plan were $13.1 million and $11.6 million, at December 31, 2010 and 2009, respectively, of which $2.3 million in both 2010 and 2009 are included in accrued salaries and benefits with the remaining amounts included in other long-term liabilities. Total expense under the plan for the years ended December 31, 2010, 2009 and 2008 was $0.8 million, $0.3 million and $1.2 million, respectively.
 
(e)   Employment Agreements
 
The Company entered into employment agreements dated April 19, 2007 with Donald E. Steen and William H. Wilcox. The agreement with Mr. Steen, who serves as the Company’s Chairman provides for annual base compensation of $300,000 (as of December 31, 2010), subject to increases approved by the board of directors, a performance bonus based on the sole discretion of the Company’s Board of Directors, and his continued employment until November 14, 2011.


F-38


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
The agreement with Mr. Wilcox, the Company’s President and Chief Executive Officer provides for annual base compensation of $600,000 (as of December 31, 2010), subject to increases approved by the board of directors, and Mr. Wilcox is eligible for a performance bonus based on the sole discretion of the Company’s Board of Directors. The agreement renews automatically for two-year terms unless terminated by either party.
 
At December 31, 2010, the Company has employment agreements with 19 other senior managers which generally include one year terms and renew automatically for additional one year terms unless terminated by either party. The total annual base compensation under these agreements is $5.7 million as of December 31, 2010, subject to increases approved by the board of directors, and performance bonuses of up to a total of $3.7 million per year.
 
(18)   Subsequent Events
 
The Company has entered into letters of intent with various entities regarding possible joint venture, development or other transactions. These possible joint ventures, developments or other transactions are in various stages of negotiation.
 
(19)   Condensed Consolidating Financial Statements
 
The following information is presented as required by regulations of the SEC in connection with the Company’s senior subordinated notes that have been registered with the SEC. While not required by SEC regulations, additional disclosures have also been presented in this note as required by the Company’s senior secured credit facility’s covenants. None of this information is routinely prepared for use by management. The operating and investing activities of the separate legal entities included in the consolidated financial statements are fully interdependent and integrated. Accordingly, the operating results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other services.
 
The $240.0 million of 87/8% senior subordinated notes and $200.0 million of 91/4%/10% senior subordinated toggle notes, all due 2017 (the Notes), were issued in a private offering on April 19, 2007 and were subsequently registered as publicly traded securities through a Form S-4 declared effective by the SEC on July 25, 2007. The exchange offer was completed in August 2007. The Notes are unsecured senior subordinated obligations of the Company; however, the Notes are guaranteed by all of the Company’s current and future direct and indirect wholly-owned domestic subsidiaries. USPI, which issued the Notes, does not have independent assets or operations. USPI’s investees in the United Kingdom are not guarantors of the obligation. USPI’s investees in the United States in which USPI owns less than 100% are not guarantors of the obligation. The financial positions and results of operations (below, in thousands) of the respective guarantors are based upon the guarantor relationship at the end of the period presented. Consolidation adjustments include purchase accounting entries for investments in which the Company’s ownership percentage in non-participating investees is not high enough to permit the application of pushdown accounting.


F-39


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
Condensed Consolidating Balance Sheets:
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
As of December 31, 2010
  Guarantors     Investees     Adjustments     Total  
 
ASSETS
Current assets:
                               
Cash and cash equivalents
  $ 60,186     $ 67     $     $ 60,253  
Accounts receivable, net
          50,082             50,082  
Other receivables
    27,313       45,146       (57,217 )     15,242  
Inventories of supplies
    685       8,506             9,191  
Prepaids and other current assets
    27,477       2,166             29,643  
                                 
Total current assets
    115,661       105,967       (57,217 )     164,411  
Property and equipment, net
    24,343       177,803       114       202,260  
Investments in affiliates
    1,010,592             (617,031 )     393,561  
Goodwill and intangible assets, net
    904,108       342,777       340,991       1,587,876  
Other assets
    91,151       2,602       (69,122 )     24,631  
                                 
Total assets
  $ 2,145,855     $ 629,149     $ (402,265 )   $ 2,372,739  
                                 
 
LIABILITIES AND EQUITY
Current liabilities:
                               
Accounts payable
  $ 1,684     $ 21,804     $     $ 23,488  
Accrued expenses and other
    236,835       37,868       (55,917 )     218,786  
Current portion of long-term debt
    4,932       19,751       (2,297 )     22,386  
                                 
Total current liabilities
    243,451       79,423       (58,214 )     264,660  
Long-term debt, less current portion
    966,999       82,732       (2,291 )     1,047,440  
Other long-term liabilities
    148,648       9,692       (520 )     157,820  
Parent’s equity
    786,757       432,261       (432,261 )     786,757  
Noncontrolling interests
          25,041       91,021       116,062  
                                 
Total liabilities and equity
  $ 2,145,855     $ 629,149     $ (402,265 )   $ 2,372,739  
                                 
 


F-40


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
As of December 31, 2009
  Guarantors     Investees     Adjustments     Total  
 
ASSETS
Current assets:
                               
Cash and cash equivalents
  $ 27,430     $ 7,460     $     $ 34,890  
Accounts receivable, net
          54,202       35       54,237  
Other receivables
    46,975       45,776       (77,505 )     15,246  
Inventories of supplies
    428       8,361             8,789  
Prepaids and other current assets
    26,264       4,518             30,782  
                                 
Total current assets
    101,097       120,317       (77,470 )     143,944  
Property and equipment, net
    16,197       181,857       452       198,506  
Investments in affiliates
    1,027,814             (672,315 )     355,499  
Goodwill and intangible assets, net
    857,802       353,212       391,173       1,602,187  
Other assets
    96,205       2,213       (73,162 )     25,256  
                                 
Total assets
  $ 2,099,115     $ 657,599     $ (431,322 )   $ 2,325,392  
                                 
 
LIABILITIES AND EQUITY
Current liabilities:
                               
Accounts payable
  $ 1,396     $ 22,079     $     $ 23,475  
Accrued expenses and other
    235,904       50,200       (75,956 )     210,148  
Current portion of long-term debt
    5,480       20,116       (2,259 )     23,337  
                                 
Total current liabilities
    242,780       92,395       (78,215 )     256,960  
Long-term debt, less current portion
    952,311       118,892       (23,012 )     1,048,191  
Other long-term liabilities
    146,072       13,122       (821 )     158,373  
Parent’s equity
    757,952       412,362       (412,362 )     757,952  
Noncontrolling interests
          20,828       83,088       103,916  
                                 
Total liabilities and equity
  $ 2,099,115     $ 657,599     $ (431,322 )   $ 2,325,392  
                                 

F-41


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
Condensed Consolidating Statements of Income:
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2010
  Guarantors     Investees     Adjustments     Total  
 
Revenues
  $ 97,463     $ 501,505     $ (22,303 )   $ 576,665  
Equity in earnings of unconsolidated affiliates
    132,846       2,116       (65,046 )     69,916  
Operating expenses, excluding depreciation and amortization
    86,521       342,690       (22,945 )     406,266  
Depreciation and amortization
    7,249       22,346       204       29,799  
                                 
Operating income
    136,539       138,585       (64,608 )     210,516  
Interest expense, net
    (61,205 )     (7,945 )     (90 )     (69,240 )
Other income (expense), net
    708                   708  
                                 
Income from continuing operations before income taxes
    76,042       130,640       (64,698 )     141,984  
Income tax expense
    (26,946 )     (5,382 )           (32,328 )
                                 
Income from continuing operations
    49,096       125,258       (64,698 )     109,656  
Loss from discontinued operations, net of tax
    (7,003 )     (533 )     533       (7,003 )
                                 
Net income
    42,093       124,725       (64,165 )     102,653  
Less: Net income attributable to noncontrolling interests
          (12,879 )     (47,681 )     (60,560 )
                                 
Net income attributable to Parent
  $ 42,093     $ 111,846     $ (111,846 )   $ 42,093  
                                 
 


F-42


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2009
  Guarantors     Investees     Adjustments     Total  
 
Revenues
  $ 96,861     $ 519,293     $ (22,679 )   $ 593,475  
Equity in earnings of unconsolidated affiliates
    133,230       2,413       (73,872 )     61,771  
Operating expenses, excluding depreciation and amortization
    101,711       346,489       (22,414 )     425,786  
Depreciation and amortization
    7,380       23,409       376       31,165  
                                 
Operating income
    121,000       151,808       (74,513 )     198,295  
Interest expense, net
    (60,386 )     (7,221 )     (5 )     (67,612 )
Other income (expense), net
    384       (11 )           373  
                                 
Income from continuing operations before income taxes
    60,998       144,576       (74,518 )     131,056  
Income tax benefit (expense)
    7,215       (6,336 )           879  
                                 
Income from continuing operations
    68,213       138,240       (74,518 )     131,935  
Earnings from discontinued operations, net of tax
    1,453       996       (996 )     1,453  
                                 
Net income
    69,666       139,236       (75,514 )     133,388  
Less: Net income attributable to noncontrolling interests
          (11,128 )     (52,594 )     (63,722 )
                                 
Net income attributable to Parent
  $ 69,666     $ 128,108     $ (128,108 )   $ 69,666  
                                 
 

F-43


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2008
  Guarantors     Investees     Adjustments     Total  
 
Revenues
  $ 93,595     $ 545,428     $ (23,925 )   $ 615,098  
Equity in earnings of unconsolidated affiliates
    114,656       2,465       (70,079 )     47,042  
Operating expenses, excluding depreciation and amortization
    77,594       377,753       (23,616 )     431,731  
Depreciation and amortization
    6,993       24,772       540       32,305  
                                 
Operating income
    123,664       145,368       (70,928 )     198,104  
Interest expense, net
    (70,024 )     (11,710 )     96       (81,638 )
Other income (expense), net
    7       25             32  
                                 
Income from continuing operations before income taxes
    53,647       133,683       (70,832 )     116,498  
Income tax expense
    (14,954 )     (7,717 )     4       (22,667 )
                                 
Income from continuing operations
    38,693       125,966       (70,828 )     93,831  
Loss from discontinued operations, net of tax
    (1,179 )     (1,140 )     1,140       (1,179 )
                                 
Net income
    37,514       124,826       (69,688 )     92,652  
Less: Net income attributable to noncontrolling interests
          (6,960 )     (48,178 )     (55,138 )
                                 
Net income attributable to Parent
  $ 37,514     $ 117,866     $ (117,866 )   $ 37,514  
                                 
 
Condensed Consolidating Statements of Comprehensive Income (Loss):
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2010
  Guarantors     Investees     Adjustments     Total  
 
Net income
  $ 42,093     $ 124,725     $ (64,165 )   $ 102,653  
Other comprehensive income:
                               
Foreign currency translation adjustments
    (11,638 )     (11,638 )     11,638       (11,638 )
Unrealized gain on interest rate swaps, net of tax
    3,408       780       (780 )     3,408  
Pension adjustments, net of tax
    724       724       (724 )     724  
                                 
Total other comprehensive income
    (7,506 )     (10,134 )     10,134       (7,506 )
                                 
Comprehensive income
    34,587       114,591       (54,031 )     95,147  
Less: Comprehensive income attributable to noncontrolling interests
          (12,879 )     (47,681 )     (60,560 )
                                 
Comprehensive income attributable to Parent
  $ 34,587     $ 101,712     $ (101,712 )   $ 34,587  
                                 
 

F-44


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2009
  Guarantors     Investees     Adjustments     Total  
 
Net income
  $ 69,666     $ 139,236     $ (75,514 )   $ 133,388  
Other comprehensive income:
                               
Foreign currency translation adjustments
    21,967       21,967       (21,967 )     21,967  
Unrealized gain on interest rate swaps, net of tax
    3,894       108       (108 )     3,894  
Pension adjustments, net of tax
    (698 )     (698 )     698       (698 )
                                 
Total other comprehensive income
    25,163       21,377       (21,377 )     25,163  
                                 
Comprehensive income
    94,829       160,613       (96,891 )     158,551  
Less: Comprehensive income attributable to noncontrolling interests
          (11,128 )     (52,594 )     (63,722 )
                                 
Comprehensive income attributable to Parent
  $ 94,829     $ 149,485     $ (149,485 )   $ 94,829  
                                 
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2008
  Guarantor     Investees     Adjustments     Total  
 
Net income
  $ 37,514     $ 124,826     $ (69,688 )   $ 92,652  
Other comprehensive income:
                               
Foreign currency translation adjustments
    (71,790 )     (71,790 )     71,790       (71,790 )
Unrealized loss on interest rate swaps, net of tax
    (10,051 )     (1,280 )     1,280       (10,051 )
Pension adjustments, net of tax
    (682 )     (682 )     682       (682 )
                                 
Total other comprehensive loss
    (82,523 )     (73,752 )     73,752       (82,523 )
                                 
Comprehensive income (loss)
    (45,009 )     51,074       4,064       10,129  
Less: Comprehensive income (loss) attributable to noncontrolling interests
          (6,960 )     (48,178 )     (55,138 )
                                 
Comprehensive income (loss) attributable to Parent
  $ (45,009 )   $ 44,114     $ (44,114 )   $ (45,009 )
                                 

F-45


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
Condensed Consolidating Statements of USPI Stockholder’s Equity:
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
    Guarantors     Investees     Adjustments     Total  
 
Balance, December 31, 2008
  $ 764,137     $ 371,335     $ (371,335 )   $ 764,137  
Net income
    69,666       139,236       (75,514 )     133,388  
Net income attributable to noncontrolling interests
          (11,128 )     (52,594 )     (63,722 )
Contribution related to equity award grants by USPI Group Holdings, Inc. 
    1,937       282       (282 )     1,937  
Acquisitions and contributions
    (9,536 )     26,410       (26,410 )     (9,536 )
Disposals and deconsolidations
    (4,798 )     (17,259 )     17,259       (4,798 )
Distributions
          (117,890 )     117,890        
Dividend on common stock
    (88,617 )                 (88,617 )
Foreign currency translation and other
    25,163       21,376       (21,376 )     25,163  
                                 
Balance, December 31, 2009
    757,952       412,362       (412,362 )     757,952  
Net income
    42,093       124,725       (64,165 )     102,653  
Net income attributable to noncontrolling interests
          (12,879 )     (47,681 )     (60,560 )
Contribution related to equity award grants by USPI Group Holdings, Inc. 
    2,294       527       (527 )     2,294  
Acquisitions and contributions
    (452 )     36,090       (36,090 )     (452 )
Disposals and deconsolidations
    (6,774 )     (5,857 )     5,857       (6,774 )
Distributions
          (112,573 )     112,573        
Dividend on common stock
    (850 )                 (850 )
Foreign currency translation and other
    (7,506 )     (10,134 )     10,134       (7,506 )
                                 
Balance, December 31, 2010
  $ 786,757     $ 432,261     $ (432,261 )   $ 786,757  
                                 


F-46


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
Condensed Consolidating Statements of Cash Flows:
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2010
  Guarantor     Investees     Adjustments     Total  
 
Cash flows from operating activities:
                               
Net income
  $ 42,093     $ 124,725     $ (64,165 )   $ 102,653  
Loss on discontinued operations
    7,003       533       (533 )     7,003  
Changes in operating and intercompany assets and liabilities and noncash items included in net income
    17,222       31,072       11,114       59,408  
                                 
Net cash provided by (used in) operating activities
    66,318       156,330       (53,584 )     169,064  
Cash flows from investing activities:
                               
Purchases of property and equipment, net
    (5,437 )     (34,598 )           (40,035 )
Purchases of new businesses and equity interests, net
    (21,698 )     (11,601 )           (33,299 )
Other items, net
    (9,306 )     (2,350 )     12,950       1,294  
                                 
Net cash used in investing activities
    (36,441 )     (48,549 )     12,950       (72,040 )
Cash flows from financing activities:
                               
Long-term borrowings, net
    14,735       (20,400 )     4,513       (1,152 )
Purchases and sales of noncontrolling interests, net
    737       349             1,086  
Distributions to noncontrolling interests
          (112,573 )     53,584       (58,989 )
Dividend payment on common stock
    (850 )                 (850 )
Decrease in cash held on behalf of noncontrolling interest holders and other
    (11,743 )     15,112       (17,463 )     (14,094 )
                                 
Net cash provided by (used in) financing activities
    2,879       (117,512 )     40,634       (73,999 )
                                 
Net cash provided by discontinued operations
          2,169             2,169  
Effect of exchange rate changes on cash
          169             169  
                                 
Net increase (decrease) in cash
    32,756       (7,393 )           25,363  
Cash at the beginning of the period
    27,430       7,460             34,890  
                                 
Cash at the end of the period
  $ 60,186     $ 67     $     $ 60,253  
                                 
 


F-47


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2009
  Guarantor     Investees     Adjustments     Total  
 
Cash flows from operating activities:
                               
Net income
  $ 69,666     $ 139,236     $ (75,514 )   $ 133,388  
Income from discontinued operations
    (1,453 )     (996 )     996       (1,453 )
Changes in operating and intercompany assets and liabilities and noncash items included in net income
    (1,582 )     30,074       20,183       48,675  
                                 
Net cash provided by (used in) operating activities
    66,631       168,314       (54,335 )     180,610  
Cash flows from investing activities:
                               
Purchases of property and equipment, net
    (5,139 )     (24,565 )           (29,704 )
Purchases of new businesses and equity interests, net
    (57,625 )     (11,816 )     9,914       (59,527 )
Other items, net
    3,837       (10,668 )     10,233       3,402  
                                 
Net cash used in investing activities
    (58,927 )     (47,049 )     20,147       (85,829 )
Cash flows from financing activities:
                               
Long-term borrowings, net
    (2,750 )     (18,905 )     1,585       (20,070 )
Purchases and sales of noncontrolling interests, net
    (4,662 )     2,595             (2,067 )
Distributions to noncontrolling interests
          (117,890 )     54,335       (63,555 )
Dividend payment on common stock
    (88,617 )                 (88,617 )
Increase in cash held on behalf of noncontrolling interest holders and other
    73,730       11,064       (21,732 )     63,062  
                                 
Net cash used in financing activities
    (22,299 )     (123,136 )     34,188       (111,247 )
                                 
Net cash provided by discontinued operations
          1,725             1,725  
Effect of exchange rate changes on cash
          196             196  
                                 
Net increase (decrease) in cash
    (14,595 )     50             (14,545 )
Cash at the beginning of the period
    42,025       7,410             49,435  
                                 
Cash at the end of the period
  $ 27,430     $ 7,460     $     $ 34,890  
                                 
 

F-48


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
                                 
          Non-Participating
    Consolidation
    Consolidated
 
Year Ended December 31, 2008
  Guarantor     Investees     Adjustments     Total  
 
Cash flows from operating activities:
                               
Net income
  $ 37,514     $ 124,826     $ (69,688 )   $ 92,652  
Loss on discontinued operations
    1,179       1,140       (1,140 )     1,179  
Changes in operating and intercompany assets and liabilities and noncash items included in net income
    11,739       24,196       12,353       48,288  
                                 
Net cash provided by operating activities
    50,432       150,162       (58,475 )     142,119  
Cash flows from investing activities:
                               
Purchases of property and equipment, net
    (4,189 )     (26,500 )           (30,689 )
Purchases of new businesses and equity interests, net
    (64,192 )     (107 )           (64,299 )
Other items, net
    (5,202 )     (3,084 )     2,411       (5,875 )
                                 
Net cash used in investing activities
    (73,583 )     (29,691 )     2,411       (100,863 )
Cash flows from financing activities:
                               
Long-term borrowings, net
    28,700       (12,051 )     1,527       18,176  
Purchases and sales of noncontrolling interests, net
    (26,430 )                 (26,430 )
Distributions to noncontrolling interests
          (113,462 )     56,948       (56,514 )
Other items, net
    (3,759 )     770       (2,411 )     (5,400 )
                                 
Net cash provided by (used in) financing activities
    (1,489 )     (124,743 )     56,064       (70,168 )
                                 
Net cash provided by discontinued operations
          1,638             1,638  
Effect of exchange rate changes on cash
          (49 )           (49 )
                                 
Net decrease in cash
    (24,640 )     (2,683 )           (27,323 )
Cash at the beginning of the period
    66,665       10,093             76,758  
                                 
Cash at the end of the period
  $ 42,025     $ 7,410     $     $ 49,435  
                                 

F-49


Table of Contents

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements — (Continued)
 
(22)   Selected Quarterly Financial Data (Unaudited)
 
                                 
    2010 Quarters
    First   Second   Third   Fourth
 
Net revenues
  $ 137,871     $ 143,190     $ 141,392     $ 154,212  
Income from continuing operations
    25,442       30,697       25,875       27,642  
Net income attributable to noncontrolling interests
    (13,635 )     (15,135 )     (14,309 )     (17,481 )
Net income attributable to USPI’s common stockholder
    12,011       15,887       11,848       2,347  
 
                                 
    2009 Quarters
    First   Second   Third   Fourth
 
Net revenues
  $ 150,178     $ 149,305     $ 145,025     $ 148,967  
Income from continuing operations
    21,402       32,522       53,254       24,757  
Net income attributable to noncontrolling interests
    (16,295 )     (16,105 )     (14,807 )     (16,515 )
Net income attributable to USPI’s common stockholder
    5,687       16,752       38,704       8,523  
 
Quarterly operating results are not necessarily representative of operations for a full year for various reasons, including case volumes, interest rates, acquisitions, changes in contracts, the timing of price changes, and financing activities. In addition, the Company has completed acquisitions and opened new facilities throughout 2009 and 2010, all of which significantly affect the comparability of net income from quarter to quarter. The results from 2009 have been adjusted to reflect the effects of discontinued operations that were reported in 2010.


F-50


Table of Contents

(2)   Financial Statement Schedule
 
The following financial statement schedule is filed as part of this Form 10-K:
 
Schedule II — Valuation and Qualifying Accounts
 
SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS
 
Allowance for Doubtful Accounts
 
                                                 
    Balance at
  Additions Charged to:           Balance at
    Beginning of
  Costs and
  Other
      Other
  End of
    Period   Expenses   Accounts   Deductions(2)   Items(3)   Period
    (In thousands)
 
Year ended December 31, 2008(1)
  $ 12,721     $ 7,568     $     $ (9,063 )   $ 318     $ 11,544  
Year ended December 31, 2009(1)
    11,544       8,958             (10,149 )     (2,193 )     8,160  
Year ended December 31, 2010(1)
    8,160       8,458             (8,742 )     (395 )     7,481  
 
Valuation allowance for deferred tax assets
 
                                                 
    Balance at
  Additions Charged to:           Balance at
    Beginning of
  Costs and
  Other
      Other
  End of
    Period   Expenses   Accounts(4)   Deductions(5)   Items   Period
    (In thousands)
 
Year ended December 31, 2008
  $ 37,822     $ 1,332     $ (596 )   $     $     $ 38,558  
Year ended December 31, 2009
    38,558                   (31,193 )     (4,082 )     3,283  
Year ended December 31, 2010
    3,283                         (2,598 )     685  
 
 
(1) Includes amounts related to companies disposed of in 2008 through 2010.
 
(2) Accounts written off.
 
(3) Primarily beginning balances for purchased businesses and entities that were deconsolidated.
 
(4) Recorded to goodwill
 
(5) Reversal of deferred tax asset allowance (Note 13), recorded as a reduction of income tax expense.
 
All other schedules are omitted because they are not applicable or not required or because the required information is included in the consolidated financial statements or notes thereto.


S-1


Table of Contents

 
TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

Consolidated Financial Statements
Years Ended June 30, 2010 and 2009
(With Independent Auditors’ Report Thereon)
 


1


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED JUNE 30, 2010 AND 2009

CONTENTS
 
         
    3  
Audited Financial Statements
       
    4  
    5  
    6  
    7  
    8  


2


Table of Contents

 
REPORT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT AUDITORS
 
To The Board of Managers
Texas Health Ventures Group, L.L.C.:
 
In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of income, of changes in equity, and of cash flows present fairly, in all material respects, the financial position of Texas Health Ventures Group, L.L.C and Subsidiaries (the “Company”) at June 30, 2010 and 2009, and the results of their operations and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
 
/s/ PricewaterhouseCoopers LLP
 
 
December 8, 2010


3


Table of Contents

 
TEXAS HEALTH VENTURES GROUP, L.L.C AND SUBSIDIARIES
 
CONSOLIDATED BALANCE SHEETS —
JUNE 30, 2010 AND 2009
 
                 
    2010     2009  
    (In thousands)  
 
ASSETS
CURRENT ASSETS:
               
Cash
  $ 522     $ 8,315  
Patient receivables, net of allowance for doubtful accounts of $12,560 and $9,097 at June 30, 2010 and 2009, respectively
    48,468       41,489  
Due from affiliate (Note 9)
    43,709       70,370  
Supplies
    8,903       7,570  
Prepaid and other current assets
    2,096       2,120  
                 
Total current assets
    103,698       129,864  
PROPERTY AND EQUIPMENT, net (Note 2)
    170,428       141,603  
OTHER LONG-TERM ASSETS:
               
Investments in unconsolidated affiliates (Note 4)
    1,871       1,687  
Goodwill and intangible assets, net (Note 6)
    143,915       137,303  
Other
    1,051       633  
                 
Total assets
  $ 420,963     $ 411,090  
                 
 
LIABILITIES AND MEMBERS’ EQUITY
CURRENT LIABILITIES:
               
Accounts payable
  $ 16,335     $ 13,063  
Accrued expenses and other
    16,504       14,316  
Due to affiliates (Note 9)
          3,119  
Current portion of long-term obligations (Note 7)
    12,887       12,856  
                 
Total current liabilities
    45,726       43,354  
LONG-TERM OBLIGATIONS, NET OF CURRENT PORTION (Note 7)
    142,709       120,357  
OTHER LIABILITIES
    14,540       13,376  
                 
Total liabilities
    202,975       177,087  
NONCONTROLLING INTERESTS — REDEEMABLE
    30,352       24,400  
COMMITMENTS AND CONTINGENCIES (Notes 7, 8, 9 and 10)
               
EQUITY:
               
Members’ equity
    172,091       194,591  
Noncontrolling interests — nonredeemable
    15,545       15,012  
                 
Total equity
    187,636       209,603  
                 
Total liabilities and equity
  $ 420,963     $ 411,090  
                 
 
See accompanying notes to consolidated financial statements.


4


Table of Contents

 
TEXAS HEALTH VENTURES GROUP, L.L.C AND SUBSIDIARIES
 
CONSOLIDATED STATEMENTS OF INCOME
FOR THE YEARS ENDED JUNE 30, 2010 AND 2009
 
                 
    2010     2009  
    (In thousands)  
 
REVENUES:
               
Net patient service revenue
  $ 478,973     $ 424,071  
Management and royalty fee income (Note 9)
    600       588  
Other income
    517       532  
                 
Total revenues
    480,090       425,191  
                 
EQUITY IN EARNINGS OF UNCONSOLIDATED AFFILIATES (Note 4)
    1,100       977  
                 
OPERATING EXPENSES:
               
Salaries, benefits, and other employee costs
    102,498       92,664  
Medical services and supplies
    120,017       98,270  
Management and royalty fees (Note 9)
    19,181       17,021  
Professional fees
    3,348       3,880  
Other operating expenses
    65,665       59,491  
Provision for doubtful accounts
    15,283       12,420  
Depreciation and amortization
    19,635       18,898  
                 
Total operating expenses
    345,627       302,644  
                 
Operating income
    135,563       123,524  
NONOPERATING INCOME (EXPENSES):
               
Interest expense
    (13,680 )     (13,251 )
Interest income (Note 9)
    338       640  
Other income (expense), net
    31       (252 )
                 
Income before income taxes
    122,252       110,661  
INCOME TAXES
    (3,009 )     (2,888 )
                 
Net income
    119,243       107,773  
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS — Redeemable
    (57,886 )     (52,871 )
NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS — Nonredeemable
    (4,444 )     (3,889 )
                 
Net income attributable to the Company
  $ 56,913     $ 51,013  
                 
 
See accompanying notes to consolidated financial statements.


5


Table of Contents

 
TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED JUNE 30, 2010 AND 2009
 
                                                 
                                  Noncontrolling
 
          Members’ Equity     Interests —
 
    Total     USP     BHS     BUMC     Total     Nonredeemable  
    (In thousands)  
 
Balance at June 30, 2008
  $ 174,532     $ 79,798     $ 1,760     $ 78,360     $ 159,918     $ 14,614  
Net income
    54,902       25,434       604       24,975       51,013       3,889  
Distributions to members
    (19,934 )     (8,132 )     (222 )     (7,986 )     (16,340 )     (3,594 )
Purchase of noncontrolling interests
    353                               353  
Sale of noncontrolling interests
    (250 )                             (250 )
Assign remaining BHS 1.1% interest in THVG to BUMC, effective June 30, 2009
                (2,142 )     2,142              
                                                 
Balance at June 30, 2009
    209,603       97,100             97,491       194,591       15,012  
Net income
    61,357       28,400             28,513       56,913       4,444  
Distributions to members
    (87,059 )     (41,368 )           (41,534 )     (82,902 )     (4,157 )
Contributions
    4,766       2,238             2,247       4,485       281  
Purchase of noncontrolling interests
    495       (95 )           (96 )     (191 )     686  
Sales of noncontrolling interests
    (1,526 )     (402 )           (403 )     (805 )     (721 )
                                                 
Balance at June 30, 2010
  $ 187,636     $ 85,873     $     $ 86,218     $ 172,091     $ 15,545  
                                                 
 
See accompanying notes to consolidated financial statements.


6


Table of Contents

 
TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 2010 AND 2009
 
                 
    2010     2009  
    (In thousands)  
 
CASH FLOWS FROM OPERATING ACTIVITIES:
               
Net income
  $ 119,243     $ 107,773  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Provision for doubtful accounts
    15,283       12,420  
Depreciation and amortization
    19,635       18,898  
Amortization of debt issue costs
    5       4  
Equity in earnings of unconsolidated affiliates, net of distributions received
    (183 )     (94 )
Changes in operating assets and liabilities, net of effects from purchases of new businesses:
               
Patient receivables
    (20,815 )     (7,988 )
Due to affiliates, net
    (3,119 )     (97 )
Supplies, prepaids, and other assets
    (835 )     (437 )
Accounts payable and accrued expenses
    2,829       (3,829 )
                 
Net cash provided by operating activities
    132,043       126,650  
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchases of new businesses and equity interests, net of cash received of $1,506 and $1,758 for 2010 and 2009, respectively
    1,506       46  
Sale of equity interests
          25  
Purchases of property and equipment
    (16,842 )     (6,611 )
Sales of property and equipment
    100       45  
Change in deposits and notes receivables
    43        
Change in cash management balances with affiliate
    26,229       (39,661 )
                 
Net cash provided by (used in) investing activities
    11,036       (46,156 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Proceeds from long-term debt
  $ 9,988     $ 3,534  
Payments on long-term obligations
    (17,703 )     (13,164 )
Distributions to noncontrolling interest owners
    (61,361 )     (53,158 )
Purchases of noncontrolling interests
    (1,838 )     (1,348 )
Sales of noncontrolling interests
    2,944       4,770  
Distributions to members
    (82,902 )     (16,340 )
                 
Net cash used in financing activities
    (150,872 )     (75,706 )
                 
(DECREASE) INCREASE IN CASH
    (7,793 )     4,788  
CASH, beginning of period
    8,315       3,527  
                 
CASH, end of period
  $ 522     $ 8,315  
                 
SUPPLEMENTAL INFORMATION:
               
Cash paid for interest
  $ 13,397     $ 13,441  
Cash paid for income taxes
    2,816       2,365  
Noncash transactions:
               
Noncash assets contributed by Members (Note 3)
    4,766        
Assets acquired under capital leases
    25,339       2,675  
 
See accompanying notes to consolidated financial statements.


7


Table of Contents

 
TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements
FOR THE YEARS ENDED JUNE 30, 2010 AND 2009
 
1.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Description of Business
 
Texas Health Ventures Group, L.L.C. and subsidiaries (THVG or the Company), a Texas limited liability company, was formed on January 21, 1997, for the primary purpose of developing, acquiring, and operating ambulatory surgery centers and related entities. Prior to June 29, 2008, Baylor Health Services (BHS), a Texas nonprofit corporation that is a controlled affiliate of Baylor Health Care System (BHCS), a Texas nonprofit corporation, owned 50.1% interest in THVG. On June 29, 2008, BHS distributed 49% of its existing 50.1% interest in THVG to Baylor University Medical Center (BUMC), a Texas nonprofit corporation whose sole member is BHCS. THVG is ultimately a subsidiary of BHCS through the combined ownership by BUMC and BHS (collectively referred to herein as Baylor). USP North Texas, Inc. (USP), a Texas corporation and subsidiary of United Surgical Partners International, Inc. (USPI), owns 49.9% of THVG. On June 30, 2009, BHS assigned its 1.1% remaining interest to BUMC. THVG’s fiscal year ends June 30. THVG’s subsidiaries’ fiscal years end December 31; however, the financial information of these subsidiaries included in these consolidated financial statements is as of and for the twelve months ended June 30, 2010 and 2009.
 
THVG owns equity interests in and operates ambulatory surgery centers, surgical hospitals, and related businesses in the Dallas/Fort Worth, Texas, metropolitan area. At June 30, 2010, THVG operated twenty-six facilities (the Facilities) under management contracts, twenty-five of which are consolidated for financial reporting purposes and one of which is accounted for under the equity method. In addition, THVG holds equity method investments in two partnerships that each own the real estate used by two of the Facilities.
 
THVG has been funded by capital contributions from its members and by cash distributions from the Facilities. The board of managers, which is controlled by Baylor, initiates requests for capital contributions. The Facilities’ operating agreements provide that cash flows available for distribution will be distributed at least quarterly to THVG and other owners of the Facilities.
 
THVG’s operating agreement provides that the board of managers determine, on at least a quarterly basis, if THVG should make a cash distribution based on a comparison of THVG’s excess cash on hand versus current and anticipated needs, including, without limitation, needs for operating expenses, debt service, acquisitions, and a reasonable contingency reserve. The terms of THVG’s operating agreement provide that any distributions, whether driven by operating cash flows or by other sources, such as the distribution of noncash assets or distributions in the event THVG liquidates, are to be shared according to each member’s overall ownership level in THVG. Those ownership levels were 50.1% for BUMC and 49.9% for USP as of June 30, 2010 and 2009.
 
Basis of Accounting
 
THVG maintains its books and records on the accrual basis of accounting, and the consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.
 
Principles of Consolidation
 
The consolidated financial statements include the financial statements of THVG and its wholly owned subsidiaries and other entities THVG controls. All significant intercompany balances and transactions have been eliminated in consolidation.
 
Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management of THVG to make estimates and assumptions that affect the


8


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
 
Recently Adopted Accounting Pronouncements
 
Effective July 1, 2009, THVG adopted Statement of Financial Accounting Standards (SFAS) No. 141 (revised 2007), Business Combinations, (SFAS 141R) and SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an Amendment of ARB No. 51 (SFAS 160). SFAS 141R and SFAS 160 are now included in the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC), Topic 805, Business Combinations and Topic 810, Consolidations, respectively. The ASC is now the source of GAAP recognized by the FASB to be applied to nongovernmental entities.
 
Under ASC 805, THVG is required to recognize the assets acquired, liabilities assumed, contractual contingencies and contingent consideration at their fair value at the acquisition date. ASC 805 further requires that acquisition-related costs are to be recognized separately from the acquisition and expensed as incurred. Among other changes, ASC 805 also requires that “negative goodwill” be recognized in earnings as a gain attributable to the acquisition, and any deferred tax benefits resulting from a business combination be recognized in income from continuing operations in the period of the combination.
 
ASC 810 now requires THVG to clearly identify and present ownership interests in subsidiaries held by parties other than THVG in the consolidated financial statements within the equity section but separate from THVG’s equity, except as noted below. It also requires the amounts of consolidated net income attributable to THVG and the noncontrolling interests to be clearly identified and presented on the face of the consolidated statement of income; changes in ownership interests to be accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary to be measured at fair value. The implementation of ASC 810 also results in the cash flow impact of certain transactions with noncontrolling interests being classified within financing activities, consistent with the view that under ASC 810 transactions between THVG (or its subsidiaries) and noncontrolling interests are considered to be equity transactions. These changes are summarized in the table below, along with the cash flow classifications of several similar types of transactions that did not change as a result of ASC 810:
 
                 
   
Before ASC 810
 
ASC 810
 
Changes in Cash Flow Classification:
               
Distributions of earnings paid to noncontrolling interests
    Operating       Financing  
Acquisitions or sales of equity interests in consolidated subsidiaries, no change of control
    Investing       Financing  
No Change in Cash Flow Classification:
               
Distributions of earnings received from unconsolidated affiliates
    Operating       Operating  
Returns of capital paid to noncontrolling interests
    Financing       Financing  
Returns of capital received from unconsolidated affiliates
    Investing       Investing  
Sales of equity interests in consolidated subsidiaries resulting in a change of control
    Investing       Investing  
Acquisitions or sales of equity interests in unconsolidated affiliates, no change of control
    Investing       Investing  
Acquisitions of equity interests in unconsolidated affiliates, resulting in change of control
    Investing       Investing  
Business combinations with no previous ownership by THVG
    Investing       Investing  


9


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
As summarized below, THVG has retrospectively applied the classification requirements as required by ASC 810 to all periods presented. The effect of these changes on previously reported consolidated financial statements is as follows (in thousands):
 
         
    June 30, 2009  
 
Consolidated Balance Sheet
       
Total equity as previously reported
  $ 194,591  
Reclassification of nonredeemable noncontrolling interests to equity as required by ASC 810
    15,012  
         
Total equity as adjusted for ASC 810
  $ 209,603  
         
Consolidated Statement of Cash Flows
       
Net cash provided by operating activities as previously recorded
  $ 73,765  
Reclassification of distributions to noncontrolling interests to financing activities
    52,885  
         
Net cash provided by operating activities as adjusted for ASC 810
  $ 126,650  
         
Net cash used in investing activities as previously reported
  $ (42,734 )
Reclassification of purchases and sales of noncontrolling interests to financing activities
    (3,422 )
         
Net cash used in investing activities as adjusted for ASC 810
  $ (46,156 )
         
Net cash used in financing activities as previously reported
  $ (26,244 )
Reclassifications of distributions to noncontrolling from interests from operating activities
    (52,885 )
Reclassifications of purchases and sales of noncontrolling interests from investing activities
    3,423  
         
Net cash used in financing activities as adjusted for ASC 810
  $ (75,706 )
         
 
Upon the occurrence of various fundamental regulatory changes, THVG could be obligated, under the terms of its investees’ partnership and operating agreements, to purchase some or all of the noncontrolling interests related to THVG’s consolidated subsidiaries. These repurchase requirements are limited to the portions of its facilities that are owned by physicians who perform surgery at THVG’s facilities and would be triggered by regulatory changes making the existing ownership structure illegal. While THVG is not aware of events that would make the occurrence of such a change probable, regulatory changes are outside the control of THVG. Accordingly, the noncontrolling interests subject to these repurchase provisions, and the income attributable to those interests, have been classified in the mezzanine, outside of equity, on THVG’s consolidated balance sheets.
 
The implementation of ASC 810 also had a significant impact on THVG’s statement of income format. Whereas in prior periods THVG’s consolidated statement of income listed “minority interests in the income of consolidated subsidiaries” above the “income tax expense” line item, that order is reversed under ASC 810, which requires that minority interests (now called “net income attributable to noncontrolling interests”) be listed below income tax expense. This change has no effect on the computation or amounts of THVG’s tax expense or payments.
 
Cash Equivalents
 
For purposes of the consolidated financial statements, THVG considers all highly liquid instruments with original maturities when purchased of three months or less to be cash equivalents. There were no cash equivalents at June 30, 2010 or 2009.


10


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
Patient Receivables
 
Patient receivables are stated at estimated net realizable value. Significant concentrations of patient receivables at June 30, 2010 and 2009 include:
 
                 
    2010   2009
 
Commercial and managed care providers
    64 %     65 %
Government-related programs
    18 %     16 %
Self-pay patients
    18 %     19 %
                 
      100 %     100 %
                 
 
Receivables from government-related programs (i.e. Medicare and Medicaid) represent the only concentrated groups of credit risk for THVG and management does not believe that there are any credit risks associated with these receivables. Commercial and managed care receivables consist of receivables from various payors involved in diverse activities and subject to differing economic conditions, and do not represent any concentrated credit risk to THVG. THVG maintains allowances for uncollectible accounts for estimated losses resulting from the payors’ inability to make payments on accounts. THVG assesses the reasonableness of the allowance account based on historic write-offs, the aging of accounts and other current conditions. Furthermore, management continually monitors and adjusts the allowances associated with its receivables. Accounts are written off when collection efforts have been exhausted.
 
Supplies
 
Supplies, consisting primarily of pharmaceuticals and supplies inventories, are stated at cost, which approximates market value, and are expensed as used.
 
Property and Equipment
 
Property and equipment are initially recorded at cost or, when acquired as part of a business combination, at fair value at the date of acquisition. Depreciation is calculated on the straight line method over the estimated useful lives of the assets. Upon retirement or disposal of assets, the asset and accumulated depreciation accounts are adjusted accordingly, and any gain or loss is reflected in earnings or loss of the respective period. Maintenance costs and repairs are expensed as incurred; significant renewals and betterments are capitalized. Assets held under capital leases are classified as property and equipment and amortized using the straight line method over the shorter of the useful lives or the lease terms, and the related obligations are recorded as debt. Amortization of property and equipment held under capital leases and leasehold improvements is included in depreciation and amortization expense. THVG records operating lease expense on a straight-line basis unless another systematic and rational allocation is more representative of the time pattern in which the leased property is physically employed. THVG amortizes leasehold improvements, including amounts funded by landlord incentives or allowances, for which the related deferred rent is amortized as a reduction of lease expense, over the shorter of their economic lives or the lease term.
 
Investments in Unconsolidated Affiliates
 
Investments in unconsolidated affiliates in which THVG exerts significant influence, but has less than a controlling ownership, are accounted for under the equity method. THVG exerts significant influence in the operations of its unconsolidated affiliates through representation on the governing bodies of the investees and additionally, with respect to the Facilities, through contracts to manage the operations of the investees.


11


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
Intangible Assets and Goodwill
 
Intangible assets consist of costs in excess of net assets acquired (goodwill), costs associated with the purchase of management service contract rights, and other intangibles. Most of these assets have indefinite lives. Accordingly, these assets are not amortized but are instead tested for impairment annually or more frequently if changing circumstances warrant. The amount by which the carrying amount would exceed fair value identified in a test for impairment would be recorded as an impairment loss in the consolidated statements of income. No such impairment was identified in 2010 or 2009. THVG amortizes intangible assets with definite useful lives over their respective useful lives to the estimated residual values and reviews them for impairment in the same manner as long-lived assets, as discussed below.
 
Impairment of Long-Lived Assets
 
Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset, or related groups of assets, may not be fully recoverable from estimated future cash flows. In the event of impairment, measurement of the amount of impairment may be based on appraisal, fair values of similar assets or estimates of future discounted cash flows resulting from use and ultimate disposition of the asset. No such impairment was identified in 2010 or 2009.
 
Fair Value of Financial Instruments
 
The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2) or unobservable inputs (Level 3), depending on the nature of the item being valued. The Company does not have financial assets and liabilities measured at fair value on a recurring basis at June 30, 2010. The carrying amounts of cash, accounts receivable, and accounts payable approximate fair value because of the short maturity of these instruments.
 
The fair value of the Company’s long-term debt is determined by estimation of the discounted future cash flows of the debt at rates currently quoted or offered to a comparable company for similar debt instruments of comparable maturities by its lenders. At June 30, 2010, the aggregate carrying amount and estimated fair value of long-term debt were $41,174,000 and $38,705,000, respectively. At June 30, 2009, the aggregate carrying amount and estimated fair value of long-term debt were approximately $41,500,000 and $40,900,000, respectively.
 
Revenue Recognition
 
THVG has agreements with third-party payors that provide for payments to THVG at amounts different from its established rates. Payment arrangements include prospectively-determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Net patient service revenue is reported at the estimated net realizable amount from patients, third-party payors, and others for services rendered, including estimated contractual adjustments under reimbursement agreements with third party payors. Contractual adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. These contractual adjustments are related to the Medicare and Medicaid programs, as well as managed care contracts.
 
Net patient service revenue from the Medicare and Medicaid programs accounted for approximately 12% and 9% of total net patient service revenue in 2010 and 2009, respectively.
 
Net patient service revenue from managed care contracts accounted for approximately 82% and 89% of net patient service revenue in 2010 and 2009, respectively.


12


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
Net patient service revenue from private payors accounted for approximately 6% and 2% of total net patient service revenue in 2010 and 2009, respectively.
 
For facilities licensed as hospitals, federal regulations require the submission of annual cost reports covering medical costs and expenses associated with services provided to program beneficiaries. Medicare and Medicaid cost report settlements are estimated in the period services are provided to beneficiaries.
 
Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is a reasonable possibility that recorded estimates with respect to the five THVG facilities licensed as hospitals may change as interpretations are clarified. These initial estimates are revised as needed until final cost reports are settled.
 
Equity in Earnings of Unconsolidated Affiliates
 
Equity in earnings of unconsolidated affiliates consists of THVG’s share of the profits and losses generated from its noncontrolling equity investments. Because these operations are central to THVG’s business strategy, equity in earnings of unconsolidated affiliates is classified as a component of operating income in the accompanying consolidated statements of income. THVG has contracts to manage these facilities, which results in THVG having an active role in the operations of these facilities.
 
Income Taxes
 
No amounts for federal income taxes have been reflected in the accompanying consolidated financial statements because the federal tax effects of THVG’s activities accrue to the individual members.
 
The Texas franchise tax applies to all THVG entities for any tax reports filed on or after January 1, 2008 and is reflected in the accompanying consolidated statements of income. Under the revised law, the tax is calculated on a margin base and is therefore reflected in THVG’s consolidated statements of income for the years ended June 30, 2010 and 2009 as income tax expense.
 
THVG follows the provisions of ASC 740, “Income Taxes”, which prescribes a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The impact on THVG’s financial statements resulting from the adoption of new provisions within ASC 740 on July 1, 2007 was not material.
 
As of June 30, 2010 and 2009, THVG had no gross unrecognized tax benefits. THVG files a partnership income tax return in the U.S. federal jurisdiction and a franchise tax return in the state of Texas. THVG is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years prior to 2006. THVG has identified Texas as a “major” state taxing jurisdiction. THVG does not expect or anticipate a significant change over the next twelve months in the unrecognized tax benefits.
 
Commitments and Contingencies
 
Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated.


13


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
2.   PROPERTY AND EQUIPMENT
 
At June 30, 2010 and 2009, property and equipment and related accumulated depreciation and amortization consisted of the following (in thousands):
 
                         
    Estimated
             
    Useful Lives     2010     2009  
 
Land
        $ 612     $  
Buildings and leasehold improvements
    5-25 years       145,242       114,414  
Equipment
    3-15 years       80,515       70,405  
Furniture and fixtures
    5-15 years       12,730       10,190  
Construction in progress
            3,441       1,536  
                         
              242,540       196,545  
Less accumulated depreciation and amortization
            (72,112 )     (54,942 )
                         
Net property and equipment
          $ 170,428     $ 141,603  
                         
 
At June 30, 2010 and 2009, assets recorded under capital lease arrangements included in property and equipment consisted of the following (in thousands):
 
                 
    2010     2009  
 
Buildings
  $ 105,186     $ 81,271  
Equipment and furniture
    14,773       16,591  
                 
      119,959       97,862  
Less accumulated amortization
    (23,893 )     (20,584 )
                 
Net property and equipment under capital leases
  $ 96,066     $ 77,278  
                 
 
3.   CAPITAL CONTRIBUTIONS BY MEMBERS
 
As discussed in Note 1, THVG receives part of its funding through cash and capital contributions from its members. During 2010, THVG received noncash capital contributions consisting primarily of investments in partnerships that operate surgery centers in the Dallas/Fort Worth area. These noncash capital contributions, including THVG’s ownership in the investee, are as follows (in thousands):
 
                     
    Ownership
  Net Assets
   
Investee
  Percentage   Contributed   Effective Date
 
DeSoto Surgicare Partners, Ltd. (DeSoto)
    50.1 %   $ 1,684     December 1, 2009
Physicians Surgical Center of Fort Worth, L.L.P. (FW Physicians)
    50.13 %     3,082     December 31, 2009
 
USP previously had a controlling interest in DeSoto and had an equity method investment (ASC 323) in FW Physicians through another subsidiary. On the effective dates listed above, USP sold 25.1% interest in DeSoto and 25.12% interest in FW Physicians to Baylor. Through the contributions of USP and Baylor, THVG obtained control of DeSoto and FW Physicians, and accounted for the acquisitions as business combinations in accordance with ASC 805. THVG recorded the contributions from Baylor at predecessor basis, as they were common control transactions between a parent and subsidiary. In this transaction, Baylor’s predecessor basis is the same as fair value since the transfer happened at the same time of the business combination for Baylor. THVG recorded the contributions from USP at fair value, based on an appraisal, as USP is a noncontrolling interest holder.
 
Concurrent with the contributions, THVG began managing the operations of these facilities. The results of these transactions are included in THVG’s consolidated results of operations from the date of contribution.


14


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
The assets acquired and liabilities assumed resulting from the above contributions are summarized
as follows (in thousands):
 
                 
    DeSoto     FW Physicians  
 
Current assets
  $ 649     $ 1,732  
Property and equipment
    2,678       2,180  
Goodwill — Parent
    402       2,547  
Goodwill — Noncontrolling interests
          372  
Other noncurrent asset
    3        
                 
Total assets acquired
    3,732       6,831  
Current liabilities
    1,154       1,556  
Long-term debt
    178       250  
                 
Total liabilities assumed
    1,332       1,806  
Noncontrolling interests
    716       1,943  
                 
Net assets acquired
  $ 1,684     $ 3,082  
                 
 
4.   INVESTMENTS IN SUBSIDIARIES AND UNCONSOLIDATED AFFILIATES
 
THVG’s investments in consolidated subsidiaries and unconsolidated affiliates consisted of the following:
 
                         
            Percentage Owned
            June 30,
  June 30,
Legal Name
 
Facility
 
City
  2010   2009
 
Consolidated subsidiaries(1):
                       
Bellaire Outpatient Surgery Center, L.L.P. 
  Bellaire Surgery Center   Fort Worth     50.1 %     50.1 %
Dallas Surgical Partners, L.L.C. 
  Baylor Surgicare   Dallas     62.6       62.6  
Dallas Surgical Partners, L.L.C. 
  Texas Surgery Center   Dallas     62.6       62.6  
Dallas Surgical Partners, L.L.C. 
  Physicians Day Surgery Center   Dallas     62.6       62.6  
Denton Surgicare Partners, Ltd. 
  Baylor Surgicare at Denton   Denton     50.1       50.1  
Frisco Medical Center, L.L.P. 
  Baylor Medical Center at Frisco   Frisco     50.3       50.1  
Garland Surgicare Partners, Ltd. 
  Baylor Surgicare at Garland   Garland     50.1       50.1  
Grapevine Surgicare Partners, Ltd. 
  Baylor Surgicare at Grapevine   Grapevine     50.1       50.3  
Lewisville Surgicare Partners, Ltd. 
  Baylor Surgicare at Lewisville   Lewisville     52.4       53.1  
MSH Partners, L.L.C. 
  Mary Shiels Hospital   Dallas     31.7       42.4  
North Central Surgical Center, L.L.P. 
  North Central Surgery Center   Dallas     32.2       32.2  
North Garland Surgery Center, L.L.P. 
  North Garland Surgery Center   Garland     51.6       52.4  
Rockwall/Heath Surgery Center, L.L.P. 
  Baylor Surgicare at Heath   Heath     50.2       50.1  
Trophy Club Medical Center, L.P. 
  Trophy Club Medical Center   Fort Worth     51.2       52.5  
Valley View Surgicare Partners, Ltd. 
  Baylor Surgicare at Valley View   Dallas     50.1       50.1  
Fort Worth Surgicare Partners, Ltd. 
  Baylor Surgical Hospital of Fort Worth   Fort Worth     50.1       50.2  
Arlington Surgicare Partners, Ltd. 
  Surgery Center of Arlington   Arlington     50.1       50.1  
Rockwall Ambulatory Surgery Center, L.L.P. 
  Rockwall Surgery Center   Rockwall     50.1       50.1  
Baylor Surgicare at Plano, L.L.C. 
  Baylor Surgicare at Plano   Plano     50.1       50.1  
Metroplex Surgicare Partners, Ltd. 
  Metroplex Surgicare   Bedford     50.1       50.1  
Arlington Orthopedic and Spine Hospitals, LLC
  Arlington Hospital   Arlington     50.1       50.1  
Baylor Surgicare at Granbury, LLC
  Granbury Surgical Plaza   Granbury     51.8       50.6  
Physicians Center of Fort Worth, L.L.P. 
  Baylor Surgicare at Fort Worth I & II   Fort Worth     50.1        
DeSoto Surgicare, Ltd. 
  North Texas Surgery Center   Desoto     50.1        
Baylor Surgicare at Mansfield, L.L.C. 
  Baylor Surgicare at Mansfield   Mansfield     51.0        
Unconsolidated affiliates:
                       
Denton Surgicare Real Estate, Ltd. 
  (2)   n/a     49.0       49.0  
Irving-Coppell Surgical Hospital, L.L.P. 
  Irving-Coppell Surgical Hospital   Irving     18.3       8.3  
MCSH Real Estate Investors, Ltd. 
  (2)   n/a     2.0       2.0  


15


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
 
(1) List excludes holding companies, which are wholly owned by the Company and hold the Company’s investments in the Facilities.
 
(2) These entities are not surgical facilities and do not have ownership in any surgical facilities.
 
Effective February 1, 2009, THVG acquired 50.63 membership units, a 50.63% equity interest, in Granbury Surgical Plaza (Granbury), for a purchase price of $805,000. Granbury, like the other facilities in which THVG invests, is operated by Baylor and USP through THVG, as described in Note 9.
 
Effective May 1, 2010, THVG assumed ownership of 51 membership units, a 51% equity interest, in Baylor Surgicare at Mansfield (Mansfield), for no consideration. Mansfield, like other facilities in which TVHG invests, is operated by Baylor and USP through THVG, as described in Note 9.
 
The following table summarizes the recorded values of the assets acquired and liabilities assumed at the dates of acquisition (in thousands):
 
                 
    2010
    2009
 
    Mansfield     Granbury Surgical Plaza  
 
Current assets
  $ 1,066     $ 2,454  
Property and equipment
    1,305       2,847  
Goodwill — parent
    1,705       3,916  
Goodwill — noncontrolling interests
    1,638        
Long-term assets
          14  
                 
Total assets acquired
    5,714       9,231  
                 
Current liabilities
    2,202       882  
Long-term liabilities
    950       1,776  
Long-term debt
    2,562       5,768  
                 
Total liabilities assumed
    5,714       8,426  
                 
Net assets acquired
  $     $ 805  
                 
 
The acquisition of Mansfield was accounted for in accordance with ASC 805 and the acquisition method was applied. The acquisition was recorded at fair value, which resulted in goodwill for the parent and noncontrolling interest holders. Fair values for noncontrolling interest holders are estimated based on market multiples and discounted cash flow models which have been derived from the Company’s experience in acquiring surgical facilities, market participant assumptions and third party valuations it has obtained with respect to such transactions. The inputs used in these models are Level 3 inputs, which under GAAP, are significant unobservable inputs. Inputs into these models include expected revenue growth, expected gross margins and discount factors.
 
The acquisition of Granbury was accounted for using the purchase method of accounting and accordingly, the purchase price has been allocated to the tangible and intangible assets acquired and liabilities assumed based on the estimated fair values at the date of acquisition.
 
The results of these acquisitions are included in THVG’s consolidated statements of income from the date of acquisition. Total acquisition costs included in professional fees on THVG’s consolidated statement of income for 2010 was $175,000.
 
5.   NONCONTROLLING INTERESTS
 
The Company controls and therefore consolidates the results of 25 of its 26 facilities. Similar to its investments in unconsolidated affiliates, the Company regularly engages in the purchase and sale of equity interests with respect


16


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
to its consolidated subsidiaries that do not result in a change of control. These transactions are accounted for as equity transactions, as they are undertaken among the Company, its consolidated subsidiaries, and noncontrolling interests, and their cash flow effect is classified within financing activities.
 
During the fiscal year ended June 30, 2010, the Company purchased and sold equity interests in various consolidated subsidiaries in the amounts of $1,838,000 and $2,944,000, respectively. The basis difference between the Company’s carrying amount and the proceeds received or paid in each transaction is recorded as an adjustment to the Company’s equity. The impact of these transactions is summarized as follows (in thousands):
 
         
    Year Ended
 
    June 30,
 
    2010  
 
Net income attributable to the Company
  $ 56,913  
Transfers to the noncontrolling interests:
       
Decrease in the Company’s equity for losses incurred related to sales of subsidiaries’ equity interests
    (805 )
Decrease in the Company’s equity for losses incurred related to purchases of subsidiaries’ equity interests
    (192 )
         
Net transfers to noncontrolling interests
    (997 )
         
Change in equity from net income attributable to the Company and transfers to noncontrolling interests
  $ 55,916  
         
 
As further described in Note 1, upon the occurrence of various fundamental regulatory changes, the Company could be obligated, under the terms of its investees’ partnership and operating agreements, to purchase some or all of the noncontrolling interests related to the Company’s consolidated subsidiaries. As a result, these noncontrolling interests are not included as part of the Company’s equity and are carried as noncontrolling interests-redeemable on the Company’s consolidated balance sheets. The activity for the years ended June 30, 2010 and 2009 is summarized below (in thousands):
 
         
Balance, June 30, 2008
  $ 15,296  
Net income attributable to noncontrolling interests
    52,870  
Distributions to noncontrolling interests
    (49,564 )
Purchases of noncontrolling interests
    (1,701 )
Sales of noncontrolling interests
    4,990  
Noncontrolling interests attributable to business combinations
    2,509  
         
Balance, June 30, 2009
    24,400  
         
Net income attributable to noncontrolling interests
    57,886  
Distributions to noncontrolling interests
    (57,204 )
Purchases of noncontrolling interests
    (1,860 )
Sales of noncontrolling interests
    4,471  
Noncontrolling interests attributable to business combinations
    2,659  
         
Balance, June 30, 2010
  $ 30,352  
         


17


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
6.   GOODWILL AND INTANGIBLE ASSETS
 
At June 30, 2010 and 2009, goodwill and intangible assets, net of accumulated amortization, consisted of the following (in thousands):
 
                 
    2010     2009  
 
Goodwill — parent
  $ 140,707     $ 136,119  
Goodwill — noncontrolling interests
    2,010        
Other intangible assets
    1,198       1,184  
                 
Total
  $ 143,915     $ 137,303  
                 
 
The following is a summary of changes in the carrying amount of goodwill for the years ended June 30, 2010 and 2009 (in thousands):
 
                 
          Noncontrolling
 
    Parent     Interests  
 
Balance, June 30, 2008
  $ 130,137     $  
Additions:
               
Acquisition of Granbury
    3,916        
Purchase of additional interests in USPD
    1,121        
Additional contribution from BHS for the Metroplex acquisition
    107        
Other
    838        
                 
Balance, June 30, 2009
    136,119        
Additions:
               
Contribution of DeSoto
    402        
Contribution of FW Physicians
    2,547       372  
Acquisition of Mansfield
    1,705       1,638  
Other
    (66 )      
                 
Balance, June 30, 2010
  $ 140,707     $ 2,010  
                 
 
As described in Note 1, with the adoption of ASC 805 and ASC 810 effective July 1, 2009, goodwill additions resulting from business combinations are recorded and assigned to the parent and noncontrolling interests.
 
Intangible assets with definite useful lives are amortized over their respective estimated useful lives. THVG records interest expense related to debt issuance costs on a straight-line basis over the term of the debt obligation, which approximates the effective interest method. The agreements underlying THVG’s management contract assets have no determinable termination date and, consequently, the related intangible assets have indefinite useful lives. Goodwill and intangible assets with indefinite useful lives are not amortized but instead are tested for impairment at least annually. No impairment was identified in 2010 or 2009.


18


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
The following is a summary of other intangible assets at June 30, 2010 and 2009 (in thousands):
 
                         
    June 30, 2010  
    Gross Carrying
    Accumulated
       
    Amount     Amortization     Total  
 
Definite useful lives:
                       
Debt issue costs
  $ 104     $ (55 )   $ 49  
Indefinite useful lives:
                       
Management contracts
    1,149             1,149  
                         
Total intangible assets
  $ 1,253     $ (55 )   $ 1,198  
                         
 
                         
    June 30, 2009  
    Gross Carrying
    Accumulated
       
    Amount     Amortization     Total  
 
Definite useful lives:
                       
Debt issue costs
  $ 84     $ (50 )   $ 34  
Indefinite useful lives:
                       
Management contracts
    1,150             1,150  
                         
Total intangible assets
  $ 1,234     $ (50 )   $ 1,184  
                         
 
Amortization of debt issue costs in the amount of approximately $5,000 and $4,000 are included in interest expense for the years ended June 30, 2010 and 2009, respectively.
 
7.   LONG-TERM OBLIGATIONS
 
At June 30, 2010 and 2009, long-term obligations consisted of the following (in thousands):
 
                 
    2010     2009  
 
Capital lease obligations (Note 8)
  $ 114,422     $ 91,679  
Notes payable to financial institutions
    41,174       41,534  
                 
Total long-term obligations
    155,596       133,213  
Less current portion
    (12,887 )     (12,856 )
                 
Long-term obligations, less current portion
  $ 142,709     $ 120,357  
                 
 
The aggregate maturities of notes payable for each of the five years subsequent to June 30, 2010 and thereafter are as follows (in thousands):
 
         
2011
  $ 9,750  
2012
    9,810  
2013
    7,062  
2014
    5,219  
2015
    3,279  
Thereafter
    6,054  
         
Total long-term obligations
  $ 41,174  
         
 
The Facilities have notes payable to financial institutions which mature at various dates through 2016 and accrue interest at fixed and variable rates ranging from 3% to 9%. Each note is collateralized by certain assets of the respective Facility.


19


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
Capital lease obligations are collateralized by underlying real estate or equipment and have interest rates ranging from 2% to 13.9%.
 
8.   LEASES
 
The Facilities lease various office equipment, medical equipment, and office space under a number of operating lease agreements, which expire at various times through the year 2030. Such leases do not involve contingent rentals, nor do they contain significant renewal or escalation clauses. Office leases generally require the Facilities to pay all executory costs (such as property taxes, maintenance and insurance).
 
Minimum future payments under noncancelable leases with remaining terms in excess of one year as of June 30, 2010 are as follows (in thousands):
 
                 
    Capital
    Operating
 
    Leases     Leases  
 
Year ending June 30:
               
2011
  $ 15,276     $ 12,992  
2012
    14,936       12,649  
2013
    14,536       11,060  
2014
    14,192       10,377  
2015
    14,506       10,435  
Thereafter
    180,738       78,524  
                 
Total minimum lease payments
    254,184     $ 136,037  
                 
Amount representing interest
    (139,760 )        
                 
Total principal payments
  $ 114,424          
                 
 
Total rent expense under operating leases was approximately $14,702,000 and $13,149,000 for the years ended June 30, 2010 and 2009, respectively, and is included in other operating expenses in the accompanying consolidated statements of income.
 
9.   RELATED-PARTY TRANSACTIONS
 
THVG operates the Facilities under management and royalty contracts, and THVG in turn is managed by Baylor and USP, resulting in THVG incurring management and royalty fee expense payable to Baylor and USP in amounts equal to the management and royalty fee income THVG receives from the Facilities. THVG’s management and royalty fee income from the facilities it consolidates for financial reporting purposes eliminates in consolidation with the facilities’ expense and therefore is not included in THVG’s consolidated revenues. THVG’s management and royalty fee income from facilities which are not consolidated was approximately $600,000 and $588,000 for the years ended June 30, 2010 and 2009, respectively, and is included in the consolidated revenues of THVG.
 
The management and royalty fee expense to Baylor and USP was approximately $19,181,000 and $17,021,000 for the years ended June 30, 2010 and 2009, respectively, and is reflected in operating expenses in THVG’s consolidated statements of income. Of the total, 64.3% and 34.0% represent management fees payable to USP and Baylor, respectively, and 1.7% represents royalty fees payable to Baylor.
 
Under the management and royalty agreements, the Facilities pay THVG an amount ranging from 4.5% to 7% of their net patient service revenue less provision for doubtful accounts annually, subject, in some cases, to an annual cap. Management and royalty fees and other reimbursable costs owed by THVG and its Facilities to USP and Baylor totaled approximately $0 and $3,119,000 at June 30, 2010 and 2009, respectively, and are included in due to affiliates in the accompanying consolidated balance sheets.


20


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
In addition, a subsidiary of USPI frequently pays bills on behalf of THVG and has custody of substantially all of THVG’s excess cash, paying THVG and the Facilities interest income on the net balance at prevailing market rates. Amounts held by USPI on behalf of THVG and the facilities totaled $43,709,000 and $70,370,000 at June 30, 2010 and 2009, respectively. The interest income amounted to $338,000 and $640,000 for the years ended June 30, 2010 and 2009, respectively.
 
10.   COMMITMENTS AND CONTINGENCIES
 
Financial Guarantees
 
THVG guarantees portions of the indebtedness of its investees to third-parties, which could potentially require THVG to make maximum aggregate payments totaling approximately $10,574,000. Of the total, $8,165,000 relates to the obligations of five consolidated subsidiaries, whose obligations are included in THVG’s consolidated balance sheet and related disclosures, and the remaining $2,409,000 relates to the obligations of unconsolidated affiliated companies, whose obligations are not included in THVG’s consolidated balance sheet and related disclosures. These arrangements (a) consist of guarantees of real estate and equipment financing, (b) are collateralized by all or a portion of the investees’ assets, (c) require payments by THVG in the event of a default by the investee primarily obligated under the financing, (d) expire as the underlying debt matures at various dates through 2021, or earlier if certain performance targets are met, and (e) provide no recourse for THVG to recover any amounts from third-parties. The fair value of the guarantee liability was not material to the consolidated financial statements and, therefore, no amounts were recorded at June 30, 2010 related to these guarantees. When THVG incurs guarantee obligations that are disproportionately greater than the guarantees provided by the investee’s other owners, THVG charges the investee a fair market value fee based on the value of the contingent liability THVG is assuming.
 
Litigation and Professional Liability Claims
 
In their normal course of business, the Facilities are subject to claims and lawsuits relating to patient treatment. THVG believes that its liability for damages resulting from such claims and lawsuits is adequately covered by insurance or is adequately provided for in its consolidated financial statements. USPI, on behalf of THVG and each of the Facilities, maintains professional liability insurance that provides coverage on a claims-made basis of $1,000,000 per incident and $11,000,000 in annual aggregate amount with retroactive provisions upon policy renewal. Certain of THVG’s insurance policies have deductibles and contingent premium arrangements. THVG believes that the expense recorded through June 30, 2010, which was estimated based on historical claims, adequately provides for its exposure under these arrangements. Additionally, from time to time, THVG may be named as a party to other legal claims and proceedings in the ordinary course of business. THVG is not aware of any such claims or proceedings that have more than a remote chance of having a material adverse impact on THVG.
 
11.   SUBSEQUENT EVENTS
 
THVG regularly engages in exploratory discussions or enters into letters of intent with various entities regarding possible joint ventures, development, or other transactions. These possible joint ventures, developments of new facilities, or other transactions are in various stages of negotiation.
 
Effective July 1, 2010, THVG acquired 51% in Metrocrest Surgery Center, LP for approximately $4 million.
 
THVG has performed an evaluation of subsequent events through December 8, 2010, which is the date the consolidated financials statements were available to be issued.


21


Table of Contents

 
TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
Consolidated Financial Statements
Years Ended June 30, 2009 and 2008
(With Independent Auditors’ Reports Thereon)
 


22


Table of Contents

 
REPORT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT AUDITORS
 
To The Board of Managers
Texas Health Ventures Group, L.L.C.:
 
In our opinion, the accompanying consolidated balance sheet and the related consolidated statements of income, of changes in members’ equity, and of cash flows present fairly, in all material respects, the financial position of Texas Health Ventures Group, L.L.C and Subsidiaries (the “Company”) at June 30, 2009, and the results of their operations and their cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit of these statements in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
 
The consolidated financial statements of the Company as of June 30, 2008 and for the year then ended were audited by other auditors whose report dated October 17, 2008 expressed an unqualified opinion on those statements.
 
/s/  PricewaterhouseCoopers LLP
 
October 28, 2009


23


Table of Contents

 
Report of Ernst & Young LLP, Independent Auditors
 
The Board Managers
Texas Health Ventures Group, L.L.C.
 
We have audited the accompanying consolidated balance sheet of Texas Health Ventures Group, L.L.C. and subsidiaries (the Company) as of June 30, 2008, and the related consolidated statements of income, members’ equity, and cash flows for the year then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.
 
We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
 
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Texas Health Ventures Group, L.L.C. and subsidiaries at June 30, 2008, and the consolidated results of their operations and their cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.
 
/s/  Ernst & Young LLP
 
October 17, 2008
Dallas, Texas


24


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
JUNE 30, 2009 AND 2008
 
                 
    2009     2008  
    (In thousands)  
 
ASSETS
CURRENT ASSETS:
               
Cash
  $ 8,315     $ 3,527  
Patient receivables, net of allowance for doubtful accounts of $9,097 and $10,448 at June 30, 2009 and 2008, respectively
    41,489       45,417  
Due from affiliate (Note 8)
    70,370       30,676  
Supplies
    7,570       7,337  
Prepaid and other current assets
    2,120       1,728  
                 
Total current assets
    129,864       88,685  
PROPERTY AND EQUIPMENT, net (Note 2)
    141,603       148,411  
OTHER LONG-TERM ASSETS:
               
Investments in unconsolidated affiliates (Note 4)
    1,687       1,618  
Goodwill and intangible assets, net (Note 5)
    137,303       131,319  
Other
    633       652  
                 
Total assets
  $ 411,090     $ 370,685  
                 
 
LIABILITIES AND MEMBERS’ EQUITY
CURRENT LIABILITIES:
               
Accounts payable
  $ 13,063     $ 18,013  
Accrued expenses and other
    14,316       13,687  
Due to affiliates (Note 8)
    3,119       3,216  
Current portion of long-term obligations (Note 6)
    12,856       12,057  
                 
Total current liabilities
    43,354       46,973  
LONG-TERM OBLIGATIONS, NET OF CURRENT PORTION (Note 6)
    120,357       123,646  
OTHER LIABILITIES
    13,376       10,238  
                 
Total liabilities
    177,087       180,857  
MINORITY INTERESTS
    39,412       29,910  
COMMITMENTS AND CONTINGENCIES(Notes 7, 8, and 9)
               
MEMBERS’ EQUITY (Note 3)
    194,591       159,918  
                 
Total liabilities and members’ equity
  $ 411,090     $ 370,685  
                 


25


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
FOR THE YEARS ENDED JUNE 30, 2009 AND 2008
 
                 
    2009     2008  
    (In thousands)  
 
REVENUES:
               
Net patient service revenue
  $ 424,071     $ 348,203  
Management and royalty fee income (note 8)
    588       600  
Other income
    532       469  
                 
Total revenues
    425,191       349,272  
EQUITY IN EARNINGS OF UNCONSOLIDATED AFFILIATES (note 4)
    977       1,059  
OPERATING EXPENSES:
               
Salaries, benefits, and other employee costs
    92,664       82,316  
Medical services and supplies
    98,270       78,203  
Management and royalty fees (note 8)
    17,021       14,546  
Professional fees
    3,880       5,714  
Other operating expenses
    59,491       52,434  
Provision for doubtful accounts
    12,420       13,646  
Depreciation and amortization
    18,898       17,706  
                 
Total operating expenses
    302,644       264,565  
                 
Operating income
    123,524       85,766  
NONOPERATING EXPENSES:
               
Interest expense
    (13,251 )     (13,570 )
Interest income (note 8)
    640       1,445  
Other expense, net
    (252 )     (61 )
                 
Income before minority interests and income taxes
    110,661       73,580  
MINORITY INTERESTS IN INCOME OF CONSOLIDATED SUBSIDIARIES
    (56,760 )     (34,341 )
                 
Income before income taxes
    53,901       39,239  
INCOME TAXES
    (2,888 )     (3,673 )
                 
Net income
  $ 51,013     $ 35,566  
                 


26


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
 
CONSOLIDATED STATEMENTS OF MEMBERS’ EQUITY
FOR THE YEARS ENDED JUNE 30, 2009 AND 2008
 
                                                         
    Contributed Capital     Retained Earnings        
    USP     BHS     BUMC     USP     BHS     BUMC     Total  
    (In thousands)  
 
Balance at June 30, 2007
  $ 45,748     $ 45,932     $     $ 21,335     $ 21,420     $     $ 134,435  
Net income
                      17,747       17,819             35,566  
Contributions
    14,381       7,457       4,092                         25,930  
Distributions to members
                      (17,971 )     (18,042 )           (36,013 )
Assign BUMC 49% of BHS’ 50.1% interest in THVG, effective June 30, 2008
          (52,983 )     52,983             (20,731 )     20,731        
Transfer of equity in accordance with L.L.C. agreement
    (1,442 )     888       554                          
                                                         
Balance at June 30, 2008
    58,687       1,294       57,629       21,111       466       20,731       159,918  
Net income
                      25,434       604       24,975       51,013  
Distributions to members
          (43 )           (8,132 )     (179 )     (7,986 )     (16,340 )
Assign remaining BHS 1.1% interest in THVG to BUMC, effective June 30, 2009
          (1,251 )     1,251             (891 )     891        
                                                         
Balance at June 30, 2009
  $ 58,687     $     $ 58,880     $ 38,413     $     $ 38,611     $ 194,591  
                                                         


27


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 2009 AND 2008
 
                 
    2009     2008  
    (In thousands)  
 
CASH FLOWS FROM OPERATING ACTIVITIES:
               
Net income
  $ 51,013     $ 35,566  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Provision for doubtful accounts
    12,420       13,646  
Depreciation and amortization
    18,898       17,706  
Amortization of debt issue costs
    3       3  
Equity in earnings of unconsolidated affiliates, net of distributions received
    (94 )     (230 )
Minority interests in income of consolidated subsidiaries, net of distributions paid
    3,875       2,280  
Changes in operating assets and liabilities, net of acquisitions
               
Patient receivables
    (7,988 )     (26,173 )
Due from (to) affiliates, net
    (97 )     743  
Supplies, prepaids, and other assets
    (437 )     (1,704 )
Accounts payable and accrued expenses
    (3,828 )     4,295  
                 
Net cash provided by operating activities
    73,765       46,132  
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchases of new businesses and equity interests, net of cash received of $1,762 and $291 for 2009 and 2008, respectively
    (5,554 )     (9,476 )
Sale of equity interests
    9,048       952  
Purchases of property and equipment
    (6,612 )     (18,301 )
Sales of property and equipment
    45       26  
Cash collections on notes receivable from affiliates
          1,338  
Change in cash management balances with affiliate
    (39,660 )     7,692  
                 
Net cash used in investing activities
    (42,733 )     (17,769 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Proceeds from long-term debt
  $ 3,534     $ 19,798  
Payments on long-term obligations
    (13,164 )     (14,089 )
Returns of capital to minority interest holders
    (274 )     (817 )
Distributions to Company members
    (16,340 )     (36,013 )
                 
Net cash used in financing activities
    (26,244 )     (31,121 )
                 
INCREASE (DECREASE) IN CASH
    4,788       (2,758 )
CASH, beginning of period
    3,527       6,285  
                 
CASH, end of period
  $ 8,315     $ 3,527  
                 
SUPPLEMENTAL INFORMATION:
               
Cash paid for interest
  $ 13,441     $ 12,814  
Cash paid for income taxes
    2,365       2,375  
Noncash transactions:
               
Noncash assets contributed by Members (note 3)
          25,930  
Asset acquired under capital leases
    2,675       1,840  


28


Table of Contents

TEXAS HEALTH VENTURES GROUP, L.L.C. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
FOR THE YEARS ENDED JUNE 30, 2009 AND 2008
 
1.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Description of Business
 
Texas Health Ventures Group, L.L.C. and subsidiaries (THVG or the Company), a Texas limited liability company, was formed on January 21, 1997 for the primary purpose of developing, acquiring, and operating ambulatory surgery centers and related entities. Prior to June 29, 2008, Baylor Health Services (BHS), a Texas nonprofit corporation that is a controlled affiliate of Baylor Health Care System (BHCS), a Texas nonprofit corporation, owned 50.1% interest in THVG. On June 29, 2008, BHS distributed 49% of its existing 50.1% interest in THVG to Baylor University Medical Center (BUMC), a Texas nonprofit corporation whose sole member is BHCS. THVG is ultimately a subsidiary of BHCS through the combined ownership by BUMC and BHS (collectively referred to herein as Baylor). USP North Texas, Inc. (USP), a Texas corporation and subsidiary of United Surgical Partners International, Inc. (USPI), owns 49.9% of THVG. On June 30, 2009, BHS assigned its 1.1% remaining interest to BUMC. THVG’s fiscal year ends June 30. THVG’s subsidiaries’ fiscal years end December 31; however, the financial information of these subsidiaries included in these consolidated financial statements is as of and for the twelve months ended June 30, 2009 and 2008.
 
THVG owns equity interests in and operates ambulatory surgery centers, surgical hospitals, and related businesses in the Dallas/Fort Worth, Texas, metropolitan area. At June 30, 2009, THVG operated twenty-three facilities (the Facilities) under management contracts, twenty-two of which are consolidated for financial reporting purposes, and one of which is accounted for under the equity method. In addition, THVG holds equity method investments in two partnerships that each own the real estate used by two of the Facilities.
 
THVG has been funded by capital contributions from its members and by cash distributions from the Facilities. The board of managers, which is controlled by Baylor, initiates requests for capital contributions. The Facilities’ operating agreements provide that cash flows available for distribution will be distributed at least quarterly to THVG and other owners of the Facilities.
 
THVG’s operating agreement provides that the board of managers determine, on at least a quarterly basis, if THVG should make a cash distribution based on a comparison of THVG’s excess cash on hand versus current and anticipated needs, including, without limitation, needs for operating expenses, debt service, acquisitions, and a reasonable contingency reserve. The terms of THVG’s operating agreement provide that any distributions, whether driven by operating cash flows or by other sources, such as the distribution of noncash assets or distributions in the event THVG liquidates, are to be shared according to each member’s overall ownership level in THVG. Those ownership levels were 50.1% for BUMC and 49.9% for USP as of June 30, 2009, and 49% for BUMC, 1.1% for BHS and 49.9% for USP as of June 30, 2008.
 
Basis of Accounting
 
THVG maintains its books and records on the accrual basis of accounting, and the consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.
 
Principles of Consolidation
 
The consolidated financial statements include the financial statements of THVG and its wholly owned subsidiaries and other entities THVG controls. THVG consolidates the results of North Central Surgical Center, L.L.P. (North Central) as a result of owning a controlling, majority interest in University Surgical Partners of Dallas, L.L.P., which in turn owns a controlling, majority interest in North Central. All significant intercompany balances and transactions have been eliminated in consolidation.


29


Table of Contents

Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management of THVG to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
 
Recently Adopted Accounting Pronouncements
 
In September 2006, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards (SFAS) No. 157, “Fair Value Measurements,” or SFAS 157, which became effective for fiscal years beginning after November 15, 2007. This statement provides a single definition of fair value, establishes a framework for measuring fair value, and expanded disclosures concerning fair value measurements. In February 2008, the FASB agreed to a one-year deferral of the effective date for non-financial assets and liabilities that are recognized or disclosed at fair values in the consolidated financial statements on a nonrecurring basis. THVG adopted the provisions of SFAS 157 on July 1, 2008 for financial assets and liabilities. The adoption did not have a material impact on THVG’s consolidated financial position or results of operations. THVG does not expect that the adoption of the provisions for non-financial assets or liabilities will have a material impact on its results of operations or financial position.
 
In February 2007, the Financial Accounting Standards Board issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities,” or SFAS 159, which became effective for fiscal years beginning after November 15, 2007, with early adoption permitted. The statement permits entities to choose to measure many financial instruments and certain other items at fair value. The unrealized gains and losses on items for which the fair value option has been elected would be reported in earnings. The objective of SFAS 159 is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. THVG adopted SFAS 159 on July 1, 2008. Since THVG has not utilized the fair value option for any allowable items, the adoption of SFAS 159 did not have an impact on THVG’s consolidated financial position or results of operations. However, in the future, THVG may elect to measure certain financial instruments at fair value in accordance with this standard.
 
In May 2009, the Financial Accounting Standards Board issued SFAS No. 165, “Subsequent Events,” or SFAS 165, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, and specifically requires the disclosure of the date through which an entity has evaluated subsequent events and the basis for that date. SFAS 165 is effective for THVG for the year ended June 30, 2009 and will be applied prospectively.
 
Recently Issued Accounting Pronouncements
 
In December 2007, the Financial Accounting Standards Board issued SFAS No. 141R, “Business Combinations,” or SFAS 141R, which broadens the guidance of SFAS No. 141, extending its applicability to all transactions and other events in which one entity obtains control over one or more other businesses. It broadens the fair value measurement and recognition of assets acquired, liabilities assumed, and interests transferred as a result of business combinations; and stipulates that acquisition related costs be expensed rather than included as part of the basis of the acquisition. SFAS 141R expands required disclosures to improve the ability to evaluate the nature and financial effects of business combinations. SFAS 141R is effective for business combinations entered into on or after July 1, 2009. THVG has not evaluated all of the provisions of SFAS 141R, however the impact of this new standard will be driven by the level of transactions and acquisitions entered into by THVG subsequent to the effective date.
 
In December 2008, the Financial Accounting Standards Board issued SFAS No. 160, “Non-controlling Interests in Consolidated Financial Statements — an amendment of ARB No. 51,” or SFAS 160, which is effective for fiscal years beginning on or after December 15, 2009. SFAS 160 requires a company to clearly identify and present ownership interests in subsidiaries held by parties other than the company in the financial statements within the equity section but separate from the company’s equity. It also requires the amounts of consolidated net income


30


Table of Contents

attributable to the parent and to the non-controlling interest to be clearly identified and presented on the face of the consolidated statement of income; changes in ownership interest to be accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary must be measured at fair value. THVG has not evaluated all of the provisions of SFAS 160, and therefore has not determined the impact on the consolidated financial position or results of operations from the adoption of SFAS 160.
 
In June 2009, the Financial Accounting Standards Board concurrently issued SFAS No. 166, “Accounting for Transfers of Financial Assets, an amendment of FASB Statement No. 140,” or SFAS 166, and Statement No. 167, “Amendments to FASB Interpretation No. 46(R),” or SFAS 167, that change the way entities account for securitizations and other transfers of financial instruments. In addition to increased disclosure, these standards eliminate the concept of qualifying special purpose entities and change the test for consolidation of variable interest entities. These standards are effective for annual reporting periods beginning after November 15, 2009. THVG has not evaluated all of the provisions of these standards, but does not anticipate a material impact on the consolidated financial position or results of operations from the adoption of SFAS 166 or SFAS 167.
 
In June 2009, the Financial Accounting Standards Board issued SFAS No. 168, “The FASB Accounting Standards CodificationTM and the Hierarchy of Generally Accepted Accounting Principles (a replacement of FASB Statement No. 162.” or SFAS 168, that establishes the FASB Accounting Standards CodificationTM (Codification) as the single source of authoritative US GAAP. The Codification does not create any new GAAP standards but incorporates existing accounting and reporting standards into a new topical structure. The Codification is effective for THVG on July 1, 2009, and beginning with the financial statements for the year ending June 30, 2010, a new referencing system will be used to identify authoritative accounting standards.
 
Cash Equivalents
 
For purposes of the consolidated financial statements, THVG considers all highly liquid instruments with original maturities when purchased of three months or less to be cash equivalents. There were no cash equivalents at June 30, 2009 or 2008.
 
Patient Receivables
 
Patient receivables are stated at estimated net realizable value. Significant concentrations of patient receivables at December 31, 2009 and 2008 include:
 
                 
    2009   2008
 
Commercial and managed care providers
    65 %     69 %
Government-related programs
    16 %     18 %
Self-pay patients
    19 %     13 %
                 
      100 %     100 %
                 
 
Receivables from government-related programs (i.e. Medicare and Medicaid) represent the only concentrated groups of credit risk for THVG and management does not believe that there is any credit risks associated with these receivables. Commercial and managed care receivables consist of receivables from various payors involved in diverse activities and subject to differing economic conditions, and do not represent any concentrated credit risk to THVG. THVG maintains allowances for uncollectible accounts for estimated losses resulting from the payors’ inability to make payments on accounts. THVG assesses the reasonableness of the allowance account based on historic write-offs, the aging of accounts and other current conditions. Furthermore, management continually monitors and adjusts the allowances associated with its receivables. Accounts are written off when collection efforts have been exhausted.
 
Supplies
 
Supplies, consisting primarily of pharmaceuticals and supplies inventories, are stated at cost, which approximates market value, and are expensed as used.


31


Table of Contents

Property and Equipment
 
Property and equipment are stated at cost or, when acquired as part of a business combination, at fair value at the date of acquisition. Depreciation is calculated on the straight line method over the estimated useful lives of the assets. Upon retirement or disposal of assets, the asset and accumulated depreciation accounts are adjusted accordingly, and any gain or loss is reflected in earnings or loss of the respective period. Maintenance costs and repairs are expensed as incurred; significant renewals and betterments are capitalized. Assets held under capital leases are classified as property and equipment and amortized using the straight line method over the shorter of the useful lives or the lease terms, and the related obligations are recorded as debt. Amortization of property and equipment held under capital leases and leasehold improvements is included in depreciation and amortization expense. THVG records operating lease expense on a straight-line basis unless another systematic and rational allocation is more representative of the time pattern in which the leased property is physically employed. THVG amortizes leasehold improvements, including amounts funded by landlord incentives or allowances, for which the related deferred rent is amortized as a reduction of lease expense, over the shorter of their economic lives or the lease term.
 
Investments in Unconsolidated Affiliates
 
Investments in unconsolidated affiliates in which THVG exerts significant influence, but has less than a controlling ownership are accounted for under the equity method. THVG exerts significant influence in the operations of its unconsolidated affiliates through representation on the governing bodies of the investees and additionally, with respect to the Facilities, through contracts to manage the operations of the investee.
 
Intangible Assets and Goodwill
 
Intangible assets consist of costs in excess of net assets acquired (goodwill), costs associated with the purchase of management service contract rights, and other intangibles. Most of these assets have indefinite lives. Accordingly, these assets are not amortized but are instead tested for impairment annually or more frequently if changing circumstances warrant. Any decrease in fair value identified in a test for impairment would be recorded as an impairment loss in the consolidated statements of income. No such impairment was identified in 2009 or 2008. THVG amortizes intangible assets with definite useful lives over their respective useful lives to the estimated residual values and reviews them for impairment in the same manner as long-lived assets, discussed below.
 
Impairment of Long-Lived Assets
 
Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset, or related groups of assets, may not be fully recoverable from estimated future cash flows. In the event of impairment, measurement of the amount of impairment may be based on appraisal, fair values of similar assets or estimates of future discounted cash flows resulting from use and ultimate disposition of the asset. No such impairment was identified in 2009 or 2008.
 
Fair Value of Financial Instruments
 
The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. In accordance with SFAS 157, the Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2) or unobservable inputs (Level 3), depending on the nature of the item being valued. The Company does not have financial assets and liabilities measured at fair value on a recurring basis at June 30, 2009. The carrying amounts of cash, accounts receivable, and accounts payable approximate fair value because of the short maturity of these instruments.
 
The fair value of the Company’s long-term debt is determined by estimation of the discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. At June 30, 2009, the aggregate carrying amount and estimated fair value of long-term debt were $41,500,000 and $40,900,000, respectively. At June 30, 2008, the aggregate carrying amount and estimated fair value of long-term debt were $43,700,000 and $44,600,000, respectively.


32


Table of Contents

Revenue Recognition
 
THVG has agreements with third-party payors that provide for payments to THVG at amounts different from its established rates. Payment arrangements include prospectively-determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. Net patient service revenue is reported at the estimated net realizable amount from patients, third-party payors, and others for services rendered, including estimated contractual adjustments under reimbursement agreements with third party payors. Contractual adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. These contractual adjustments are related to the Medicare and Medicaid programs, as well as managed care contracts.
 
Net patient service revenue from the Medicare and Medicaid programs accounted for approximately 9% and 8% of total net patient service revenue in 2009 and 2008, respectively.
 
Net patient service revenue from managed care contracts accounted for approximately 89% and 85% of net patient service revenue in 2009 and 2008, respectively.
 
Net patient service revenue from private payors and charity care programs accounted for approximately 2% and 7% of total net patient service revenue in 2009 and 2008, respectively.
 
For facilities licensed as hospitals, federal regulations require the submission of annual cost reports covering medical costs and expenses associated with services provided to program beneficiaries. Medicare and Medicaid cost report settlements are estimated in the period services are provided to beneficiaries.
 
Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is a reasonable possibility that recorded estimates with respect to the five THVG facilities licensed as hospitals may change by a material amount as interpretations are clarified. These initial estimates are revised as needed until final cost reports are settled.
 
Equity in Earnings of Unconsolidated Affiliates
 
Equity in earnings of unconsolidated affiliates consists of THVG’s share of the profits and losses generated from its noncontrolling equity investments. Because these operations are central to THVG’s business strategy, equity in earnings of unconsolidated affiliates is classified as a component of operating income in the accompanying consolidated statements of income. THVG has contracts to manage these facilities, which results in THVG having an active role in the operations of these facilities.
 
Income Taxes
 
No amounts for federal income taxes have been reflected in the accompanying consolidated financial statements because the federal tax effects of THVG’s activities accrue to the individual members.
 
The Texas franchise tax now applies to all THVG entities for any tax reports filed on or after January 1, 2008 and is reflected in the accompanying consolidated statements of income. Under the revised law, the tax is calculated on a margin base and is therefore reflected in THVG’s consolidated statements of income for the years ended June 30, 2008 and 2009 as income tax expense.
 
FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes- an interpretation of FASB Statement No. 109, Accounting for Income Taxes,” (FIN 48), prescribes a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. Prior to FIN 48, the determination of when to record a liability for a tax exposure was based on whether a liability was considered probable and reasonably estimable in accordance with FASB Statement No. 5,“Accounting for Contingencies.” On July 1, 2007, THVG adopted FIN 48 with no material impact on THVG’s consolidated financial statements.
 
As of June 30, 2009 and 2008, THVG had no gross unrecognized tax benefits. THVG files a partnership income tax return in the U.S. federal jurisdiction and a franchise tax return in the state of Texas. THVG is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years prior to 2005. THVG has


33


Table of Contents

identified Texas as a “major” state taxing jurisdiction. THVG does not expect or anticipate a significant increase over the next twelve months in the unrecognized tax benefits.
 
Commitments and Contingencies
 
Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated.
 
2.   PROPERTY AND EQUIPMENT
 
At June 30, 2009 and 2008, property and equipment and related accumulated depreciation and amortization consisted of the following (in thousands):
 
                         
    Estimated
             
    Useful Lives     2009     2008  
 
Buildings and leasehold improvements
    5-25 years     $ 114,414     $ 110,629  
Equipment
    3-15 years       70,405       68,405  
Furniture and fixtures
    5-15 years       10,190       8,880  
Construction in progress
            1,536       124  
                         
              196,545       188,038  
Less accumulated depreciation and amortization
            (54,942 )     (39,627 )
                         
Net property and equipment
          $ 141,603     $ 148,411  
                         
 
At June 30, 2009 and 2008, assets recorded under capital lease arrangements included in property and equipment consisted of the following (in thousands):
 
                 
    2009     2008  
 
Buildings
  $ 81,271     $ 81,112  
Equipment and furniture
    16,591       16,163  
                 
      97,862       97,275  
Less accumulated amortization
    (20,584 )     (15,823 )
                 
Net property and equipment under capital leases
  $ 77,278     $ 81,452  
                 
 
3.   CAPITAL CONTRIBUTIONS BY MEMBERS
 
As discussed in Note 1, THVG receives part of its funding through cash and capital contributions from its members. During 2008, THVG received noncash capital contributions consisting primarily of investments in partnerships that operate surgery centers in the Dallas/Fort Worth area.
 
These noncash capital contributions, including THVG’s ownership in the investee, are as follows (in thousands):
 
                     
    Ownership
  Net Assets
   
Investee
  Percentage   Contributed   Effective Date
 
Arlington Surgicare Partners, Ltd. (Arlington)
    50.1 %   $ 12,683     July 1, 2007
Rockwall Ambulatory Surgery Center, L.L.P. (Rockwall) 
    50.1 %     3,766     July 1, 2007
Metroplex Surgicare Partners, Ltd. (Metroplex)
    50.1 %     9,438     June 30, 2008
 
USP and Baylor previously owned the assets (noted in the table above) through another company they operate, THVG/HealthFirst (HealthFirst), which is a subsidiary of USP. On the effective dates listed above, HealthFirst, which held the assets and managed the facilities, distributed the assets to USP and Baylor, who in turn recontributed


34


Table of Contents

the majority of the assets to THVG. THVG recorded the contribution from Baylor at Baylor’s carrying value, as this was a contribution between a parent and subsidiary. THVG recorded the contribution from USP at fair value, based on an appraisal, as USP is a non-controlling member. Using these different bases is appropriate under generally accepted accounting principles and causes USP’s capital account to be greater than 49.9% of THVG’s total capital. However, any distributions of THVG’s assets continue to be allocated according to overall ownership levels, which are 50.1% to Baylor and 49.9% to USP as of June 30, 2009 and 2008, respectively. Accordingly, the impact of the difference has been reallocated on the accompanying consolidated statements of members’ equity to ensure that the capital account balances of THVG’s members correspond to the proportions at which net assets would be distributed. Concurrent with the contributions, THVG began managing the operations of the facility. The results of these transactions are included in THVG’s consolidated results of operations from the date of contribution.
 
The assets acquired and liabilities assumed resulting from the above contributions are summarized as follows (in thousands):
 
                         
    Arlington     Rockwall     Metroplex  
 
Current assets
  $ 2,955     $ 1,250     $ 2,002  
Property and equipment
    4,196       805       1,436  
Goodwill
    11,912       8,254       8,424  
Other noncurrent assets
    164       20       25  
                         
Total assets acquired
    19,227       10,329       11,887  
Current liabilities
    2,360       905       1,172  
Long-term debt
    3,412       5,606       267  
Other noncurrent liabilities
          8        
                         
Total liabilities assumed
    5,772       6,519       1,439  
Minority interests
    772       44       1,010  
                         
Net assets acquired
  $ 12,683     $ 3,766     $ 9,438  
                         


35


Table of Contents

4.   INVESTMENTS IN SUBSIDIARIES AND UNCONSOLIDATED AFFILIATES
 
THVG’s investments in consolidated subsidiaries and unconsolidated affiliates consisted of the following:
 
                         
            Percentage Owned
            June 30,
  June 30,
Legal Name
 
Facility
 
City
  2009   2008
 
Consolidated subsidiaries(1):
                       
Bellaire Outpatient Surgery Center, L.L.P. 
  Bellaire Surgery Center   Fort Worth     50.1 %     50.1 %
Dallas Surgical Partners, L.L.P. 
  Baylor Surgicare   Dallas     62.6       56.9  
Dallas Surgical Partners, L.L.P. 
  Texas Surgery Center   Dallas     62.6       56.9  
Dallas Surgical Partners, L.L.P. 
  Physicians Day Surgery Center   Dallas     62.6       56.9  
Denton Surgicare Partners, Ltd. 
  Baylor Surgicare at Denton   Denton     50.1       50.1  
Frisco Medical Center, L.L.P. 
  Baylor Medical Center at Frisco   Frisco     50.1       50.1  
Garland Surgicare Partners, Ltd. 
  Baylor Surgicare at Garland   Garland     50.1       50.1  
Grapevine Surgicare Partners, Ltd. 
  Baylor Surgicare at Grapevine   Grapevine     50.3       50.1  
Lewisville Surgicare Partners, Ltd. 
  Baylor Surgicare at Lewisville   Lewisville     53.1       52.8  
MSH Partners, L.P. 
  Mary Shiels Hospital   Dallas     42.4       56.9  
North Central Surgical Center, L.L.P. 
  North Central Surgery Center   Dallas     32.2       28.9  
North Garland Surgery Center, L.L.P. 
  North Garland Surgery Center   Garland     52.4       52.4  
Rockwall/Heath Surgery Center, L.L.P. 
  Baylor Surgicare at Heath   Heath     50.1       50.1  
Trophy Club Medical Center, L.P. 
  Trophy Club Medical Center   Fort Worth     52.5       50.5  
Valley View Surgicare Partners, Ltd. 
  Baylor Surgicare at Valley View   Dallas     50.1       50.1  
Baylor Surgical Hospital of Fort Worth Surgicare Partners, Ltd. 
  Fort Worth   Fort Worth     50.2       50.1  
Arlington Surgicare Partners, Ltd. 
  Surgery Center of Arlington   Arlington     50.1       50.1  
Rockwall Ambulatory Surgery Center, L.L.P. 
  Rockwall Surgery Center   Rockwall     50.1       50.1  
Baylor Surgicare at Plano, L.L.C. 
  Baylor Surgicare at Plano   Plano     50.1       50.1  
Metroplex Surgicare Partners, Ltd. 
  Metroplex Surgicare   Bedford     50.1       50.1  
Arlington Orthopedic and Spine Hospitals, LLC
  Arlington Hospital   Arlington     50.1       50.1  
Baylor Surgicare at Granbury, LLC
  Granbury Surgical Plaza   Granbury     50.6        
Unconsolidated affiliates:
                       
Denton Surgicare Real Estate, Ltd. 
  (2)   n/a     49.0       49.0  
Irving-Coppell Surgical Hospital, L.L.P. 
  Irving-Coppell Surgical Hospital   Irving     18.3       18.4  
MCSH Real Estate Investors, Ltd. 
  (2)   n/a     2.0       2.0  
 
 
(1) List excludes holding companies, which are wholly owned by the Company and hold the Company’s investments in the Facilities.
 
(2) These entities are not surgical facilities and do not have ownership in any surgical facilities.
 
Additionally, in the ordinary course of business, THVG engages in purchases and sales of individual partnership units with physicians who invest in the Facilities and invests cash in projects under development. These transactions are summarized as follows:
 
  •  Net payments made for the year ended June 30, 2008 for the purchase of additional interests in University Surgical Partners of Dallas, L. L. P. (USPD) totaling approximately $3,774,000. USPD consists of the following facilities: Baylor Surgicare, Texas Surgery Center, and Physicians Day Surgery Center.
 
  •  Net proceeds received for the year ended June 20, 3009 from sales of additional interests in MSH Partners, L.P. (Mary Shiels Hospital) totaling approximately $1,983,000.
 
  •  Payments made of $3,579,000 and proceeds received of $5,306,000 for the year ended June 30, 2009, and payments made of $1,538,000 and proceeds received of $952,000 for the year ended June 30, 2008, related


36


Table of Contents

  to other transactions, primarily purchases and sales of individual partnership units with physicians who invest in the facilities.
 
Effective February 1, 2009, THVG acquired 50.63 membership units, a 50.63% equity interest, in Granbury Surgical Plaza (Granbury), for a purchase price of $805,000. Granbury, like the other facilities in which THVG invests, is operated by Baylor and USP through THVG, as described in Note 8.
 
The following table summarizes the recorded values of Granbury’s assets acquired and liabilities assumed at the date of acquisition, as determined by internal and third-party valuations (in thousands):
 
         
    Granbury Surgical Plaza  
 
Current assets
  $ 2,454  
Property and equipment
    2,847  
Goodwill
    3,916  
Long-term assets
    14  
         
Total assets acquired
    9,231  
         
Current liabilities
    882  
Long-term liabilities
    1,776  
Long-term debt
    5,768  
         
Total liabilities assumed
    8,426  
         
Net assets acquired
  $ 805  
         
 
The acquisition of Granbury was accounted for using the purchase method of accounting and accordingly, the purchase price has been allocated to the tangible and intangible assets acquired and liabilities assumed based on the estimated fair values at the date of acquisition. Some of those estimates are preliminary and subject to further adjustment. The results of the acquisition are included in THVG’s consolidated results of operations from the date of acquisition.
 
5.   GOODWILL AND INTANGIBLE ASSETS
 
At June 30, 2009 and 2008, goodwill and intangible assets, net of accumulated amortization, consisted of the following (in thousands):
 
                 
    2009     2008  
 
Goodwill
  $ 136,119     $ 130,137  
Other intangible assets
    1,184       1,182  
                 
Total
  $ 137,303     $ 131,319  
                 


37


Table of Contents

The following is a summary of changes in the carrying amount of goodwill for the years ended June 30, 2009 and 2008 (in thousands):
 
         
Balance, July 1, 2007
  $ 92,332  
Additions:
       
Contribution of Arlington (note 3)
    11,912  
Contribution of Rockwall (note 3)
    8,254  
Contribution of Metroplex (note 3)
    8,317  
Acquisition of Plano
    4,299  
Purchase of additional interests in USPD
    3,360  
Other
    1,663  
         
Balance, June 30, 2008
    130,137  
Additions:
       
Acquisition of Granbury
    3,916  
Purchase of additional interests in USPD
    1,121  
Additional contribution from BHS for the Metroplex acquisition
    107  
Other
    838  
         
Balance, June 30, 2009
  $ 136,119  
         
 
Intangible assets with definite useful lives are amortized over their respective estimated useful lives. THVG records interest expense for intangible debt issue costs on a straight-line basis over the term of the debt obligation, which approximates the effective interest method. The agreements underlying THVG’s management contract assets have no determinable termination date and, consequently, the related intangible assets have indefinite useful lives. Goodwill and intangible assets with indefinite useful lives are not amortized but instead are tested for impairment at least annually. No impairment was recorded in 2009 or 2008.
 
The following is a summary of intangible assets at June 30, 2009 and 2008 (in thousands):
 
                         
    June 30, 2009  
    Gross Carrying
    Accumulated
       
    Amount     Amortization     Total  
 
Definite useful lives:
                       
Debt issue costs
  $ 84     $ (50 )   $ 34  
Indefinite useful lives:
                       
Management contracts
    1,150             1,150  
                         
Total intangible assets
  $ 1,234     $ (50 )   $ 1,184  
                         
 
                         
    June 30, 2008  
    Gross Carrying
    Accumulated
       
    Amount     Amortization     Total  
 
Definite useful lives:
                       
Debt issue costs
  $ 79     $ (47 )   $ 32  
Indefinite useful lives:
                       
Management contracts
    1,150             1,150  
                         
Total intangible assets
  $ 1,229     $ (47 )   $ 1,182  
                         
 
Amortization of debt issue costs in the amount of $3,000 is included in interest expense for both years ended June 30, 2009 and 2008.


38


Table of Contents

6.   LONG TERM OBLIGATIONS
 
At June 30, 2009 and 2008, long-term obligations consisted of the following (in thousands):
 
                 
    2009     2008  
 
Capital lease obligations (Note 7)
  $ 91,679     $ 92,044  
Notes payable to financial institutions
    41,534       43,659  
                 
Total long-term obligations
    133,213       135,703  
Less current portion
    (12,856 )     (12,057 )
                 
Long-term obligations, less current portion
  $ 120,357     $ 123,646  
                 
 
The aggregate maturities of long-term obligations for each of the five years subsequent to June 30, 2009 and thereafter are as follows (in thousands):
 
                 
2010
          $ 10,015  
2011
            9,667  
2012
            8,751  
2013
            4,368  
2014
            3,103  
Thereafter
            5,630  
                 
Total long-term obligations
          $ 41,534  
                 
 
Capital lease obligations are collateralized by underlying real estate or equipment and have interest rates ranging from 3.50% to 12.66%.
 
The Facilities have notes payable to financial institutions which mature at various dates through 2016 and accrue interest at fixed and variable rates ranging from 3.11% to 9.5%. Each note is collateralized by certain assets of the respective Facility.
 
7.   LEASES
 
The Facilities lease various office equipment, medical equipment, and office space under a number of operating lease agreements, which expire at various times through the year 2029. Such leases do not involve contingent rentals, nor do they contain significant renewal or escalation clauses. Office leases generally require the Facilities to pay all executory costs (such as property taxes, maintenance and insurance).
 
Minimum future payments under noncancelable leases with remaining terms in excess of one year as of June 30, 2009 are as follows (in thousands):
 
                 
    Capital
    Operating
 
    Leases     Leases  
 
Year ending June 30:
               
2010
  $ 13,069     $ 10,272  
2011
    12,517       8,996  
2012
    12,124       8,925  
2013
    11,922       8,259  
2014
    11,671       8,007  
Thereafter
    151,961       74,057  
                 
Total minimum lease payments
    213,264     $ 118,516  
                 
Amount representing interest
    (121,585 )        
                 
Total principal payments
  $ 91,679          
                 


39


Table of Contents

Total rent expense under operating leases was approximately $13,149,000 and $12,163,000 for the years ended June 30, 2009 and 2008, respectively, and is included in other operating expenses in the accompanying consolidated statements of income.
 
8.   RELATED-PARTY TRANSACTIONS
 
THVG operates the facilities under management and royalty contracts, and THVG in turn is managed by Baylor and USP, resulting in THVG incurring management and royalty fee expense payable to Baylor and USP in amounts equal to the management and royalty fee income THVG receives from the Facilities. THVG’s management and royalty fee income from the facilities it consolidates for financial reporting purposes eliminates in consolidation with the facilities’ expense and therefore is not included in THVG’s consolidated revenues. THVG’s management and royalty fee income from facilities which are not consolidated was approximately $588,000 and $600,000 for the years ended June 30, 2009 and 2008, respectively, and is included in the consolidated revenues of THVG.
 
The management and royalty fee expense to Baylor and USP was $17,021,000 and $14,546,000 for the years ended June 30, 2009 and 2008, respectively, and is reflected in operating expenses in THVG’s consolidated statements of income. Of the total, 64.3% and 34.0% represent management fees payable to USP and Baylor, respectively, and 1.7% represents royalty fees payable to Baylor.
 
Under the management and royalty agreements, the Facilities pay THVG an amount ranging from 4.5% to 7% of their net patient service revenue less provision for doubtful accounts annually, subject, in some cases, to an annual cap. Management and royalty fees and other reimbursable costs owed by THVG and its Facilities to USP and Baylor totaled $3,119,000 and $3,216,000 at June 30, 2009 and 2008, respectively, and are included in due to affiliates in the accompanying consolidated balance sheets.
 
In addition, a subsidiary of USPI frequently pays bills on behalf of THVG and has custody of substantially all of THVG’s excess cash, paying THVG and the Facilities interest income on the net balance at prevailing market rates. Amounts held by USPI on behalf of THVG and the facilities totaled $70,370,000 and $30,676,000 at June 30, 2009 and 2008, respectively. The interest income amounted to $604,000 and $1,306,000 for the years ended June 30, 2009 and 2008, respectively.
 
9.   COMMITMENTS AND CONTINGENCIES
 
Financial Guarantees
 
As of June 30, 2009, THVG issued guarantees of portions of the indebtedness of its investees to third-parties, which could potentially require THVG to make maximum aggregate payments totaling approximately $10,100,000. Of the total, $7,500,000 relates to the obligations of four consolidated subsidiaries, whose obligations are included in THVG’s consolidated balance sheet and related disclosures, and the remaining $2,600,000 relates to the obligations of unconsolidated affiliated companies, whose obligations are not included in THVG’s consolidated balance sheet and related disclosures. These arrangements (a) consist of guarantees of real estate and equipment financing, (b) are collateralized by all or a portion of the investees’ assets, (c) require payments by THVG in the event of a default by the investee primarily obligated under the financing, (d) expire as the underlying debt matures at various dates through 2021, or earlier if certain performance targets are met, and (e) provide no recourse for THVG to recover any amounts from third-parties. The fair value of the guarantee liability was not material to the consolidated financial statements and, therefore, no amounts were recorded at June 30, 2009 related to these guarantees. When THVG incurs guarantee obligations that are disproportionately greater than the guarantees provided by the investee’s other owners, THVG charges the investee a fair market value fee based on the value of the contingent liability THVG is assuming.
 
Litigation and Professional Liability Claims
 
In their normal course of business, the facilities are subject to claims and lawsuits relating to patient treatment. THVG believes that its liability for damages resulting from such claims and lawsuits is adequately covered by insurance or is adequately provided for in its consolidated financial statements. USPI, on behalf of THVG and each of the Facilities, maintains professional liability insurance that provides coverage on a claims-made basis of


40


Table of Contents

$1,000,000 per incident and $11,000,000 in annual aggregate amount with retroactive provisions upon policy renewal. Certain of THVG’s insurance policies have deductibles and contingent premium arrangements. THVG believes that the expense recorded through June 30, 2009, which was estimated based on historical claims, adequately provides for its exposure under these arrangements. Additionally, from time to time, THVG may be named as a party to other legal claims and proceedings in the ordinary course of business. THVG is not aware of any such claims or proceedings that have more than a remote chance of having a material adverse impact on THVG.
 
10.   SUBSEQUENT EVENTS
 
THVG regularly engages in exploratory discussions or enters into letters of intent with various entities regarding possible joint venture, development, or other transactions. These possible joint ventures, developments of new facilities, or other transactions are in various stages of negotiation.
 
THVG has performed an evaluation of subsequent events thru October 28, 2009, which is the date the consolidated financials statements were available to be issued.


41


Table of Contents

 
(4) Exhibits:
 
         
Exhibit
   
Number
 
Description
 
  2 .1   Agreement and Plan of Merger dated as of January 27, 2006, by and among United Surgical Partners International, Inc., Peak ASC Acquisition Corp. and Surgis, Inc. (previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on January 31, 2006 and incorporated herein by reference).(1)
  2 .2   Agreement and Plan of Merger, dated as of January 7, 2007, by and among the Company, UNCN Holdings, Inc. and UNCN Acquisition Corp. (previously filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Commission on January 8, 2007 and incorporated herein by reference).(1)
  3 .1   Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1(A) to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)
  3 .2   Amended and Restated Bylaws (previously filed as Exhibit 3.1(B) to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)
  4 .1   Indenture governing 87/8% Senior Subordinated Note due 2017 and 91/4%/10% Senior Subordinated Toggle Note due 2017, among the Company, the Guarantors named therein and U.S. Bank National Association, as trustee. (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)
  4 .2   Form of 87/8% Senior Subordinated Note due 2017 and 91/4%/10% Senior Subordinate Toggle Note due 2017 (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)
  10 .1   Credit Agreement, dated as of April 19, 2007, among USPI Holdings, Inc., the Company, as Borrower, the Lenders party thereto, Citibank, N.A., as Administrative Agent and Collateral Agent, Lehman Brothers, Inc., as Syndication Agent, and Bear Stearns Corporate Lending., Inc. and UBS Securities LLC, as Co-Documentation Agents.(1)
  10 .2   Amendment No. 1 to that certain Credit Agreement dated as of April 19, 2007, among United Surgical Partners International, Inc., USPI Holdings, Inc., as Borrower, the Lenders party thereto, Citibank, N.A., as Administrative Agent and Collateral Agent, Lehman Brothers, Inc., as Syndication Agent, and Bear Stearns Corporate Lending, Inc. and UBS Securities LLC, as Co-Documentation Agents (previously filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Commission on August 4, 2009 and incorporated herein by reference).(1)
  10 .3   Guarantee and Collateral Agreement, dated as of April 19, 2007, among USPI Holdings, Inc., the Company, the subsidiaries of the Company identified therein and Citibank, N.A., as Collateral Agent.(1)
  10 .4   Employment Agreement, dated as of April 19, 2007, by and between the Company and Donald E. Steen (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .5   Employment Agreement, dated as of April 19, 2007, by and between the Company and William H. Wilcox (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .6   Employment Agreement, dated as of April 19, 2007, by and between the Company and Brett P. Brodnax (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .7   Employment Agreement, dated as of April 19, 2007, by and between the Company and Niels P. Vernegaard (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .8   Employment Agreement, dated as of April 19, 2007, by and between the Company and Mark A. Kopser (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .9   Employment Agreement, dated as of April 21, 2009, by and between the Company and Philip A. Spencer.(2)(3)
  10 .10   USPI Group Holdings, Inc. 2007 Equity Incentive Plan (previously filed as an exhibit to the Company’s Quarterly Report on Form 10-Q (No. 333-144337) and incorporated herein by reference).(1)(3)


IV-1


Table of Contents

         
Exhibit
   
Number
 
Description
 
  10 .11   First Amendment to the USPI Group Holdings, Inc. 2007 Equity Incentive Plan (previously filed as an exhibit to the Company’s Current Report on Form 10-K filed with the Commission on February 26, 2009 and incorporated herein by reference).(1)(3)
  10 .12   Amended and Restated Deferred Compensation Plan (previously filed as an exhibit to the Company’s Current Report on Form 10-K filed with the Commission on February 26, 2009 and incorporated herein by reference).(1)(3)
  10 .13   Form of Indemnification Agreement between United Surgical Partners International, Inc. and its directors and officers (previously filed as an exhibit to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference).(1)(3)
  21 .1   List of the Company’s subsidiaries.(2)
  24 .1   Power of Attorney — Donald E. Steen(2)
  24 .2   Power of Attorney — Joel T. Allison(2)
  24 .3   Power of Attorney — Michael E. Donovan(2)
  24 .4   Power of Attorney — John C. Garrett, M.D.(2)
  24 .5   Power of Attorney — D. Scott Mackesy(2)
  24 .6   Power of Attorney — James Ken Newman(2)
  24 .7   Power of Attorney — Boone Powell, Jr.(2)
  24 .8   Power of Attorney — Paul B. Queally(2)
  24 .9   Power of Attorney — Raymond A. Ranelli(2)
  31 .1   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002(2)
  31 .2   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002(2)
  32 .1   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002(2)
  32 .2   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002(2)
 
 
(1) Previously filed.
 
(2) Filed herewith.
 
(3) Management contract or compensatory plan or arrangement in which a director or executive officer participates.

IV-2


Table of Contents

SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
United Surgical Partners International, Inc.
 
  By: 
/s/  William H. Wilcox
William H. Wilcox
President, Chief Executive Officer and Director
 
Date: February 25, 2011
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in capacities and on the dates indicated.
 
             
Signature
 
Title
 
Date
 
         
*

Donald E. Steen
  Chairman of the Board   February 25, 2011
         
/s/  William H. Wilcox

William H. Wilcox
  President, Chief Executive Officer and Director (Principal Executive Officer)   February 25, 2011
         
/s/  Mark A. Kopser

Mark A. Kopser
  Executive Vice President and Chief Financial Officer (Principal Financial Officer)   February 25, 2011
         
/s/  J. Anthony Martin

J. Anthony Martin
  Vice President, Corporate Controller And Chief Accounting Officer (Principal Accounting Officer)   February 25, 2011
         
*

Joel T. Allison
  Director   February 25, 2011
         
*

Michael E. Donovan
  Director   February 25, 2011
         
*

John C. Garrett, M.D.
  Director   February 25, 2011
         
*

D. Scott Mackesy
  Director   February 25, 2011
         
*

James Ken Newman
  Director   February 25, 2011
         
*

Boone Powell, Jr.
  Director   February 25, 2011


IV-3


Table of Contents

             
Signature
 
Title
 
Date
 
         
*

Paul B. Queally
  Director   February 25, 2011
         
*

Raymond A. Ranelli
  Director   February 25, 2011
 
 
John J. Wellik, by signing his name hereto, does hereby sign this Annual Report on Form 10-K on behalf of each of the above-named directors and officers of the Company on the date indicated below, pursuant to powers of attorney executed by each of such directors and officers and contemporaneously filed herewith with the Commission.
 
  By: 
/s/  John J. Wellik
John J. Wellik
Attorney-in-fact
 
Date: February 25, 2011


IV-4


Table of Contents

INDEX TO EXHIBITS
 
         
Exhibit
   
Number
 
Description
 
  2 .1   Agreement and Plan of Merger dated as of January 27, 2006, by and among United Surgical Partners International, Inc., Peak ASC Acquisition Corp. and Surgis, Inc. (previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on January 31, 2006 and incorporated herein by reference).(1)
  2 .2   Agreement and Plan of Merger, dated as of January 7, 2007, by and among the Company, UNCN Holdings, Inc. and UNCN Acquisition Corp. (previously filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Commission on January 8, 2007 and incorporated herein by reference).(1)
  3 .1   Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1(A) to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)
  3 .2   Amended and Restated Bylaws (previously filed as Exhibit 3.1(B) to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)
  4 .1   Indenture governing 87/8% Senior Subordinated Note due 2017 and 91/4%/10% Senior Subordinated Toggle Note due 2017, among the Company, the Guarantors named therein and U.S. Bank National Association, as trustee. (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)
  4 .2   Form of 87/8% Senior Subordinated Note due 2017 and 91/4%/10% Senior Subordinate Toggle Note due 2017 (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)
  10 .1   Credit Agreement, dated as of April 19, 2007, among USPI Holdings, Inc., the Company, as Borrower, the Lenders party thereto, Citibank, N.A., as Administrative Agent and Collateral Agent, Lehman Brothers, Inc., as Syndication Agent, and Bear Stearns Corporate Lending., Inc. and UBS Securities LLC, as Co-Documentation Agents.(1)
  10 .2   Amendment No. 1 to that certain Credit Agreement dated as of April 19, 2007, among United Surgical Partners International, Inc., USPI Holdings, Inc., as Borrower, the Lenders party thereto, Citibank, N.A., as Administrative Agent and Collateral Agent, Lehman Brothers, Inc., as Syndication Agent, and Bear Stearns Corporate Lending, Inc. and UBS Securities LLC, as Co-Documentation Agents (previously filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Commission on August 4, 2009 and incorporated herein by reference).(1)
  10 .3   Guarantee and Collateral Agreement, dated as of April 19, 2007, among USPI Holdings, Inc., the Company, the subsidiaries of the Company identified therein and Citibank, N.A., as Collateral Agent.(1)
  10 .4   Employment Agreement, dated as of April 19, 2007, by and between the Company and Donald E. Steen (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .5   Employment Agreement, dated as of April 19, 2007, by and between the Company and William H. Wilcox (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .6   Employment Agreement, dated as of April 19, 2007, by and between the Company and Brett P. Brodnax (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .7   Employment Agreement, dated as of April 19, 2007, by and between the Company and Niels P. Vernegaard (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .8   Employment Agreement, dated as of April 19, 2007, by and between the Company and Mark A. Kopser (previously filed as an exhibit to the Company’s Registration Statement on Form S-4 (No. 333-144337) and incorporated herein by reference).(1)(3)
  10 .9   Employment Agreement, dated as of April 21, 2009, by and between the Company and Philip A. Spencer.(2)(3)
  10 .10   USPI Group Holdings, Inc. 2007 Equity Incentive Plan (previously filed as an exhibit to the Company’s Quarterly Report on Form 10-Q (No. 333-144337) and incorporated herein by reference).(1)(3)


IV-5


Table of Contents

         
Exhibit
   
Number
 
Description
 
  10 .11   First Amendment to the USPI Group Holdings, Inc. 2007 Equity Incentive Plan (previously filed as an exhibit to the Company’s Current Report on Form 10-K filed with the Commission on February 26, 2009 and incorporated herein by reference).(1)(3)
  10 .12   Amended and Restated Deferred Compensation Plan (previously filed as an exhibit to the Company’s Current Report on Form 10-K filed with the Commission on February 26, 2009 and incorporated herein by reference).(1)(3)
  10 .13   Form of Indemnification Agreement between United Surgical Partners International, Inc. and its directors and officers (previously filed as an exhibit to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference).(1)(3)
  21 .1   List of the Company’s subsidiaries.(2)
  24 .1   Power of Attorney — Donald E. Steen(2)
  24 .2   Power of Attorney — Joel T. Allison(2)
  24 .3   Power of Attorney — Michael E. Donovan(2)
  24 .4   Power of Attorney — John C. Garrett, M.D.(2)
  24 .5   Power of Attorney — D. Scott Mackesy(2)
  24 .6   Power of Attorney — James Ken Newman(2)
  24 .7   Power of Attorney — Boone Powell, Jr.(2)
  24 .8   Power of Attorney — Paul B. Queally(2)
  24 .9   Power of Attorney — Raymond A. Ranelli(2)
  31 .1   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002(2)
  31 .2   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002(2)
  32 .1   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002(2)
  32 .2   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002(2)
 
 
(1) Previously filed.
 
(2) Filed herewith.
 
(3) Management contract or compensatory plan or arrangement in which a director or executive officer participates.

IV-6